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(i) ABSTRACT 
 
 
Purpose: Some randomized trials are reported widely, while others remain unpublished. It is 
essential to systematic reviewers and meta-analysts that factors leading to publication bias in the 
form of delayed or non-publication of an eligible study are identified. This thesis is an attempt to 
do this.  
 
Data: The set of randomized trials identified by the Childhood Acute Lymphoblastic Leukaemia 
(ALL) Collaborative Group was used. This consists of 149 trials comprising 243 randomized 
comparisons (randomizations), starting prior to 1 January 1988, reported in 257 articles, published 
prior to 1 January 2000. Each mention of a randomization in an article (irrespective of whether 
results are given) generates a publication record, of which there are 610. 
 
Methods: The main focus is on identifying which trial characteristics lead to a delay in publication 
of a randomization. Time to the first mention of a randomization in an article (irrespective of 
whether any results are given) and to the first reporting of its results are both modelled using 
ordinary linear regression (the independence model). However, when these analyses are extended 
to include all mentions and all reportings of results respectively, non-independence necessitates the 
use of techniques for dealing with repeated measures. In such cases the independence model is the 
starting point, the residuals from which are used to form the covariance matrix, which in turn is 
used to suggest plausible correlation structures for repeated measures models. Generalised 
estimating equation (GEE) analysis is used to select an appropriate correlation structure, and a 
linear mixed effects model serves to confirm this. The conclusions are then discussed in the context 
of other studies identified. Finally logistic regression is used to identify trial characteristics 
associated with a randomization remaining unpublished, and Poisson and negative binomial models 
to identify those affecting frequency of reporting.  
 
Results: Evidence was found of ‘pipeline bias’ in the reporting of first results since, although 
direction of effect was not found to be significant, highly statistically significant results are 
published faster than others. However this is not so for first mentions. Negative results (i.e. those in 
favour of the standard/control) arm were submitted for first publication faster than all others, 
although this did not effect time to publication. In addition, geographic location is an important 
predictor of whether a randomization is ever mentioned in an article, frequency of mentions and of 
time to first publication and results from single-centre trials are published more frequently than 
those with multi-centre participation. 
 
Conclusions: Although ‘pipeline bias’ was identified in the analysis of time first reporting of 
results, it was not present in the analysis of time to first mention, and so not a problem for those 
wishing only to identify randomized trials for inclusion in meta-analyses. The importance of 
geographic location suggests that the practice of contacting known trialists is worthwhile in 
addition to the computerised literature searches and should be continued. 
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SUMMARY 
 
Chapter 1 provides an introduction to this thesis. It includes a brief history of the use of 
randomized trials in childhood acute lymphoblastic leukaemia and a description of some trial 
characteristics. 
 
Chapter 2 describes the main aim of the thesis, which is to discover which trial characteristics are 
likely to affect three time periods: from the end of the accrual period to submission for publication, 
from receipt of the article by the publisher to actual publication, and the sum of these, the time 
from close of trial to publication. A literature search was conducted on this topic, and this is also 
mentioned in this chapter. 
 
Chapter 3 describes the data collected; information on the set of clinical trials used, and the 
publications related to these trials. This chapter also deals with the data management process, 
inclusion/exclusion criteria and checking procedures. Chapter 4 explains how more meaningful 
variables were derived from collectable variables. It also describes some of the problems relating to 
data collection and coding and how these were overcome. 
 
Chapter 5 looks at how the preliminary analyses were undertaken. Since the data are reportings of 
randomizations from clinical trials, there may be several records relating to a single randomization, 
which are not independent of each other. The problem of non-independence, and how it is 
overcome, using repeated measures analysis, is dealt with in Chapters 9-11. However, models that 
assume independence are used for the preliminary analyses in order to identify subsets of the 
explanatory variables which may be significant in the final analysis. The independence models are 
valid without further work when dealing with the first mention, or the first reporting of results, of 
each trial. Also covered in Chapter 5 are the exploratory graphical analyses and diagnostic plots. 
There are also sections on problems relating to the preliminary analyses, the incorporation of 
interaction terms, the use of indicator variables to represent classes of a categorical variable, the 
range of values over which the analyses are valid and outlying observations.  
  
xv 
The six analyses for which the independence model can be used without adjustment are for the 
three response variables; time from close of trial to submission of article, time from receipt of 
article to publication, and time from close of trial to publication, each measured for the first 
mention of each trial and for the first reporting of results for each trial. The findings are given in 
Chapter 6. 
 
Chapter 7 reports the results of the six preliminary analyses, which will need to be adjusted to take 
into account repeated measures. These are for the three response variables; time from close of trial 
to submission of article, time from receipt of article to publication, and time from close of trial to 
publication, each analysed for all mentions of each trial, and for all reportings of results for each 
trial. 
 
Chapter 8 describes the method for obtaining the covariance matrix for each of the six analyses that 
involve repeated measures. This is used to suggest plausible correlation structures for repeated 
measures models. For each analysis this involves taking the residuals from the independence 
model, finding the covariance between the first and second publication, the second and third, the 
first and third and so on and developing an empirical correlation structure. Several possible 
correlation structures and preliminary investigations into selecting the most appropriate are 
discussed. 
 
Chapter 9 discusses the application of generalised estimating equations (GEE) to the largest of the 
six datasets in order to select the most appropriate correlation structure to impose on all six datasets 
requiring repeated measures. A linear mixed effects model is also used in order to confirm the 
findings from the GEE analyses. 
 
The two correlation structures judged most appropriate are then imposed on all six analyses and the 
final choice is made in Chapter 10. Chapter 11 reports the final results for the six analyses 
incorporating repeated measures analyses using GEE.  
 
xvi 
Chapter 12 describes an investigation into how the group of reportings of randomizations published 
prior to closure differ from the rest, and whether the results of the analyses change when these are 
excluded. 
 
Chapter 13 presents the results of the twelve analyses in tabular form and discusses possible 
implications for the identification of randomized trials for inclusion in meta-analyses. The findings 
are also compared with those from other studies. 
 
Chapter 14 begins with an introduction to other questions which can be answered from the data 
collected. The bulk of the chapter deals with one of the two main topics, that of investigating which 
trial characteristics affect whether or not a randomization is ever mentioned in an article, and 
whether or not its results are ever reported. The second main topic, trial characteristics affecting the 
number of articles in which a randomization is mentioned and the number of articles in which its 
results are published, is covered in Chapter 15. 
 
An update of the data since the cut-off date for analysis is given in Chapter 16, and the main 
findings are summarized in the concluding chapter, 17. 
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1  INTRODUCTION 
 
1.1  Introduction 
This chapter provides a brief history of the use of randomized trials of treatments for childhood 
acute lymphoblastic leukaemia, describes some of the more interesting trial characteristics, and 
introduces the current project undertaken [Burrett and Clarke (2002)]. 
 
1.2  The use of randomized trials of treatments for childhood acute lymphoblastic leukaemia 
During the 1950s randomized trials became increasingly common as a way of assessing  treatments 
for many health conditions. However, leukaemia was not one of these. It was, at that time, a fatal 
disease. The general policy was to use any treatment that might prolong survival.  
 
However, attitudes were changing. In 1963 the Medical Research Council Working Party on the 
Evaluation of Different Methods of Therapy in Leukaemia, in their paper comparing high and low 
dose steroids in the treatment of leukaemia in adults, stated that ‘current forms of treatment (for 
leukaemia) were in need of critical appraisal’ and that ‘the (1957 Steering) Committee (had) 
recommended that six Working parties should be formed, and that one of them should examine the 
possibilities of carrying out therapeutic trials in leukaemia’ [MRC (1963)]. 
 
Through the 1960s, survival rates in childhood acute lymphoblastic leukaemia gradually improved. 
By 1971 investigators at the St Jude hospital in Memphis concluded ‘Childhood lymphocytic 
leukaemia can no longer be considered an incurable disease. Palliation is no longer a justifiable 
approach to its initial treatment’   [Pinkel et al (1971)]. Randomized trials were needed to 
distinguish between treatments with moderate differences in their effects on survival or disease-
free survival. 
 
In the early years of the 21st century, children with acute lymphoblastic leukaemia have a good 
chance of cure.  Randomized trials are now used not only to investigate survival and disease-free 
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survival differences between treatments but also to investigate differences in their late effects and 
toxicity, and need to be larger than before, in order to detect smaller differences in outcomes 
between increasingly complex treatment regimens. 
 
In the following examples the typical survival rates for the early 1970s and late 1980s were 
obtained from unpublished graphs using data from the series of Medical Research Council UKALL 
trials [personal communication with Dr S Richards] and the estimates of sample sizes number of 
events required are taken from Machin and Campbell (1987). Details of the trials are given in 
Appendix I.  
 
• For patients recruited in the early 1970s, when the survival rate at ten years was typically 
40%, in order to detect a 5% difference between two randomized treatments at the 5% 
level with a two-sided test with 80% power, 832 patients are required for each treatment 
arm, i.e. for a two-arm trial 1664 patients must be recruited. (Larger differences require a 
far smaller number of patients, for example to detect a 15% difference with the same 
significance level and power, only 89 patients are needed in each arm, i.e. a total of 178 for 
a two-arm randomization.)  
 
• In contrast, the ten year survival rate for patients recruited in the late 1980s was typically 
70%. This requires far smaller numbers of patients to be recruited. Using the same 
significance level and power, 343 per treatment arm are required (a total of 686 for a two-
arm randomization) in order to detect a 5% difference between the two treatments and 29 
per treatment arm (a total of 58) in order to detect a 15% difference. At first glance it may 
seem as if the targets for more recent trials should be easily achievable. However, the event 
rate for patients in these more recent trials is very low and the differences in outcome to be 
detected are very small. The number of events needed to detect a 5% difference is 343 in 
each treatment arm (a total of 686 in total for a two-arm randomization). In order to obtain 
a sufficient number of events far greater numbers of patients are needed.  
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The data on number of randomized patients in Section 1.4 indicates how rarely these targets were, 
and are, achieved. Therefore individual randomized trials are still rarely big enough to provide 
reliable evidence on some important outcomes on their own. Sufficiently large-scale randomized 
evidence might only be possible through systematic reviews. For these to be valid, as high a 
proportion of relevant trials as possible must be included [Clarke and Stewart (1994)], and this 
thesis is based on the trials that have been identified for a systematic review of treatments for 
childhood acute lymphoblastic leukaemia. 
 
1.3  Current project 
Trial identification can be the most difficult and time-consuming part of systematic reviews. It 
needs to overcome recognised biases that lead to some trials being published quickly and/or more 
than once while others never reach publication. 
 
The Cancer Overviews Group at the Clinical Trial Service Unit, University of Oxford has 
considerable experience in the identification of randomized trials [EBCTCG (1990)]. In the early 
1990s it began a collaborative overview of individual patient data from randomized trials of any 
treatment of childhood leukaemia [Childhood ALL Collaborative Group (1996)]. 
 
The methods used for trial identification included computer-aided literature searches (on-line and 
using CD-ROM); hand-searching of journals and of abstract books from major meetings; searching 
trial registers; and contacting known trialists who might have conducted, or know of, further trials. 
 
A register was compiled of randomized trials, begun before 1 January 1988 and therefore eligible 
for the collaborative overview, and of reports of these trials published before 1 January 2000. 
 
1.4  A description of some of the main variables 
A total of 149 randomized trials and 257 reports of these have been identified (some of which 
reported more than one trial or randomization). The 149 trials include a total of 243 separate 
randomizations, since some trials involved more than one randomization (for example, for 
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induction and maintenance treatments). Ninety trials (60%) contained one randomization, 35 trials 
contained two, 19 trials three, two trials contained 4 and 5 and one contained ten randomizations. 
Of the 257 reports, 195 were journal articles, 51 meeting abstracts and 11 book chapters. 
 
In many of the analyses presented here it will be the randomization rather than the trial which is 
the object of interest. For example, a trial may consist of two randomizations, each addressing a 
completely separate treatment question; the first between two induction treatments and the second 
between two different lengths of maintenance treatment. Throughout this report the terms ‘trial’ 
and ‘randomization’ will be used in this sense. 
 
Unfortunately for some randomizations even the most basic information is missing. For example 
the Cancer Overviews Group may have identified a randomization but not know either when it took 
place or the number of patients it accrued. Although individual patient data is requested from the 
trialists, which could provide such information, there is no guarantee that this will be provided in 
all cases.  
 
Number of patients  
Data on the number of randomized patients were available for 212 of the 243 randomizations 
(Figure 1.1). The median number of patients accrued was 126. Less than 200 patients were accrued 
by 134 of the 212 randomizations (63%). Of these, 41 (19% of the 212) accrued fewer than 50 
patients. Five randomizations included more than 1000 patients. The randomization with the most 
patients was the CCG-105 trial, which randomized 1606 children into four arms: intensified 
induction and consolidation, delayed intensification, both or neither. (The trial also contained a 
two-way randomization between cranial irradiation and methotrexate.) [Tubergen et al (1993b)] 
 
Geographic location  
Data are available on whether a trial is single- or multi-centre for 147 of the 149 trials. Of these 
123 (84%) are multi-centre and 24 single-centre.  
 
Information is available on whether a trial took place in one country or was international  
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for 129 of the 149 trials. Of these 129, 82 (64%) were single-country trials and 40 (31%) involved 
a few adjacent countries. For example those run by the BFM Children’s Group (based in Germany) 
involved West Germany and Austria and trials coordinated by GATLA included Argentina, Brazil, 
Cuba and Uruguay.  Only 7 trials (5%) recruited patients in different continents. For example, the 
USA Cancer and Leukemia Group B (CALGB) have run trials collaborating with Switzerland, 
Finland and South Africa. 
 
 
 
Figure1.1 Randomizations: number of patients accrued  
31 randomizations do not contribute to the figure because the number of patients accrued is currently not 
available. 
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Date of start of trial 
As mentioned above, trials beginning in or after 1988 were excluded from the list that forms the 
basis of this report. Data on the date the trial started are available for 139 of the 149 trials (Figure 
1.2). The earliest identified randomized trial in childhood acute lymphoblastic leukaemia began in 
1962. This was an immunotherapy trial run by the French Institut de Cancerologie et 
d’Immunogenetique (INSERM) [Mathe et al (1977a)]. There has been a steady increase in the 
number of new trials starting since then. The year 1979 appears to have been particularly 
productive, with 18 of the 139 (13%) trials with known start date beginning then. The five 
randomizations with the largest number of patients began in 1978, 1981, 1983 (2 trials) and 1985. 
 
 
Figure 1.2 Trials: year started 
10 randomized trials do not contribute to the figure because the year they started is currently not available. 
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Duration of accrual period 
Data are available on the length of time that the randomization was open for 219 of the 243 
randomizations (Figure 1.3). The median length of this period was 2 years and 7 months. 18 of the 
219 randomizations (8%) were open for more than 5 years. 
 
 
 
Figure 1.3 Randomizations: length of accrual period 
24 randomizations do not contribute to the figure because one or both of their start and close date are 
currently not available. 
  
 
Method of randomization 
This was rarely reported in these trials in childhood leukaemia, as has been found in studies in 
other areas of health care [Juni et al (2001)]. Out of these 243 randomizations, information on the 
method of randomization was available in the reports for only 47. Of these, six randomizations 
were done via a central computer, 24 via notification to a central office and 17 using sealed 
envelopes in the individual centres.  
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Frequency of publication 
Figure 1.4 shows the distribution of frequency of publication for the randomizations.  Publications 
have not been found for 26 (11%), and these are assumed to be unpublished. Most randomizations 
have been published more than once, although the most frequent number of publications per 
randomization is one [84 (35%) of 243 randomizations]. The five randomizations with the largest 
number of patients were published three, four, five and six (2 trials) times. 
 
Figure 1.4 Randomizations: number of publications 
 
 
The most frequently published randomization (13 reportings) was SJCRH X, a single 
randomization equivalence trial, conducted by the St Jude Children’s Research Hospital in 
Memphis, USA [Abromowitch et al (1988a, b), Bowman et al (1984), Mulhern et al (1991), Ochs 
et al (1983), Ochs et al (1986), Ochs et al (1989), Ochs et al (1991a), Pui et al (1985), Pui et al 
(1989), Pui et al (1991), Pui et al (1992), Williams et al (1991)]. This was a randomization 
between two first-line consolidation and maintenance treatments. The second treatment group 
included cranial irradiation during consolidation and a more complex maintenance regimen than 
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the first. The trial was open between May 1979 and January 1984, and accrued 309 patients. It was 
funded with both Government and charity money. The randomization procedure was done using a 
central computer and a minimisation of imbalance design. The trial was open to standard risk 
children and was a single-centre study. 
 
The first report for the trial was published in December 1983 [Ochs et al (1983)], and the first 
report giving results appeared in March 1984 [Bowman et al (1984)]. The thirteenth reporting was 
in February 1992 [Pui et al (1992)]. All reports were published in the English language. Eight of 
the articles reported results. Six of these reported on the main questions in the study, by comparing 
the relapse rates and in particular the CNS (central nervous system) relapse rates for the two 
randomized treatment groups. The other two articles dealt with other outcomes only: one compared 
the testicular relapse rates for the two groups, and the other the incidence of acute myeloid 
leukaemia as a secondary disease. 
 
1.5  Conclusion 
This introductory chapter gives a historical and descriptive account of randomized trials in 
childhood leukaemia since the earliest such studies in the 1960s. It focuses on trials that began 
before 1988 in order to make use of the register of trials that was developed for a systematic review 
of treatments for acute lymphoblastic leukaemia in children. Many randomized trials will have 
started since then, [Childhood ALL Collaborative Group (2001)], but the comprehensive searching 
done for this existing register has not yet been done for more recent trials. The number of 
randomized trials starting each year has increased from one or two in the 1960s to an annual 
average of five or six in the 1980s. However trials remained relatively small, with more than half of 
all randomizations accruing less than 200 patients, and only five having more than 1000. Most 
trials were published more than once, typically in journals. Unfortunately, as has been found with 
other series of trials, the reporting of the methods of these randomized trials in leukaemia could 
have been better. 
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Since many of the trials of treatments for childhood leukaemia are small, systematic reviews are 
essential in order to obtain sufficient numbers of patients to produce reliable results. In order to be 
unbiased, these should include patients from all eligible randomizations if possible. The primary 
aims of the project investigating this series of randomized trials are to assess the extent of 
searching needed to identify trials and to discover which factors are leading to publication bias in 
the form of delayed publication or to a randomization remaining unpublished, since this could, in 
turn, bias the findings of the systematic review.  
 
This brief introduction highlights some important factors relating to this: the longevity of 
randomized trial research in this disease, the fact that most of these trials have been relatively small 
and conducted within single countries, and that many of them have been published once only. 
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2 AIMS 
 
2.1  Introduction 
This chapter begins by stating the main aims of this thesis. Various types of bias in the reporting of 
clinical trials are then described. It then sets out the main questions asked in this study. Finally a 
literature search undertaken to identify similar research in other areas is described. 
 
2.2 Main aim of this thesis 
 
As was stated in Section 1.5, since many of the trials of treatments for childhood leukaemia are 
small, systematic reviews and meta-analyses are essential in order to obtain sufficient numbers of 
patients to produce reliable results. Ideally all eligible randomizations should be identified and 
included. However some are more quickly and more widely published, and hence more easily 
identified than others. Publication bias in the form of non-publication or delayed publication could 
therefore lead to the results of a systematic review being based on a biased sample of randomized 
trials.  
 
“It is of the utmost importance that as high a proportion as possible of all relevant trials are 
identified, regardless of their results or publication status. Any trials that are missing should not be 
too numerous or unrepresentative to affect the results of the meta-analysis in any important way.” 
[Stewart and Clarke (1995)] 
 
The main aim of the thesis is therefore to identify, and where possible, to quantify potential biases 
in types of trial identified and included in meta-analyses and to get some idea of the effect of this 
bias. 
 
 
2.3  Bias in the reporting of clinical trials 
In the introduction to the paper ‘Modelling publication bias in meta-analysis: a review’, Sutton et al 
(2000) describe various types of bias that can cause problems when conducting meta-analyses. 
Apart from publication bias, where research with statistically significant results is more likely to be 
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submitted and published than that with ‘null’ or non-significant results, four other types of bias are 
outlined:  
• Pipeline bias – results with smaller p-values associated with them are likely to be published 
faster than others 
• Subject reporting bias – only results of a trial with the smallest p-values are reported 
• Duplication reporting bias – authors deliberately report the same results more than once 
• Language bias – for example where only papers written in the English language are 
searched for trials for inclusion. 
The first of these, ‘pipeline bias’, is the primary focus of this thesis but the importance of trial 
characteristics other than the p-values associated with results is also investigated.     
 
 2.4  Questions to be asked 
Methods currently used for trial identification are as follows: 
 
• Hand-searching abstract books from conferences worldwide for relevant trials 
• Computer-aided literature searching, on-line and using CD-ROM 
• Searching trial registers 
• Contacting trialists and asking whether they know of any other randomized trials apart 
from those already identified. This is especially useful for identifying unpublished trials 
 
Which factors affect how long the searching process should continue in order to identify all trials 
through publication? 
The sooner a trial is reported, the sooner it can be identified by those conducting meta-analyses, 
and the sooner its results can be incorporated into the meta-analysis. To discover why some trials 
take longer to get published than others, it is necessary to investigate which factors (or trial 
characteristics) affect the following three time periods: 
• Time from close of randomization to date of submission/receipt for publication (an 
indication of how important the trialists consider their findings) 
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• Time from date of receipt/submission to date of publication (an indication of how 
important the journal editors consider the trial) 
• Time from close of trial to date of publication (the sum of the above two time periods, and 
for which there are much more data available than for either of the above alone) 
 
Only a small proportion of the journals (and no meeting papers or books) state date of 
submission/receipt. Some also give date of acceptance of the article. However the date of close of 
randomization and date of publication are known in almost all cases. Time from date of 
submission/receipt to date of publication is more useful than time from date of acceptance to date 
of publication because the time taken for the editor’s decision to be made is included in the former.  
 
Analyses of how various trial characteristics affect the above three time periods provide the basis 
of this thesis. 
 
How wide does the search need to be?  
The more widely a trial is published the more likely it is to be identified by those conducting meta-
analyses, and its results included. Therefore the other major aspect to investigate is why some trials 
are published many times, some once only and others not at all.  Also how do trials published in the 
most prestigious journals differ from the other trials? The latter is important since trials reported in 
such journals are more easily located and hence more likely to be included in systematic reviews. 
    
This means looking at the following questions: 
 
• Which trial characteristics affect the number of articles in which a randomization is 
mentioned, or whether a randomization is published more than the median number of 
times?  
• Which trial characteristics affect the type of journal in which a randomization appears?  
• How do the unpublished randomizations differ from those published? 
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Some of these questions will be discussed in Chapters 15 and 16 and it is intended that they should 
be investigated fully at a later date. 
 
2.5  Literature search 
A brief literature search was undertaken. This deals only with the main topic of this thesis; factors 
affecting length of time to publication for a randomization, as opposed to those affecting either the 
number of times published or causing it to remain unpublished.  
 
The Cochrane Methodology Register (in Issue 3, year 2002 of the Cochrane Library) was searched 
on 7 September 2002. It contained a total of 3866 references at that time. The keywords searched 
for were ‘publication’ and ‘delay’, such that both were required. This produced a list of 14 
references with abstracts. All 14 were read on screen and of these seven were found to be relevant. 
Each of these seven abstracts mentions a time period to do with publication as a response variable 
and various trial characteristics, typically the p-values associated with results, which were 
investigated to see if they had an effect on the time period. Full papers were obtained where 
possible. This summary of other similar research is not an attempt at a systematic review of the 
literature, merely an attempt to put the findings from this project in the context of other work in the 
field.  
 
Chapter 13 contains a comparison of these studies with the work in this thesis and Appendix XIX 
summarises the studies identified in tabular form. A brief description is given for each study, 
including the time period response variable, the characteristics of the trials investigated and a 
summary of the findings. 
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3  DATA AND DATA MANAGEMENT 
 
3.1  Introduction 
This chapter begins by describing the data used; the set of randomized clinical trials and the 
publications relating to them. This is followed by sections on how the data were collected and the 
structure of the data. The data management process is described next and the algorithm for the 
main data management program is given. A list of the trial characteristics collected is given, as are 
the inclusion/exclusion criteria, and the checking procedure used. There are also sections focusing 
on new trials found and on why some records were deleted from the database. 
 
3.2  Data 
The closed set of trials used is as follows: all properly randomized trials beginning before 1 
January 19881 and all articles referring to these trials published before 1 January 2000, as identified 
by the Cancer Overviews Group at the Clinical Trial Service Unit, University of Oxford. Appendix 
I summarises the trials, randomizations and articles used to compile the data. For some  
randomizations additional information was obtained from the trial protocol. These are listed in 
Appendix II. Trials still open to randomization would have been eligible for inclusion, as well as 
those that have closed. However, although date of closure is missing for 20 of the 243 
randomizations, it is believed that all had closed by the cut-off date for analysis, 28/11/00. 
 
All properly randomized trials in childhood acute lymphoblastic leukaemia (ALL) were eligible for 
inclusion in this thesis. Randomizations, for example, between treatments for relapsed patients, and 
between antibiotic treatments were not included in the 1992 Collaborative Overview, but are 
included here. 
 
                                                          
1
 This was the set of trials included in the Second International Collaborative Workshop on Childhood ALL 
Studies at the end of 1992. 
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3.3  Starting point for data collection 
The starting point for data collection is the trial summary. For each randomization they identify, the 
Cancer Overviews Group produce a trial summary, which provides the following information: 
• name and reference code of the group running the trial 
• name and reference code of the randomization 
• name and reference code of the trial that the randomization is linked to (In some cases this 
will be the same as the randomization reference code.) 
• type of trial (for example whether the randomization is between different lengths of 
treatment or between different types of therapy) 
• entry dates (start and close date of the randomization period) 
• total number of patients randomized 
• status code (‘ok’ indicates that the randomization procedure used is valid, the other three 
codes ‘nr’, ‘bin’, or ‘dup’ indicate that it is not. Further explanation will be given in 
Section 3.6.) 
• whether the results have been published and, if so, whether as an abstract or in full 
• eligibility criteria relating to age, white blood count, other disease details, risk group, prior 
treatment etc. 
• treatment arms (brief outline) 
• which are the main questions (if there are several treatment arms, which comparisons the 
trialists consider most important) 
• list of publications reporting this randomization 
• contact details for the trialists 
• treatment arms (in more detail) 
  
As mentioned above, the trial summaries list the publications for each randomization.  Each article 
is important, as the goal is not to discover in which article a randomization was first identified, but 
rather all possible articles in which it could have been found. All the listed articles were read, all 
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details on trial listings (except the last two) were checked and additional information was filled in 
on a coding sheet. It was especially important to check the entry dates for the randomizations, since 
the start date determined whether a randomization was eligible for inclusion. A single article might 
report several trials, each consisting of several randomizations. Coding sheets were completed for 
all reportings of all eligible randomizations.  
 
The data from the coding sheets were then entered into an ACCESS database using codes rather 
than descriptive character fields wherever possible, so that they were in a suitable format for 
analysis. For each categorical variable, a new code was added whenever necessary without too 
much consideration at that stage. The categories were combined more meaningfully, once there 
was a feel for the data.  
 
3.4  Structure of the data 
The ACCESS database consists of four tables. Three contain roughly the same information as each 
of the coding sheets; a table for variables to do with the article itself, another for variables specific 
to the trial and a third for those to do with the randomization. The fourth table links the article with 
the trials it reports. 
 
In the publications table, each article was assigned a unique reference number in the order the data 
were entered into the database from the coding sheet.  
 
In the trials table, each trial also has a unique identifier – this is the number assigned to the trial by 
the Cancer Overviews Group. The first three digits indicate the group of trialists who conducted the 
trial, and the fourth and fifth specify the particular trial. 
 
The randomizations table differs importantly from the tables for publications and trials. Since each 
trial may contain more than one randomization, and each publication may report more than one 
trial, there is a record for each reporting of each randomization, i.e. multiple records for each 
randomization. Again each record has its own unique identifier, assigned by the computer in order 
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of entry to the database. The randomization code (assigned by the Cancer Overviews Group) and 
the code of the trial to which it belongs are also stored. From here onwards these randomization 
records, each obtained from a different article, are referred to as ‘publication records’. 
 
In addition a ‘definitive record’ for each randomization was created. This contains the ‘best’ data 
for each field taken from looking at all reportings together with information from other sources 
where available such as raw data, the Cancer Overviews Group trial listings, trial protocols and 
Clinprot trial summaries. Clinprot is an electronic protocol database, a register of trials. The trials 
for which there are further data either from Clinprot or from the full trial protocol are listed in 
Appendix II. For randomizations published several times or for which a protocol is available, the 
definitive record is likely to be complete. However, for others, particularly those remaining 
unpublished, important information may be missing.  
 
By definition the definitive record only contains data unchanging over time, for example size of 
trial, start and close dates for entry. In contrast, details such as results reported are specific to a 
publication record. For some analyses it is sufficient to use just the definitive records. For others it 
is necessary to look at all reportings, i.e. the set of publication records. Also, the number of 
reportings of each randomization must be attached to the definitive record for that randomization.   
 
An ACCESS ‘query’ was compiled to pull together from the three tables all fields that might be 
useful in the analyses. At this stage descriptive fields such as name of journal and authors’ details 
were omitted. The data in the query were then read in as a SAS dataset. SAS was used for the 
majority of the data management as well as for the analysis.  
 
Each record in these data is a randomization record, either a publication record relating to an 
individual randomization from a particular article or a randomization’s definitive record. 
Information about its trial has been appended, as has information about the article, if it is a 
publication record. If the record is a definitive record, this is indicated. 
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The algorithm for the main data management program, JMAIN.SAS, is given as Appendix III. This 
performs the following tasks: 
• Reads in the data from the ASCII file produced from the ACCESS query. 
• Incorporates special records from a small dataset. These were created to replace individual 
records, which have publication dates that tie. The reasons for this will be discussed in 
Section 5.3.1.   
• Excludes records where the randomization and/or the article are ineligible. See Section 3.6. 
• Creates new variables for the purpose of combining categories of some variables more 
meaningfully. This will be discussed further in Sections 3.14 and 4.2.  
• Date fields are character fields of the form DD/MM/YYYY. For each date field, creates a 
numerical SAS date variable for use in arithmetic operations, and also a discrete ‘year’ 
variable for use in some graphs. 
• Converts numerical unknowns such as ‘999’ into missing values. 
• For dichotomous yes/no variables where blank and ‘no’ are essentially the same, converts 
blanks to ‘no’.  
• Splits the records into ‘publication records’ and ‘definitive records’ and creates a new 
permanent dataset for each. 
• Totals the number of publication records for each randomization and attaches this 
information to the definitive record for that randomization. 
• Removes dates too inaccurate to be useful in the analyses, and positively misleading. These 
have either year or year and decade unknown and should be replaced by missing values. 
They cannot be removed earlier in the process since estimated start of randomization and 
date of publication are used in deciding whether the randomization/publication satisfies the 
date inclusion criteria. 
• Calculates new variables from existing ones such as duration of randomization period = 
close date – start date. This will be discussed further in Section 4.2. 
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• Creates a new ‘merged’ dataset using data from the ‘definitive records’ dataset for 
unchanging variables such as size of trial, start date etc. and data from the ‘publications’ 
dataset for those that vary between reportings such as publication date or details of the 
results reported. This is the dataset used for the majority of the analyses.   
• Attaches an ‘order of publication number’ to each record. For each randomization this 
specifies the order in which the articles were published. Records which contain results 
have an additional order number assigned, so that it is also possible to know, for each 
randomization, the first article to publish the results, the second and so on. The merged 
datasets with publication ordering are kept as two permanent datasets, for all records and 
all records containing results respectively. 
 
3.5  Trial characteristics  
Appendix IV contains two listings of the trial characteristics collected. The first is in alphabetical 
order and gives the variable’s (SAS) name and meaning, its primary use being as a look-up table. 
The second lists the variables in logical order, with the original categories tidied up and made 
meaningful in the data management program. As well as the description of the variable, its SAS 
name as used in the analyses is given, as are its type (dichotomous/categorical/continuous), 
whether it is in the ‘publication records’ dataset, the ‘definitive records’ dataset or both, and the 
number and percentage of missing values. For continuous explanatory variables the mean, standard 
deviation and range are given as Appendix V. 
 
3.6  Exclusion criteria for randomizations 
• Randomization opened on or after 1 January 1988. 
• Those believed by the Cancer Overviews Group to be duplicates. These are marked status 
‘dup’ on the trial summaries. 
• Those allocated status ’bin’ by Cancer Overviews Group. For example studies identified 
which did not accrue any patients. 
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• Those believed by the Cancer Overviews Group not to have been properly randomized, i.e. 
where the treatment allocation could have been predicted. These have status ’nr’ and 
include cases where date of birth has been used to allocate treatment. This is not a valid 
randomization technique since the allocated treatment can be predicted in advance. 
• Where the randomization is known to have been intended to be exclusively for adult 
patients. Publications relating to these have not been sought systematically by the Cancer 
Overviews Group. However some were found by chance and include older paediatric 
patients whose data were used in the 1992 overview. Different groups use different cut-off 
ages for inclusion in paediatric trials, for example Medical Research Council trials in the 
UK use 15 years but many US trials use 21.  
 
3.7  New randomizations identified 
Identification of new randomizations was not an aim of this project. It was assumed that the Cancer 
Overviews Group’s thorough procedures would have already done this. However during the 
process of data collection, 23 (what were thought to be) new randomizations were identified. These 
were checked with the Cancer Overviews Group. Subsequently six were discovered to be 
duplicates of randomizations already found and seven had already been found but were rejected 
because they were either not randomized or not properly randomized. This left nine genuine new 
randomizations. Both publication records and definitive records for these were added to the 
database. The randomization IDs assigned are for the purpose of this project only and numbered in 
reverse, starting at 99 for each trial group. For example there are four new randomizations for trial 
group 14, namely 1499, 1498, 1497 and 1496. Details of the new randomizations have been passed 
to the Cancer Overviews Group for processing and inclusion in future meta-analyses. 
 
Brief descriptions of the genuine new randomizations identified now follow. Four of the new 
randomizations found are from trials conducted by Cancer and Leukaemia Group B (CALGB), 
USA (group 14), two from the Children’s Cancer Group (CCG), USA (group 16) and three from 
GATLA, Argentina (group 21). 
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• 1499 is one of three randomizations belonging to trial 1402 (ALGB 6601). The other two 
had already been identified in the usual way. This randomization began in 1966 and was 
open to patients on a particular arm of another randomization (1403). It was between 
continuing maintenance with twice weekly methotrexate after 8 months versus stopping 
treatment. There are two publications, a journal article, publication 52 [Holland and 
Glidewell (1972a)] which mentions 8 other randomizations, and a book chapter, 
publication 53 [Holland (1978)]. The former states that 8 out of the 43 patients on Regimen 
C (Treatment 3) were allocated to continue the maintenance treatment and that these 
numbers were too small to form any conclusions.   
 
• 1498 is also mentioned in publication 53 [Holland (1978)]. This is one of four 
randomizations from trial 1404 (ALGB 6801). Again the other randomizations had been 
identified already. The entry period began in 1973. This was a maintenance duration 
randomization, open to patients on the best arm from randomization 1406 and still in 
remission at 5 years. 
 
• 1497 is one of a pair of randomizations from trial 1428 (ALGB). The other randomization 
had already been identified. The entry period was during the 1960s and 19 patients, who 
had relapsed but were still in second remission, were randomized between two 
maintenance treatments: subcutaneous cytosine arabinoside + intramuscular methyl both 
weekly versus oral 6-mercaptopurine + oral methotrexate single dose. This was reported as 
a journal article, publication 71 [Jones et al (1972)], which states that the maintenance 
treatment received was not a determinant of length of remission. The stronger treatment 
fared worse than the less intensive.  
 
• 1496 is one of a pair of randomizations from trial 1429 (CALGB 6611). The other had 
already been identified. The entry period of this 3-arm maintenance randomization began 
in 1966. The arms were daunarubicin weekly versus oral mercaptopurine 90 mg/m2/day + 
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intramuscular methotrexate 15 mg/m2/wk versus subcutaneous arabinoside 30 mg/m2/wk  + 
intramuscular methylglyoxal bis guanylhydrazone 350 mg/m2/wk. This is mentioned in the 
journal article, publication 288 [Jones et al (1971)]. 
 
• 1699 is one of two randomizations from trial 1645 (ALBG 6601). Again the other had 
already been found. It was open between 1963 and 1967 and accrued 165 patients. This 
was a maintenance randomization of cyclic versus sequential chemotherapy. Its only 
mention is as a meeting abstract, publication 107 [Nesbit et al (1973)]. It is worth noting 
that this was the main randomization of the trial. The randomization that was found in the 
routine way was for maintenance duration, to stop or continue after 2½ years’ treatment, 
and it accrued only 15 patients. 
 
• 1698 is one of three randomizations from trial 1612 (CCG-141). It opened in 1975 and 
randomized between two CNS treatments, 24Gy cranial irradiation + intrathecal 
methotrexate versus intrathecal methotrexate. It is mentioned in a journal article, 
publication 97 [Bleyer et al (1983a)]. 
 
One journal article, publication 284 [Sackmann-Muriel et al (1998)] provided the means to 
identify the following three randomizations. The new randomizations described so far are all 
linked to known trials. However the following had not been found previously: 
 
• 2199 (Protocol 11-ALL-67) is a single-randomization trial which was open between 
November 1967 and September 1970. It compared two maintenance treatments; 
methotrexate 30mg/m2 versus 15mg/m2 twice weekly, both arms also receiving 6-
mercaptopurine + vincristine + prednisolone pulses every 6 months with a total duration of 
treatment of 5 years. 
 
• The other two randomizations 2198 and 2197, identified in this article belong to the same 
trial, Protocol 1-ALL-76. Both were open between January 1976 and December 1978 and 
accrued 336 patients. 2198 was a maintenance randomization between 
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vincristine/prednisolone alternating with cytarabine-cyclophosphamide and 
vincristine/prednisolone alone. 2197 randomized patients between immunoestimation with 
levamisole versus not, during continuation treatment.   
 
3.8  Comparing trial characteristics between randomized and non-randomized trials 
Data on non-randomized studies and their reportings have not been collected, although some non-
randomized studies were found unintentionally by the Cancer Overviews Group while searching 
for randomized studies. These are not included in this thesis. However in some studies, non-
randomized patients were treated alongside randomized patients, and mentioned in papers, which 
describe the randomized group, for example, the non-randomized patients in UKALL I who were 
treated at centres giving CNS prophylaxis to all or none of their patients, as opposed to 
randomizing between the two treatments. See publications 5 [Medical Research Council (1973)] 
and 1 [Medical Research Council (1975)]. A code to indicate this is attached to the randomization 
record so that this information could be retrieved easily. The data from the non-randomized 
contingent are not used for this thesis, but have been typed separately into the ‘notes’ section of the 
record for the randomization to which it is linked. Therefore it would be possible to pull out 
randomizations with a non-randomized contingent and compare, for example, the benefits of CNS 
treatment for those from the randomized group who received it with those who received it but 
where randomization did not take place.  Also it would be possible to compare CNS treatment 
versus control in the randomized patients with CNS treatment versus the control group of the non-
randomized patients. Using only the non-randomized patients treated alongside those who were 
randomized into the study provides a closed and well-defined set. 
 
3.9  Exclusion criteria for publications 
• Date of publication on or after 1 January 2000. This date was chosen to create a closed set 
of publications. It is likely that most articles relating to trials that opened before 1 January 
1988 would have been published by this date. For some articles the date of publication is 
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incomplete, for example frequently the journal reference includes the year of publication 
but gives no mention of the month or day. If, however, the date of publication is known to 
be during the 1990s or known to be post millennium, it is clear whether or not the article 
should be included in data used for this thesis. 
 
• Review articles summarising several trials. To be excluded the publication has to satisfy all 
the following: (i) reports trials conducted by more than one group of trialists (ii) not written 
by a Working Party member (iii) reports summaries of past trials only, with no new results. 
The reason for this is that the aim is to include new information. Therefore a report of 
results from analysis of updated data from a randomization previously reported is eligible, 
but re-reporting of unchanged results is not. 
 
• Reports of meta-analyses, whether or not new information is reported, for both published 
and unpublished trials. 
 
• Draft papers, since these were only available for one trial group, the Medical Research 
Council, UK. 
 
• Unpublished articles, since these have not been collected systematically. 
 
• Clinprot is an online electronic database of records for clinical trial protocols, maintained 
by the National Cancer Institute in the USA. It was searched for randomized trials of 
treatments for leukaemia in 1989. This, alongside the full trial protocol, where available, 
can be used to check trial characteristics. However, neither Clinprot, nor the full trial 
protocol, count as publications in themselves. 
 
• Articles which do not include any of the following: that a randomized allocation was used, 
any details of the treatment arms, information on outcome by treatment. An example of an 
article excluded for this reason is publication 208, the conference abstract Rivera et al 
(1989).  
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3.10  Duplicate publications 
Attempts to publish a paper are generally sequential in that it is submitted to a journal and, if 
rejected, then submitted to a second. An example of where this procedure appears not to have been 
followed, and a pair of duplicate publications resulted, is the article Comparison of Intermittent or 
Continuous Methotrexate Plus 6-Mercaptopurine in Regimens for Standard-Risk Acute 
Lymphoblastic Leukemia in Childhood (JCCLSG-S811) by The Japanese Children's Cancer and 
Leukemia Study Group, which was published in Cancer, publication 161 [Koizumi et al (1988a)] 
and also in Medical and Pediatric Oncology, publication 163 [Koizumi et al (1988b)]. Both are 
included in the data since both are a possible source from which a randomization can be identified. 
 
3.11  What counts as a ‘publication’ of a randomization? 
An article may report a randomization in detail but mention several others briefly. The following 
are examples of situations where a very brief mention warrants representation as a publication 
record, provided that it is clear that randomization took place: 
• This is the first mention of a randomization. For example, if the article reports the results 
of a first randomization and mentions that the trial also contains a second, and the latter is 
not cited at the end of the paper. 
• The design of the next trial is mentioned, typically in the discussion.  
• Previous trials, which have never been reported, are mentioned. 
 
Some examples 
An interesting example is publication 37 [Riehm et al (1984)]. In this article the discussion 
between several collaborators was reported verbatim. The following exchange is sufficient to 
establish the existence of a randomization: 
SIMONE: How long should you give maintenance therapy?  
RIEHM: As Dr Pinkel pointed out, there may be differences regarding high risk patients. 
We have a randomized study designed to answer that question, but at this point I would 
speculate that 1½ years is enough. For low-risk patients, I’m not sure.   
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This was the first mention of the maintenance duration randomization (1204) of trial ALL-BFM-81 
(1204).  
 
Publication 54 [Rowland et al (1984)] is an example of where it is easy to decide which 
randomizations should have a publication record.  It is entitled ‘Effects on Different Forms of 
Central Nervous System Prophylaxis on Neuropsychologic Function in Childhood Leukaemia’. In 
the ‘patients and methods’ section it states clearly the four CNS prophylaxis randomizations 
reported in the paper, and that there were also randomized comparisons between induction and 
between maintenance therapies in the trials, which have already been published. Therefore 
publication records were created for the four CNS randomizations only. These are 1405 from the 
ALGB 6801 trial (1404), 1408 from the CLB 7111 trial (1407), 1414 from the CLB7411 trial 
(1414) and 1416 the sole randomization of the CLB7611 trial (1416). 
 
Not all articles are as clear. Publication 46 [Riehm et al (1987)], discusses the use of risk factors for 
prognosis in five BFM studies since 1970. The following sentence suggests three randomizations. 
In fact there are two only, 1204 for maintenance duration, and 1205 for CNS prophylaxis 
treatments, the latter for standard risk patients only. “Randomizations for preventative CNS 
irradiation in SR patients, duration of therapy, and the introduction of a more intensive therapy in 
HR patients have been the rationals and questions in study ALL-BFM 81.” 
 
Publication 69 [Rausen et al (1979)] reports the three randomizations (1423, 1424 and 1425) of the 
Group 14 trial: CLB 6911 4-way (1423). In the discussion, reference is made to the induction 
randomization (1407) of the CLB 7111 trial. However a publication record was not created, since 
this is not the first mention, and the word ‘randomization’ is not used in connection with it. Instead 
it is stated that: ‘An extension of these observations led to the evaluation of L-asparaginase therapy 
in combination in newly diagnosed children with acute lymphocytic leukemia by the Cancer and 
Leukemia Group B (Protocol 7111).’ There is also a reference to a relapse trial, ALGB, trial name 
unknown, (1428), but again this had been previously reported and so no publication record was 
created. 
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It can be difficult to know whether previous trials have been reported or not. Publications 18 [Peto 
et al (1986)] and 19 [Eden et al (1987)] are very similar. Both compare the Group 27 trial UKALL 
VIII (2727) with previous trials UKALL II –VII.  However, the former states that UKALL IV, V 
and VI were previously unpublished. Therefore a publication record was created for each 
randomization mentioned in the article. However, the latter, a book publication, does not mention 
this and, so, publication records for the previous randomizations have not been created from this 
second article.     
 
However, enough information must be given to decide that there are at least two treatment arms, 
and that a randomization process is used. An example of where insufficient information is given is 
publication 55 [Holland and Glidewell (1972b)], which reports three of the randomizations (1404, 
1405 and 1406) from the Group 14 ALGB 6801 trial (1404). Publication records were created for 
these. It also mentions a later trial CLB 7111 (1407), stating that ‘Protocol 7111 ... contains 
therapeutic programs incorporating the best regimens shown in Figures … and a modification of 
6601 with intensive parenteral courses of methotrexate and of 6-mercaptopurine together with 
vincristine and prednisolone reinforcement dosing. The early results are superior to our prior 
regimens.’ Since no indication is given that trial CLB 7111 is randomized and neither the number 
of arms nor what they consist of is clear, no publication records were created for any of the three 
randomizations belonging to trial CLB 7111.  
 
Some examples of publication records and articles deleted from the ACCESS tables will be given 
in Section 3.12. 
 
Since one criterion for trial inclusion is that the entry period must start before 1 January 1988, 
some of the later papers report both eligible and ineligible trials. An example of this is publication 
283 [Richards et al (1998)]. This describes combined results from two Medical Research Council 
childhood ALL randomized trials, UKALL X which is eligible and UKALL XI which is not. A 
publication record was made for UKALL X (randomization 2730) only and not for UKALL XI 
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(randomizations 2932, 2733 and 2734). Currently there are ineligible randomizations in the 
ACCESS database – usually references to future trials. These are not included in any analyses.   
  
3.12  Examples and notes on which randomizations are included from an article and have a 
publication record in the randomizations table in ACCESS and which do not 
Why have some records been deleted from the randomizations table in ACCESS? 
This occurs with Group 27 (Medical Research Council, UK), the first group dealt with. Some 
randomizations were mentioned very briefly in an article, but not reported as such. If the reference 
was to a previous trial, a publication record has not been created, but if to a future trial, and 
therefore probably a first mention, then one has. 
 
An example of this is publication 10 [Chessells et al (1992a)]. Primarily this paper deals with trial 
UKALL X (2730), which has a single randomization between four intensification treatments. 
However a previous trial, UKALL VIII (2727), consisting of an induction randomization (2727) 
and a maintenance duration randomization (2728) is mentioned also. Initially these were entered on 
computer as records 383 and 384 in the randomizations table but they have subsequently been 
deleted. 
 
Publication 1 [Medical Research council (1975)] reports the CNS prophylaxis randomization 
(2701) of the UKALL I trial (2701), record 363 in the randomizations table. It also briefly 
mentions a second randomization belonging to that trial, for maintenance duration/immunotherapy 
(randomization 2702). Since this is a later randomization, probably not previously mentioned, it 
should have a record in the randomization table. Due to initial indecisiveness it was first entered as 
record 364 in the randomization table, then deleted, and finally re-instated as record 405. 
 
A similar situation arose with publication 4 [Campbell et al (1973)] which also primarily reports 
the CNS prophylaxis randomization in UKALL I (randomization 2701, record 370 in the 
randomizations table) but also briefly mentions the second randomization for maintenance 
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duration/immunotherapy (randomization 2702). This latter randomization was first entered as 
record 372, deleted, then re-instated as record 406. 
 
This should serve as an explanation for the missing record numbers in the randomizations database. 
With an auto-numbering system, this was unavoidable. 
 
Why are some records deleted from the articles table in ACCESS? 
Again, Group 27 was the pilot for this work, being the first group dealt with. Publication 12 was 
from Clinprot, not strictly a publication. It was later decided that any information from this source 
should be added to the ‘publication 0’ (definitive) record for each randomization in the 
randomizations table in order to eliminate unnecessary records.  
 
The ‘publication 0’ record for each randomization is an amalgamation of data from all publications 
found, the Cancer Overviews Group’s trial list (available for all randomizations) and from Clinprot 
and/or any trial protocols obtained from the groups. There is a separate field in the database, which 
specifies the sources. 
 
3.13  Checking procedure 
A series of codes were used to denote queries and points of interest. These are numerical codes 
entered into the ‘notes’ field of randomization or article records in the ACCESS database. At the 
end of the data collection process the codes were evaluated and checked where considered 
necessary. Records with codes corresponding to the following were checked, and the data amended 
where appropriate: 
• Studies thought to be newly found randomizations. These were added to the database and 
the Cancer Overviews Group were informed. 
• Review articles and editorials summarising several (often past) trials. Some of these were 
excluded. 
• Two or more publications for the same abstract or full paper. These were left in the 
database but investigated to see if there was anything unusual about the trial reported.  
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• Only combined results, for randomizations from more than one trial, were given. These 
were removed from all records. 
• Only combined results for randomizations from the same trial were given. These were 
attached to all relevant records.  
• Only combined results were given and it is uncertain whether they are for randomizations 
from the same or different trials. These were checked, re-classified and dealt with as 
described above. 
• Possibly for exclusion (miscellaneous category) 
• Unclear which data relate to adult patients (for exclusion) and which to children 
• Number of patients and possibly other data seems to have been attached to the wrong 
randomization of a particular trial. 
 
Notes codes relating to the following were not investigated, since the Cancer Overviews Group 
have investigated these thoroughly as part of their identification process: 
• The trial – randomization structure appears wrong  
• A proper method of randomization appears not to have been used 
 
Records with other notes codes were not investigated unless outliers from the preliminary analyses 
had these attached to them. In this case other observations used in the analysis were checked for the 
code. If no others had the code, then the code might be significant. If, however, several non-outliers 
also had the code then it is unlikely that it is important. 
 
After exclusions were removed, 257 articles reporting 149 trials, consisting of 243 randomizations 
remained. There were 610 publication records.  
 
3.14  The trial characteristics (variables) considered 
The trial characteristics collected are listed in Appendix IV. Here the variable name as used in the 
analysis is given along with a description of what it is, its type (categorical, continuous or 
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dichotomous) and whether it is found in publication records, definitive records or both. The latter 
was discussed in Section 3.4.  
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4  DERIVING MEANINGFUL VARIABLES FROM COLLECTABLE VARIABLES 
 
4.1  Introduction 
The information that is easiest to collect is not necessarily in the most useful form. This chapter 
begins by dealing with the process of calculating the latter from the former, describing the 
derivation of individual variables. Next some of the problems relating to data collection and 
coding, and their solution, are outlined. These include: (i) the need to re-assess definitions and 
make corrections, (ii) variables of interest that could not be collected and other variables used as 
surrogates, (iii) variables collected which could not be analysed, (iv) variables with missing values 
that could be estimated and (v) categorical variables with an uneven spread of data. The final 
section of this chapter deals with other points of interest concerning individual variables.  
 
4.2  Calculated variables 
For calculated variables, data from the definitive record were used where possible, since this is 
considered most accurate. For example when calculating the time interval from close of 
randomization to date of publication (TCLPUB) using the merged dataset, the date of close of 
randomization (NCLOSE) was taken from the definitive record. However date of publication 
(NDPUB) is different for each article and so was taken from the publication record.  The following 
are examples of calculated variables: 
 
Duration of randomization period 
The duration of randomization period (DURRAN) is the difference between date randomization 
started (NSTART) and date randomization closed (NCLOSE). 
 
Target accrual reached 
The target accrual number is considered reached (TARGET) if actual number of patients (NOPAT) 
is equal to or exceeds planned size of randomization (PLSIZE).  
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Multi-centre participation 
A trial is considered to be multi-centre (MULTIC) if the number of centres participating is greater 
than or equal to five; multi-centre (limited) if the number of centres is two, three or four; and 
single-centre if only one centre participates. 
 
Target number of centres reached 
The target number of centres is considered reached (CTARGET) if actual participation is as great 
as or greater than planned centre participation. This is calculated by comparing multi-centre code 
(MULTIC) with planned centre code (PLCENT), both of which have the same three categories; 
multi-centre, multi-centre (limited) and single-centre. A disadvantage of comparing MULTIC and 
PLCENT by category is that, for example, if the planned number of centres was stated to be 10 but 
only 6 actually participated, this would resolve as target number of centres reached. However, to 
use the actual numbers to calculate CTARGET would lead to a far larger proportion of missing 
values for this variable, since often both intended and actual participation are stated as simply 
‘multi-centre’. 
 
Decline in interest  
The decline in interest in a randomized comparison (WANE) can be assessed crudely by 
subtracting the accrual time to randomize the first half of the patients from that for the second half 
i.e. (date last patient accrued – date middle patient accrued) –  
(date middle patient accrued – date first patient accrued)  
These accrual dates were obtained from raw data collected by the Cancer Overviews Group. 
 
Number of questions 
In a randomization, if the number of treatment arms is greater than two, number of questions 
(comparisons) (NOQ) depends on what the arms (ARMS) are, since some comparisons are more 
important than others. For most randomizations the number of (important) questions is known to 
the Cancer Overviews Group. For the rest a crude count, based on the number of treatment pairs 
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there are, can be used. For a randomization with N arms, number of questions = 1 + 2 + …+ (N-1) 
= N(N-1)/2 (Table 4.1) It was necessary to use this for 12 randomizations. 
 
The number of arms and the number of questions are, of course, very highly correlated (Pearson  
Correlation coefficient ρ = 0.94412 using the definitive records for the 243 randomizations). In any 
regression analysis only one of ARMS or NOQ was used at a time. If it was eliminated, the other 
was tried in its place. If it remained in the reduced set of significant variables, the other was also 
tried to see if this improved the fit of the model.  
Number of arms Number of questions 
2 1 
3 3 
4 6 
5 10 
6 15 
7 21 
8 28 
 
Table 4.1 Number of arms and number of questions 
 
 
Size of randomization 
The scatter diagram of the time period in question against number of patients accrued (NOPAT) in 
Figure 4.1 shows bunching to the left, indicating that a logarithmic transformation of ‘number of 
patients’ is necessary. The order of magnitude, expressed by LOGSIZE = log10 (NOPAT), is of 
interest rather than the actual number of patients accrued. Under this transformation the graph 
shows a more even spread. 
 
The three key time periods being investigated 
• Time from close of randomization to date of submission/receipt of article (TCLREC). The 
date of submission is assumed to be the same as the date of receipt for analysis purposes. 
• Time from submission/receipt of article to publication (TRECPUB) 
• Time from close of randomization to publication (TCLPUB) 
For brevity these time periods will be referred to as ‘close to submission’, ‘receipt to publication’ 
and ‘close to publication’. 
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Figure 4.1 Use of scatter plots to determine whether the use of a transformation of a 
continuous variable is necessary. Example: time from close to publication vs. size of  
trial and vs. log10 (size of trial) 
 
 
Length of follow-up period 
When reporting results, some articles state the median or mean length of follow-up (FUPDAYS). If 
this is not given, but the cut-off date for analysis is given, it can be estimated roughly in the 
following way: 
 length of follow-up period =cut-off date for analysis – ½ (start date + close date)   
 
Time from cut-off date for analysis to submission of article 
Conversely, if the cut-off date for analysis is unknown, but the mean or median number of days on 
follow-up is known, then an estimate for the time from cut-off date for analysis to submission can 
be calculated using: 
time from cut-off date for analysis to submission of article 
= date article received – [½ (start date + close date) + number of days on follow-up] 
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4.2.1  How some of the results variables were obtained 
From each reporting of a randomization, up to two main trial questions (e.g. survival, event-free 
survival etc.) and up to two main results were collected. The reason for allowing two main 
questions and results is that it is not always clear from the article which is the main question and 
main result. For each result the following information was sought: 
• type (the same categories as for the main questions, for example; survival, event-free 
survival etc.) 
• statistical method used 
• length of follow-up of the study 
• whether the article answered the main questions 
• p-values associated with the results 
• clinical significance 
• direction (The direction of a result is considered positive if the experimental arm fared 
better than the standard arm, negative if it fared worse and null if there was no difference 
between the two.) 
 
From the pairs of question and result fields an overall value was selected for use in the analyses. To 
make this selection hierarchical systems were used, as listed in the algorithm for the data 
management program given as Appendix III. However this method led to a complication which is 
described in Section 4.4 in the discussion of the relationships between the three variables used to 
represent the results of a randomization. 
 
Statistical technique (TECH) 
 
The broad categories used, ranked in order of merit, are: 
• Cox regression (proportional hazards): a form of survival analysis but with the added 
advantage of allowing extra variables to be included in the analysis 
• longitudinal (survival analysis) methods i.e. methods for analysing curves such as Kaplan 
Meier and log rank tests 
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• cross-sectional tests which analyse data at one point in time, such as the Mantel-Haenszel 
or chi-square test, generally not thought to be as good as either of the above 
• other methods 
 
If either result was obtained using Cox Regression, then the overall statistical technique for that 
publication record is ‘Cox Regression’. Otherwise, if one or both used a longitudinal method, then 
the overall technique is ‘longitudinal’. Otherwise, if cross-sectional methods were employed, then 
the overall technique is ‘cross-sectional’. If another method was used then the category is ‘other’.   
 
Whether the article has answered the trial questions (ANSWER) 
To decide whether the article has answered the main question(s) stated in that article the following 
strategy was used. If two main questions were stated and both were answered, or if only one main 
question was stated and it was answered then the paper has answered the main questions. If no 
main questions were described in the paper then it is not known whether they were answered. 
Otherwise the paper is considered not to have answered the main questions. 
  
Statistical significance (LOGPEST)  
An important variable is the measure of statistical significance. From each article two main results 
were coded and, of the two, that with the smallest p-value was used. Some articles reported actual 
p-values. Others stated that the results were significant or not at a particular level (0.05, 0.01 or 
0.001). One way of representing statistical significance in the regression is to take the logarithm of 
the p-value in each case. However, since the p-value was not always reported, this would have led 
to many missing values. An alternative method is to treat statistical significance as a categorical 
variable with, for example, 0=not significant, 1=significant at the 0.05 level, 2=significant at the 
0.01 level and 3=significant at the 0.001 level, which would have resulted in fewer missing values. 
However, information concerning the spacing between the significance levels would have been 
lost. Therefore, for each category of statistical significance a typical value of p was assigned and 
log e of this taken, creating the new variable, LOGPEST. This is the distance of log e (typical value 
of p) for each category from that for the not significant/not reported category, and can be treated as 
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a continuous variable, with the spacing between values for each category built in. The five 
categories are given in Table 4.2. 
 
Statistical significance                     Typical value of p log e  
(typical value of p)
 
Spacing 
(LOGPEST) 
Not significant/not reported 0.15 -1.9 0 
Possibly significant 0.075 -2.6 0.7 
Significant at 0.05 level 0.05 -3.0 1.1 
Significant at 0.01 level 0.01 -4.6 2.7 
Significant at 0.001 level 0.001 -6.9 5 
 
Table 4.2 Levels of statistical significance and how these are represented in the analyses 
 
An additional variable (LOGPNR) is set to 1 if statistical significance is not reported and to 0 if it 
is. By using the two variables LOGPEST and LOGPNR in conjunction it is possible to distinguish 
between results that are not significant and those that were not reported. 
 
Initially the intention was to record whether the p-values reported were one- or two-sided. Since a 
two-sided p-value is more conservative, the reporting of a one-sided p-value could indicate that the 
result would not have been significant if a 2-sided test had been used. However this was abandoned 
since it was rarely reported. 
 
Clinical significance (CLNSG) 
Clinical significance can be thought of as a hard measurement (calculated), rather than merely an 
impression. McNeil (1996) gives the following definition in his comparison of statistical and 
clinical significance: 
 
“It is important to understand the difference between ‘statistical’ and ‘clinical’ significance. 
According to scientific convention, a finding is statistically significant if the p-value associated 
with the null hypothesis of interest is smaller than 0.05. On the other hand, a result is clinically 
important if the confidence interval for the parameter of interest differs from the null value by a 
worthwhile amount.” 
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However, for the purpose of this project, where articles rarely give concrete figures either for the 
‘worthwhile amount’ or the confidence interval, it is necessary to use the impression given by the 
paper.  A result was considered to be clinically significant if the wording of the text, irrespective of 
the p-value stated, suggested that it clearly favoured the experimental arm, or in the case of an 
equivalence trial the experimental arm was at least as good as the standard arm. A result was 
considered to be not clinically significant if it favoured the standard (control) treatment. If the 
impression was less clear then ‘possibly’ and ‘not known’ categories were used.  
 
If one or both of the two main results were reported to be clinically significant then the overall 
clinical significance category is ‘yes’. Otherwise, if one or both of the results might possibly be 
clinically significant then it is ‘possibly’. Where the article implies that neither result is clinically 
significant or that it is too early to tell then the clinical significance category is ‘no’. Where no 
information is given about clinical significance, the category is ‘not reported’.     
 
Direction of results (POSNG) 
As has been mentioned previously, results can be positive (the new treatment was found to be 
better than the standard treatment), negative (the new treatment was found to be less effective than 
the standard treatment) or null (results are about the same for the two treatment arms).  
 
If both main results (or one if only one was reported) are positive, or if one is positive and the other 
null, then the direction category for the publication record is ‘positive’. Similarly, if both main 
results (or one if only one was reported) are negative, or if one is negative and the other null, then 
the direction category for the publication record is ‘negative’. If both main results (or one if only 
one was reported) are null then the direction category is ‘null’. If one main result is positive and the 
other negative, then the direction category is ‘opposite’. If no indication of direction of results is 
given then the category is ‘not reported’. 
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4.3  Some problems relating to data collection and coding and how they were solved 
4.3.1  The need to re-assess definitions and make corrections 
For each of the following variables, the data collection process was well underway when it became 
necessary to re-assess definitions and make corrections. 
 
Clinical significance (CLNSG) 
It is important not to be influenced by the p-value associated with a result when deciding whether 
that result is clinically significant. Late realisation of this necessitated re-reading the results section 
of each article and re-classifying clinical significance where appropriate, whilst attempting to 
ignore the p-values quoted.  
 
Whether data from a meeting abstract have necessarily been presented at a meeting (PRESENTD) 
Articles can be from journals, books or meeting abstracts (PUBTYPE). Also there is a variable 
indicating whether or not data from the article have been presented at a meeting (PRESENTD). 
Initially the assumption had been made that data from a meeting abstract must necessarily have 
been presented at that meeting and the ‘presented’ flag set accordingly. Later, after discussion with 
colleagues, it was decided that this is incorrect and the ‘presented’ flag should only be set to ‘yes’ 
if the article actually stated that the data had been presented at a particular meeting or if a meeting 
abstract contained results. This has since been corrected. However, there remains the problem that 
results obtained between the submission of the abstract and the meeting presentation may have 
been presented even though the abstract does not contain them. 
 
Equivalence trials (EQUIV) 
The purpose of many trials is to discover whether a new treatment is better than the standard 
treatment. However, others aim to show that a less toxic treatment is equally as effective as the 
standard treatment. The latter are known as ‘equivalence trials’. There is a variable in the data to 
indicate whether a randomization is thought to be an equivalence trial. Special care must be taken 
when coding results of equivalence trials. For example; a null result (no statistical difference in the 
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results of two or more treatment arms) in an equivalence trial can be (and probably is) clinically 
significant. [Djulbegovic and Clarke (2001)]  
 
Combined results 
Some articles combine data from more than one randomization as a result. It was decided that if 
these randomizations belong to the same trial then the results should be attached to both/all records 
for those randomizations. However if the randomizations are from different trials, the results 
should not be attached to either/any. An example of attaching combined results to more than one 
randomization record is trial 2403, COALL 85/89, which contains two randomizations, 2403 and 
2404. Randomization 2403 compared slow rotation of six drug combinations versus rapid rotation. 
Randomization 2404 also compared slow rotation versus rapid, but using only five drug 
combinations (dropping the high dose cytosine arabinoside and asparaginase block, [Janka-Schaub 
et al (1988), Janka-Schaub et al (1990), Janka et al (1991), Janka-Schaub et al (1996)] publications 
158, 159, 156 and 157 respectively. Where combined results are reported, whether or not the 
results are attached, this is indicated by a code in the notes. 
 
Start and close date for entry period (NSTART, NCLOSE) 
If a trial contained more than one randomization, often the start and close dates for entry were only 
reported for the first randomization. If the second randomization was at a late stage in the 
treatment, for example for an extra year’s maintenance duration, using the same entry dates for 
both randomizations would be inaccurate. For this reason raw individual patient data were used to 
check and refine these dates. The date of randomization was obtained for the first and last few 
patients in each randomization. These data had been collected, by the Cancer Overviews Group, 
from the trialists who had conducted the randomizations, for use in the overview. 
  
Number of patients (NOPAT) 
The number of patients, for a given randomization, is often reported differently between articles. 
Likely reasons for this variation are that an article may include some adult patients, or that some 
patients may be registered but relapse, die or become protocol deviants before the point of 
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randomization. The latter is a flaw in the trial design and makes the analysis more difficult, since 
all randomized patients must be included and analysis should be by intention to treat. In order to 
avoid this problem, the randomization process should take place as late as possible. Papers may 
also include non-randomized patients who had been treated alongside those who had been 
randomized. The individual patient data were used to help decide on the correct number of patients 
randomized. 
 
4.3.2  Variables of interest that could not be collected and other variables that could be used 
as surrogates 
Cost of the trial 
This was not mentioned in any article. It may be possible to obtain the estimated cost (as opposed 
to the actual cost) by contacting all trial groups. However since the cost of follow-up of trial 
patients is unlikely to be available, this idea was abandoned. Instead, size of the randomization, the 
number of patients accrued (NOPAT), can be used as a surrogate for cost. 
 
4.3.3  Variables collected that could not be used in the analyses 
Decline in interest in a randomized comparison (WANE) 
Unfortunately the data used to assess this were available for only 105 of the 243 randomizations 
(43%). For 85 of these 105 (81%), the accrual times for the first and second halves of the 
randomization were judged to be similar (i.e. less than 6 months difference). Six randomizations 
took considerably less time (i.e. more than 6 months quicker) to accrue the second half of their 
patients than the first half. This might be an indication that the interest in the trial increased over 
time. However, 14 randomizations took more than six months longer to accrue the second half of 
their patients than the first, which might indicate a decline in interest in randomizing into the trial. 
Due to the large number of missing values for this variable, it could not be incorporated into the 
analyses. 
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Details of the randomization procedure and trial design 
Four variables to do with the randomization procedure and trial design were created using the 
sparse information reported in a few articles and trial protocols: 
 
• Method of randomization used (RANDMETH) has the following categories: ‘by a central 
computer’ (the most reliable), ‘notification to a central office’ (less good), and ‘use of 
sealed envelopes’ (believed to be the least secure i.e. the easiest to predict). This is known 
for only 47 of the 243 randomizations (19%). 
 
• Timing of late randomization (RANDTIME). As mentioned previously, the randomization 
procedure should be scheduled as late into the trial as possible, so that few randomized 
patients relapse, die or deviate from the protocol. This variable is only applicable to 
randomizations where the arms differ late on in the protocol. The categories are ‘late 
randomization done at correct time’ and ‘late randomization done too early’. There is 
sufficient information on this for 67 of the 243 randomizations (28%). 
 
• Randomization design (RDESIGN) has three categories: ‘simple randomization’, ‘block 
randomization’ and ‘minimisation of imbalance’. Simple randomization is self-
explanatory. No attempt is made to balance either the numbers randomly assigned to the 
different treatment arms, or to balance for any additional factor, for example by sex. An 
example of block randomization is as follows: if the randomization is between two 
treatment arms (A and B) and uses a block of size four, the number of patients randomized 
to each treatment will always be equal every fourth patient. For example if the first three 
patients of four are allocated A, B, B then the fourth must receive A. Minimisation of 
imbalance is a more complex way of balancing the numbers allocated to two or more 
treatment arms. The advantage of this is that it is possible to balance groups for several 
factors, for example, age group, sex, white blood count group, hospital entering the patient 
into the study. This is known for only 13 of the 243 randomizations (5%).  
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• Whether any attempt was made to balance or not (BALANCED) is the fourth variable, 
which is known for 94 of the 243 randomization (39%). 
 
Due to the vast majority of observations having missing values for all four of the above, none of 
these could be used in any analyses. 
 
Statistical techniques used (TECH)  
Another variable, not initially collected, is the statistical method reported. It was decided, towards 
the end of the data collection process to go back through all articles for this. One intention was to 
investigate whether a conclusion obtained using a new technique is more or less likely to be 
published and how the use of different statistical methods has changed over time. Another was to 
look at whether non-standard tests are used in order to obtain a significant result, not achievable 
using standard methods. However, in order to do this properly it must be known whether or not the 
group conducting the trial routinely uses the non-standard test, and this information was not 
available. These questions were not investigated due to the large proportion of articles that fail to 
report methods used. Of the 394 publication records which contain results, the statistical technique 
is given for 201 (48%). The categories for this variable were described in Section 4.2.1.  
 
Number of days on follow-up (FUPDAYS) 
As was described in Section 4.2, if either the mean or median time on follow-up is reported, then 
this is used. Otherwise the following estimate is calculated: 
cut-off date for analysis – ½ (start date + close date) 
 
If the response variable is ‘time from close to submission’, or ‘to publication’, then number of days 
on follow-up is necessarily significant. The controlled period from trial closure to cut-off date for 
analysis must not be included in the response variable. An alternative approach is to use as the 
response variable ‘time from cut-off date for analysis to submission’, rather than ‘time from close 
of randomization to submission’. However, this idea was abandoned for two reasons: 
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• ‘Time from close of randomization to submission for publication’ is more meaningful than 
‘time from cut-off date for analysis to submission for publication’. 
• The cut-off date for analysis is dependent on the date of submission, and may also be 
dependent on explanatory variables, perhaps the best example being the statistical 
significance of the results. If a randomization is published early there will be fewer events 
and so the p-value associated with the result may remain greater than 0.05. If published late 
there will be more events, perhaps resulting a p-value of less than 0.05. 
  
The only time period analysed, for which number of days on follow-up can used, is time from 
receipt of article to publication. When all records containing results are included there are 50% 
missing values for this variable. When first results only are included, 60% observations have 
missing values. So again the variable cannot be used. 
 
Risk group (RISK) 
Data were collected on the type of patients who were eligible for randomization. As well as age 
group, the risk group was often also specified. The following categories were used: 
• any 
• low 
• low-standard 
• standard 
• standard-high 
• high 
 
Preliminary graphs did not indicate any association between risk group and any of the ‘time to’ 
response variables. There was still no pattern when the categories were compressed as follows: 
• any 
• low/standard 
• standard/high 
• high 
 
Also for any regression there are approximately 40% observations with this variable missing. 
Therefore this variable was omitted from the analyses. 
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Target number of patients reached Yes/No (TARGET) 
As described previously this variable is calculated using the actual number of patients accrued 
(NOPAT) and the intended number of patients (PLSIZE). Unfortunately the latter is rarely given 
resulting in TARGET being missing for 206 of the 243 randomizations (85%). For this reason  
TARGET is excluded from the analyses.   
 
4.3.4  Variables with missing values that could be estimated 
Dates 
ACCESS and SAS were both used in this project. These require full dates to be used. Where partial 
dates only are known a qualifier is used to indicate the accuracy of that date: 
• If month and year are known the date used is 15/MM/YY and qualifier is set to 1. 
• If year only is known the date used is 30/06/YY and the qualifier is set to 2. 
• If year is not known but the decade is then the date used is 30/12/Y4 where Y=6 for the 
1960s for example, i.e. the middle of the decade is used, and the qualifier is set to 3. 
• If the decade is unknown it is estimated, the date is set to 30/12/Y4 similarly, taking the 
decade most likely to be correct, and the qualifier is set to 4.  
 
Dates with qualifiers 3 and 4 are used only for deciding whether randomizations and articles are 
eligible for inclusion (as described in Sections 3.6 and 3.9). For analysis purposes they are 
considered potentially misleading and have been removed. 
 
International/single-country participation (INTERNL) 
If it is known whether a group generally conducts international or single-country trials but this 
information is missing for a small proportion of their randomizations, it can be assumed that the 
missing information is the same as the typical policy for the group. 
 
Multi-centre/single-centre participation (MULTIC) 
Similarly, if a trial group usually runs multi-centre (or single-centre) trials, it can be assumed that 
the randomizations where this information is missing are also multi-centre (or single-centre). There 
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is also a variable to indicate whether the randomization was planned as a multi- or single-centre 
trial (PLMULTIC). Missing data for this can be imputed in the same way.  
 
Country group of the centre conducting the trial (CGROUP) 
The broad categories ‘North America’, ‘Europe’ and ‘Other’ were obtained using the first three 
digits of the trial or randomization identifier in conjunction with the list of centres provided by the 
Cancer Overviews Group.    
 
Country group of publisher (JGROUP) 
Again the three categories are ‘North America’, ‘Europe’ and ‘Other’. The articles themselves, the 
Internet and informed colleagues provided this information. A third variable was then created. This 
indicates whether the country group of those conducting the trial is the same as that of the journal 
publishing it (SGROUP).  
 
 
4.3.5  Categorical variables with a very uneven spread of data 
The following meaningful categorical variables, with few enough missing values to be useful in 
analyses, have a very uneven spread of data. None were excluded from the analyses for this reason.  
 
However it is important to be aware of this since missing values, either for the response or for any 
of the explanatory variables used, result in a reduced dataset being used in the analysis. This could 
mean that a particular category of a variable may be represented by only one or two observations. 
If membership of that category appears to have a significant effect on the response i.e. it remains in 
the model, this must be investigated, since a single observation (or two observations) should not be 
allowed to influence the choice of model so strongly.  
 
This is usually taken care of when consulting preliminary graphs prior to the analysis. Categorical 
variables are graphed using box-plots, as will be described in Section 5.3.2. Often it is appropriate 
to pool a category with few observations with another category, and so the problem of a category 
with few observations having undue effect on the choice of model does not arise. 
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Table 4.3 lists variables where at least one category (not including the missing values category) 
contains less than 10% of the total. The figures quoted may be based on the total number of trials, 
randomizations, articles or publication records, whichever is most appropriate for that variable.  
 
Funding (FUNDG) 
Category      Number of trials (%) 
1=Government     53 (35.6%)     
2=drug company     1 (0.7%) 
3=charity     1 (0.7%) 
4=Government + charity    28 (18.8%) 
5=Government + charity + drug-company  1 (0.7%) 
missing      65 (43.6%) 
Total      149 (100%)   
 
Treatment type (TXCHEMO) 
Category      Number of randomizations (%) 
Chemotherapy     167 (68.7%) 
Bone Marrow Transplant    1 (0.4%) 
Radiotherapy     54 (22.2%) 
Immunotherapy     11 (4.5%) 
Antibiotic     3 (1.2%) 
missing      7 (2.9%) 
Total      243 (100%) 
 
Age eligibility (AC) 
Category      Number of randomizations (%) 
Children only     214 (88.1%) 
Both adults and children    23 (9.5%) 
missing      6 (2.5%) 
Total      243 (100%) 
 
Multi-centre/single-centre participation (MULTIC) 
Category      Number of randomizations (%) 
Multi-centre (>=5)     199 (81.9%) 
Limited multi-centre (2-4)    9 (3.7%) 
Single-centre     32 (13.2%) 
missing      3 (1.2%) 
Total      243 (100%) 
 
Target number of centres reached? (CTARGET) 
Category      Number of randomizations (%) 
Yes      169 (69.6%) 
No      8 (3.3%) 
missing      66 (27.2%) 
Total      243 (100%) 
 
International/single-country participation (INTERNL) 
Category      Number of randomizations (%) 
Single-country     126 (51.9%) 
Limited international    68 (28.0%) 
International     19 (7.8%) 
missing      30 (12.4%) 
Total      243 (100%) 
 
Publication type (PUBTYPE) 
Category      Number of articles (%) 
Journal      195 (75.9%) 
Book      11 (4.3%) 
Meeting abstract     51 (19.8%) 
Total      257 (100%) 
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Country group of publisher (JGROUP) 
Category      Number of articles (%) 
US      164 (63.8%) 
Europe      74 (28.8%) 
Other      2 (0.8%) 
Missing      17 (6.6%) 
Total      257 (100%) 
 
Published in full in the English language? (ENGLISH) 
Category      Number of articles (%) 
Yes      250 (97.3%) 
No      7 (2.7%) 
Total      257 (100%) 
 
Clinical significance (CLNSG) 
Category  Number of publication records (%) 
Yes  191 (31.3%) 
Possibly  17 (2.8%) 
No  121 (19.8%) 
Not reported  281 (46.1%) 
Total      610 (100%) 
 
Table 4.3 Distributions of categorical variables with a very uneven spread of data 
 
 
4.4  Other points of interest concerning individual variables  
The majority of the explanatory variables are categorical. Some are graded or ordered categorical 
variables with more than two categories. For each categorical variable indicator (or dummy) 
variables are used, numbering one less than the number of categories. If an indicator variable is 
found to be the least significant at a stage in the backwards elimination process of the regression, 
care must be taken to combine categories in a meaningful way. 
 
Trial category 
Randomizations were categorised by the treatments being compared:  
• induction 
• central nervous system prophylaxis 
• intensification 
• maintenance 
• a combination of induction, intensification and maintenance 
• duration of treatment 
• testicular radiotherapy 
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• bone marrow transplant 
• immunotherapy 
• treatment after relapse 
• miscellaneous such as antibiotic or cardio protection 
 
For analysis purposes, two new variables were created from the above: 
• first-line or relapse therapy 
• chemotherapy only or transplant or radiotherapy or antibiotic or other 
 
Funding source (FUNDG) 
The categories for funding source are Government, drug company, charity or any combination of 
these. This field is attached to the trial as opposed to the individual randomization, since it is 
unlikely to differ between randomizations belonging to the same trial. It may be interesting to look 
at changes in funding source over time, for example to investigate whether there may be a trend 
from Government funding to funding from other sources. This has not been addressed in this thesis. 
 
Main questions, main results and whether the main questions have been answered: in publication 
records and in the definitive record 
Data on two of the main questions, two of the main results, and whether the two main questions 
have been answered, have been collected from each publication. The main question asked in a 
study is often survival. The main result reported may also be what the trial was designed to look at 
e.g. survival. However it could be an additional finding, with more endpoints available for analysis 
and having a smaller p-value associated with it for example event-free survival, disease-free 
survival or relapse in a specific site. Often, in the paper, the main question is not specified.  
 
It is a fairly straightforward process to deal with one article at a time, and to decide whether the 
main questions as reported in that paper have been answered in it. However there are other 
measures of interest to do with the main questions of the trial and whether these have been 
answered. One of these is the overall main question of the trial at its conception. This may not 
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necessarily be mentioned in a paper, particularly if the article is reporting the answer to a different 
question. It is likely to be stated in the trial protocol or Clinprot, neither of which are available for 
many of the randomizations.  
 
An attempt was made to estimate the overall main question for each randomization, using all 
available sources. If the trial protocol or Clinprot are available, the main questions specified 
(CQUEST1 and CQUEST2) take precedence over those mentioned in articles (PQUEST1 and 
PQUEST2). If more than two questions were stated in the protocol, then two were selected using 
the hierarchy given below. These were ranked in order, with the exception of 3, 4 & 5, ranked 
equal. 
1=survival 
2=EFS (including DFS)2 
3=treatment-related deaths 
4=achieving CR 
5=any relapse 
6=specific relapse sites 
7=toxicity 
8=other  
 
Otherwise the articles alone were used to deduce the main questions. Here the main questions 
stated in all articles for a randomization were pooled and the two with the highest ranks from the 
hierarchy were used.  These were attached to the definitive record for that randomization. A new 
variable was then created to specify whether the two overall main questions were ever answered in 
any article, or if there was only one question, whether this was ever answered (ANSEVER). If so, it 
is set to ‘yes’. If there was no indication anywhere what the main questions were, it is set to 
‘unknown’. Otherwise it is set to ‘no’. This information is also stored in the definitive record.   
 
                                                          
2
 Note: Event Free Survival (EFS) is time from diagnosis until induction death or failure, death in remission 
or first relapse. Disease-free survival (DFS) is the time from achieving complete remission to relapse or 
death. 
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Unfortunately, the main questions for randomizations where Clinprot and/or the trial protocols 
were available differed so greatly from those for randomizations where articles were the only 
source that ‘whether ever answered’ (ANSEVER) was not used in the analyses. Its inclusion might 
have led to bias between the two groups.  However it is valid to use ‘whether the main questions 
stated in a paper were answered in that paper’ (ANSWER) in the analyses, since this is available 
for the whole set of publication records. 
 
Relationships between the three variables used to represent the results of a randomization 
(i) Statistical significance and direction of results 
Section 4.2.1 explained how three results variables, measures of statistical significance, clinical 
significance and direction of results, were collected for two of the main results for each 
randomization reported in an article and how a hierarchy was used to select the definitive value 
from the two, to be used in the analyses.   
 
Frequency tables for level of statistical significance versus direction of results and for level of 
statistical significance versus clinical significance categories were produced. From the former it 
can be seen that the majority of statistically significant results (p<0.05) are in a positive direction, 
i.e. in favour of the experimental treatment arm. Of the 610 records, 129 have one or both results 
with statistical significance p<0.05. Of these 129, 80 (62%) are positive, 21 (16%) are negative, i.e. 
in favour of the standard treatment, 17(13%) are in opposite directions, i.e. one result is positive 
and the other negative, 10 (8%) have direction not reported and 1 (<1%) is a null result. This latter 
observation has been investigated, as described below. 
 
If, for a particular record Result 1 has a p-value of <0.05 associated with it and Result 2 does not, 
but it is unclear whether Result 1 is in favour of the experimental arm or of the standard arm, then 
the values used in the analyses are as follows: statistical significance is taken from Result 1, since a 
p-value of less than 0.05  takes precedence over a p-value of greater than 0.05, whereas direction of 
result is taken from Result 2 since a null result takes precedence over ‘not known’. Therefore the 
record contains a result both statistically significant at p=0.05 and null. 
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Record 697 contains the results of randomization 1902, an immunotherapy randomization from a 
two-randomization trial 1901 (EORTC 58741), open between 1972 and 1980 and accruing 123 
patients. The record is from the sole publication for that randomization, publication 135 [Otten et al 
(1988b)]. The two results extracted are as follows: 
Result 1: Disease-free survival: The difference between the two arms is statistically 
significant with p=0.024, but it is unclear which was the experimental arm, so the direction 
is coded as ‘unknown’. 
Result 2: Survival: The result is null with 65% survival in both arms. Therefore statistical 
significance is ‘no’. 
Therefore the data from this record used in the analysis are statistical significance ‘p<0.05’, from 
Result 1,  and direction ‘null’, from Result 2. 
 
(ii) Statistical significance and clinical significance       
The frequency table for level of statistical significance versus clinical significance category shows 
that of the 129 records for which statistical significance of one or both results is p<0.05 or better, 
the majority of these, 93 (72%), are also clinically significant. Eleven (9%) were clearly stated to 
be not clinically significant, 4 (3%) can be interpreted as ‘possibly’ clinically significant, and for 
21 (16%) clinical significance was not stated. Section 4.3.1 described how an attempt was made to 
prevent  knowledge of the p-values associated with the results reported from influencing the coding 
of clinical significance. 
 
The correlations between variables representing statistical significance, clinical significance and 
direction of results were obtained. These are generally low, possibly due to the fact that the results 
variables are obtained by using the ‘best of two’ results in each case, leading to a dilution of the 
correlation between each pair of results variables. The correlation coefficients of greatest 
magnitude are: 
• Direction of result is null and result is not clinically significant ρ = 0.44 
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• Statistical significance (a continuous variable with a high value indicating a small p-value) 
and result is clinically significant ρ = 0.44 
• Statistical significance is not reported and result is clinically significant (i.e. results clearly 
favour the experimental arm, or in the case of an equivalence trial the experimental arm is 
as good as the standard arm) ρ = - 0.40 
• Statistical significance is not reported and result is clearly not clinically significant (i.e. 
results favour the standard treatment) ρ = -0.40 
 
Subgroups reported 
It is important to record whether an article reports the results for subgroups as well as or instead of 
for the whole group randomized. [Counsell et al (1994), Clarke and Halsey (2001)] The larger the 
number of subgroups used, the more likely it is that a significant result will be obtained, unless 
multiple comparisons procedures are used. By chance alone, from twenty subgroups, there is likely 
to be one with a p-value of less than < 0.05. It is important to note that if results are reported by 
subgroups separately for each variable, this is an additive process. For example if there are three 
age groups, five white blood count categories and the two sexes, then there is a total of ten 
subgroups. If, however, results are given for combinations of these, for example, for older males 
with a high white blood count, the process is multiplicative. In this case there are 3×5×2 = 30 
possible subgroups, and it is likely that at least one will have a result with a p-value <0.05 
associated with it by chance. Variable SUBGRP has value 1 if one or more subgroup results are 
reported and 0 if no subgroup results are reported. 
 
Journals/Books/Meeting papers (PUBTYPE)  
Of the 257 articles, 195 are from journals, 11 from book chapters and 51 from meeting abstracts. 
Preliminary graphs confirm that, as expected, randomizations are published as meeting abstracts 
before being reported as full journal articles. Of the journal articles 82 (42%) give date of 
submission/receipt and 89 (46%) give date of acceptance. No articles from books or meeting papers 
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give either date of receipt or date of acceptance. Therefore variable PUBTYPE is not included in 
any of the ‘time from close to submission’ or ‘time from receipt to publication’ analyses. 
 
Impact Factor (IMPACT) 
The definition of impact factor is as follows: 
 
“The journal impact factor is a measure of the frequency with which the “average article” in a 
journal has been cited in a particular year.  The purpose of the impact factor is to help the reader 
to evaluate a journal’s relative importance, especially when comparing it to others in the same 
field. It is calculated by dividing the number of current citations to articles published in the two 
previous years by the total number of articles published in the two previous years.” 3 
   
The impact factor for any journal changes from year to year, and ideally the value attached to an 
article should be taken from the edition for the year in which the article was published. However 
since the year of publication for the articles included in this data ranges from 1965 to 1999, this 
would not be practical. Also it is likely that the earlier articles pre-date this measure of readership.  
The 1995 edition impact factor was used irrespective of the year of publication, since this lies 
within the range of year of publication for the articles included, and it was assumed that any 
changes in impact factor over time would make little difference to the models.   
 
A summary of the distribution of the variable ‘impact factor’ for the 257 articles used in this thesis 
is given in Table 4.4. and an alphabetical list of journals, the number of articles used from each and 
the impact factor is given as Appendix VI. For journals which have not been assigned an impact 
factor, and for most meeting papers and all books, the impact factor has been set to zero for the 
purpose of this project. Where a journal is linked to particular scientific meeting, the abstracts from 
that meeting are assigned the same impact factor as the journal. There is an additional variable 
(NOIMPACT) which is set to 1 if there is no impact factor and to 0 if there is an impact factor. 
This overcomes the problem of missing values.  
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Impact Factor Frequency Cumulative 
Frequency 
Percentage Cumulative 
Percentage 
No impact factor 79 79 30.7 30.7 
0.071-0.754 12 91 4.7 35.4 
1.073-1.582 37 128 14.4 49.8 
2.095-2.864 48 176 18.7 68.5 
3.106-4.549 14 190 5.4 73.9 
6.922 24 214 9.3 83.2 
8.206-8.569 21 235 8.2 91.4 
17.49 12 247 4.7 96.1 
22.412 10 257 3.9 100.0 
 
Table 4.4 Distribution of values for journal impact factor 
This includes book chapters and meeting abstracts  
 
The articles used in this project are taken from 44 different journals, 8 books and 11 meeting 
abstract books. Considering journals alone, 17 have an impact factor greater than 2, of which 10 are 
American, 6 European and for one the country group of publisher is unknown. There are five 
journals with impact factor greater than 5, of which four are American; New England Journal of 
Medicine (with an impact factor of 22.412), Blood (8.569), Cancer Research (8.206) and Journal 
of Clinical Oncology (6.922), and one is European (British); Lancet (17.490). 
 
Article published in the English language (ENGLISH) 
97% of the articles used are in the English language. Of the remaining articles four are in German; 
publications 33 [Henze (1981)], 34 [Henze (1982)], 35 [Schrappe (1987)] and 256 [Zintl (1992)] 
and there is one in each of the following languages: Dutch; publication 133 [van der Does-van den 
Berg (1989)], Spanish; publication 257 [Ortega Aramburu (1985)] and Japanese; publication 164 
[Children’s Cancer and Leukemia Study Group (1989)]. All seven articles also give the abstract in 
English. In the absence of a translation, due to financial constraints, it was necessary to use the 
abstract alone to collect data. However this may be a biased approach. It would be useful to take a 
sample of abstracts from full papers in English and compare the data from these with those from 
the English abstracts from the papers in other languages. For example perhaps only striking results 
                                                                                                                                                                               
3
 The source is the Institute for Scientific Information: Journal Citation Reports 1995 Science Edition. The 
1995 edition was used rather than a more recent version because only articles published before 1 January 
2000 have been included in this thesis. 
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are given in abstracts, so it may appear that foreign papers are more likely to report striking results 
than those in English. This is a possible topic for future investigation but the sample available in 
this study (i.e. seven non-English articles) is too small to provide a meaningful basis for such 
investigation. 
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 5  PRELIMINARY ANALYSES 
5.1  Introduction 
This chapter starts by stating the twelve analyses to be performed. It then describes the problem of 
having only a partial date of publication for some records, and hence not knowing for some 
randomizations which article is the first mention or the first reporting of results. A solution to this 
is then described, and also the case of ‘true ties’, where a randomization is reported in two papers, 
within the same issue of a journal, and how this is dealt with.  
 
The second part of this chapter deals with the strategy for conducting the preliminary analyses: the 
use of preliminary graphs, the analysis itself - selecting the model that best fits the data, and the use 
of diagnostic plots to check that the assumptions of the model are satisfied.  
 
The third part of the chapter deals with problems that arose relating to the preliminary analyses and 
their solutions, notably (i) choosing the best model when, due to missing values for some of the 
variables, there are several contenders, and (ii) the introduction of new variables, including 
interaction terms, at a late stage.  
 
The next part of the chapter summarises the guidelines used in deciding whether a variable, or a 
particular class of a categorical variable, should be included in an analysis. It also explains how 
categorical variables are represented. A section on the range of values over which the regressions 
are valid follows. Finally there is a section about atypical observations, describing one particular 
observation in detail. This features in both some of the ‘time to first’ analyses and some of the ‘all 
records’ analyses and so is covered in this chapter. 
 
5.2  The twelve analyses to be performed 
In order to investigate which trial characteristics affect time to publication, twelve analyses are run. 
In each case the response variable is one of the following three time periods: 
• Time from close to submission (TCLREC) 
• Time from receipt to publication (TRECPUB) 
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• The sum of the above, time from close to publication (TCLPUB)    
 
For each of the three time periods, four analyses are done using: 
• All mentions of each randomization 
• All reportings of results for each randomization 
• The first mention of each randomization 
• The first reporting of results for each randomization 
For brevity, these analyses will be referred to as ‘all mentions’, ‘all results’, ‘first mentions’ and 
‘first results’, respectively. 
 
The amount of information in a record varies. Some contain detailed results whereas others 
mention only that a trial was randomized.  
 
The purpose of looking at mentions is that this is of significance to meta-analysts, who need to 
identify all relevant trials, if possible, for inclusion. Detailed results are not essential for this 
process. On the other hand, analyses done using only those records reporting results are important 
since clinicians treating patients will be influenced by the results reported. Table 5.1 shows how 
much data are available to answer each of the questions. 
 
 All TCLREC  
present 
TRECPUB 
present 
TCLPUB  
present 
All mentions 610 209 218 582 
All results 394 129 137 372 
1st mentions 217 63 72 195 
1st results 188 52 60 170 
 
Table 5.1 Number of observations available for inclusion in analyses 
 
Initially the plan was to investigate which variables affected time from close to submission 
(TCLREC) and time from receipt to publication (TRECPUB) and then try only the significant 
variables from the two analyses for the combined time period ‘close to publication’ (TCLPUB). 
This would have cut down the number of full preliminary analyses from 12 to 8.  However because 
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there are so many more data available for analysing ‘close to publication’ (TCLPUB), it was 
decided that all 12 regressions should be run from scratch. 
 
5.3  The strategy used for conducting the preliminary analyses 
5.3.1  Using the correct dataset 
The relevant dataset must be used depending on whether the analysis to be done involves all 
mentions, all results, first mentions or first results. The main data management program, for which 
the algorithm is given as Appendix III, contains the various options. For analyses involving all 
mentions, and all reportings of results, the merged dataset (i.e. the set of publication records but 
using data from the definitive records where appropriate) can be used without any modification.   
 
However for analyses of the first mention or the first reporting of results for each randomization, a 
modified dataset must be used. The reason for this is that in order to select the first mention or first 
result published for a randomization it is necessary to first put the records in chronological order of 
publication. This involved much more work than was initially thought. To begin with the merged 
dataset was sorted by randomization, and within randomization, by date of publication. 
 
Incomplete dates 
The date of publication is not always given in full. Sometimes only the month and year, or the year 
alone is known. For one article even the year of publication had to be estimated.  
 
Dates where the year or decade are unknown are considered too inaccurate to be useful in 
regression analyses. However they can still be used to put articles in chronological order of 
publication. To have obtained full dates of publication for all 257 articles would have been 
impractical. Instead all cases where inaccurate dates led to the order of publication of a 
randomization being unknown were found and accurate dates sought for these only. Of the 610 
publication records, there were forty cases where randomizations had an order of publication tying 
for two records, three cases where the order number tied for three records and one case where the 
order number tied for four records. 
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Methods used to obtain more accurate dates are as follows:  
• The publishers of 16 journals and books were contacted and asked for an accurate date of 
publication for each of the articles in question. Alternatively, if the publisher explained the 
numbering system for journal issues, the publication dates were estimated. Addresses and 
fax numbers were obtained using the Internet. If both were given, both were used. The 
telephone was used as a last resort. 
 
• If no reply was received from the publisher, MEDLINE and EMBASE on the Internet were 
used to find the article. This yielded only four of the 45 outstanding dates. In most cases 
the date of article given by MEDLINE was the same as that on the hard copy of the article, 
from which the information was taken originally. 
 
‘True ties’ 
Having obtained the previously missing dates of publication, one problem remained – that of ‘true 
ties’. This is when one issue of a journal reports two or more articles describing the same 
randomization. The date of publication is necessarily the same for both articles, although the dates 
of submission and acceptance may differ. A solution to this was to combine the records for each 
randomization from that issue into a single joint record. There were nine genuine tying pairs and 
one genuine tying trio. To deal with these SAS was used to create a small dataset of ten records 
combining the data from the ties. When analysing data using only the first mention, or first results, 
for each randomization, this small dataset is merged with the full dataset and the 21 records that the 
‘tie’ dataset replaces are deleted.  
 
The ‘true ties’ are as follows: 
• Randomizations 1205 and 1208, CNS prophylaxis randomizations from trials ALL-BFM-
81 (1205) and ALL-BFM-83 (1206) are both mentioned in two articles, publications 32 
[Riehm et al (1990)] and 47 [Buhrer et al (1990)], which are in the 1990 edition of 
Haematology and Blood Transfusion volume 33.  1206, a maintenance duration 
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randomization, also from ALL-BFM-83, is mentioned in both of these as well, and in 
publication 41 [Henze et al (1990b)], again in the same book. 1207, the intensification 
randomization from the same trial, is mentioned in publications 32 [Riehm et al (1990)] 
and 41 [Henze et al (1990b)]. 
 
• Randomizations 1603 (combination) and 1604 (CNS prophylaxis) from trial CCG-105 
(1603) are mentioned in publications 82 [Tubergen et al (1993a)] and 84 [Tubergen et al 
(1993b)], a pair of consecutive articles, published in Journal of Clinical Oncology 1993; 
volume 11 no. 3 (March) pages 520-526 and 527-537. 
 
• Randomization 1604 is also mentioned in two meeting abstracts for the 26th Annual 
Meeting of the American Society of Clinical Oncology; publications 78 [Tubergen et al 
(1990)] and 79 [Gilchrist et al (1990)]. 
 
• Randomization 2701 (CNS prophylaxis) from the MRC UKALL I trial (2701) is 
mentioned in publications 5 [Medical Research Council (1973)] and 4 [Campbell et al 
(1973)], a pair of consecutive articles in British Medical Journal 1973 volume 2, pages 
381-384 and 385-388 respectively. 
 
• Finally randomization 2708 (maintenance duration) from the MRC UKALL III trial (2706) 
is mentioned in publications 16 [Medical Research Council (1982a)] and 15 [Medical 
Research Council (1982b)], a pair of consecutive articles in Medical and Pediatric 
Oncology volume 10 (5) pages 501-510 and 511-520 respectively. 
 
The only ties for first mention are those for randomizations 2701and 2708. The only tie for first 
reporting of results is that for 2701. The other ties are for subsequent reportings. 
 
5.3.2  Preliminary graphs 
Having selected the appropriate data, preliminary graphs were produced in order to help rule out 
some of the many explanatory variables that could be included in the analyses. Since many of the 
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variables have missing values, not all can be included in the analyses, as this would seriously 
reduce the amount of the available data that could be used. Therefore it is essential that those 
variables most likely to affect the response are identified. 
 
• Firstly the response variable to be considered was chosen. This is one of the following: 
time from close to submission, time from receipt to publication, or time from close to 
publication.  
 
• Then the appropriate dataset was selected from the following: ‘all mentions’, ‘all results’, 
‘first mentions’ or ‘first results’. 
 
• For the chosen dataset, using only records where the chosen response variable is present, 
bar charts were produced for all meaningful variables, in order to see the spread of the data 
and the proportion of observations for which data are missing. If, for example, 98% of the 
records are one category of a variable, it is unlikely that that variable would have an effect 
on the response. Similarly, a variable with missing values for the majority of the 
observations would also be of little importance. 
 
• For each continuous explanatory variable, a scatter plot was produced of the response 
versus that variable. The purpose of this is to see whether there is a linear relationship 
between the two, whether a transformation is needed or whether no relationship is 
indicated. An example of where graphs show that a transformation is indicated is given in 
Section 4.2. 
 
• Similarly, for each categorical explanatory variable, a box-plot was produced of the 
response versus each class. The bottom and top edges of the box are the 25th and 75th 
percentiles and the horizontal line is the median. If the box for one category could fit inside 
the box for another, it was assumed that the two categories were similar and could be 
pooled. (Of course, ordered categories could only be pooled if they were consecutive.) This 
was useful for reducing the number of dummy (indicator) variables needed in the analysis, 
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and could also be used to rule out variables altogether in some cases. In Figure 5.1 
examples using the ‘all mentions’ dataset indicate that ‘whether published in the English 
language or not’ may have an effect on the response variable, ‘time from close to 
publication’, whereas  ‘international, limited international or single-country participation’ 
looks unlikely to have an effect. 
 
E=f u l l En g l i s h A= f u l l o t h e r wi t h En g l i s h a b s t r a c t
Day s f r o m c l o s e t o p u b l i c a t i o n
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Figure 5.1 Use of box-plots to determine whether classes of a categorical variable can be  
combined. Examples: time from close to publication vs. whether or not article is  
published in the English language and vs. whether level of participation is international, international  
(limited) or single-country. 
 
 
For each analysis the preliminary graphs and the proportion of missing values were used to help 
rule out variables for inclusion in the analysis. If a variable had more than 25% missing values, it 
was excluded.  
 
5.3.3  Analysis 
Once the list of possibly informative explanatory variables had been chosen, the preliminary 
analysis could be done. Multiple linear regression with backward elimination was used to obtain, 
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from these, the reduced set of significant variables. In this way the effect of each of the possible 
explanatory variables on the response variable was adjusted for that of the others. The method used 
is as follows:  
 
• All variables were included in the model to begin with, and at each step the variable with 
the largest p-value was dropped, reducing to a set of variables all with p<0.05.  Two pairs 
of variables are very highly correlated. These are number of trial arms (ARMS) and 
number of questions (NOQ), as discussed in Section 4.2, and start (NSTART) and close 
(NCLOSE) dates of accrual period. For the number of arms and number of questions the 
Pearson Correlation coefficient ρ = 0.94412 (p<0.0001), using the definitive records for all 
243 randomizations. For the start and close dates of the accrual period the Pearson 
Correlation coefficient ρ = 0.97210, (p<0.0001) using the 219 of the 243 definitive records 
for randomizations for which both start and close date are present. Only one from each pair 
was used in the initial regression with backwards elimination, generally ARMS and 
NSTART. Then, at the stage that one of these was dropped from the model, as the least 
significant variable, its opposite number was tried. If the first of the pair remained in the 
reduced set, its opposite number was then tried to see whether this improved the model. If 
both elements of a pair were included at the same time, their correlation could make them 
appear less significant than they are. Methods for selecting the model that best fits the data, 
from several possibilities, are described at the end of this section. 
 
• Many of the variables considered are categorical; some of which have more than two 
categories. To include a categorical variable with n categories in the analysis it is necessary 
to use (n-1) indicator variables. 
 
• The backward elimination process was done ‘by hand’ rather than using an automated 
procedure. The reason for this is that if an indicator variable, specifying a category of one 
of the categorical variables, is the least significant variable, it can only be dropped if it 
makes sense to pool this category with the default category, not specified by an indicator 
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variable. Otherwise categories must be pooled in a different way, with reference to the 
box-plots. The automated method is far quicker but would not necessarily have made 
sensible pooling choices. 
 
• Once the reduced set of significant variables was obtained, an attempt was made to 
improve on the fit of the model to the data. Each variable not used because of missing 
values and each variable thrown out during the elimination process was added in to the 
reduced set, one at a time. If a variable was dropped with a p-value of greater than 0.2 it 
was not tried again, as it is unlikely that it would be significant. Where a categorical 
variable with more than two categories was re-tried all indicator variables for it were put 
back in, so that all levels were represented. As an indicator variable became the least 
significant variable, categories were re-pooled. 
 
• If two variables were highly correlated (with correlation coefficient greater than 0.4, say) 
and the first was included in the reduced set of significant variables and the second not, 
then the first was replaced by the second to see if this improved the fit of the model. If the 
second variable had more missing values than the first it was not tried. 
 
• Once confident that the best main effects model has been found, interaction terms were 
tried. Only interactions of order 1 (i.e. involving two main terms only) were considered. If 
an interaction term is significant, but the p-value of one or both of the main terms exceeds 
0.05, there are differing opinions as to whether these main terms should be retained in the 
model (hierarchical modelling) or not. In the analyses reported here they have been kept. 
For an interaction term to be considered it must be believed that it has an effect on the 
response variable over and above that of the main effects separately. 
 
• Interactions were only tried if both the main terms were either significant or eliminated 
with a p-value <0.2, since if the main terms were not at all significant, it is unlikely that 
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their interaction would be. Also interactions were not introduced if they contained many 
missing values, the same rule applying here as for the inclusion of main terms. 
 
• Where an interaction was found to be significant, the analysis was re-run trying marginally 
significant variables (the last few to be dropped in the elimination process).  
 
Selecting the model that best fits the data 
The large number of missing values in the data, despite best efforts to find these, meant that for 
each analysis there were several contenders for best-fitting model. Adding in a variable to the 
reduced set sometimes resulted in one or more of the existing variables becoming no longer 
significant. This necessitated the task of comparing two or more models with different numbers of 
explanatory variables and which use different numbers of observations.  
 
There are three methods for doing this: 
• Two (or more) models are compared using only those observations which have no missing 
values for any of the variables in either (any) model. A forward stepwise multiple 
regression is performed allowing variables from both models to be selected.  
 
• The mean is calculated for each of the variables containing missing values and used where 
data  are missing. A similar forward stepwise multiple regression procedure is then used. 
 
• The problem is solved if both the above methods result in the same model being selected. 
Otherwise a more complicated imputation method could be tried. This involves estimating 
each explanatory variable with missing values by regressing on other explanatory 
variables, which are not in the model, and then using this estimate in the model, in the 
same way the mean is used. 
 
In practice the first two of these three approaches were used, and this was a sufficient basis on 
which to select the best-fitting model. The chosen model was then applied to the real data, i.e. 
using all available observations for the combination of variables used in the model and without 
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substituting in estimates of missing values. In some cases a variable of borderline significance, but 
with a p-value less than 0.05, when the two methods for comparing models were used, was found 
to have a p-value greater than 0.05 once the real data were used, and so was then dropped. 
 
5.3.4  Checking model assumptions (diagnostic plots) 
Once the best-fitting model was selected, the assumptions of the model were checked. 
1. The association between the response and the explanatory variables is linear 
2. The assumption of constant variance 
To check the above assumptions are satisfied, the standardised residuals were plotted against the 
fitted values. If the variance is constant the points will be scattered evenly above and below the X-
axis and  not form a wedge shape. An uneven spread could indicate that an important variable has 
been omitted, or that the relationship between the response and the explanatory variables is not 
linear. Ninety-five percent of observations should lie within two standard deviations. Observations 
lying outside three standard deviations are considered extreme outliers and have been investigated 
further, by looking at the studentised residuals (where each residual is divided by its standard 
error). The last few steps of the regression were re-run excluding the outlier(s) to see whether the 
significance of the variables changed. 
 
For each regression a plot of Cook’s distances (high influence points) against fitted values was 
obtained. This indicates how much effect any individual observation has on the model, i.e. how 
much the fitted values would change if that observation was omitted from the analysis. If an 
observation has an exceptionally large Cook’s distance it could be atypical and have too great an 
influence on the model and should possibly be excluded, if reasonable to do so. The Cook’s 
distances should be considered relatively rather than absolutely. One can appear large compared to 
the rest, but only because the others are small and an observation with a large Cook’s distance need 
not necessarily be an outlier. 
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3. The assumption of normality 
The normality assumption was checked using a normal probability plot. Here the residuals are 
plotted against their normal scores. The result is a straight line if the data are normally distributed. 
Any outliers show up at the extremities. 
 
Examples of the three diagnostic plots used are given for the first of the ‘time to first’ analyses in 
Section 6.3. 
 
4. The assumption of independence of observations 
The final assumption is that of independence of observations. As was described in Section 3.4, 
since each randomization belongs to a trial, which may comprise more than one randomization, it is 
important to consider whether randomizations belonging to the same trial may be correlated and, if 
so, whether ‘trial’ should be built into the models. A decision was made not to include ‘trial’ in the 
model for the following reasons: 
• An investigation was undertaken which indicated that analysing the data at ‘trial’ level and 
at ‘randomization’ level had similar effects on the time-period response variable. From this 
it was inferred that the correlations between randomizations belonging to the same trial are 
not of great importance. This is described in Section 8.20. 
• The object of interest is the randomization rather than the trial, since it is the randomization 
that is used in meta-analyses. 
• The 243 randomizations in this set of data are from a total of 195 trials. If ‘trial’ was to be 
incorporated into the model, this would need to be done using a categorical variable with 
194 indicator variables (or as a class variable with 195 categories) which may lead to 
overparameterisation and hence unreliable findings.    
 
The three regressions using the first mention for each randomization, and the three using the first 
results, have one record per randomization. For these independence can be assumed. Providing the 
other assumptions are also satisfied, the regressions performed as described previously are 
satisfactory. The results of these will be reported in the next chapter.   
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However the three regressions using all mentions and the three using all reportings of results can 
have multiple records per randomization. Therefore for these analyses independence of 
observations cannot be assumed, and this must be adjusted for. In order to do this, a repeated 
measures analysis must be applied to the data. However the independence model serves as a useful 
preliminary investigation and the results will be given in Chapter 7. 
 
5.4  The ordinary linear regression model  
In order to clarify the notation that will be used to describe the repeated measures model in Section 
9.2, an outline of the basic method using ordinary linear regression model, used for the final 
models where independence can be assumed and for the preliminary analyses, is given below. 
 
The ordinary linear regression, or independence, model is  
y = X β + ε  
 
where y is the n × 1 column vector of values for the response variable for n observations 
 
β is the (p + 1) × 1 column vector of parameters to be estimated (There are p explanatory  
 
variables in the model) 
  
X is the n × (p+1) matrix containing the values for the explanatory variables 
  
ε is the n × 1 column vector of values of the residuals for the n observations 
 
 
It requires that the following assumptions are satisfied: 
 
Yi  has distribution N (µi , σ2) ,  i = 1 …  n 
 
i.e.  the response variable is approximately normally distributed with the mean independent of the 
variance, and the variance is constant. 
 
Since for a normal distribution, the probability density function (pdf) is 
f (y / µ , σ2 ) = 1/√(2πσ2) exp [- (y
 
– µ)2  /2σ2] -∞ < y < ∞, 
the pdf for a single observation is 
f (yi / µi , σ2 ) = 1/√(2πσ2) exp [- (yi – µi)2  /2σ2] 
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and therefore the joint pdf for n independent observations is the product 
f (y1 … yn / µ , σ2 ) =  C
n
i 1=
1/√(2πσ2) exp [- (yi – µi)2  /2σ2]    
    = 1/√(2πσ2) n exp [-∑
=
n
i 1
 (yi – µi)2  /2σ2] 
 
The likelihood function, L, is a measure of how likely values y1 … yn are to have come from a  
distribution based on given values of µ and σ2. 
L (µ , σ2  / y1 … yn) = f (y1 … yn / µ , σ2 ) = 1/√(2πσ2) n exp [-∑
=
n
i 1
 εi
2  /2σ2] 
To maximize the likelihood is to minimize the sum of squares, ∑
=
n
i 1
 ε i
2  
= ∑
=
n
i 1
 (yi – µi)2 . 
Replacing µ by the linear combination of explanatory variables, 
 
µ = X β 
 
For the ith observation 
 
µi = Xi β  (the ith row of matrix X)  
 
Therefore it is necessary to minimise ∑
=
n
i 1
 ε i
2  
= ∑
=
n
i 1
 (yi – Xi β)2 . 
 
The estimating equations 
 ∂ [∑
=
n
i 1
 ε i
2
 ] / ∂βj = 0 ,  j = 0 …  p  
solve to  
βˆ = (XT X) -1 XT Y ,  where XT is the transpose of matrix X 
 
σ2  is estimated by s2 = RSS / [n-(p+1)], where RSS is the residual sum of squares. This is unbiased. 
 
5.5  Some problems relating to the preliminary analyses 
A summary of the problems encountered and possible solutions: 
 
• Many variables were considered, some of which are highly correlated. Preliminary 
analyses were used to reduce the number. For each analysis, a correlation matrix for all the 
possible explanatory variables was produced. To decide between two highly correlated 
variables the criterion was to keep the most meaningful or that with fewer missing values. 
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• Many observations have missing values for some of the variables. This reduces the 
proportion of the dataset that can be analysed and can also result in not knowing which of 
several possible preliminary models should be used. The number of explanatory variables 
and number of observations used may vary between models. Solutions to these problems 
are as follows:  
(i) Some missing values could be imputed using common sense, as described in Section 
4.3.4. 
(ii) Variables with more than 25% missing values were omitted from the regressions. The 
reason for this is that a variable missing for a very large proportion of observations is 
unlikely to have much influence on the response. 
(iii) Variables with some missing values (but 25% or less) were included in the analysis, 
but not in the initial regression with backwards elimination. They were tried one by 
one, once a reduced set of variables, with  p-values <0.05, had been found, to see 
whether the fit of the model could be improved. However this sometimes resulted in 
several possible models being produced, containing a varying number of explanatory 
variables and based on a varying number of observations. 
(iv) If there is a choice between two models, differing by one variable only, similar with 
regards to quality of fit, and where the two variables in question are highly correlated, 
the criterion for inclusion in the model is the variable which is most meaningful, or that 
with fewer missing values, as previously mentioned. 
(v) If a large number of observations are excluded due to missing values for one variable, 
that variable should probably be omitted. If it is highly correlated with another variable 
with fewer missing values, the latter would act as a surrogate. 
(vi) If there is more than one possible ‘best-fitting model’, the contenders can be compared 
using the tests described in Section 5.3.3. 
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• Some less obvious variables were added at a later stage for the sake of covering all options. 
Fortunately, these did not have missing values and were tried one-by-one into the best 
fitting model found so far. These are discussed in Section 5.6. 
 
• Multiple records per randomization, due to several reportings of some randomizations. 
Repeated measures analysis are used to compensate for this, as will be described in 
Chapters 8, 9 and 10. 
 
5.6  New variables introduced at a late stage 
The following variables, suggested by initial findings, were introduced at a late stage into the 
analysis. Also it was not feasible to consider further variables until some of the original variables 
had been dropped. In Chapters 6 and 7, where the results of the ordinary linear regression analyses 
are reported, the variables considered from the start are referred to as ‘initial variables’ and those 
introduced later as ‘second stage variables’. Since the choice of interactions considered was also 
made on the basis of initial findings, these too are included in the second group of variables. 
Second stage variables were added in one-by-one to the best-fitting model obtained using the initial 
stage variables. Most of the analyses show a marked improvement in the proportion of variability 
explained by the model (R2) once the second stage variables were incorporated. 
 
‘Not reported’ variables and categories for results fields and journal impact factor  
At first it appeared that the large number of missing values for statistical significance, clinical 
significance and direction of results meant that these important variables could not be included in 
the ‘all mentions’ and ‘first mentions’ analyses, using the ‘25% or less missing values’ criterion for 
inclusion of variables. Later it became clear that ‘not reported’ is an important category. This was 
rectified in different ways depending on whether the variable in question is categorical or 
continuous. 
 
For the categorical variables clinical significance (CLNSG) and direction of results (POSNG) this 
was resolved by introducing ‘X = not reported’ as an additional category.  
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Similarly the variable indicating whether the main question(s) stated in the paper had been 
answered in that paper (ANSWER) was given an ‘X = not reported’ category in addition to the 
yes/no options.  
 
The continuous variable indicating statistical significance (LOGPEST) was set to zero if data were 
missing. In addition a new dichotomous variable (LOGPNR) was introduced to indicate whether 
statistical significance was reported or not. This was set to 1 if statistical significance was not 
reported, and to 0 if it was. Using the two variables in conjunction it is possible to tell which 
records have non-significant results and which do not report results, even though LOGPEST is zero 
for both categories.  
 
A similar solution was used for the continuous variable ‘impact factor’ (IMPACT), which was 
missing for records from all books and from some journals and meeting abstracts. If no impact 
factor existed for an article, IMPACT was set to 0. A new variable NOIMPACT was also 
introduced. This was set to 1 if impact factor was missing and to 0 if present.   
 
‘Developing’ country (DEVLPNG) 
The categories for variable ‘country group of trialists’ are ‘North America’, ‘Europe’ and ‘Other’. 
It became apparent from one of the analyses that this was not sufficient. ‘Other’ includes India, 
South Africa, Argentina, Japan, Peru, Brazil, Australasia, Taiwan and Israel. For the purposes of 
this research, Australasia and Japan are probably more similar to North America or Europe than to 
some of the other countries in the ‘Other’ category. Also Poland is the only Eastern European 
country in the ‘Europe’ category. For this reason the country group categories were left unchanged, 
but an additional variable (DEVLPNG) created. This was set to 1 if the country running the trial is 
considered a ‘developing’ country and to 0 if considered a ‘developed’ country. Countries 
considered to be ‘developing’ are all those in the ‘Other’ country group listed above, minus Japan 
and Australasia, plus Poland.   
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Number of trials (NTREP) and number of randomizations (NRREP) reported in article  
Rather surprisingly, one of the variables found to be significant in several of the preliminary 
analyses was the number of randomizations (NRAND) belonging to a trial. This could be acting as 
a surrogate for the number of randomizations (or trials) reported in an article. This led to the 
creation of two new variables. Preliminary graphs indicated that a logarithmic transformation, 
LOGNTREP = log 10 (NTREP) should be tried in addition to NTREP. 
 
Number of co-authors (AUTHORS) 
It had been suggested that a large number of co-authors might result in an increased time from 
close to submission. This was only included at a late stage. The number of authors named in an 
article range from one to 42. A logarithmic transformation, LOGAUTH = log 10 (AUTHORS) was 
used. The reason for this is the hypothesis that the difference in effect on the response time variable 
of two authors collaborating compared with a sole author is greater than that when comparing, say, 
eleven authors with ten. Also, where an article names a very large number of authors, for example 
publication 267, [Tokyo Children’s Cancer Study Group, Tsuchida et al (1991)] with 42 authors 
(the entire membership of the trial working party), it is likely that only a few of those named were 
actually involved in the writing. This variable was tried in all 12 regressions.  
 
An additional complication is that early papers, which reported Medical Research Council trials, 
did not name the authors. Authorship was stated as ‘Medical Research Council Working Party’ and 
the working party members were listed elsewhere in each of the following; publications 277 
[Medical Research Council (1971)], 5 [Medical Research Council (1973)], 1 [Medical Research 
Council (1975)], 2 [Medical Research Council (1977)], 3 [Medical Research Council (1978)], 16 
[Medical Research Council (1982a)] and 15 [Medical Research Council (1982b)]. In some of these 
articles, members of the writing committee are indicated [Medical Research Council (1975), 
Medical Research Council (1977), Medical Research Council (1978)] but in others there is no 
indication of how many people were involved. In those analyses where LOGAUTH was found to 
be significant, or was eliminated from the regression at p<0.2, the regression was re-run, replacing 
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LOGAUTH with new variable LOGMRC. LOGMRC = log 10 (AUTHMRC), where AUTHMRC is 
equal to the number of authors (AUTHORS) where given, but set to 30, a typical size of an 
Medical Research Council working party, where not given. The results of the two regressions were 
then compared. 
 
A related variable, which was not considered, is the number of affiliations of the named authors. 
This is often stated on the paper. However, since it had not been used to compile references, it was 
not collected for this project.  Also there is the added problem of not knowing whether ‘the same 
affiliation’ means ‘working in the same building’, since it is the latter which is the variable of 
interest. For example, working party members listed as belonging to the Medical Research Council 
are located around the UK.  
 
Another possible variable to consider might be whether an article mentions working party 
collaboration or not. Again this has not been collected, and would require a further check of all the 
original articles.  
 
5.7 Interaction terms 
Interactions were only considered if the two main terms (or categories of terms, in the case of 
categorical variables) were either significant or eliminated with a p-value of <0.2.  
 
If one of the main effects is categorical (with n classes) and the other continuous, the interaction is 
expressed by the (n-1) indicator variables which describe the categorical variable each multiplied 
by the continuous variable. Interactions of this type considered are:  
• Conducted by trialists in North America and published in a journal with a high impact 
factor 
• Multi-centre trial and results with smaller p-values 
• International trial and results with smaller p-values 
• Large trial and clinically significant 
• International trial published in a journal with a high impact factor 
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• Large trial with a positive result  
• Equivalence trial and results with larger p-values 
• North American trial and results with smaller p-values  
• North American trial and longer duration of randomization period. (This was tried because, 
surprisingly, the number of randomizations was found to be significant in several 
regressions, and some US trials were segmented into many randomizations due to arms 
being dropped and replaced throughout the course of the trial.) 
• Large North American trial 
 
For an interaction between two continuous variables, one is kept as continuous and the other 
converted into a categorical variable. For example the continuous variable LOGSIZE, log 10 
(number of patients), was converted into a categorical variable with two classes i.e. either ‘greater 
than’ or ‘less than or equal to’ the median number of patients (median=146). Similarly, the 
continuous variable expressing statistical significance, the distance of log e (typical value of p) for 
each category from that for the not significant/not reported category, LOGPEST, was replaced by a 
categorical variable with three classes, highly significant (p<0.0001), significant (p<0.05 but 
>0.0001) and non-significant (p>0.05). An interaction dealt with in this way is: 
• Large trial and results with smaller p-values 
This was tried in two ways, taking size of trial as the continuous variable and statistical 
significance as the categorical, and vice versa.   
 
In the case of an interaction between two categorical variables, the interaction is the specified 
criteria versus all other combinations. Interactions of this type are: 
• Conducted by North American trialists and published by a North American journal 
• Multi-centre trial with a clinically significant result 
• International trial with a clinically significant result 
• Multi-centre trial with a positive result  
• International trial with a positive result  
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• Equivalence trial with a clinically significant result 
• Equivalence trial with either a null or a negative result  
• North American trial with a clinically significant result 
• North American trial with a positive result  
• Multi-centre North American trial  
• International North American trial 
 
To begin with the choice of interaction between categorical variables was made with the intention 
of investigating the category most likely to result in a shorter time to publication. However, later it 
was decided also to look at the opposite category, that which may result in a delay to publication. 
This yielded some interesting results. This latter group of interactions considered included: 
• Small trial with results with larger p-values 
• Single-centre trial with results with larger p-values 
• Single-country trial with results with larger p-values 
• Small trial with results not clinically significant 
• Single-centre trial with results not clinically significant 
• Single-country trial with results not clinically significant 
• Small trial with direction of results other than positive 
• Single-centre trial with direction of results other than positive 
• Single-country trial with direction of results other than positive 
• Trial conducted outside North America and Europe with results with larger p-values  
• Trial conducted outside North America and Europe with results not clinically significant 
• Trial conducted outside North America and Europe with direction of results other than 
positive 
• Small trial conducted outside North America and Europe 
• Single-centre trial conducted outside North America and Europe 
• Single-country trial conducted outside North America and Europe 
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Since there are many interactions that could be considered, it was decided, in the case of an 
interaction between two categorical variables, each with several categories, to try only the 
interactions using those categories where the significance of the main term strongly suggested an 
effect was likely. For example, if for direction of results, the response variable did not differ 
significantly between positive and null results,’ non-positive results’ would not have been tried as 
an interaction with another variable. 
 
5.8  Criteria for including variables, or categories of variables, in the analyses 
For all twelve ‘How long?’ analyses, a variable was included only if there were 25% or less 
observations with missing values.  
 
For categorical variables, preliminary graphs (box-plots) were also used to decide which variables 
might have an effect on the response, and which categories could be pooled from the start. The 
categorical variables were represented by indicator (or dummy) variables, one less than the number 
of categories for each variable. The first three letters of the name of each dummy variable are 
DUM. The last part of the name is descriptive. Generally, variable names are consistent between 
analyses. However this is not so for the dummy variables. For example variable CGROUP is the 
country group of the trialists, and has categories North America (A), Europe (E) and Other (O). For 
one analysis, preliminary graphs may indicate that North American randomizations should be 
compared with those from European and other countries combined. In this case DUMCGRP is set 
to 1 if CGROUP= E or O and to 0 if CGROUP= A. However another analysis may involve 
comparing randomizations conducted in other countries with those from North America and 
Europe combined. In this case DUMCGRP is set to 1 if CGROUP=O and to 0 if CGROUP = A or 
E. If all three country groups need to be represented separately then two dummy variables 
DUMCGRP1 and DUMCGRP2 are used. The name and meaning of each dummy variable is given 
at the start of the output for each regression in Appendices VIII and IX.  
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For continuous variables, preliminary graphs (scatter plots) were produced. Provided that there 
were 25% or less missing values, all continuous variables were included in the initial regression. 
There were three reasons for this: firstly, it is more difficult to assess whether a continuous (as 
opposed to a categorical) variable will affect the response merely by looking at the graph. Secondly 
there is no extra work involved in order to try continuous variables in the regression (unlike with 
categorical variables where indicator variables must be created). Thirdly there are relatively few 
continuous variables. Scatter plots were also used to decide whether any of the continuous 
variables required the use of a transformation.  
 
In the initial stage, variables with no, or few, missing values, and which might affect the response 
were included in the initial regression using a backwards elimination procedure. Once a reduced set 
of significant variables was obtained, the variables with missing values, but not more than 25% 
missing, were added in one-by-one to see if a better fitting model could be found. 
 
The second stage variables, none of which have any missing values, were then tried in turn. 
Finally, those interactions thought possibly to have an effect were also tried. 
 
Appendix VII lists all variables tried in each of the twelve ‘How long?’ analyses in tabular form. 
The following details are given: 
• The stage in the analysis at which each variable was tried 
• The proportion of missing values for those variables for which this is of note 
• For categorical variables, the pooling choices made 
• Box-plots were used to decide which categorical variables to use and how to pool classes. 
In most cases the indication was clear, but cases where the decision to include a particular 
variable or pooling was borderline, are also shown in the table 
• For interaction terms tried, the combination selected versus all others is specified 
 
The alphabetical list of variables and their meanings given in Appendix IV is useful for 
interpreting the table. 
82 
 
5.9  Range and mean of the response variable for each analysis 
For each analysis, the mean and the range of the response variable is given. Since open 
randomizations can be reported, for example by reference to a subsequent trial starting, in the 
discussion section of an article, it is possible that the minimum time from close of randomization to 
submission or minimum time from close of randomization to publication may be negative. This 
may be exacerbated (or lessened) by the fact that some of the dates of both publication and close of 
randomization are inaccurate, i.e. only the year is known and, for analysis purposes, 30 June has 
been used.  
 
5.10  Typical change in the response variable caused by each explanatory variable 
The typical change in the response variable caused by each explanatory variable is given for the 
final choice of model for each analysis of a ‘time to’ response variable. These are reported in 
Chapter 6 for the analyses of first mentions and first resportings of results, and in Chapter 11 for 
the analyses of all mentions and all reportings of results. For each variable the typical change was 
obtained using the coefficient (β estimate) given in Appendix VIII in the case of analyses of first 
mentions and first reportings of results, and in Appendices XV and XVIII for the analyses of all 
mentions and all reportings of results.  
 
The following method was used to calculate the typical effects: 
• In the case of an indicator variable specifying the effect of a class of a categorical variable, 
the typical effect (in days) is given by the coefficient from the appropriate analysis 
• In the case of a continuous variable an estimate is calculated by multiplying its standard 
deviation as given in Appendix V by the coefficient. 
 
From Appendix V it can be seen that time from close to publication (mean 4 years 11 months) is 
largely made up from the time from close to submission (mean 5 years 3 months), with time from 
receipt to publication making a very small contribution (mean 10 months). The reason that the 
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mean time from close to submission appears longer than the mean time from close to publication is 
that both date of close of randomization and date of submission of article are known for only 209 
publication records, whereas both date of close of randomization and date of publication are known 
for 582 publication records, and so latter is more representative of the whole set of reportings. 
Since the time from receipt to publication is far shorter than the other two time intervals, the typical 
effect any variable this is much smaller.  
 
5.11  Atypical observations 
From the diagnostic plots an observation is considered atypical if one or both of the following 
apply: 
• It is an extreme outlier i.e. the magnitude of its studentised residual is greater than 3. 
• It has a much larger Cook’s distance than that of most other records  
 
Some articles generate records which are all atypical. In one case (record 967) an individual record 
is atypical although all other records from the same publication are not. Certain outlying 
publications and individual records appear in several of the analyses. 
 
Record 967 is an important outlier in two of the ‘time to first’ analyses and also in two of the 
‘repeated measures’ analyses, and so is described here. Other atypical publications and individual 
records apply to either one or the other and so are discussed at the beginning of the chapter 
reporting their results. The purpose of this is to show patterns common to several regressions and to 
allow the publication ID and/or record ID to be used without further explanation when reporting 
the results.  
 
For all atypical articles and individual records, the following checks were made for  typographical 
errors:   
• The dates of submission/receipt, acceptance and publication held in the computer were 
checked against the original article. 
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• The date of close of randomization (and date of start) was checked against the information 
held in the ACCESS database for all randomizations which had one or more atypical 
records. The reason for this is that the date used in the analysis was taken from the 
definitive record for each randomization, which was compiled using information from all 
publication records for that randomization. 
 
No typographical errors were found.  
 
As described Section 3.13, if an observation was found to be atypical, (i.e. an outlier with 
studentised residual of magnitude greater than or equal to 3 and/or a large Cook’s distance relative 
to those of other observations), any notes codes attached to that observation were examined. If 
other non-outlying observations were also found to have that notes code, the notes code could be 
ignored safely. Otherwise it was investigated further. For all twelve ‘How long?’ analyses the notes 
codes attached to atypical observations were also attached to others and so could be ignored.    
 
Record 967 
Record 967 represents the data on trial 2199’s sole randomization 2199, reported in publication 284 
[Sackmann-Muriel et al (1998)], and is an outlier in many analyses. 
 
It appeared as an outlier in two of the ‘time to first’ analyses, ‘time from close to submission’ and 
‘close to publication’ for ‘first mentions’. Publication 284 generated seven records in total, of 
which records 974, 973 and 972 were also used in these two analyses and not found to be atypical. 
Record 967 was not used in any of the other four ‘time to first’ analyses because it has a missing 
value for one of the variables in the final model for ‘time from receipt to publication for first 
mentions’, country group of publisher (JGROUP), and it does not contain results and so could not 
be used in any of the three ‘first results’ analyses.  
 
Similarly it is also an outlier in the ‘time from close to submission’ and ‘time from close to 
publication for all mentions’ analyses. All seven records from publication 284 were used in these 
analyses, and again none, apart from 967, were atypical, with the exception of 955 in the former. 
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Record 967 could not be included in the other four preliminary analyses for the ‘repeated 
measures’ data for exactly the same reasons as for the ‘time to first’ analyses; that JGROUP is 
missing for this record, and this variable is in the model for ‘time from receipt to publication for all 
mentions’, and that the record contains no results and so is excluded from the three ‘all results’ 
analyses. 
  
Randomization 2199 was not found during the routine identification process conducted by the 
Cancer Overviews Group. The GATLA Protocol 11-ALL-67 is an early Argentinian trial, open 
between November 1967 and September 1970, and does not appear to have been published until 
1998. It was received by the journal on 21 September 1996. It accrued only 38 patients and 
compares two maintenance treatments: Methotrexate given at doses 30mg/m2 versus 15mg/m2, 
twice weekly, with both arms receiving 6-mercaptopurine + vincristine + prednisolone pulses every 
six months. The duration of treatment was five years. Other studies conducted by this group at 
around the same time were not randomized and are not included in this thesis. The time from close 
to submission is 26 years 2 months, and from close to publication is 27 years 9 months.    
 
This observation has been included in the analyses. It is certainly atypical, lying well into the tail of 
the normal distribution, but since there is no reason to believe that the randomization procedure 
used in the trial is invalid, the randomization would be eligible for inclusion in meta-analyses. The 
regressions for which it is an outlier have also been re-run excluding it. Where its exclusion would 
have led to a change in the conclusions this is discussed in the appropriate section.  
 
It is worth noting the enormity of the typical effect of variable DEVLPNG (trial conducted in a 
developing country), in the reportings of the analyses that follow. From Appendices VIII, XV and 
XVIII it can be seen this variable has a large coefficient, which has a large standard error. Also 
only 15 of the 243 randomizations were conducted in developing countries. While undoubtably this 
is an important explanatory variable, its typical effect is likely to have been over-emphasised by the 
inclusion of record 967. To a lesser degree variable CGROUP (country group of trialists) is 
affected similarly. This should be borne in mind when interpreting the findings.
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6  FINAL RESULTS OF THE SIX ‘TIME-TO-FIRST’ ANALYSES 
 
6.1  Introduction 
This chapter begins by describing two outlying observations from the analysis of time from close to 
publication for first mentions. The results from the six ‘time to first’ analyses are then reported. 
These use the three time period response variables: ‘time from close to submission’, ‘time from 
receipt to publication’, and the sum of these, ‘time from close to publication’, firstly for the first 
mentions and then for the first results for each randomization.  Since all the assumptions of the 
linear regression model, including that of independence of observations, are satisfied, these are the 
final results. Details of the variables tried in these analyses are given in Appendix VII and the 
output for the final choice of model in each case is given in Appendix VIII. 
 
6.2 Outlying articles and records 
The atypicality of the following observations can probably be safely disregarded. 
 
Publication 135 
Publication 135 [Otten et al (1988b)], generated two records, 696 and 697, for the two 
randomizations 1901 and 1902 belonging to trial 1901, EORTC  58741. This is the sole reporting 
of this trial. Both records appeared as outliers in the ‘time to publication for first results’ analysis 
(with standardised residuals of approximately 3.3 and 3.4 respectively) and the second and third 
largest Cook’s distances respectively. The randomization was open between May 1971 and January 
1979. It was published as an abstract for the Medical and Pediatric Hematology (SIOP) meeting 
and was referred to in the title as ‘a long term evaluation’. For a first publication and in abstract 
form the time from close to publication is unusually long at 9 years 8 months. 
 
Record 716 
Publication 148 [Sackmann-Muriel et al (1978)] generated three records, 716, 717 and 718, relating 
to randomizations 2101, 2102 and 2103 belonging to trial 2101, GATLA 72, open between October 
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1972 and December 1975. The first two are used in the ‘time from close to publication for first 
results’ analysis, with the first having the largest Cook’s distance. It was not an outlier but had a 
low studentised residual (-2.3). The article was published in October 1978 in Cancer which has 
impact factor 2.864. The results were null, and neither statistically nor clinically significant.  Time 
from close to publication is short, 2 years 10 months.  
 
6.3 For the first mention of each randomization, which trial characteristics affect the time 
from close to submission? 
The best fitting model using the initial set of variables 
Time from close to submission is longer for randomizations with the following characteristics: 
• Shorter duration of accrual period (DURRAN) (p<0.0001) 
• Conducted outside North America (CGROUP) (p<0.0001) 
• Trial comprises fewer randomizations (NRAND) (p=0.0032) 
(R2=0.401878, F- statistic=13.21, p-value<0.0001, based on all 63 observations) 
 
Comments on diagnostic plots 
This analysis resulted in one extreme outlier; record 967, which is described in Section 5.10. It had 
by far the largest Cook’s distance and a studentised residual of 4.28.  
 
This was removed and the regression re-run. This gave a similar result; R2=0.398250, F=12.80,  
p-value<0.0001 using 62 observations. The three variables remained in the model each acting in 
the same direction, the significance of the first two remaining at <0.0001, and that of NRAND 
dropping to 0.0128.  
 
The three diagnostic plots are given in Figures 6.1, 6.2 and 6.3. 
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Figure 6.1 Linear regression model using the initial set of variables for time from close to submission for  
first mentions. Diagnostic plot to check model assumption of constant variance of response variable:  
standardised residuals vs. fitted values 
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Figure 6.2  Linear regression model using the initial set of variables for time from close to submission for  
first mentions. Diagnostic plot to check model assumption of normality of response variable: residuals vs. 
their normal scores 
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Figure 6.3 Linear regression model using the initial set of variables for time from close to submission for  
first mentions. Diagnostic plot to highlight atypical observations: Cook’s distances vs. fitted values 
 
There were now two new outliers from trial 2198 reported in publication 284; record 972 
(randomization 2198) and record 973 (randomization 2197), both had studentised residuals equal to 
3.32 and large Cook’s distances. These, like 967, are newly found randomizations. The third largest 
studentised residual (2.49) is record 974 (randomization 2104) also from publication 284. Record 
908 (trial 30501, which has sole randomization 30501 and is reported in publication 269) also had a 
large Cook’s distance and a fairly high but negative studentised residual (-1.94). In order of 
magnitude the four largest Cook’s distances are for records 972 and 973 (superimposed), 974 and 
908. The table in Appendix I provides further details of these randomizations.  
 
All three records belong to the ‘Other’ category for country group of trialists. The first two 
randomizations were conducted in Argentina, a ‘developing’ country, and the third in Australasia, 
‘developed’.  Also residuals were large and positive for the first two and fairly large and negative 
for the third, indicating that the third record should not be grouped with the first two. This led to 
the introduction of a new variable to distinguish between randomizations conducted by trialists in 
‘developing’ countries and those in ‘developed’ countries (DEVLPNG). This new variable was 
subsequently tried in other analyses.  
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Comments on the final model 
The only new significant variable to be added to the model once the second stage variables were 
included is whether the randomization was conducted in a ‘developing’ or a ‘developed’ country 
(DEVLPNG). When this, the country group of trialist (DUMCGRP) and the interaction term for 
North American trials published in North American journals were all in the model, the vector of 
interactions was almost identical to that of one of the main effects, indicating that the interaction 
term practically reproduces one of the columns in the design matrix. 
 
No outliers remained in the final model, although observation 967, which has previously been 
described, has a large Cook’s distance. When removed the model remained unchanged (F=36.21 
on 62/63 observations). It was decided that this record should be left in. Although there is not a 
suitable formal test to compare the model developed using only the initial set of variables and the 
final model, it is worth noting that the value of R2, the measure of how much variability in the 
response variable, ‘time from close to submission’, is explained by the model, has increased 
substantially from 0.40 to 0.77. 
 
Final results 
Time from close to submission is longer for randomizations with the following characteristics: 
• Shorter duration of accrual period (DURRAN) (p<0.0001), typical effect 2 years 7 months 
• Conducted outside North America (CGROUP) (p<0.0001), typical effect 3 years 8 months 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001), typical effect 13 years 8 
months 
• Trial comprises fewer randomizations (NRAND) (p=0.0125), typical effect 11 months 
(R2=0.774776, F- statistic=49.88, p-value<0.0001 based on all 63 observations) 
Mean and range of response variable: 1412 ( –1113 to 9503) days, i.e. approximately 3 years 10 
months (–3 years 1 month to 26 years 0 months).  
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6.4  For the first mention of each randomization, which trial characteristics affect the time 
from receipt to publication? 
The best fitting model using the initial set of variables 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Trial comprises fewer randomizations (NRAND) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p=0.0002)  
(R2=0.400376, F-statistic=21.37, p-value<0.0001, based on 67 of the 72 observations) 
 
Comments on the final model 
Before trying the interactions between country group and duration of accrual period, and between 
country group and whether there was international participation or not, the following model was 
obtained: 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Trial comprises fewer randomizations (NRAND) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p<0.0001) 
• Reported in articles which mention fewer randomizations (NRREP) (p=0.0002) 
• No clear indication given of whether results are clinically significant or not (DUMCLN) 
(p=0.0328) 
(R2=0.530205, F-statistic=17.49, p-value<0.0001 based on 67 out of 72 observations (93%))  
 
There were no outliers or observations with large Cook’s distances. The observations omitted are 
due to missing values for publisher country group (JGROUP). 
 
Whether considering main effects alone, or including interactions, this has been the most difficult 
analysis to model, since missing values have caused instability. Introduction of the interactions 
between country group and duration of accrual period, and between country group and whether 
there was international participation or not resulted in the creation of four other possible models. 
These are all based on smaller numbers of observations. Given that the dataset is small, the 
response variable only present for 72 observations, and the models unstable, conservation of 
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observations is important. The analyses using the other four models are based on 59 observations 
(82%) (three) and 54 (75%) (one).  
 
The model selected was the only one which added terms but did not result in any of the four 
variables NRAND, JGROUP, NRREP or CLNSG being dropped. The additional main effects 
CGROUP and DURRAN are non-significant (p=0.0710 and p=0.6869 respectively) but are 
retained because of the moderate significance of the interaction between country group and 
duration of accrual period (p=0.0263). It is unclear as to whether the model chosen is the most 
appropriate, but it is the cautious choice.  
 
Analysis of diagnostic plots indicates no outliers or observations with large Cook’s distances. The 
additional observations omitted are due to missing values for duration of accrual period 
(DURRAN). 
 
Final results 
Time from receipt to publication is longer for randomizations with the following characteristics: 
Main effects: 
• Trial comprises fewer randomizations (NRAND) (p=0.0135), typical effect 1 month 
• Published in a North American or European journal (JGROUP) (p<0.0001), typical effect 
8 months 
• Fewer randomizations reported in each article (NRREP) (p=0.0010), typical effect 1 month 
• No clear indication given of whether results are clinically significant or not (DUMCLN) 
(p=0.0175), typical effect 2 months 
Interaction: 
• For trials conducted outside North America, longer duration of accrual period 
(CGROUP*DURRAN) (p=0.0263), typical effect 2 months 
[In addition the typical effects of the non-significant main effects CGROUP and shorter duration 
of randomization period DURRAN are 4 months and 1 week respectively.] 
(R2=0.610919, F-statistic=11.44, p-value<0.0001 based on 59 out of 72 observations (82%)) 
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Mean and range of response variable: 231 (18 to 497) days, i.e. approximately 8 months (1 month 
to 1 year 4 months).  
 
6.5  For the first mention of each randomization, which trial characteristics affect the time 
from close to publication? 
The best fitting model using the initial set of variables 
Time from close to publication is longer for randomizations with the following characteristics: 
• Earlier randomizations (NSTART) (p<0.0001) 
• Shorter duration of randomization period (DURRAN) (p=0.0042) 
• Treatment type is immunotherapy as opposed to radiotherapy or chemotherapy 
(TXCHEMO) (p=0.0352) 
• Trials conducted outside North America and Europe (CGROUP) (p<0.0001) 
• Randomization has not been presented at a meeting (PRESENTED) (p=0.0005) 
• Published in a journal with a low or no impact factor (IMPACT) (p=0.0352) 
• Main question stated in article is clearly either answered or not answered in the article, as 
opposed to when this is not reported (ANSWER) (p=0.0137) 
• Not an equivalence trial (EQUIV) (p=0.0287) 
(R2=0.405110, F-statistic=15.66, p-value<0.0001 based on 193 out of 195 observations) 
 
Comments 
A preliminary graph indicated that publication type (PUBTYPE) i.e. whether the article was 
published in a book, journal or meeting abstract may be important. Book publication appeared to 
take longer. However, this variable was abandoned when it became clear that there was only one 
book publication in the dataset used. The spread of data for some of the other variables used is also 
uneven, but all categories of all other variables contain at least five observations. To show how 
much more extreme the problem with publication type is than with other variables, the categorical 
variables with the most uneven spread of data in this analysis are shown here: 
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Publication type (PUBTYPE):  
154 (79%) journals, 1 book (0.5%) 40 abstracts (20.5%) 
Treatment type (TXCHEMO):  
5 (2.6%) immunotherapy, 188 (96.4%) other categories, 2 (1%) missing 
Target number of centres reached? (CTARGET):  
7 (3.6%) no, 152 (78%) yes, 36 (18.4%) missing  
Published in English language? (ENGLISH):  
185 (94.9%) yes, 10 (5.1%) no 
First-line treatment? (FIRSTL):  
170 (87.2%) first-line, 17 (8.7%) relapse/refractory, 8 (4.1%) missing  
 
Table 4.3 lists all variables for which one category (excluding the missing values category) 
contains less than 10% of the total, when all 610 records are included. 
 
Comments on the final model 
Incorporating the second stage variables resulted in treatment type (TXCHEMO) (immunotherapy 
versus all other categories) being dropped (p=0.2719) and two new variables entering the model; 
trial conducted by ‘developing’/’developed’ country (DEVLPNG) and number of trials reported in 
article (NTREP). Note that TXCHEMO has a correlation coefficient >0.3 with both country group 
of trialists (CGROUP) and DEVLPNG. None of the interaction terms tried was significant. 
 
There was one extreme outlier (record 967 see Section 5.9). The studentised residual for this 
observation was >4 and it had by far the largest Cook’s distance. However, when the regression 
was re-run omitting this observation, the model remained unchanged, i.e. all the variables in it 
remained significant. (F=15.57 on 194/195 observations). Therefore it was decided to leave this 
record in the analysis. There were also two borderline outliers; record 533, the only record of the 
nine from publication 57 included in this analysis, with studentised residual 3.02, and record 564, 
one of a pair from publication 72, the other not used in this analysis, with studentised residual 3.09. 
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Final results 
Time from close to publication of article is longer for randomizations with the following 
characteristics: 
• Earlier randomizations (NSTART) (p<0.0001), typical effect 1 year 3 months 
• Shorter duration of accrual period (DURRAN) (p=0.0083), typical effect 7 months 
• Conducted outside North America and Europe (CGROUP) (p=0.0434), typical effect 1 
year 9 months 
• Not presented at a meeting (PRESENTD) (p=0.0003), typical effect 1 year 9 months 
• Reported in a journal with a low or no impact factor (IMPACT) (p=0.0089), typical effect 
8 months 
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper (ANSWER) (p=0.0002), typical effect 1 year 9 months 
• Not an equivalence trial (EQUIV) (p=0.0094), typical effect 1 year 5 months 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001), typical effect 5 years 3 
months 
• Reported in articles which mention a greater number of trials (NTREP) (p<0.0001), typical 
effect 8 months 
(R2=0.489958, F-statistic=19.75, p-value<0.0001 based on all 195 observations) 
Mean and range of response variable: 1262 (-1679 to 10150) days, i.e. approximately 3 years 5 
months (-4 years 7 months to 27 years 9 months).  
 
6.6  For the first reporting of results for each randomization, which trial characteristics affect 
the time from close to submission? 
The best fitting model using the initial set of variables 
Time from close to submission is longer for randomizations with the following characteristics: 
• Earlier close date (NCLOSE) (p=0.0116) 
96 
• Multi-centre participation (MULTIC) (p=0.0065) 
• Conducted in a European country (CGROUP) (p=0.0207) 
• Conducted in a country other than North America or Europe (CGROUP) (p=0.0063),  
the latter having a greater effect than the former.  
(R2=0.298416, F statistic=5.00, p-value=0.0019 based on all 52 observations) 
 
Comments on final model 
In the final analysis no interactions were significant.  
Diagnostic plots showed no outliers and no observations with large Cook’s distances. 
 
Final results 
Time from close to submission is longer for randomizations with the following characteristics: 
• Earlier close date (NCLOSE) (p=0.0036), typical effect 1 year 4 months 
• Multi-centre participation (MULTIC) (p=0.0063), typical effect 1 year 11 months 
• Conducted in a European country (CGROUP) (p=0.0008), typical effect 3 years 6 months 
• Conducted in a country outside North America and Europe (CGROUP) (p=0.0007), typical 
effect 5 years 5 months 
(A clearer interpretation of the previous two results is that results of North American trials are 
submitted fastest, followed by those from European trials, with those from trials conducted 
elsewhere having the longest time from close to submission).  
• Published in a journal with a high impact factor (IMPACT) (p=0.0242), typical effect 1 
year 10 months 
• Direction of result is not negative (POSNG) (p=0.0147), typical effect 2 years 6 months 
• Direction of result is not positive or null POSNG (p=0.0107), typical effect 2 years 2 
months 
(A clearer interpretation of the latter two results is that randomizations with negative results are 
submitted more quickly than those with positive or null results, with those with opposite results or 
where the direction of results is not reported taking the longest time.)  
  
97 
(R2=0.460099, F-statistic=5.36, p-value=0.0002 based on all 52 observations) 
Mean and range of response variable:  1294 (-191 to 4026) days, i.e. approximately 3 years 5 
months (-6 months to 11 years 0 months).  
 
6.7 For the first reporting of results for each randomization, which trial characteristics 
affect the time from receipt to publication? 
The best fitting model using the initial set of variables 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Trials comprises fewer randomizations (NRAND) (p=0.0030) 
• Funded by charity as well as Government money (FUNDG) (p=0.0153) 
• An indication of whether the paper is answering the main trial questions as specified in the 
paper, or not, as opposed to not reporting this (ANSWER) (p=0.0337) 
• Treatment type is immunotherapy or chemotherapy rather than radiotherapy (TXCHEMO) 
(p=0.0449) 
(R2=0.327469, F-statistic=5.36, p-value=0.0013 based on 49 of the 60 observations) 
 
Comments on the final model 
The effects of number of trials and number of randomizations mentioned in an article (NTREP and 
NRREP) are in opposite directions. 
There were no outliers or observations with large Cook’s distances. 
 
Final results 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Funded by charity as well as Government money (FUNDG) (p=0.0003), typical effect 3 
months 
• Reported in an article which mentions a larger number of trials (NTREP) (p=0.0001), 
typical effect 1 month 
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• Reported in an article which mentions a smaller number of randomizations (NRREP) 
(p<0.0001), typical effect 2 months 
• Has been presented at a major meeting (PRESENTD) (p=0.0032), typical effect 2 months 
• Results not clearly reported as clinically significant (CLNSG) (p=0.0056), typical effect 3 
months 
• Results not clearly reported as not clinically significant (CLNSG) (p=0.0040), typical 
effect 3 months, 
the effect of the latter being only marginally greater than that of the former. 
(A clearer interpretation of the latter two results is that results clearly not clinically significant are 
published fastest, closely followed by those which clearly are clinically significant. Where clinical 
significance is not reported, the time from receipt to publication is longest.)  
(R2=0.583463, F-statistic=9.81, p-value<0.0001 based on 49 out of 60 observations) 
Mean and range of response variable: 232 (18 to 421) days, i.e. approximately 8 months (1 month 
to 1 year 2 months).  
 
6.8  For the first reporting of results for each randomization, which trial characteristics affect 
the time from close to publication? 
The best fitting model using the initial set of variables 
Time from close to publication is longer for randomizations with the following characteristics: 
• Earlier randomizations (NSTART) (p=0.0007) 
• Shorter duration of randomization period (DURRAN) (p<0.0001) 
• Treatment type is immunotherapy as opposed to radiotherapy, chemotherapy or antibiotic 
(TXCHEMO) (p=0.0498) 
• Conducted outside North America and Europe (CGROUP) (p=0.0083) 
(R2=0.221724, F-statistic=11.68, p-value<0.0001 based on 169 out of 170 observations) 
 
Comments 
The one missing value is for treatment type (TXCHEMO), a variable of borderline significance. 
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Comments on the final model 
Incorporating the second stage variables resulted in treatment type (TXCHEMO) which was of 
only borderline significance, being dropped (p=0.0651). New significant main effects are impact 
factor (IMPACT), whether the journal had an impact value associated with it (NOIMPACT), 
clinical significance (CLNSG), statistical significance (LOGPEST) and direction of results 
(POSNG). Two interactions are also significant. These are European trials published in journals 
with a high impact factor, and null results from randomizations conducted outside North America 
and Europe. The introduction of the latter caused start of accrual period (NSTART), which was of 
borderline significance (p=0.0439) to be dropped (p=0.1098). When country group of trialists was 
split into ‘North America’ versus ‘Europe’ versus ‘Other’, so that the categories of this variable 
used in the interactions were also included as main effects, the two main terms were not significant. 
The interaction between statistical significance and null result was also significant, but this was 
found to be based on a subset of size 1. Record 697, (randomization 1902) is the only occurrence of 
a record with statistical significance ‘p<0.05’ and direction of results ‘null’ associated with it. This 
interaction term is therefore not included in the model. This observation is discussed in more detail 
in Section 4.4.  
 
Diagnostic plots now show a pair of outliers, records 696 and 697, from randomizations 1901 and 
1902 respectively, from publication 135.  These have studentised residuals of 3.3 and 3.4 and the 
second and third largest Cook’s distances, with record 716 one of a pair from publication 148 
having the largest. 
 
Note the increase in the proportion of variability explained by the model once the second stage 
variables are incorporated, from a poor R2 value of 0.22 to a moderate 0.36. 
The revised model is now given. 
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Final results 
Time from close to publication of article is longer for randomizations with the following 
characteristics: 
Main effects: 
• Shorter duration of accrual period (DURRAN) (p=0.0002), typical effect 9 months 
• No clear indication of whether clinically significant or not is given (CLNSG) (p=0.0060), 
typical effect 1 year 3 months 
• Reported in a journal with an impact factor associated with it (NOIMPACT) (p<0.0001), 
typical effect 2 years 
• Results with larger p-values associated with them (LOGPEST) (p=0.0153), typical effect 6 
months 
• Published in a journal with a low impact factor (IMPACT) (p=0.0062), typical effect 9 
months 
• Direction of results not null (POSNG) (p=0.0127), typical effect 1 year 2 months 
Interactions: 
• Conducted by European trialists and reported in a publication with a high impact factor 
(CGROUP*IMPACT) (p=0.0006), typical effect 1 year 9 months 
• Conducted outside North America and Europe and results are null (CGROUP*POSNG) 
(p=0.0023), typical effect 4 years 6 months 
[The typical effects of the non-significant main effects CGROUP are: conducted outside Europe 7 
months, and conducted outside North America and Europe 1 month.] 
(R2=0.364055 F-statistic=9.10, p-value<0.0001 based on all 170 observations) 
Mean and range of response variable: 1310 (-972 to 4326) days, i.e. approximately 3 years 7 
months (–2 years 8 months to 11 years 10 months).  
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7  PRELIMINARY RESULTS OF THE ‘ALL MENTIONS’ AND ‘ALL REPORTINGS OF 
RESULTS’ ANALYSES 
 
7.1  Introduction 
This chapter begins by explaining why, if the assumption of independence is not satisfied, the 
correlations must be compensated for. This is followed by a description of atypical publications 
and individual observations which were outliers in one or more of the ‘all mentions’ and ‘all 
reportings of results’ analyses. The findings from these six analyses are then described.  These are 
the analyses with the three time period response variables; ‘time from close to submission’, ‘time 
from receipt to publication’ and the sum of these, ‘time from close to publication’, firstly for all 
records (i.e. all mentions of all randomizations) and then for all records which contain results. 
Since there can be more than one record relating to each randomization, the assumption of 
independence is not satisfied, and so the correlations should be accounted for. Therefore the results 
of the analyses reported in this chapter are preliminary findings only. Details of the variables tried 
in these analyses are given in Appendix VII and the output for the final choice of preliminary 
model in each case is given as Appendix IX.  
 
7.2 The need to account for repeated measures 
In the three analyses involving all mentions and the three involving all results, some 
randomizations generate several records, and so records are not independent. Therefore repeated 
measures need to be compensated for. However before this stage it is necessary to perform 
preliminary analyses which use the same methods as the final analyses for the ‘time to first’ 
questions reported in the previous chapter. 
 
Reasons for using preliminary analyses with multiple linear regression (the independence model): 
• To get a feel for the data 
• To reduce the number of variables that need investigating with repeated measures analysis.  
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• To obtain preliminary graphs and diagnostic plots. The diagnostics from multiple linear 
regression, for analysing residuals, are good and well trusted. 
• Repeated measures analysis involves an iterative method, which uses much more computer 
time than multiple linear regression.  
• To avoid the risk of over parameterisation. When repeated measures are used and 
correlation structures are introduced, more parameters are introduced. If there are too many 
explanatory variables, there is a risk of over-parameterising. This can lead to the 
likelihoods being flat and the algorithms that maximise the likelihoods running into 
convergence difficulties.  
 
There are two aspects of repeated measures which need to be investigated: 
• clustering, where each randomization is a cluster 
• serial correlation, where for a randomization the time to publication of the first article is 
correlated with that of the second, that of the second with that of the third, that of the first 
with that of the third and so on 
 
7.3  Outlying articles and records 
Publication 61 
Publication 61 [Jones et al (1991)] generated three records, 546, 547 and 548, reporting 
randomizations 1407, 1408 and 1409 respectively, all from trial 1407 (CLB 7111). This article is 
the fifth mention and fourth reporting of results for randomization 1407, the seventh mention and 
third reporting of results for randomization 1408 and the fourth mention and third reporting of 
results for randomization 1409. Randomizations 1407 and 1408 opened 5 February 1971, and 1408 
opened 12 July 1971. All three closed in March 1974. The article was received by the publisher 16 
April 1990, accepted 21 February 1991 and published sometime during 1991, the day and month 
unknown. This trio of records was atypical in four out of six of the following analyses.   
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For ‘close to publication’ for ‘all mentions’ and for ‘close to submission’ and ‘close to publication’ 
for ‘all results’, all three records were atypical. For ‘close to submission’ for all ‘mentions’ 546 and 
548 were outliers. The time from close to submission for this article was long (16 years 1 month), 
also resulting in a long time from close to publication. The time from receipt to publication was not 
exceptional for this trio of records.  
 
Record 547 reports results that are highly statistically significant (p<0.001) and both records 546 
and 547 report clinically significant results, All three randomizations recruited large numbers of 
patients, 646, 467 and 493 respectively. Also, randomization 1407 has eight treatment arms. It 
appears that this large trial, with randomizations which have yielded results of statistical and 
clinical significance, was considered worthy of long-term follow-up 16 years later. Clinical and/or 
statistical significance is present in all four models for which these records are outliers or have 
large Cook’s distances. Also either number of arms or number of questions is present in three out 
of the four models, the exception being ‘time from close to publication for all mentions’. 
 
Publication 100 
Publication 100 [Bleyer et al (1991)] also generated three records, 628, 629 and 630, reporting 
1618, 1619 and 1621, the three randomizations from trial 1618 (CCG-161). This article is the 
fourth mention and second reporting of results for randomization 1618, the fifth mention and 
second reporting of results for randomization 1619 and the eighth mention of randomization 1621. 
It did not report the results of randomization 1621. The article was received by the publisher 13 
February 1989, accepted 20 November 1990 and published in June 1991. The long delay between 
receipt and publication (2 years 4 months) meant that all three records from this article were 
atypical in the ‘time from receipt to publication for all mentions’ analysis, and 628 and 629 in the 
‘time from receipt to publication for all results’ analysis. The journal in question is Journal of 
Clinical Oncology, an American publication with a high impact factor of 6.922 associated with it. 
The trial is multi-centre and was conducted in the US. The numbers of patients accrued for each 
104 
randomization was large, 529, 625 and 285 respectively. Record 628 reports results of clinical 
significance and record 629 results of statistical significance (p<0.01).  
 
Publication 95  
Publication 95 [Lange et al (1996)] generated one record only, 615 (for randomization 1611, the 
sole randomization of trial 1611 (CCG-139)). It is the second mention and the second reporting of 
results for this randomization. Again the time from receipt to publication was exceptionally long (2 
years 2 months). The article was submitted/received 2 May 1994, accepted 15 December 1994 and 
published some time in 1996, month and day unknown. However, for the purpose of analysis, 
where only the year of a date is known, the publication date is set to 30 June 1996 and could 
actually be up to six months earlier (or later). Again this record is extreme in two analyses, ‘time 
from receipt to publication’ for ‘all mentions’ and for ‘all reportings of results’. However, it is 
possible that this observation is less (or more) extreme than it appears. 
 
Publication 64 
This publication [Hill et al (1994)], generated one record, 551 (for randomization 1416, the sole 
randomization from trial 1416 (CLB 7611)). It is the eighth mention and fifth reporting of results 
for this randomization. This record was atypical in two analyses, ‘time from close to publication’ 
for ‘all mentions’ and for ‘all results’. The accrual period was from 12 November 1976 to late 1979 
and the article was published as a meeting abstract in March 1994, 14 years 5 months after close of 
randomization. Dates of receipt and acceptance are unknown, and so this record could not be 
included in the ‘time from close to submission’ and ‘time from receipt to publication’ analyses. 
Randomization 1416 accrued a large number of patients (506) and this record reports a statistically 
significant result (p<0.01). Again, this is a large randomization with a statistically significant 
result, and in the opposite direction to expected, which may explain why it was considered worthy 
of reporting 14 years after it closed. However, perhaps it is unusual in that it was mentioned in an 
abstract so long after closure.  
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Publication 160 
This publication [Koizumi et al (1991)] also generated a single record, 740 (for randomization 
2601, the sole randomization from trial 2601 (JCCLSG S-811)). It is the fourth mention and third 
reporting of results for this randomization and was found to be an atypical observation for the ‘time 
from receipt to publication for all mentions’ analysis. The accrual period was from late 1980 until 
early 1984. The article was received by the publisher 16 November 1990, accepted 4 March 1991 
and published some time during 1991, so the time from receipt to publication is short (just under 7 
½ months). As with publication 95, since the date of publication is not precisely known, this 
observation could be less (or more) extreme than it appears. 
 
The atypical nature of the following observations can probably be disregarded: 
 
Records 528, 529 and 531 
Publication 57 [Bleyer 1990] generated nine records, three of which appeared as atypical 
observations in two analyses. These are 528 and 529, randomizations 1410 and 1411 from trial 
1410 (CLB 7112 relapse) and 531, randomization 1413 from trial 1412 (CLB 7211 relapse). This 
article is the second mention and the second reporting of results for randomizations 1410, 1411 and 
1413. The two analyses in which is was found to be an outlier are ‘time from close to publication’ 
for ‘all mentions’ and for ‘all results’. The former used all nine records, the latter records 526, 527, 
528, 529 and 531. The atypical records are for two early trials reported in the article, and those 
which recruited the fewest patients. The randomizations from trial 1410 were open during 1971, 
and that from trial 1412 was open during 1972, precise dates unknown. This is a book publication 
with dates of receipt and acceptance unknown and date of publication some time during 1990. 
Again, since the date of close of accrual period and publication are not precisely known, these 
observations could be less (or more) extreme than they appear.  
 
Record 508 
This record is one of nine generated by publication 52 [Holland and Glidewell (1972a)]. It is the 
first mention of randomization 1407 from trial 1407 (CLB 7111) and does not report its results. It 
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only appears as an outlier in the ‘time from close to submission for all mentions’ analysis. All 
records from publication 52 are used in the analysis, with the exception of 1068 (a newly found 
randomization linked to trial 1402). No other record from this publication except 508 is atypical, 
including 509 and 510, which are also linked to trial 1407. Randomization 1407 has a large number 
of arms (8) and this is a variable used in the model.   
 
Record 955 
This record, like 967, is from publication 284. However, whilst 967 is for a very early 
randomization (accrual period November 1967 to September 1970), 955 is for randomization 2105 
from trial 2105 (GATLA 7 LLA-87), open between July 1987 and December 1989, so of short 
duration and the most recent trial reported in this article. This is the second mention of record 955 
and does not report its results. This record shows up as atypical once only, in the ‘close to 
submission’ analysis using all mentions. All seven records from the publication are used and no 
others are exceptional. 
 
7.4  For all mentions of each randomization, which trial characteristics affect the time from 
close to submission? 
The best fitting model using the initial set of variables 
Time from close to submission is longer for randomizations with the following characteristics: 
• Larger number of patients accrued (LOGSIZE) (p=0.0247) 
• Shorter duration of accrual period (DURRAN) (p=0.0006) 
• Conducted outside North America (CGROUP) (p=0.0078) 
• Not presented at a major meeting (PRESENTD) (p=0.0021) 
(R2=0.143962, F-statistic=7.61, p-value<0.0001  based on 186 out of 209 observations) 
 
Comments 
An alternative model was also being considered at this point.  (R2=0.1755, F=8.73, p-value<0.0001 
using 169 of the 209 observations). This used variable impact factor (IMPACT) instead of country 
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group (CGROUP), but was abandoned due to the 9 % missing values for variable IMPACT.  
Variable CGROUP had no missing values. The model using IMPACT would have used 169 
observations out of a possible 209, as opposed to 186. However once the not reported category for 
impact factor was introduced, IMPACT had no missing values. It was tried in the model again with 
the second stage variables. It is worth noting that country group can be thought of as a surrogate for 
impact factor. At this initial stage the two have a high negative correlation of ρ=-0.51    
 
Comments on the final choice of preliminary model 
There were two possible choices for the best preliminary model. The first is as follows: 
Time from close to submission is longer for randomizations with the following characteristics: 
Main effects: 
• Shorter duration of accrual period (DURRAN) (p=0.0001) 
• From a publication with no or a low impact factor (IMPACT) (p=0.0201) 
• Results have smaller p-values associated with them (LOGPEST) (p=0.0032) 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001) 
• Reported in an article which mentions a greater number of trials (LOGNTREP) 
(p=0.0313) 
• Reported in an article which mentions fewer randomizations (NRREP) (p=0.0002) 
• Conducted outside North America (CGROUP) (p=0.0165) 
Interaction  terms: 
• For trials conducted outside North America, a smaller number of patients accrued 
(CGROUP*LOGSIZE) (p=0.0214) 
(R2=0.414273, F-statistic=13.83, p-value<0.0001 based on 186/209 observations) 
 
log 10 (number of patients accrued) (LOGSIZE) is of borderline significance (p=0.0522), but is 
retained in any case due to the significance of its interaction with country group of trialists. This 
main effect acts in the opposite direction from that of the interaction, i.e. a longer time from close 
to submission is associated with the accrual of a larger number of patients. 
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Both country group (CGROUP) and impact factor (IMPACT) remain in the model, although highly 
correlated, as does duration of randomization (DURRAN).  Whether presented at a meeting 
(PRESENTD) is now no longer significant (eliminated at p=0.0700).  
 
Diagnostic plots of this model indicate an outlier, record 955 with a studentised residual of -3.4 and 
the largest Cook’s distance, with record 967 from the same publication having the second largest.  
 
When the regression was run omitting record 967, from publication 284, the interaction between 
LOGSIZE and CGROUP was no longer significant (p=0.1065).  For this reason, the only moderate 
significance of the interaction term (p=0.0214) and the loss of 13 observations (6%) its inclusion 
would have caused, the model without the interaction term and main effect LOGSIZE was chosen. 
The simpler model is robust to the inclusion/exclusion of record 967, and is based on all 
observations for which the response variable is present. 
 
For the final model the diagnostic plots showed records 548 from publication 61 and 955 from 
publication 284 to be outliers, with studentised residual of approximately 3 and -3.5 respectively. 
Record 546, also from publication 61 also had a studentised residual of almost 3. Records 955 and 
967 had the two largest Cook’s distances, in that order. 
Hence the model of choice is as follows. Note the improved fit of the model once the second stage 
variables were included, R2=0.427824, compared with the poor value of R2=0.143962 when only 
the initial set of variables were used. 
 
Preliminary results 
Time from close to submission is longer for randomizations with the following characteristics: 
• Shorter duration of accrual period (DURRAN) (p=0.0001) 
• From a publication with no or a low impact factor (IMPACT) (p=0.0012) 
• Results have smaller p-values associated with them (LOGPEST) (p=0.0006) 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001) 
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• Reported in an article which mentions a greater number of trials (LOGNTREP)) 
(p=0.0090) 
• Reported in an article which mentions fewer randomizations (NRREP) (p<0.0001) 
(R2=0.427824, F-statistic=25.17, p-value<0.0001 based on all 209 observations) 
Mean and range of response variable: 1923 (-1113 to 9503) days,i.e. approximately 5 years 3 
months (–3 years 1 month to 26 years 0 months).  
 
7.5  For all mentions of each randomization, which trial characteristics affect the time from 
receipt to publication? 
The best fitting model using the initial set of variables 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Later start date of accrual period NSTART (p<0.0001) 
• Trials comprises fewer randomizations (NRAND) (p<0.0001) 
• Published in a non-European journal (JGROUP) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p<0.0001), 
the latter having a greater effect than the former. 
(A clearer interpretation of the above two results is that the time from receipt to publication is 
shortest for randomizations reported in non-American, non-European publications, followed by 
those reported in European publications, with those reported in American publications taking 
the longest time.)   
• Not presented at a major meeting (PRESENTD) (p=0.0065) 
(R2=0.323848, F-statistic=18.58, p-value<0.0001 based on 200 of the 218 observations) 
 
Comments  
Once second stage variables were incorporated duration of randomization period (DURRAN) 
became significant and whether presented at a major meeting (PRESENTD) and number of 
randomizations (NRAND) were dropped. DURRAN is highly correlated with NRAND (ρ>0.4). 
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Also the number of randomizations reported in article (NRREP) was significant. This may explain 
some of the variation in NRAND not accounted for by DURRAN. The relationship between 
NRAND and DURRAN is interesting. Within most trials, randomizations address totally different 
questions. For example one  may be between induction treatments and another radiotherapy doses. 
In other trials there can be several randomizations from the same question. For example, a 
randomization between maintenance treatments may start by comparing two therapies, then add a 
third arm, then drop one of the original arms. This is recorded as three randomizations belonging to 
the same trial. In this case duration of randomization period (DURRAN) is likely to be highly 
negatively correlated with number of randomizations (NRAND).  Unfortunately there is not a 
variable in the data to distinguish between what could be referred to as ‘separate randomizations’ 
and ‘serial randomizations’. Many of the serial randomizations are from trials performed in the 
US. Separate randomizations are more common than serial randomizations, and are more likely to 
affect publication, since if one randomization is reported the other is also likely to be mentioned 
and vice versa. Serial randomizations are likely to be written up together, quoting joint results.  
 
In order to try interactions, indicator variables were used that divided country group (CGROUP) 
further to ‘North America’ versus ‘Europe’ versus’ Other’. Although none of the interactions tested 
were significant, the variable distinguishing European trial groups from others was, and its 
introduction resulted in country group of publisher (JGROUP) ‘European’, being dropped. 
 
Identical regressions were produced whether LOGAUTH or LOGMRC was used. This shows that 
for the few early articles describing Medical Research Council trials, which do not list the authors, 
whether an approximate working party size is used, or an estimate of the number of people on the 
writing committee, makes little difference. 
A possible model is as follows: time from receipt to publication is longer for randomizations with 
the following characteristics: 
• Later start date of accrual period (NSTART) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p<0.0001) 
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• Longer duration of accrual period (DURRAN) (p=0.0002) 
• Reported in articles which mention fewer randomizations (NRREP) (p<0.0001) 
• Conducted outside Europe (CGROUP) (p<0.0001) 
• Larger number of co-authors (LOGAUTH/LOGMRC) (p=0.0339) 
(R2=0.451353, F-statistic=25.78, p-value<0.0001 based on 195 out of 218 observations) 
 
Diagnostic plots are given as Figures 7.1 and 7.2. The former shows that three extreme outliers 
remain; records 628, 629 and 630, the trio from publication 100, which all have studentised 
residuals of approximately 4, and record 615 which has studentised residual of approximately 3. 
The four largest Cook’s distances in order are 629, 630, 615 and 628, although these are not 
extremely large. The graph of residuals against fitted values (Figure 7.1) produced a wedge-shape 
rather than a random spread, indicating that the variance is dependent on the mean. 
 
Both logarithmic, to base 10, and square root transformations of the response variable were tried. 
Diagnostic plots indicated that both models are a better fit to the data than with the untransformed 
response, and that the square root transformation is the one to use. The plots for the chosen model 
are given as Figures 7.3 and 7.4.  
 
The scatter plot of standardised residuals versus fitted values (Figure 7.3) shows a more even 
spread, indicating that the square root of the response variable ‘time from receipt to publication’ 
has constant variance. The line in the graph of residuals versus their normal scores (Figure 7.4) is 
now straighter, showing that the square root of the response variable ‘time from receipt to 
publication’ is approximately normally distributed. 
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Figure 7.1 Linear regression model of time from receipt to publication for all  
mentions before transformation. Standardised residuals vs. fitted values 
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Figure 7.2 Linear regression model of time from receipt to publication for all  
mentions before transformation. Residuals vs. their normal scores 
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Figure 7.3 Linear regression model of time from receipt to publication for all 
mentions after square root transformation. Standardised residuals vs. fitted values 
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Figure 7.4 Linear regression model of time from receipt to publication for all 
mentions after square root transformation. Residuals vs. their normal scores 
 
 
Preliminary results 
√(time from receipt to publication) is longer for randomizations with the following characteristics: 
• Later start date of accrual period (NSTART) (p<0.0001) 
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• Published in a North American or European journal (JGROUP) (p<0.0001) 
• Longer duration of accrual period (DURRAN) (p=0.0002) 
• Reported in articles which mention fewer randomizations (NRREP) (p<0.0001) 
• Conducted outside Europe  (CGROUP) (p<0.0001) 
• Larger number of co-authors (LOGAUTH/LOGMRC) (p=0.0121) 
(R2=0.502887, F-statistic=31.70, p-value <0.0001 based on 195 out of 218 observations) 
Mean and range of response variable: 284 (18 to 859) days, i.e. approximately 9 months (1 month 
to 2 years 4 months).  
 
7.6  For all mentions of each randomization, which trial characteristics affect the time from 
close to publication? 
The best fitting model using the initial set of variables 
Time from close to publication is longer for randomizations with the following characteristics: 
• Earlier start of accrual period (NSTART) (p<0.0001) 
• Shorter duration of randomization period (DURRAN) (p<0.0001) 
• Participation of five or more centres (MULTIC) (p=0.0003)  
• Conducted outside North America and Europe (CGROUP) (p<0.0001) 
• Published in full in the English language (ENGLISH) (p=0.0045) 
• Has not been presented at a meeting (PRESENTD) (p<0.0001) 
• Trial comprises fewer randomizations (NRAND) (p=0.0444) 
(R2=0.218208, F-statistic=22.85, p-value<0.0001  based on 581 out of 582 observations) 
 
Comments 
Another possible model consisted of the above variables but with log 10 (number of patients 
accrued) (LOGSIZE) replacing MULTIC and NRAND (R2 = 0.1945, F-statistic = 20.73 using 522 
of the 582 observations). However this was abandoned since LOGSIZE had missing values for 
10% of observations, whereas MULTIC had less than 1% missing values. However, MULTIC may 
be seen as a surrogate for LOGSIZE since their correlation coefficient is moderately high at 0.41. 
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Comments on the final choice of preliminary model 
There is a choice between two possible models. The first is as follows; time from close to 
publication of article is longer for randomizations with the following characteristics: 
Main effects: 
• Earlier start of accrual period (NSTART) (p<0.0001) 
• Short duration of accrual period (DURRAN) (p=0.0031) 
• Published in full in the English language (ENGLISH) (p=0.0037) 
• Not presented at a major meeting (PRESENTD) (p<0.0001) 
• Results are clearly reported as clinically significant (CLNSG) (p=0.0051) 
• Clinically significance is not reported (CLNSG) (p=0.0051), 
the former having a slightly greater effect than the latter. 
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper (ANSWER) (p<0.0001) 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001) 
• Reported in articles which mention a greater number of trials (NTREP) (p=0.0003) 
• Reported in articles which mention fewer randomizations (NRREP) (p=0.0272) 
• Reported in a publication with a low or no impact factor (IMPACT) (p=0.0348) 
• Reported in a journal article or book chapter as opposed to a meeting abstract (PUBTYPE) 
(p=0.0403) 
• Conducted outside Europe (CGROUP) (p=0.0018) 
• Conducted outside North America and Europe (CGROUP) (p=0.0127), 
the latter having a greater effect than the former. 
• Participation of five or more centres (MULTIC) (p<0.0001) 
Interactions: 
• For trials conducted outside North America, the effect of the participation of less than five 
centres is to delay publication (CGROUP*MULTIC) (p=0.0012) 
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• In the case of trials conducted outside North America and Europe, a smaller number of 
patients accrued is also significant (CGROUP*LOGSIZE) (p=0.0117) 
(R2=0.344253, F-statistic=14.64, p-value<0.0001 based on all 521 out of 582 observations) 
 
It is worth noting the following points: This model contains sixteen main terms and two 
interactions. The effects of number of trials and number of randomizations mentioned in an article 
(NTREP and NRREP) are in opposite directions. The introduction of the non-significant variable 
LOGSIZE (p=0.3962) because of its moderately significant interaction with country group 
(p=0.0117), results in a loss of 60 observations.  
 
Diagnostic plots show that several outliers remain (records 546, 547 and 548, the trio from 
publication 61, records 528, 529 and 531 from publication 57 and record 551 from publication 64). 
All have studentised residuals greater than 3. Record 967 from publication 284 has a large Cook’s 
distance.  
 
When record 967 was omitted, the interaction between LOGSIZE and CGROUP became non-
significant, and hence variable LOGSIZE could be dropped also, meaning that the 60 observations 
could now be used. The model without this interaction was robust to the inclusion/exclusion of 
record 967. For reasons of this robustness, the additional 60 observations that could be included 
(581 out of the 582 observations for which the response variable was present can now be used) and 
the only moderate significance of the interaction term (p=0.0117) the simpler model was chosen.   
 
Diagnostic plots for the final choice of model show that several outliers remain (records 546, 547 
and 548, the trio from publication 61, records 528, 529 and 531 from publication 57, record 551 
from publication 64 and record 967 from publication 284). All have studentised residuals greater 
than 3. Record 967 from publication 284 has a large Cook’s distance.  
 
Preliminary results 
Hence, the model of choice is: time from close to publication of article is longer for randomizations 
with the following characteristics: 
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Main effects: 
• Earlier start of accrual period (NSTART) (p<0.0001) 
• Shorter duration of accrual period (DURRAN) (p<0.0001) 
• Published in full in the English language (ENGLISH) (p=0.0041) 
• Not presented at a major meeting (PRESENTD) (p<0.0001) 
• Results are clearly reported as clinically significant (CLNSG) (p=0.0030) 
• Clinically significance is not reported (CLNSG) (p=0.0028), 
the former having a marginally greater effect than the latter. 
(A clearer interpretation of the above two findings is that results clearly reported as not or only 
possibly clinically significant are published fastest, followed by those where no indication of 
clinical significance is given, with results clearly reported as clinically significant having  longest 
time to publication.) 
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper (ANSWER) (p<0.0001) 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001) 
• Reported in articles which mention a greater number of trials (NTREP) (p<0.0001) 
• Reported in articles which mention fewer randomizations (NRREP) (p=0.0021) 
• Reported in a publication with a low or no impact factor (IMPACT) (p=0.0252) 
• Reported in a journal article or book chapter as opposed to a meeting abstract (PUBTYPE) 
(p=0.0253) 
• Conducted outside Europe (CGROUP) (p=0.0004) 
• Participation of five or more centres (MULTIC) (p<0.0001) 
Interaction: 
• For trials conducted outside North America the effect of participation of less than five 
centres is to delay publication (CGROUP*MULTIC)  (p=0.0006) 
(R2=0.341276, F-statistic=18.26, p-value<0.0001 based on 581 out of 582 observations) 
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Mean and range of response variable: 1793 (–1679 to 10150) days, i.e. approximately 4 years 11 
months (–4 years 7 months to 27 years 9 months).  
 
7.7  For all reportings of results for each randomization, which trial characteristics affect the 
time from close to submission? 
The best fitting model using the initial set of variables 
Time from close to submission is longer for randomizations with the following characteristics: 
• Greater number of questions (NOQ) (p=0.0053) 
• Multi-centre participation rather than single-centre (MULTIC) p=0.0238) 
• Limited international or single-country rather than truly international participation 
(INTERNL) (p=0.0353) 
• Not presented at a major meeting (PRESENTD) (p=0.0045) 
(R2=0.196965, F-statistic=7.48, p-value<0.0001 based on 127 out of 129 observations) 
 
Comments 
Another possible model at this stage was as above but with statistical significance (LOGPEST) 
replacing MULTIC. (F=11.10, p-value =0.0001, R2= 0.2894 using 114/129 observations) However 
this was abandoned because of the large number of missing values, despite the superior value of R2. 
 
As explained in Section 5.5, during the initial stage none of the results variables had a ‘not 
reported’ category, leading to a high proportion of missing values for each. This was rectified at the 
second stage. 
 
It was thought that MULTIC might be considered a surrogate for LOGPEST. However, the 
correlation coefficient between the two is only 0.13277 (p=0.0559 on 208/209 observations). The 
interaction between these two variables will be tried, i.e. results with smaller p-values from large 
multi-centre trials versus the rest.  
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Comments on the final choice of preliminary model 
There are two outliers (records 547 and 548 with studentised residuals 3.5 and 3.9 respectively). 
Record 546 has a large Cook’s distance. The trio is from publication 61 and is left in the analysis. 
 
None of the interactions tried were significant. 
 
Note that this model includes variable LOGPEST (and MULTIC has been dropped), as in the 
alternative model using the initial set of variables only, but since the ‘not reported’ category for 
LOGPEST was introduced with the second stage variables, all 129 observations are now used in 
the analysis. The value of R2 has improved from a poor 0.196965 for the chosen initial model, and 
0.2894 for the alternative model for which there was a loss of 12% of observations, to 0.323121 
using all available data. 
 
Preliminary results 
Time from close to submission is longer for randomizations with the following characteristics: 
• Greater number of questions (NOQ) (p=0.0011) 
• Not presented at a major meeting (PRESENTD) (p=0.0003) 
• From a publication with no or a low impact factor (IMPACT) (p=0.0100) 
• Results have smaller p-values associated with them (LOGPEST) (p=0.0034) 
• Clinical significance is ‘yes’, ‘possibly’ or not reported as opposed to ‘no’ (CLNSG) 
(p=0.0363) 
• Direction of results is not reported (POSNG) (p=0.0475) 
(R2=0.323121, F-statistic=9.71, p-value<0.0001 on all 129 observations) 
Mean and range of response variable: 1867 (–191 to 5876) days, i.e. approximately 5 years 1 
month (–6 months to 16 years 1 month).  
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7.8  For all reportings of results for each randomization, which trial characteristics affect the 
time from receipt to publication? 
The best fitting model using the initial set of variables 
Time from receipt to publication is longer for randomizations with the following characteristics: 
• Trial comprises fewer randomizations (NRAND) (p=0.0035) 
• Multi-centre participation (MULTIC) (p<0.0001)  
• Published in a non-European journal (JGROUP) (p=0.0003) 
• Published in a North American or European journal (JGROUP) (p=0.0034), 
the latter having a greater effect than the former. 
• Not presented at a major meeting (PRESENTD) (p=0.0014) 
(R2=0.286860, F-statistic=9.98, p-value<0.0001 based on 130 of the 137 observations) 
 
Comments on the final choice of preliminary model 
Once second stage variables are incorporated, duration of randomization period (DURRAN) 
becomes significant and number of randomizations (NRAND) is dropped. The two have a 
correlation coefficient of –0.29. The relationship between these two variables has been discussed in 
Section 7.5. Other new main effects to enter the model at the second stage are whether an 
international trial (INTERNL) and whether the main questions have been answered (ANSWER).  
In addition the interaction between whether an international trial (INTERNL) and impact factor 
(IMPACT) is also significant.  
 
Diagnostic plots indicate one slightly large Cook’s distance (record 615 from publication 95) and 
two outliers with studentised residuals of approximately 3 (records 628 and 629, two of the three 
records from publication 100). These are not extreme and all are left in. 
 
Again there is a large improvement in the proportion of variability explained by the model once the 
second stage variables are included, R2 increased from 0.29 to 0.52. 
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Preliminary results 
Time from receipt to publication is longer for randomizations with the following characteristics: 
Main effects: 
• Multi-centre participation (MULTIC) (p<0.0001) 
• Published in a non-European journal (JGROUP) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p<0.0001), 
the latter having a greater effect than the former.  
(A clearer explanation of the two findings above is that results published in non-US, non-European 
journals are published more quickly than those published in European journals, with those 
published in North American journals having the longest time to publication.) 
• Longer duration of accrual period (DURRAN) (p<0.0001) 
• The main questions as stated in the paper are answered in the paper (ANSWER) 
(p=0.0042) 
• Not presented at a major meeting (PRESENTD) (p=0.0113) 
• Trials with limited international or single-country, as opposed truly international, 
participation (INTERNL) (p=0.0002) 
Interaction  term: 
• Truly international trials with results published in a high impact factor journal 
(INTERNL*IMPACT) (p=0.0016) 
(R2=0.516723, F-statistic=13.19, p-value<0.0001 based on 121 out of 137 observations) 
Mean and range of response variable: 284 (18 to 859) days, i.e. approximately 9 months (1 month 
to 2 years 4 months).  
 
It is interesting to note that the effect of being an international trial reduces the time from receipt to 
publication, but where the results of an international trial are published in a journal with a non-zero 
impact factor the reduction is not as great. For journals with an impact factor of less than 8, the 
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time to publication is reduced. For journals with a higher impact factor, the effect is reversed and 
the time to publication is increased. 
 
 
7.9  For all reportings of results for each randomization, which trial characteristics affect the 
time from close to publication? 
The best fitting model using the initial set of variables 
Time from close to publication is longer for randomizations with the following characteristics: 
• Larger number of questions (NOQ) (p=0.0008) 
• Shorter duration of randomization period (DURRAN) (p<0.0001) 
• Randomization has not been presented at a meeting (PRESENTD) (p=0.0019) 
• Direction of results is not null (POSNG) 4 (p=0.0066) 
(R2=0.140677, F-statistic=13.22, p-value<0.0001 based on 328 out of 372 observations) 
 
Comments 
There was another possible model at this stage. This used clinical significance (CLNSG) instead of 
direction of results (R2=0.1574, F=14.39, p-value<0.0001 using 313 out of 372 observations). The 
first model was chosen as a starting point, in order to conserve observations used. It is interesting to 
note that once the second stage variables are included and non-reported options for results variables 
are used, clinical significance remains in the final model and direction of results is eliminated.   
 
Comments on the final choice of preliminary model 
The diagnostic plots for the final model show that there is one observation with a large Cook’s 
distance (record 546), and records 547 and 548 are outliers. This is the trio of records from 
publication 61. Also outliers are records 528, 529 and 531 from publication 57 (the other records 
from publication 57 are not outliers) and record 551 (the sole record from publication 64). All 
                                                          
4
 As was explained in Section 5.5, during the initial stage none of the results variables had a ‘not reported’ 
category, leading to a high proportion of missing values for each. This was rectified at the second stage. 
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outliers have studentised residuals greater than 3 and those for records 547 and 548 are 
approximately 4. 
 
The low value of R2  (0.216225), the proportion of variability of the response variable that is 
explained by the model and a guide of the appropriateness of the model, is of some concern. A 
value of at least 0.3 is aimed for. 
 
Preliminary results 
Time from close to publication of article is longer for randomizations with the following 
characteristics: 
Main effects: 
• Greater number of questions (NOQ) (p=0.0190) 
• Earlier close date of accrual period (NCLOSE) (p=0.0002) 
• Not presented at a meeting (PRESENTD) (p=0.00012) 
• Results are clearly reported as clinically significant or not reported at all (CLNSG) 
(p=0.0076) 
• A clear indication is given as to whether or not the main questions in the paper are 
answered in that paper (ANSWER) (p=0.0045) 
• Treatments for relapse or refractory disease (DUMFL) (p=0.0081)  
• Reported in articles which mention a greater number of trials (NTREP) (p=0.0069) 
• Results with smaller p-values (LOGPEST) (p<0.0001) 
Interaction: 
• Positive results with larger p-values (POSNG*LOGPEST) (p=0.0002) 
• Negative results with larger p-values (POSNG*LOGPEST) (p=0.0082), 
the first of these having a marginally greater effect than the second.  
(R2=0.216225, F-statistic=8.00, p-value<0.0001 based on 361 out of 372 observations) 
Mean and range of response variable: 1830 (-972 to 6940) days, i.e. approximately 5 years 0 
months (-2 years 8 months to 19 years 0 months). 
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8  REPEATED MEASURES ANALYSIS 
 
8.1  Introduction 
This chapter starts by explaining the structure of the data and why the observations are not 
independent. There follows a summary of the assumptions of linear regression models and how all 
except that of independence are satisfied. This is followed by an explanation that an adjustment 
must be made to the independence model in order to compensate for the repeated measures and that 
this involves incorporating the covariances between values of the response variable, and hence 
between the residuals, for first, second, third etc. publications, from the analysis using the 
independence model. For each of the six analyses, the covariance matrix is obtained. 
 
The rest of the chapter describes a preliminary investigation into modelling the covariance matrix. 
Five possible correlation structures are described; independence, unstructured, exchangeable, 
stationary m-dependent and autoregressive. The reason for trying to find a plausible correlation 
structure rather than using the unstructured model is to avoid over-parameterisation. Therefore 
exploratory analyses are performed using the residuals from the independence model. This is done 
for the analyses using the two largest datasets, ‘time from close to publication’ for ‘all mentions’ 
and for ‘all reportings of results’.  For brevity these analyses will be referred to as ‘all mentions’ 
and ‘all results’ respectively in this chapter. 
 
The variance inflation factor method is then introduced. This simple model, although too much of 
an over-simplification for these data, serves the purpose of giving some feel for the order of 
correction to be expected from the repeated measures analysis. The variance inflation factor 
method is equivalent to the first iteration of the generalised estimating equation (GEE) process in 
the case of the exchangeable correlation structure. 
 
A preliminary investigation using a similar method is then undertaken to obtain empirical 
correlation matrices using other structures.  
  
125 
 
8.2  Structure of the data 
Some randomizations are reported once only and others several times. An article may report more 
than one trial, each comprising several randomizations. In the publications database each mention 
of a randomization counts as a record. Thus there can be multiple records relating to each 
randomization, i.e. clustering where each randomization is a cluster, and so records are not 
independent. Therefore, for each of the three analyses using all mentions of a randomization, and 
the three which use all results, repeated measures analysis must be incorporated.  
 
Since several publications report the same randomization, it is necessary to investigate for that 
randomization the serial correlations i.e. how the second publication is related to the first in terms 
of the response variable, the response variable being a time period; from close to submission, from 
receipt by publisher to publication or the sum of these, from close to publication.  Similarly the 
relationship of the third publication to the first, the third to the second, the fourth to the third and so 
on should be investigated, and whether this is common to all randomizations. There may be, for 
example, a ‘first publication effect’ in as much as the first reporting may be generally quicker or 
slower than subsequent reportings. By using a repeated measures analysis, the correlation between 
the responses is built into the model obtained from the preliminary analysis, the independence 
model.  
 
If the data are clustered but this is not accounted for (i.e. the records are assumed to be 
independent, as in the preliminary analyses) the estimation of the variance for each coefficient may 
be smaller than it is in reality, in which case the variables in the model would appear to be more 
significant than they are.  A set of non-independent records might be considered equivalent to a 
smaller sample of independent records, which would have a larger variance.    
 
The significance of variable Xi is calculated from  the value of )ˆ.(./ˆ ii est ββ= ,  
126 
where iβˆ  is the estimate of parameter βi  and s.e.( iβˆ ) is the standard error of iβˆ . The effect that the 
incorporation of repeated measures will have on the preliminary model is to increase s.e.( iβˆ ). 
However it is possible for the algorithm to give a different weighting in estimating iβˆ , which could 
increase it. Therefore iβˆ could become large enough to reduce its p-value but it is unlikely that it 
would change much from the independence case, and this would not justify including explanatory 
variables dropped from the preliminary model, unless their exclusion was borderline.  
 
8.3  Assumptions of linear regression models 
For the preliminary analysis, linear regression with backwards elimination was used to obtain a 
reduced set of significant variables. Linear models require the following assumptions: 
• The response variables (and hence the residuals) are independent. 
• The response variables (and hence the residuals) have a normal distribution with constant 
variance. The residuals have mean equal to zero i.e. distribution N (0, σ2). 
 
Diagnostic plots indicate that the second assumption is satisfied. When the residuals are plotted 
against normal scores the line produced is fairly straight, indicating a normal distribution. When 
(standardised) residuals are plotted against fitted values the random pattern observed suggests 
constant variance. However, clearly the data cannot satisfy the first assumption.  
 
There are two aspects to consider; correlation between the response variable for publication records 
relating to (i) the same randomization, and (ii) randomizations belonging to the same trial. In order 
to compensate for the former an adjustment is needed. This involves incorporating the covariances 
between values of the response variable (and hence between the residuals) for first publications of 
each randomization, second publications and so on into the findings from the preliminary 
regression analyses. A investigation into correlation between randomizations belonging to the same 
trial was also undertaken. This is reported in Section 8.20.   
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The algorithm for the program used to produce the correlation matrix for the residuals from the 
independence model is given as Appendix X (i). The correlation matrices obtained from the 
residuals from the six analyses are given as Appendix XI. 
 
8.4  Method for obtaining the correlation matrix for each of the six analyses 
When looking at all mentions, variable ALLORDER specifies the order of the record for the 
randomization to which it refers, by date of publication. There is an equivalent variable 
RESORDER for the dataset containing only those records which report results.  
 
The regression is run using the best fitting independence model. Residuals are output for the 
purpose of model testing and also to form the covariance matrix. The order number and the 
randomization ID are known for each residual. The residuals from the first reportings are renamed 
RESID1, those from second reportings RESID2 and so on. This is done up to and including the 
fifth reportings. Although some randomizations have been reported more than five times, (one 
randomization was published thirteen times), there are not enough sixth and subsequent reportings 
to warrant continuing the process. A correlation (standardised covariance) matrix is then calculated 
for variables RESID1, RESID2 … RESID5. There are a few cases where articles reporting the 
same randomization share the same publication date, and so their order will tie. There are eight 
cases of ties between pairs of records and one case of a tie of a trio of records. These are listed 
below.  For the purpose of obtaining the covariance matrix for residuals, the ties are not  treated as 
such, but will be in order of publications ID (the number assigned to the article as it was entered 
into the computer). As well as being the simplest solution, it is also logical to do this since if, for 
example, the 2nd and 3rd articles relating to a randomization are published on the same day, the time 
between those two publications, i.e. zero days, is included in the calculation of the matrix.  
 
Some of the ties are due to the exact date of publication being unknown i.e. day or day and month 
missing. As was discussed in Section 5.3.1, it was a time-consuming task to discover which article 
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was the first to mention or report results for each randomization, and it was not considered worth 
the extra effort needed to break ties between the 2nd and 3rd publications, 3rd and 4th etc..  
 
The following randomizations are reported in articles with tied publication dates. Note that where 
the 1st and 2nd tie, this is a genuine tie, which has been fully investigated, with both articles 
appearing in the same issue of a journal. 
1205: 3rd and 4th   (publications 32 and 47) 
  1206: 2nd, 3rd and 4th   (publications 32, 41 and 47) 
 1207: 2nd and 3rd   (publications 32 and 41) 
 1208: 2nd and 3rd  (publications 32 and 47) 
 1603: 2nd and 3rd   (publications 82 and 84) 
 1604: 2nd and 3rd, 4th and 5th (publications 78 and 79, 82 and 84) 
 2701: 1st and 2nd   (publications 4 and 5) 
 2708: 1st and 2nd   (publications 15 and 16) 
 
The references for these publications are listed in publication number order in Appendix I.  
 
Correlation matrices were calculated for the residuals from each of the six analyses, which 
contained repeated measures. Only the correlation coefficients from the residuals from the analyses 
on the two largest datasets are discussed here. Those from the residuals from the other four 
analyses are based on small numbers of observations, and so are less reliable. However all six are 
given in Appendix XI. 
 
The elements forming the leading diagonal of the correlation matrix are, of course, unity. The other 
elements are examined, grouped by their distance from the leading diagonal. The purpose of this is 
to try to identify a plausible correlation structure so that this can be built into the repeated measures 
analysis. The structure developed for the two largest datasets will be applied to the other four 
analyses also. The estimates for the correlation coefficients will be different for the six analyses, 
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but the most suitable correlation structure found, using the two largest datasets, will be imposed on 
all six. 
 
8.5  Possible correlation structures 
These are described in Zeger and Liang (1986), and a more comprehensive explanation is given in 
Diggle et al (1994). 
 
Independence 
If none of the correlation coefficients are found to be significant then repeated measures need not 
be used. The preliminary analysis will suffice. Incorporation of the identity matrix has no effect on 
the original model. 
 1 0 0 – 
 0 1 0 – 
  0 0 1 – 
 - - - -  
 
 
Unstructured (Non-independence) 
All correlation coefficients are different. GEE work best on large datasets and convergence 
problems arise from datasets which are too small for the method. This structure is not considered 
because of the high degree of parameterisation it requires. 
 1 
  
ρ12  ρ13   – 
 
ρ21  1    ρ23  – 
 
ρ31  ρ32  1    – 
 -     -    -    -  
 
where ρji  =ρij   
 
 
Exchangeable 
All correlation coefficients are assumed to be equal. The advantage of this is that it produces the 
minimum parameterisation. The disadvantage is that the correlation structure is not likely to be a 
good approximation to the real covariance matrix, but it does give a useful guide to the effect of 
allowing for correlation. In this structure clustering is modelled, but not serial correlation. 
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             1 ρ ρ - 
ρ 1 ρ - 
ρ ρ 1 -  
- - - -
 
 
 
Stationary m-dependent 
Here all elements distance 1 from the leading diagonal have the same correlation coefficient, ρ1, all 
those distance 2 have coefficient ρ2 and so on. 
m = the number of diagonals where ρk is non-zero  
 1 
  
ρ1   ρ2  – 
 
ρ1   1    ρ1  – 
 
ρ2   ρ1   1   – 
 -     -    -   -  
  
 
Autoregressive 
This is similar to the stationary m-dependent correlation structure, except ρ2,  ρ3 and so on are 
functions of ρ1, so that only one new parameter need be introduced.   
 1
  
ρ|t2-t1| 
 
ρ|t3-t1| 
– 
 
ρ|t1-t2| 1
  
ρ|t3-t2|
 –
 
 
ρ|t1-t3|
    
ρ|t2-t3| 
 
1
      – 
 -      -       -      -  
 
where |ti-tj|=|tj-ti| 
 
For the purpose of analysing these data  i and j are integers representing the order of publication for 
articles reporting a particular randomization. 
Therefore ti = i and |ti-tj|=|i-j|, giving the simplified correlation structure:   
1 
  
ρ
    
ρ2
  – 
 
ρ
    
1
    
ρ
   – 
 
ρ2 
  
ρ
    
1
   – 
 -     -    -   - 
  
 
8.6  The correlation matrix for the residuals from the independence model analysis of time 
from close to publication for all mentions 
All the 1-step correlation coefficients are highly significant: 
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ρ12  =0.35271 p<0.0001 (n=128) 
ρ23  =0.46667 p<0.0001 (n=90) 
ρ34  =0.66755 p<0.0001 (n=68) 
ρ45  =0.75220 p<0.0001 (n=44) 
 
The 2-step correlation coefficients are less significant and less correlated: 
ρ13  =0.16092 p=0.1297 (n=90) n/s 
ρ24  =0.40235 p=0.0007 (n=68) 
ρ35  =0.45929 p=0.0017 (n=44) 
 
The 3-step correlation coefficients are: 
ρ14  =0.16406 p=0.1813 (n=68) n/s  
ρ25  =0.20546 p=0.1809 (n=44) n/s  
 
The 4-step correlation coefficient is: 
ρ15  = -0.05110 p=0.7418 (n=44) n/s 
 
The pattern that emerges is one of highly significant strong correlations between successive groups 
of residuals. As the orders of publication become further apart the correlation coefficients between 
them become weaker and less significant. The strong pattern in the correlation matrix suggests use 
of the stationary m-dependent or autoregressive correlation structure. 
 
Note that as i and j increase, the ρij calculated will be less accurate since the number of 
observations, nij, on which it is based is smaller. For example; for correlation coefficients distance 
2 from the leading diagonal, the value of coefficient ρ13 is more representative of those lying on 
that diagonal than that of
 
ρ35, although the latter is stronger and has a higher significance level. This 
is worth bearing in mind when trying to decide on a suitable correlation structure. Also the higher 
the value of a ρij, the more likely it is to be significant. For small correlations, the dataset used may 
be too small to show significance.  
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8.7  Estimation of the correlation coefficient for an exchangeable correlation structure using 
the variance inflation factor method: all mentions 
The variance inflation factor method of Rao and Scott (1992) is an adaptation to binary data of the 
effective sample size effect outlined by Kish (1965). 
 
The formula for calculating an estimate, ρest, of the correlation coefficient for an exchangeable 
correlation structure of dimensions m×m, and hence the variance inflation factor is as follows: 
 
Let the correlation matrix produced from the residuals from the independence model have elements 
ρij, where the subscripts refer to the ith and jth repeated measure and nij is the number of pairs of 
observations used to calculate ρij. 
For nij pairs of observations  
 
  zij  = ln √ [(1 + ρij ) / (1 - ρij )] 
 
 zest = ∑
=
m
i 2
∑
−
=
1
1
i
j
 (nij - 3) zij 
                                                                                
          
   
          ∑
=
m
i 2
∑
−
=
1
1
i
j
 (nij - 3)  
 
where nij  > 3 
 
and the estimate of the pooled correlation is  
 
ρest   =  e 
estZ2
 - 1 
                __________ 
                  e 
estZ2
+ 1  
      
For the ‘time from close to publication for all mentions’ analysis, the estimate of the correlation 
coefficient for an exchangeable correlation structure is 
ρest =0.37837 
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8.8  The variance inflation factor (VIF) 
For each of the six analyses involving repeated measures, the output from the preliminary 
(independence) model is given in Appendix IX. In each case, the parameter (β) estimates together 
with the standard error (σ), the t-statistic and the p-value for each are output.  
 
The variance inflation factor compensates for the correlation by enlarging the variance. This is the 
traditional method for dealing with repeated measures, but is only suitable for use with an 
exchangeable correlation structure.  
 
Since the β estimates have a t-distribution, t=(x - µ) / s, the estimated variance, s2, must be divided 
by the variance inflation factor. 
 
The variance inflation factor = 1 - ρest2 
 
Therefore the estimated standard error, s, must be divided by √VIF, i.e. by √(1 - ρest2). 
 
The exchangeable correlation structure is easily incorporated into the preliminary model using the 
variance inflation factor.  
 
To incorporate the exchangeable correlation matrix  
s new = s old / √VIF 
t new = βˆ / s new 
 
Since the t-value for each variable is divided by the same constant, it will be the least significant 
variables, if any, which will be dropped from the model.    
 
8.9  Calculation of revised estimates of the standard errors of the parameter (β) estimates, t- 
and p-values imposing an exchangeable correlation structure calculated using the variance 
inflation factor method: all mentions 
Now the variance inflation factor=0.85684 
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The standard error, s, of each β-estimate is divided by √VIF=0.92566 and the p-values calculated. 
A 2-tailed t-test is used for the regression, since the β-estimates can be positive or negative. The 
original and new values for the standard error of β, t and p are given in the Table 8.1. 
 
 
VARIABLE       BETA     SE_OLD      T_OLD     PROB_OLD     SE_NEW      T_NEW     PROB_NEW 
  
INTERCPT    2344.83    266.143     8.81042     0.00000    287.517     8.15545     0.00000 
NSTART        -0.15      0.029    -5.28143     0.00000      0.031    -4.88881     0.00000 
DURRAN        -0.44      0.104    -4.22610     0.00003      0.112    -3.91193     0.00010 
DUMCGRP1    -535.11    149.114    -3.58863     0.00036    161.089    -3.32185     0.00095 
DUMCGRP2*     23.51    253.833     0.09262     0.92624    274.219     0.08573     0.93171 
DUMENG      1048.55    364.272     2.87849     0.00415    393.527     2.66451     0.00793 
PRESENTD    -637.95    118.341    -5.39076     0.00000    127.844    -4.99001     0.00000 
DUMCLN1      444.48    149.161     2.97985     0.00301    161.140     2.75833     0.00600 
DUMCLN2      438.23    145.795     3.00575     0.00277    157.504     2.78231     0.00558 
DUMANS       523.72    122.078     4.29001     0.00002    131.882     3.97109     0.00008 
DEVLPNG     2182.69    423.091     5.15890     0.00000    457.070     4.77539     0.00000 
NTREP        243.98     51.860     4.70453     0.00000     56.025     4.35480     0.00002 
NRREP        -91.03     29.393    -3.09703     0.00205     31.753    -2.86680     0.00430 
IMPACT       -25.62     11.417    -2.24402     0.02522     12.334    -2.07720     0.03823 
DUMPUBT3    -354.65    158.095    -2.24328     0.02527    170.792    -2.07652     0.03830 
DUMMULT      813.22    163.454     4.97524     0.00000    176.581     4.60538     0.00001 
ICGMUL2     1226.46    355.925     3.44585     0.00061    384.509     3.18968     0.00150 
 
 
Indicator variables 
 
DUMMULT = 1 if MULTIC = Yes 
DUMMULT = 0 if MULTIC = Limited or No 
 
DUMCGRP1 = 1 if CGROUP = Europe 
DUMCGRP1 = 0 if CGROUP = America or Other 
 
DUMCGRP2 = 1 if CGROUP = Other 
DUMCGRP2 = 0 if CGROUP = America or Europe 
* This main term was not significant before the exchangeable correlation matrix was 
imposed. It was retained because of the significance of the interaction term.  
 
DUMENG = 1 if ENGLISH = A (i.e. published in a language other than English, with an English 
    abstract) 
DUMENG = 0 if ENGLISH = E (i.e. published in full in English) 
  
DUMCLN1 = 1 if CLNSG = Yes 
DUMCLN1 = 0 if CLNSG = No, Possibly or not reported 
 
DUMCLN2 = 1 if CLNSG = not reported 
DUMCLN2 = 0 if CLNSG = Yes, No, Possibly 
 
DUMANS = 1 if ANSWER = Yes or No 
DUMANS = 0 if ANSWER = not reported 
 
PUBTYPE3 = 1 if PUBTYPE = Meeting abstract 
PUBTYPE3 = 0 if PUBTYPE = Journal or Book 
 
 
Interaction term 
 
ICGMUL2 = 1 if non-US trial with less than 5 centres 
ICGMUL2 = 0 otherwise  
 
Table 8.1 Revised estimates of the standard errors of the parameter (β) estimates, t- and p-values imposing 
an exchangeable correlation structure calculated using the variance inflation factor method: all mentions 
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All variables significant in the independence model remained significant. None of the terms in the 
independence model were borderline, so applying the variance inflation factor was unlikely to 
result in terms being dropped. However, this may not be the case with some of the other analyses. 
 
The algorithm for the program to calculate: the correlation coefficient ρ for a matrix with an 
exchangeable correlation structure, the variance inflation factor and revised t-statistics and p-values 
for parameter estimates is given as Appendix X (ii). The output, from each of the six analyses is 
given as Appendix XII. 
 
The method of variance inflation factor with an exchangeable correlation structure is not 
satisfactory for use with these data. The assumption that all correlation coefficients are the same is 
not tenable in the light of the correlation structure which emerged from the residuals of the 
independence model. However, it is worth doing in order to indicate that it is unlikely that a 
repeated measures approach will change the basic model.  
 
8.10  Generalised estimating equations (GEE) 
An alternative method is that of generalised estimating equations (GEE), a type of mixed effect 
model [Zeger and Liang (1986)]. This can be used with other correlation structures such as the 
stationary m-step dependent and autoregressive structures and so is more suited for use with these 
data.  
GEE use an iterative procedure to calculate the correlation coefficient, ρ. Initially ρ is set to zero 
for the preliminary analysis. The residuals are used to calculate the first estimation of ρ. The 
regression is then re-run, this time incorporating ρ. New residuals are obtained and hence a second, 
more accurate, estimate of ρ. The process is repeated until ρ convergence is adequate. As well as 
estimating ρ the GEE produces the new parameter estimates, standard errors, t-statistics and p-
values. 
 
136 
A limitation of GEE is that they may not converge well on small datasets. Two of the six datasets 
cannot be regarded as large, these being ‘time from close of randomization to submission’, and 
‘time from receipt to publication’, for all records which report results, which use 129 and 121 
observations respectively. However the response variables are normally distributed, which is an 
advantage when using GEE because the likelihood is then exact. 
 
The results of applying GEE to the data using the stationary m-step dependent and autoregressive 
correlation structures will be discussed in Chapter 9. Before this, a preliminary investigation using 
these structures is undertaken.  This uses a method similar to that for calculating the variance 
inflation factor, used in estimation of the correlation coefficient for an exchangeable correlation 
structure. This is in fact the first approximation to the correlation structure that the GEE method 
will use. There is an argument that for small datasets, except for the case of the exchangeable 
correlation structure, the process should not be continued past this first step. This is because 
convergence problems may occur, producing unreliable results due to flat likelihoods, and so for 
small datasets this section of the procedure alone may be optimal. Whatever the size of dataset, this 
preliminary investigation is essential as a check that the extra parameterisation introduced is not 
producing unreliable results, due to convergence problems, when the full GEE is used.   
 
8.11  A preliminary investigation to impose a stationary m-dependent correlation structure: 
all mentions  
The second correlation structure tried was the stationary m-dependent. This requires that a separate 
correlation coefficient be calculated for each diagonal. The formula used to calculate these is that 
used to estimate the correlation coefficient for the exchangeable correlation structure. However, 
here it is applied separately to each diagonal and so four different correlation coefficients result and 
four new parameters are introduced. As with the exchangeable correlation structure, the residuals 
from the independence model are used to calculate the m-step coefficients, from which the 
correlation matrix is formed. This is, in effect, reproducing the first iteration of the GEE procedure. 
The algorithm for the program to do this is given as Appendix X (iii), and the correlation 
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coefficients estimated for the four analyses for which there are sufficient observations are given in 
Appendix XIII. 
 
The estimates for the correlation coefficients for the analysis using the largest dataset, ‘time from 
close to publication for all mentions’ are as follows:  
ρ1 = 0.51840 ρ2 = 0.31154 ρ3 = 0.18015 ρ4 = -0.05110  
where ρd = the correlation coefficient for all elements distance d from the leading diagonal. 
 
8.12  The Mantel test  
This correlation matrix was then tested against the matrix formed from the residuals from the 
independence model using the Mantel test [Manly (1986)], a permutation test. The program for 
applying the Mantel test is given as Appendix XIV. However a brief description of the process 
follows: 
 
Let M be the correlation matrix formed from the residuals from the independence model. 
Let E be the matrix constructed using the correlation coefficients estimated, using a stationary m-
dependent correlation structure: 
1.00000 0.51840 0.31154 0.18015   -0.05110  
0.51840 1.00000 0.51840 0.31154 0.18015 
 E = 0.31154 0.51840 1.00000 0.51840 0.31154 
0.18015 0.31154 0.51840 1.00000 0.51840 
     -0.05110  0.18015 0.31154 0.51840 1.00000 
 
A Mantel’s Z value is then calculated from the elements of matrices M and E using the formula:   
 Z = ∑
=
n
i 2
ij
i
j
ijem∑
−
=
1
1
 
 
Z is the sum of the products of the elements in the lower diagonal parts of the matrices M and E. 
 
Then the 120 possible permutations of the elements of the estimated matrix E are obtained. For 
each a Z-value is calculated using a permutation of E and the unpermutated original matrix M. In 
this way a distribution of Z is obtained. 
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It is the position of the Z-statistic for matrix E within the distribution of the Z-values which is of 
interest, rather than the value of Z.  If there is a positive correlation between the estimated matrix E 
and the original matrix M the Z-value obtained will tend to be greater than others in the 
distribution. If matrices M and E are not correlated then the Z-value would be expected to be 
typical of the distribution.  
 
Therefore the null hypothesis can be stated as: 
H0: Estimated matrix E is no better correlated with matrix M than random matrices made 
from the permutations of elements of E.  
 
The proportion of permutations with a Z-statistic greater than or equal to that for the estimated 
matrix is equal to the p-value. 
  
For the ‘time from close to publication for all mentions’ analysis, the Z-value for the unpermutated 
matrix E with M is 1.54851, which is high compared to that for other permutations of E. Of the 
120 Z values obtained, that for the unpermutated estimated matrix E was joint highest with one 
other. Due to the symmetrical nature of the matrix E and its permutations there are two of every Z-
value produced i.e. 60 pairs. Therefore the significance of this result is p=2/120=0.01667, which is 
sufficient to reject H0. Thus the estimated matrix E can be considered a good approximation to M.   
 
Next the correlation between the lower elements of matrices M and E (Pearson’s correlation 
coefficient) was calculated.  
                                                       _  _ 
r =                              Z – n(n – 1) m e  / 2    
          ______________________________________________________________________                                                                                 
         √ (∑
=
n
i 2
∑
−
=
1
1
i
j
mij
2
 – n(n – 1) 
−
m 2 /2) (∑
=
n
i 2
∑
−
=
1
1
i
j
eij
2
 – n(n –1)
−
e 2/2)
 
−
m  = mean of the mij values 
−
e    = mean of the eij values 
n×n    = dimensions of matrices M and E 
n(n-1)/2= number of lower diagonal elements in matrices M and E 
 
 
The correlation coefficient r = 0.84893, a high positive correlation. 
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8.13  A preliminary investigation to impose an autoregressive correlation structure: all 
mentions 
Lastly an autoregressive correlation structure was tried. Here, elements distance 1 from the leading 
diagonal have the value ρ, those distance 2 from the leading diagonal have value ρ2, those distance 
3 have value ρ3 and so on. The advantage of this over the stationary m-dependent structure is that 
only one new parameter is introduced rather than four. If the correlation between this structure and 
the original covariance matrix is almost as good as that between the stationary m-dependent 
structure and the original covariance matrix, then this may be the structure to use. However, a 
disadvantage of the autoregressive structure is that it does not allow a limited number of non-zero 
coefficients to be set. 
 
The estimate of the correlation coefficient for elements distance 1 from the leading diagonal was 
obtained in the same way as for the stationary m-dependent structure, and so has the same value, ρ 
= 0.51840. 
 
The estimates for the correlation coefficients for the other elements are as follows: 
distance 2 from the leading diagonal: ρ2 = 0.26874 
distance 3 from the leading diagonal: ρ3 = 0.13931 
distance 4 from the leading diagonal: ρ4 = 0.07222 
 
Mantel’s test gives Z = 1.48336 (p=0.01667 using 120 observations). 
 
Pearson’s correlation coefficient between matrix E estimated using an autoregressive structure and 
matrix M is r = 0.82115. 
 
8.14  Conclusion: all mentions 
 
As expected, both models are good approximations to the matrix formed from the residuals from 
the independence model, M. Estimated matrix E using an autoregressive structure is not as highly 
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correlated with M as E using the stationary m-dependent structure. However this is offset against 
the need for only one new parameter rather than m.  
 
In matrix M, the correlation coefficients distance 3 or more from the leading diagonal are small and 
not statistically significant, and those distance 1 are both greater and far more significant than those 
distance 2, suggesting that the stationary m-dependent structure with either m=2 or m=1 is the most 
appropriate. Since the autoregressive structure does not allow the setting of all coefficients distance 
3 and greater to be zero this is less suitable.   
 
8.15  The correlation matrix for the residuals from the independence model analysis of time 
from close to publication for all results  
The investigations performed on the largest dataset, where the response variable is ‘time from close 
of randomization’ and all records are used, are now repeated for the second largest dataset, that 
where the response variable is the same but where only records reporting results are used.  Again 
see Appendix XI for the correlation matrix obtained from the residuals from the independence 
model. 
 
All the 1-step correlation coefficients are highly significant: 
ρ12  =0.53121 p<0.0001 (n=91) 
ρ23  =0.75606 p<0.0001 (n=54) 
ρ34  =0.73189 p<0.0001 (n=29) 
ρ45  =0.89130 p<0.0001 (n=13) 
 
The 2-step correlation coefficients are less significant and less correlated: 
ρ13  =0.56003 p<0.0001 (n=54) 
ρ24  =0.38425 p=0.0396 (n=29) 
ρ35  =0.63482 p=0.0198 (n=13) 
 
The 3-step correlation coefficients are: 
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ρ14  =  0.08945 p=0.6445 (n=29) n/s  
ρ25  = -0.10232 p=0.7394 (n=13) n/s 
 
The 4-step correlation coefficient is: 
ρ15  = -0.13473 p=0.6608 (n=13) n/s 
 
The pattern of the correlation matrix for the ‘results only’ dataset with response variable ‘close to 
publication’ is similar to when all records are used, except the 1- and 2-step correlation coefficients 
here are greater. Again, correlations and significance levels decrease with distance apart. Also the 
numbers of observations on which the coefficients are calculated diminish sharply. 
 
8.16  Estimation of the correlation coefficient for an exchangeable correlation structure and 
revised standard errors of the parameter (β) estimates, t- and p-values using the variance 
inflation factor method: all results 
The correlation coefficient for an exchangeable correlation structure for the ‘time from close to 
publication for all results’ analysis was estimated as ρest =0.55167.  
Hence the variance inflation factor (VIF) was calculated to be 0.69566. 
 
Dividing the standard error of each β estimate by √VIF = 0.83406 does increase the p-values 
considerably, proclaiming a weakening in the evidence for variable number of questions (NOQ), as 
shown in Table 8.2.  
 
Note that main terms specifying direction of results (DUMDIR1 and DUMDIR2) were not 
significant in the independence model and are retained only due to the significance of their 
interaction with statistical significance (LOGPEST). 
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VARIABLE       BETA     SE_OLD      T_OLD     PROB_OLD     SE_NEW      T_NEW     PROB_NEW 
 
INTERCPT    2036.56    301.806     6.74791     0.00000    361.852     5.62816     0.00000 
NOQ           47.86     20.309     2.35650     0.01899     24.350     1.96546     0.05014 
NCLOSE        -0.10      0.027    -3.77133     0.00019      0.032    -3.14552     0.00180 
PRESENTD    -461.68    141.864    -3.25439     0.00125    170.089    -2.71436     0.00697 
DUMCLN2     -405.87    151.038    -2.68719     0.00755    181.088    -2.24128     0.02563 
DUMANS       416.20    145.726     2.85604     0.00454    174.719     2.38211     0.01774 
DUMFL        692.59    259.924     2.66458     0.00806    311.637     2.22242     0.02689 
NTREP        136.21     50.084     2.71971     0.00686     60.049     2.26840     0.02391 
LOGPEST      330.63     83.769     3.94693     0.00010    100.436     3.29198     0.00110 
DUMDIR1      276.15    171.197     1.61308     0.10762    205.257     1.34541     0.17936 
DUMDIR2      339.43    220.885     1.53669     0.12527    264.831     1.28169     0.20079 
LPDIR1      -390.87    103.790    -3.76600     0.00019    124.439    -3.14107     0.00183 
LPDIR2      -386.69    145.513    -2.65741     0.00823    174.464    -2.21644     0.02730 
 
 
Indicator variables 
 
DUMCLN2 = 1 if CLNSG = No or Possibly 
DUMCLN2 = 0 if CLNSG = Yes or not reported 
 
DUMANS = 1 if ANSWER = Yes or No 
DUMANS = 0 if not reported 
 
DUMFL = 1 if FIRSTL = Treatment for relapse or refractory disease 
DUMFL = 0 if FIRSTL = First-line treatment 
 
DUMDIR1 = 1 if POSNG = Positive 
DUMDIR1 = 0 if POSNG = Negative, Null, Opposite or not reported 
  
DUMDIR2 = 1 if POSNG = Negative 
DUMDIR2 = 0 if POSNG = Positive, Null, Opposite or not reported 
 
 
Interaction terms 
 
LPDIR1 = LOGPEST * DUMDIR1 
LPDIR2 = LOGPEST * DUMDIR2 
 
Table 8.2 Revised estimates of the standard errors of the parameter (β) estimates, t- and p-values imposing 
an exchangeable correlation structure calculated using the variance inflation factor method: all results 
 
 
8.17  A preliminary investigation to impose a stationary m-dependent correlation structure: 
all results 
The estimates for the correlation coefficients for the analysis using the ‘time from close to 
publication for all results’ dataset were calculated as: 
ρ1 = 0.66706 ρ2 = 0.52135 ρ3 = 0.03624 ρ4 = -0.13473 
where ρd = the correlation coefficient for all elements distance d from the leading diagonal. 
 
Hence Mantel’s Z value = 2.78240 (p=0.01667 using 120 observations) and the correlation 
between the lower elements of the matrix formed from the residuals from the independence model 
and those from the estimated m-dependent correlation structure is r = 0.94739.   
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8.18  A preliminary investigation to impose an autoregressive correlation structure: all 
results 
Since the correlation coefficients for all elements distance 1 from the leading diagonal were 
calculated as ρ= 0.66706, those for elements distance 2, 3 and 4 from the leading diagonal were set 
to ρ2 = 0.44497, ρ3 = 0.29682 and ρ4 = 0.19800 respectively. 
 
Hence Mantel’s Z value =2.61361 (p=0.01667 using 120 observations) and the correlation between 
the lower elements of the matrix formed from the residuals from the independence model and those 
from the estimated m-dependent correlation structure is r = 0.90111.  
 
8.19  Conclusion: all results 
The results are similar to those for the ‘all mentions’ dataset. Again both models are good 
approximations to the correlation matrix formed from the residuals from the independence model, 
M. The correlation of M with the matrix E having a stationary m-dependent structure is slightly 
higher and slightly more significant, than that with matrix E having an autoregressive structure. 
Again, in matrix M only the correlation coefficients distance 1 and 2 from the leading diagonal are 
statistically significant, the former much more so that the latter, indicating that the stationary m-
dependent with  m=2 or perhaps m=1 is the correlation structure of choice.  
 
8.20  An investigation into the many-to-one relationship between randomizations and trials 
Having established that the incorporation of repeated measures analysis will solve the problem of 
non-independence of records due to multiple reportings of the same randomization, there remains a 
further problem. There is clustering, since several randomizations may belong to the same trial. 
This applies to all twelve analyses, not just the six, which have repeated measures per 
randomization. 
 
To investigate whether this has an important effect on the response, correlation matrices were again 
produced for the residuals from the analyses on the two largest datasets, but this time by trial rather 
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than randomization. The object was to compare these by eye with those for the randomizations. If 
the patterns are very similar, the randomization-trial clustering can be ignored. The method used is 
approximate and the results are not stated, just the overall impression.  
 
For the largest dataset, that for analysing time from close to publication for all mentions, the 
correlation matrix obtained for trials echoes that for randomizations although higher correlations 
remain at the 3rd and 4th steps. The associated significance levels are also higher. So correlations 
extend further back with the trials correlation matrix than with the randomizations correlation 
matrix. However since the patterns of the two matrices are similar, the randomizations-trial 
clustering can be safely ignored.  
 
When applied to the second dataset, that for analysing close to publication for all reportings of 
results, the trials correlation matrix produced was very similar to that for randomizations. 
Therefore, again, the clustering of randomizations-trial can be safely ignored. 
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9  APPLICATION OF GENERALISED ESTIMATING EQUATIONS (GEES) TO THE 
LARGEST DATASET  
 
9.1  Introduction 
This chapter begins by describing the full method of generalised estimating equation (GEE) 
analysis for use with correlated data. This can be used to obtain not only the coefficients for any 
correlation structure, but also the revised t-statistics and p-values for the parameter estimates.  
Firstly the general model is discussed and then its application to these particular data. This method 
is then applied to the analysis using the largest of the six datasets, ‘time from close to publication 
for all mentions’, imposing different correlation structures in turn. There follows a section on how, 
for each variable in the model, the p-value alters when different structures are applied. Diagnostic 
plots from the analyses with different correlation structures imposed are also compared. Finally, a 
linear mixed effects model is run, in order to confirm the findings from the GEE analyses.   
 
9.2  Generalised linear models (GLM)   
The notation established here will be used for the section on GEE (Section 9.3). 
Let Y be a random variable whose probability function depends on a single parameter, θ.  If the 
distribution of Y can be written in the form 
 f (y ;θ) = exp [a(y)b(θ) + c(θ) + d(y)],  where a, b, c and d are functions, 
then the distribution of Y belongs to the exponential family.  
If a(y)=y then the distribution is in the canonical form and b(θ) is the natural parameter of the 
distribution. Any other parameters in the expression are treated as nuisance parameters. The 
Poisson, normal, and binomial distributions all belong to the exponential family and can be written 
in the canonical form. [McCullagh and Nelder (1986), Dobson (1990)]  
 
In generalised linear models the maximum likelihood estimates are obtained for the parameters 
using an iterative procedure. 
 
In generalised linear models the link function is defined as  
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 g (µi )  = αi + ∑
=
p
j 1
 
βij x ij   
= Xi β  for the ith observation. 
The link function describes the model used.  
 
Examples 
• Normal distribution 
For the ith observation, E[Yi] = Xi β  
Therefore  g (µi ) = µi 
i.e. the link function for the ordinary linear regression, which is used to model data where 
the response variable has a normal distribution, is the identity function. 
 
• Logistic regression 
For the ith observation, log [pi  / (1-pi) ] = Xi β , 
where pi = the probability of success of 1 trial. 
 i.e. where P(Xi=1) = pi and P(Xi=0) = (1- pi) 
  and E(Xi) = pi = µi 
Therefore g (µi ) = logit (µi) 
i.e. the link function for the logistic regression model is the logit function. The logistic 
regression model will be used in Chapter 14 to model whether or not a randomization is 
ever published. 
 
• Poisson regression 
For the ith observation, the parameter of the Poisson distribution is modelled by   
log (µi) = αi + ∑
=
p
j 1
 
βij x ij  = Xi β,  
where µi is the Poisson parameter for the ith observation. 
Therefore g (µi ) = log (µi)  
i.e. the link function for the Poisson regression model is the logarithmic function. The 
Poisson model will be used in Chapter 15 for modelling frequency of publication. 
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9.3  The GEE method 
Specify the link function, g (µ
 i)  
In GEE the link function is the same as for the GLM, as described in Section 9.2. 
 
Specify the mean-variance relationship 
 
Generalised estimating equations use a quasi-likelihood which has the form of a normal likelihood, 
with the variance expressed as a function h, say, of the mean. The variance of Yi , is written in the 
form V (Yi) =  h(µi ) / φ, where φ is a scale parameter, which is treated as a nuisance parameter. A 
quasi-likelihood is used because the exact likelihood function cannot be written down in non-
independent cases, except for the normal distribution. Non-normality is accounted for by 
incorporating a relationship between the variance and the mean. [Zeger SL and Liang K (1986)] 
 
Examples 
• Poisson distribution 
If E (Yi) =  µi  then V (Yi) = µi  , and so h(µi ) = µi   
 
• Normal distribution 
E (Yi) =  µi   
V(Yi) = σ2 , which is constant and so independent of µi   
In the case of the normal distribution, there is no relationship between the mean and the 
variance and the likelihood is exact. In fact, in this thesis, GEE are only used for normally 
distributed data.  
 
Specify the correlation structure 
As described in Section 8.5, possible correlation structures are independence, unstructured, 
exchangeable, stationary m-dependent and autoregressive.  
In the independence model (See Section 5.4) 
L = 1/√(2πσ2 ) n exp  [-∑
=
n
i 1
 ε i
2  /2σ2] 
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where ε i2  = ∑
=
n
i 1
 ( yi – µi )2   
    =  [y1-µ1   y2-µ2  …  yn-µn ] y1-µ1  
                  y2-µ2 
   
                     ..  
      yn-µn  
 
     = (y – µ) T (y – µ) 
 
So  L = 1/√(2πσ2 ) n exp [- (y – µ) T I (y – µ) /2σ2] 
 
 
For the non-independence model, the likelihood function is 
 
L* = 1/√(2πσ2 ) n exp [- (y – µ) T S-1 (y – µ) /2σ2],  
 
where S is the variance/covariance matrix for the residuals. 
 
For non-normal data, this likelihood is used as a quasi-likelihood, non-normality being accounted 
for by the mean-variance relationship, i.e. if E (Yi) = µi  then V (Yi) =  h(µi ) / φ. 
Using imposed correlation structure R, model parameter estimates with their variances and 
covariances are obtained by using the quasi-likelihood equations. 
In the special case of normal data, the quasi-likelihood is the likelihood proper 
LQ = 1/√(2πσ2 ) n exp [- (y – µ) T S-1 (y – µ) /2σ2] , 
 
where the covariance matrix for the ith group is Si = Vi ½ Ri Vi ½  where Ri is the correlation matrix  
and Vi ½ is a diagonal matrix with jth entry √[V(µij )/φ] 
LQ is maximum when (y – µ) T S-1 (y – µ) is minimum. 
So to maximize the quasi-likelihood, this expression is differentiated with respect to α and βj where 
j = 1 …  p (p+1 parameters) 
∂/∂βj [(y – µ) T S-1 (y – µ)] = 0 
-∂µT/∂β
 
[ S-1 (y – µ)] +
 
[(y – µ) T S-1. - ∂µT/∂β] = 0 
-2 ∂µT/∂β
 
[ S-1 (y – µ)] = 0 
which gives the generalized estimating equations 
∂µT/∂β
 
[ S-1 (y – µ)] = 0 
Now the link function is  g (µi ) where  
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 g (µi )  = αi + ∑
=
p
j 1
 
βij x ij  , i = 1 …  n 
Therefore  
 µi   =  g -1 [αi + ∑
=
p
j 1
 
βij x ij ], i = 1  … n 
where g -1 (αi , βi1,  βi2, … βip) is the inverse link function 
Substitute the inverse of the link function for µi  in the equations and solve for α and β j, j=1 …  p, 
and their variances and covariances. 
These equations must be solved iteratively. 
 
The iterative process is as follows: 
• Corrected parameter estimates α and βj , j=1 …  p, are obtained and hence new residuals  
• Hence a corrected estimation of correlation matrix R is calculated. The structure of R 
chosen is kept the same, but the coefficients are corrected. 
• Hence the corrected variance/covariance matrix S is calculated 
• The inverse of the corrected matrix S, S-1 is calculated and substituted into the quasi-
likelihood expression. 
• The new generalized estimating equations are the solved. 
The first iteration was the independence model. 
This process is repeated until convergence is reached for the parameter (β) estimates, their 
variances and covariances and the correlation matrix estimate R. 
 
 
9.4  Application of the GEE method  
Before applying GEE analysis, the independence model was run in order to obtain the residuals 
which were used in an exploratory procedure for investigating plausible structures for the 
correlation matrix R.  This was described in Chapter 8. Those structures were then imposed upon R 
and the GEE analysis was run. 
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9.4.1  Application of the GEE method to these particular data 
Link function 
In each of the analyses, the ‘time to’ response variable is approximately normally distributed, as 
was indicated by the diagnostic scatter plot of residuals versus their normal scores. An example is 
given as Figure 6.2. Therefore the link function used in the GEE analysis is the identity. 
 
The mean-variance relationship 
Since the response variable is normally distributed the variance is not a function of the mean, and 
the assumption of constant variance is satisfied. The latter was confirmed by the diagnostic plot of 
standardised residuals versus fitted values. An example is given as Figure 6.1.  It is a reasonable 
assumption that the variance for the first publications is the same as that for  the second, third and 
so on. Since the response is normal, the likelihood is exact. 
 
Specifying the correlation structure 
The preliminary investigations in Chapter 8 suggested that the stationary m-dependent m=2 and 
m=1 structures are likely to be most suitable for these data. This is what one might intuitively 
expect. However, for comparison only the exchangeable, stationary m-dependent m=3 and 
autoregressive will also be tried. In addition the independence model will also be run in order to 
check that the findings are the same as those from the preliminary model, which were reported in 
Section 7.6. 
 
 
9.4.2  Using SAS to run GEE analysis  
The GENMOD procedure in SAS fits generalized linear models. One of its applications is to use 
generalised estimating equations (GEE) to fit models to correlated data resulting from repeated 
measures. The GEE method is recommended for use with files containing a large number of fairly 
small clusters where the correlation matrix itself is not the object of interest. In this case it is the 
parameter (β) estimates which are of interest. From here onwards the term ‘β estimate’ will be used 
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in preference to ‘parameter estimate’ since the coefficients of the correlation matrix are also 
parameters.  
 
The SAS commands for running the GEE analysis are given as Appendix X (iv). This is run on the 
largest dataset, that for the ‘time from close to publication for all mentions’ analysis. In the 
REPEATED statement the correlation structure is specified. Options include independent, 
unstructured (not applicable), exchangeable, stationary m-dependent and autoregressive correlation 
structures. It is also possible to specify the actual correlation coefficients of the matrix, although 
this option is not used. The clustering variable, the randomization ID (RANID), is also specified. 
The program requests that the working correlation matrix is printed out and that the Z- and p- 
values obtained using standard error estimates based on Fisher’s (expected) information are given. 
Estimates based on observed information are also obtained for the purpose of confirming the 
findings from the former, and are discussed briefly in Section 11.8.  
 
9.5  Application of GEE analysis to the largest of the six datasets 
The dataset used is that for ‘time from close to publication for all mentions’.  
Generalised estimating equation analysis was used with the following structures in turn: 
• Independence 
• Exchangeable 
• Autoregressive 
• Stationary m-dependent with m set to 3, 2 and 1 respectively. 
 
From the preliminary investigations the most likely correlation structures appear to be the 
stationary m-dependent, with m = 1 or 2. The generalised estimating equation analysis was run on 
the others as well for comparison only. Although the preliminary investigations suggested that the 
autoregressive correlation structure might be plausible, since this involved the introduction of a 
single new parameter, ρ, as opposed to m new parameters for the stationary m-dependent 
correlation structure, this was based on a 5×5 working correlation matrix, with 4 bands, plus the 
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leading diagonal of unity in each case. The number of bands can be specified when the stationary 
m-dependent correlation structure is imposed, setting all other correlation coefficients to zero. 
However, for all other correlation structures i.e. for the unstructured, exchangeable and 
autoregressive structures, the working correlation matrix is forced to be the full 13×13 matrix.  
 
To return to the original data; the correlation matrix for the residuals from the independence model 
indicated that the correlation coefficients between the response for consecutive reportings were 
strong and positive, and, more importantly, highly significant: 
ρ12  =0.35271 p<0.0001 (n=128) 
ρ23  =0.46667 p<0.0001 (n=90) 
ρ34  =0.66755 p<0.0001 (n=68) 
ρ45  =0.75220 p<0.0001 (n=44) 
 
They became less strong and less significant for those publications distance 2 apart: 
ρ13  =0.16092 p=0.1297 (n=90) n/s 
ρ24  =0.40235 p=0.0007 (n=68) 
ρ35  =0.45929 p=0.0017 (n=44) 
 
Correlation coefficients for publications distance 3 or more apart were both weak and have p-
values > 0.05 associated with them. 
 
This would suggest that a correlation structure with a limited number of non-zero bands is 
appropriate. Since this is not so for the autoregressive correlation structure, the stationary m-
dependent structure, with either m = 1 or 2, may be a better choice. 
 
9.6  An investigation into how far the p-values of the parameter (β) estimates alter when 
different correlation structures are imposed 
Appendix XV gives the output from the generalised estimating equation analysis applied to the 
largest dataset, with each correlation structure imposed. Each variable from the independence 
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model is taken in turn and the significance of its parameter (β) estimate, compared when each of 
the correlation structures is imposed. This listing is given as Appendix XVI. 
 
There are three comparisons to be made: 
• Whether there is a clustering effect, where each randomization is a cluster. This involves 
comparing the p-values when the exchangeable correlation structure is applied with those 
from the independence model. 
• Whether there is a serial correlation effect. This is done by comparing the p-values from 
the stationary m-dependent and autoregressive correlation structures with those from the 
exchangeable one. 
• Finally how much the p-values for the parameters vary, when the four correlation 
structures representing a serial correlation effect are applied. 
 
The findings are as follows: 
• Eight of the 17 variables were very highly significant, p<0.0001 in the independence 
model. Of these, four including the intercept remained so under all correlation structures 
imposed. 
• Of the other 13 variables, the p-value of  five remained roughly the same under the 
exchangeable, but increased under the stationary m-dependent and autoregressive 
structures.  
• For six variables the p-value was largely unchanged no matter which correlation structure 
was used.  
• For the only interaction term in the model, the p-value did not differ much between the 
exchangeable, stationary m-dependent and autoregressive models, but was greater for these 
than for the independence model. 
• The final term was non-significant in the independence model and remained so whichever 
correlation structure was applied 
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• Notably, it was seen that for each variable, the results are similar whichever of  the three 
most appropriate correlation structures, i.e. the autoregressive and m-step dependent with 
m=2 and m=1, are imposed. 
 
9.7  Variables significant in the independence model but no longer significant once a 
correlation structure is imposed  
All variables in the independence model remained significant no matter which correlation structure 
was imposed.  
 
The variable, ‘country group of trialists is Europe or Other, as opposed to North America’, 
(CGROUP) was not statistically significant in the independence model (p=0.9262). However, this 
was retained due to the significance of the interaction between country group of trialist and whether 
participation was multi-centre or single-centre (p=0.0006). As expected, this main term remained 
non-significant when the various correlation structures were applied.  
 
9.8  Comparing diagnostic plots for the various correlation structures 
Standardised residuals versus fitted values 
Whichever correlation structure is imposed, including the independence model, the plot of 
standardised residuals versus fitted values does not alter noticeably. The diagnostic plots using the 
independence, exchangeable and stationary m-step, m=2, dependent correlation structures are given 
in Figure 9.1.  
 
The result in each case is a random spread, indicating constant variance, especially if those 
observations with a negative fitted value are ignored. It is reasonable to ignore them since this 
group of observations are those for which the date of publication is before the date of close of 
randomization i.e. those randomizations which are mentioned in a publication while the 
randomization is still open for accrual, or even prior to opening for accrual, and so are atypical. If 
these are left in, the spread is slightly more wedge-shaped. 
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Figure 9.1 Time from close to publication for all mentions. Standardised residuals vs. fitted values:  
(i) independence model (ii) using generalized estimating equation analysis with an exchangeable correlation 
structure and (iii) with a stationary m-dependent, m=2, correlation structure  
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Figure 9.2 Time from close to publication for all mentions. Residuals vs. their normal scores 
(i) independence model (ii) using generalized estimating equation analysis with an exchangeable correlation 
structure and (iii) with a stationary m-dependent, m=2, correlation structure 
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Residuals versus normal scores  
The plots for residuals versus their normal scores for independence, exchangeable and stationary 
m-dependent, m=2, correlation structures are given in Figure 9.2. Again, whichever correlation 
structure is used, the residuals versus normal scores plot remains largely unaltered. The line is 
fairly straight, indicating a normal distribution with a slight kink for the largest residuals. The line 
is marginally straighter when either of the correlation structures are used, indicating a slightly 
better fit to the data, but the difference is negligible. 
 
Conclusion 
Whichever correlation structure is applied, both constant variance and normality are reasonable 
assumptions, as they were for the independence model. 
 
9.9  The linear mixed effects model with grouped data 
As described in Section 5.4, the ordinary linear regression model (independence model) can be 
written as 
 y = X β   
where β is the vector of fixed-effects parameter estimates 
For the ith group (randomization in this case) 
 yi = X i β + ε i 
A linear mixed effects model for the ith group is  
 yi = X i β + Z i b + ε i  
where: 
b is the unknown vector of random-effects such that b ~ N (0, Σ b), i.e. b is normally distributed 
with mean vector zero and variance/covariance matrix Σ b. 
 
The columns of Z are usually a subset of those of X, i.e. values of a subset of the explanatory 
variables, acting on each group separately. 
 
ε is the vector of residuals and is generally of the form ε ~ N (0, σ2 I).  
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Random effects bi and residuals εi  are assumed to be independent. However, a useful extension 
enables the modelling of non-constant variances and also special within-group correlation 
structures. In such cases ε is the vector of within-group errors and has the form ε ~ N (0, Σ), where 
the variance/covariance matrix Σ is to be estimated. The general case is the unstructured form. 
However, the same correlation structures as were used in GEE analysis can be imposed on the 
linear mixed effects models, and for the same reason – to avoid over-parameterisation. 
 
9.10  Using a linear mixed effects model to confirm the findings from the GEE analysis 
A linear mixed effects model was run using the MIXED procedure in SAS with the commands 
given in Appendix X (v). Different correlation structures were imposed and the β estimates, 
estimates of the standard errors of these and p-values obtained compared with those from the 
generalised estimating equations. Although the linear mixed effect model calculates the β estimates 
using a different method from the generalised estimating equations, the purpose of using this 
method in addition to GEE is as a mutual check. If the β estimates and the estimates of their 
standard errors found using the linear mixed effects model are very similar to those from the GEE 
analysis when a particular correlation structure is imposed, this gives more confidence that the 
correlation structure chosen is appropriate. The output from the program running the linear mixed 
effects model is given as Appendix XVII. The findings are summarized below. 
 
Independence correlation structure  
As expected, the β estimates, standard errors and t values obtained using the linear mixed effects 
model are identical to the β estimates, standard errors and Z values obtained using GEE. The p-
values are almost identical, slightly higher in the linear mixed effects model, the difference 
negligible. The output from the linear mixed effects model is also identical to that from the GLM 
procedure used for the preliminary analysis. This provides a good starting point for any 
comparisons. 
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Exchangeable correlation structure 
The β estimates, standard errors of these, t-values and p-values obtained using the linear mixed 
effects model are all very similar to the estimates obtained using GEE analysis. The p-values of all 
variables remain <0.05 with the linear mixed effects model also. 
 
Autoregressive correlation structure 
The β estimates, standard errors and t-values obtained using the linear mixed effects model are 
broadly similar to those obtained from the GEE analysis, but the comparative significance of the 
variables is not retained in all cases. ‘Number of randomizations reported in a publication’ 
(NRREP) has p-value 0.0375 when GEE are used but p=0.0700 under the linear mixed effects 
model. The p-values of the other variables remain <0.05 when the linear mixed effects model is 
applied. 
 
Stationary m-dependent (m=3) correlation structure 
Estimates from the linear mixed effects analysis differed substantially from those from the GEE 
analysis. Some variables of moderate or borderline significance when GEE were used were no 
longer significant when a linear effects model was used.  
• Conducted in Europe (CGROUP): p=0.0060 increased to p=0.0736 
• Article published in a language other than English (ENGLISH): p=0.0433 increased to 
p=0.3811 
• Reported in articles that mention fewer randomizations (NRREP): p=0.0487 increased to 
p=0.1700 
• Impact factor of journal (IMPACT): p=0.0099 increased to p=0.3162 
• Publication type: meeting abstracts versus journal articles and book chapters 
(PUBTYPE3): p=0.0453 increased to p=0.1845 
 
However, for ‘indication as to whether the main questions, as stated in the paper, are answered in 
the paper’ (ANSWER) the p-value of 0.0092 increased to only 0.0237. 
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So again, the comparative significance of the variables is not retained in all cases, between the 
independence model and when a correlation structure is imposed using GEE, between the 
independence model and when the correlation structure is imposed using a linear mixed effects 
model, or between the same correlation structure being imposed using GEE and a linear mixed 
effects model. 
 
In the independence model, impact factor of journal (IMPACT) and publication type; meeting 
abstracts versus book chapters and journals (PUBYTPE3) had by far the largest p-values, 
p=0.0252 and 0.0253 respectively, apart from one of the indicator variables for country group 
(CGROUP)(p=0.9262), which was retained only due to the significance of its interaction with 
multi-centre versus single-centre participation (MULTIC). The two indicator variables representing 
clinical significance (CLNSG) are next, p=0.0030 and 0.0028. These remain significant under both 
the GEE and linear mixed effects models, p=0.0021 and 0.0314, and 0.0015 and 0.0302 
respectively. Note how the p-value for the former has become slightly more significant under both, 
and the latter far less so.  
 
Stationary m-dependent (m=2) correlation structure 
The estimates obtained using the two procedures are broadly similar. The comparative significance 
of the variables when the GEE and the linear mixed effects methods are used was not retained in all 
cases. 
When the linear mixed effects model was used, variable ‘published in full in a language other than 
English’ (ENGLISH) had p-value 0.1065, whereas with the GEE model p=0.0349. The p-values of 
all other variables remained at <0.05 under both procedures. 
 
Stationary m-dependent (m=1) correlation structure 
The estimates obtained using the two procedures are broadly similar. Again, the comparative 
significance of variables, between the GEE findings and the linear mixed effects model, is not 
retained for all variables. The results when the latter was used are almost identical to those using 
the independence model. p-values for all variables remained at <0.05 under both models. 
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Summary of findings 
Running the linear mixed effects model broadly confirms the GEE findings when imposing a 
correlation structure of type exchangeable, autoregressive and stationary m-dependent with m=2 
and with m=1. 
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10  APPLYING THE GENERALISED ESTIMATING EQUATION ANALYSIS WITH 
STATIONARY M-DEPENDENT, M = 2 AND M = 1, CORRELATION STRUCTURES  
TO ALL SIX  DATASETS INVOLVING REPEATED MEASURES 
 
10.1  Introduction 
As discussed in the previous chapter the stationary m-dependent correlation structures with m=2 
and m=1 appear to be most appropriate for the data. It was decided to apply both to the remaining 
five datasets and compare the results before deciding on the final model. The findings are 
summarized below, together with those for the largest dataset, on which the various correlation 
structures were piloted. 
 
10.2  Time from close to submission for all mentions 
For each variable the p-values obtained under the stationary m-dependent correlation structure with 
m=2 and with m=1 are very similar. All variables remain significant, i.e. p<0.05, under both 
models. 
 
10.3  Time from receipt to publication for all mentions 
Again, for each variable the p-values obtained under the stationary m-dependent correlation 
structure with m=2 and with m=1 are very similar. All variables remain significant under both 
models. 
 
10.4  Time from close to publication for all mentions 
There was very little difference between the p-values obtained for each variable, using the 
stationary m-dependent correlation structure with m=2 and with m=1. The p-values of all variables 
remained <0.05 [with the exception of country group of trialists (CGROUP): Other versus North 
America and Europe’, which was non-significant under the independence model, and retained only 
due to the significance of its interaction with single-centre versus multi-centre participation 
(MULTIC)]. 
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10.5  Time from close to submission for all results 
Again, the p-values are very similar using the stationary m-dependent correlation structure with 
m=2 and with m=1. In both cases there is only marginal evidence for the retention of variable 
‘clinical significance’ (CLNSG) (p=0.1051 and p=0.1030 respectively). Direction of results is of 
borderline significance (p=0.0450 and p=0.0449 respectively) but remains in the model.  
 
The analysis, therefore, will be re-run omitting variable CLNSG. 
 
10.6  Time from receipt to publication for all results 
p-values were similar for most variables, but with a notable difference: 
 
Under the stationary m-dependent correlation structure with m=2, presented at a major meeting 
(PRESENTD) is dropped from the model at p=0.1257 and impact factor of journal (IMPACT) is 
retained (p=0.0244).  
 
Under the stationary m-dependent correlation structure with m=1, PRESENTD is retained, with 
p=0.0435. However the p-value for IMPACT increases to 0.0836, but will remain in the model due 
to the significance of its interaction with whether there was international participation or not 
(INTERNL).  
 
Under the independence model, PRESENTD was retained (p=0.0113) and IMPACT was non-
significant (p=0.1759), but again retained due to the significance of its interaction with INTERNL. 
Apart from IMPACT, PRESENTD was the least significant variable in the model.  
 
If it is decided that the m=2 model is to be used, the analysis must be re-run, omitting variable 
PRESENTD. 
 
10.7  Time from close to publication for all results 
Again, when the stationary m-dependent, m=2 and m=1, correlation structures are applied the p-
values obtained are similar. The p-values for the same five variables increase to >0.05. These are: 
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• Number of questions (NOQ): p=0.1771 and p=0.1566 respectively 
• Clinical significance (CLNSG): p=0.1015 and p=0.0755 respectively 
• First-line versus relapse treatment (FIRSTL): p=0.0817 and p=0.0753 respectively 
• The two indicator variables representing direction of results (POSNG): p=0.2560 and 
p=0.2659 respectively, and p=0.0669 and p=0.1000 respectively. 
 
When the independence model was used, the p-values for the two indicator variables representing 
POSNG were also >0.05, and were retained only because of the significance of their interaction 
with statistical significance (LOGPEST). Under the stationary m-step dependent correlation 
structures, m=2 and m=1, again these are retained only because of the significance of the 
interaction terms. 
 
A backwards elimination procedure must now be used beginning by dropping the least significant 
main term, NOQ. 
 
10.8  Conclusion 
The two correlation structures, which looked most appropriate from the original data, the stationary 
m-dependent, with m=2 and with m=1, give very similar results. For the correlation matrices 
formed from the residuals from the independence model for the two largest datasets, the 
correlations for publications distance 1 apart are strong and highly statistically significant, and 
those distance 2 apart are less strong but still mostly statistically significant. Those distance 3 or 
more apart were neither strong nor statistically significant. Therefore it has been decided to use the 
m=2 correlation structure. 
 
For the three analyses where imposing the stationary m-dependent,  m=2, correlation structure 
resulted in one or more terms becoming no longer significant, a backwards elimination procedure 
was used to obtain a reduced set of significant variables. The three datasets in question are the three 
time period response variables for all reportings of results. The findings from all six analyses with 
repeated measures are described in the following chapter. 
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11  FINAL RESULTS FOR THE SIX REGRESSIONS INCORPORATING REPEATED 
MEASURES ANALYSIS USING GENERALISED ESTIMATING EQUATIONS (GEES) 
 
11.1  Introduction 
As discussed previously, six datasets contain more than one record for some randomizations, i.e. 
repeated measures for the same observation. This has now been compensated for by using 
generalised estimating equations, imposing a stationary m-dependent, m=2,  correlation structure. 
The final results are now given and the output for these is in Appendix XVIII, with the exception of 
those for the analysis of time from close to publication for all mentions, which was given in 
Appendix XV. This chapter ends with a short section showing that whether the standard error 
estimates were obtained using the expected or observed information makes little difference to the 
outcome. 
 
11.2  For all mentions of each randomization, which trial characteristics affect the time from 
close to submission? 
Time from close to submission is longer for randomizations with the following characteristics: 
• Shorter duration of accrual period (DURRAN) (p=0.0014), typical effect 1 year 
• From a publication with no or a low impact factor (IMPACT) (p=0.0007), typical effect 1 
year 7 months 
• Results have smaller p-values associated with them (LOGPEST) (p=0.0002), typical effect 
10 months 
• Conducted in a ‘developing’ country (DEVLPNG) (p<0.0001), typical effect 12 years 
• Published in an article which mentions a greater number of trials (LOGNTREP) 
(p=0.0356), typical effect 6 months 
• Published in an article which mentions fewer randomizations (NRREP) (p=0.0012), 
typical effect 10 months 
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This is based on all 209 observations. The mean and range of response variable are approximately 
5 years 3 months (–3 years 1 month to 26 years 0 months). The correlation coefficients used in the 
working correlation matrix were calculated as 0.5276 for those distance 1 from the leading 
diagonal and 0.4617 for those distance 2. This means that the model used assumes that, for any 
randomization, the correlation between the time from close to submission of one article and that for 
the next is 0.5276, the correlation between that for the article and the next-but-one is 0.4617 and 
that there is no correlation between time from close to submission for articles further apart.    
 
11.3  For all mentions of each randomization, which trial characteristics affect the time from 
receipt to publication? 
√(time from receipt to publication) is longer for randomizations with the following characteristics: 
• Later start date of accrual period (NSTART) (p<0.0001) 
• Published in a North American or European journal (JGROUP) (p<0.0001) 
• Longer duration of accrual period (DURRAN) (p=0.0002) 
• Reported in articles which mention fewer randomizations (NRREP) (p<0.0001) 
• Conducted outside Europe (CGROUP) (p<0.0001) 
• Larger number of co-authors (LOGAUTH/LOGMRC) (p=0.0089) 
 
This is based on 195 out of 218 observations. The mean and range of time from receipt are 
approximately 9 months (1 month to 2 years 4 months). The correlation coefficients used in the 
working correlation matrix were calculated as 0.0006 for those distance 1 from the leading 
diagonal and -0.2442 for those distance 2.  
 
11.4  For all mentions of each randomization, which trial characteristics affect the time from 
close to publication? 
Time from close to publication of article is longer for randomizations with the following 
characteristics: 
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Main effects: 
• Earlier start of accrual period (NSTART) (p<0.0001), typical effect 1 year 
• Shorter duration of accrual period (DURRAN) (p=0.0008), typical effect 8 months 
• Published in full in the English language (ENGLISH) (p=0.0349), typical effect 1 year 10 
months 
• Not presented at a major meeting (PRESENTD) (p<0.0001), typical effect 1 year 5 months 
• Results are clearly reported as clinically significant (CLNSG) (p=0.0030), typical effect 1 
year 2 months 
• Clinical significance is not reported (CLNSG) (p=0.0169), typical effect 10 months 
(A clearer interpretation of the above two findings is that results clearly reported as not or only 
possibly clinically significant are published fastest, followed by those where no indication of 
clinical significance is given, with results clearly reported as clinically significant having the 
longest time to publication.)  
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper (ANSWER) (p=0.0054), typical effect 9 months 
• Conducted in a ‘developing’ country (DEVLPNG)(p<0.0001), typical effect 6 years 2 
months 
• Reported in articles which mention a greater number of trials (NTREP) (p=0.0002), 
typical effect 7 months 
• Reported in articles which mention a smaller number of randomizations (NRREP) 
(p=0.0362), typical effect 4 months 
• Reported in a publication with a low or no impact factor (IMPACT) (p=0.0128), typical 
effect 5 months 
• Reported in a journal article or book chapter as opposed to a meeting abstract (PUBTYPE) 
(p=0.0316), typical effect 10 months 
• Conducted outside Europe (CGROUP) (p=0.0076), typical effect 1 year 4 months 
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• Participation of five or more centres (MULTIC) (p=0.0001), typical effect 2 years 2 
months 
Interaction: 
• However, for trials conducted outside North America, participation of less than five centres 
also increases time to publication (CGROUP*MULTIC) (p=0.0066), typical effect 3 years 
4 months 
[The typical effect for the non-significant main term CGROUP (conducted outside North America 
and Europe) is 5 months].  
 
This is based on 581 out of 582 observations.  The mean and range of response variable are 
approximately 4 years 11 months (–4 years 7 months to 27 years 9 months). The correlation 
coefficients used in the working correlation matrix were calculated as 0.4514 for those distance 1 
from the leading diagonal and 0.1436 for those distance 2.  
 
11.5  For all reportings of results for each randomization, which trial characteristics affect 
the time from close to submission? 
Time from close to submission is longer for randomizations with the following characteristics: 
• Greater number of questions (NOQ) (p=0.0035), typical effect 7 months 
• Not presented at a major meeting (PRESENTD) (p=0.0016), typical effect 1 year 8 months 
• From a publication with no or a low impact factor (IMPACT) (p=0.0041), typical effect 1 
year 5 months 
• Results have smaller p-values associated with them (LOGPEST) (p<0.0001), typical effect 
9 months 
• Direction of results is not reported (POSNG) (p=0.0449), typical effect 1 year 9 months 
 
This is based on all 129 observations. The mean and range of response variable are approximately 
5 years 1 month (–6 months to 16 years 1 month). The correlation coefficients used in the working 
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correlation matrix were calculated as 0.5657 for those distance 1 from the leading diagonal and 
0.0650 for those distance 2.  
 
11.6  For all reportings of results for each randomization, which trial characteristics affect 
the time from receipt to publication? 
Time from receipt to publication is longer for randomizations with the following characteristics: 
Main effects: 
• Limited international or single-country as opposed to truly international participation 
(INTERNL) (p<0.0001), typical effect 1 year 2 months 
• Multi-centre participation (MULTIC) (p<0.0001), typical effect 4 months 
• Published in a non-European journal (JGROUP) (p<0.0001), typical effect 5 months 
• Published in a North American or European journal (JGROUP) (p<0.0001), typical effect 
1 year 1 month  
(Results published in non-US, non-European journals are published more quickly than those 
published in European journals, with those published in North American journals taking longest.) 
• Longer duration of accrual period (DURRAN) (p<0.0001), typical effect 2 months 
• The main questions as stated in the paper are answered in the paper (ANSWER) 
(p=0.0053), typical effect 2 months 
Interaction: 
• Truly international trials published in journals with a high impact factor also have a longer 
time to publication (INTERNL*IMPACT) (p=0.0005), typical effect 9 months 
[The typical effect of the non-significant main term lower impact factor (IMPACT) is 1 month]. 
For journals with a non-zero impact factor of less than 8, international trials have a shorter time to 
publication. For those with an impact factor of greater than 8, time to publication is increased. 
 
This is based on 121 out of 137 observations. The mean and range of the response variable are 
approximately 9 months (1 month to 2 years 4 months). The correlation coefficients used in the 
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working correlation matrix were calculated as -0.5996 for those distance 1 from the leading 
diagonal and 0.0805 for those distance 2.  
 
11.7  For all reportings of results for each randomization, which trial characteristics affect 
the time from close to publication? 
Time from close to publication of article is longer for randomizations with the following 
characteristics: 
Main effects: 
• Earlier close date of accrual period (NCLOSE) (p=0.0001), typical effect 10 months 
• Not presented at a meeting (PRESENTD) (p=0.0014), typical effect 1 year 
• A clear indication is given as to whether or not the main questions in the paper are 
answered in that paper (ANSWER) (p=0.0119), typical effect 10 months 
• Reported in articles which mention a greater number of trials (NTREP) (p=0.0071) typical 
effect 4 months 
• Direction of result is negative (POSNG) (p=0.0399), typical effect 1 year 
• Results with smaller p-values (LOGPEST) (p<0.0001), typical effect 1 year 
Interaction: 
• Results clearly in favour of either the experimental (p=0.0001) or the standard (p=0.0061) 
arm and the associated p-values are larger, the former having a very slightly greater effect 
than the latter (POSNG*LOGPEST), typical effect 1 year 1 month in each case 
[The typical effect of the non-significant main term POSNG (direction of results is positive) is 8 
months.] 
 
In the case of results in favour of the standard arm the effect of the interaction is in the opposite 
direction to that of the main term. A negative result only leads to a delay in publication if it is 
significant only at the p=0.05 level or if significance is not achieved. Otherwise the time to 
publication is shortened. 
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This is based on all 372 observations.  The mean and range of  the response variable are 
approximately 5 years 0 months (-2 years 8 months to 19 years 0 months). The correlation 
coefficients used in the working correlation matrix were calculated as 0.5526 
for those distance 1 from the leading diagonal and 0.1911 for those distance 2.  
 
It is interesting to note that ‘direction of result is negative’ (POSNG)  had a p-value of 0.1253 when 
the independence model was used, and was retained only due to the significance of the interaction 
between statistical significance and direction of results.  
 
11.8 A comparison of the results obtained using standard error estimates based on  
the observed information with those obtained using Fisher’s (expected) information  
 
All the results quoted are based on Fisher’s (expected) information. Results based on the observed 
information were also produced. Although the p-values for some variables in some analyses varied 
considerably between the two methods, the final choice of variables, each with a p-value < 0.05 
remained unchanged for five out of six of the analyses. The exception is the analysis of time from 
close to submission for all reportings of results, where the p-value for direction of results 
reported/not reported increased from p=0.0449 when expected information standard error estimates 
were used to p=0.1109 when the observed information standard error estimates were used, 
weakening the case for retaining  this variable. 
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12  REPORTINGS OF RANDOMIZATIONS THAT ARE PUBLISHED BEFORE 
CLOSURE 
 
12.1  Introduction 
Section 3.11 described how although an article may report one randomization in detail, it may also 
mention several other studies briefly, and that provided it is clear that from the brief description 
that the latter are randomized, they too are eligible for inclusion in the analyses reported in this 
thesis. Sometimes open trials, and occasionally future trials, are mentioned, typically in the 
discussion. In such cases the dates of submission and publication are before the date of closure, 
leading to negative times from close to submission and publication respectively. All of the analyses 
reported throughout this thesis use all publication records (‘the whole set’) (provided missing 
values do nor preclude this) including those where the ‘time to’ response variable is negative 
(‘negative responses’), since a brief mention of an open or future randomization is sufficient for 
its identification. However open and future trials differ from closed trials (‘positive responses’) in 
that since their data are not mature, there is necessarily a delay to when they can actually be used in 
meta-analyses. 
 
This chapter investigates whether this group of mentions are atypical. Eight of the twelve ‘time to’ 
analyses included negative responses. These are the analyses of ‘time from close to submission’ 
and ‘time from close to publication’ for first mentions, first reportings of results, all mentions and 
all reportings of results. These are re-run, firstly on the set of negative responses alone, and then on 
the set of positive responses alone, to see if any of significant variables obtained with the whole set 
are no longer significant. In each case the set of variables found to be significant in the analysis 
using all available records was taken and a process of backwards elimination used in order to 
obtain a revised model. The remaining four ‘time to’ analyses are for the response variable ‘time 
from receipt to publication’, for which the response is always necessarily positive.  
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In the following descriptions of variables no longer found to be significant when only positive 
responses are used, the variables are listed in the order in which they were dropped from the model 
and in each case the  p-value quoted is that at the point the variable was dropped. 
 
 
12.2  Time from close to submission for first mentions 
Of the 63 publication records used in the analysis of the whole set the time from close to 
submission was negative for 10 and positive for 53. 
 
Analysis of negative responses 
Two variables were found to be significant predictors of a longer time from close to submission. 
These are a shorter duration of randomization period (DURRAN) (p=0.0204) and if the trial 
comprises fewer randomizations (NRAND) (p=0.0427). These effects act in the same directions as 
in the analysis of the whole set of observations. 
 
Analysis of positive responses 
All variables significant in the analysis using the whole set of records remain so when the negative 
responses are removed, and all act in the same directions as in the analysis of the whole set.  
 
12.3  Time from close to publication for first mentions 
Of the 195 publication records used in the analysis of the whole set the time from close to 
publication was negative for 32 and positive for 163. 
 
Analysis of negative responses 
Three variables are significant predictors of a longer time from close to publication. These are, 
again, shorter duration of randomization period (DURRAN) (p=0.0098), and also if a clear 
indication is not given as to whether the main questions in the paper are answered in that paper 
(ANSWER) (p=0.0119) and if reported in articles which mention fewer trials (NTREP) 
(p=0.0255). In this analysis both ANSWER and NTREP act in the opposite direction to when used 
in the analysis of the whole set. 
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Analysis of positive responses 
Three variables significant in the analysis of the whole set are now no longer so. These are: the 
duration of randomization period (DURRAN) (p=0.8791), country group of trialist; Europe and 
Other versus North America (CGROUP) (p=0.4018) and impact factor of journal (IMPACT) 
(p=0.0939). Note that whereas CGROUP was the least significant variable in the analysis of the 
whole set (p=0.0434) and IMPACT was moderately significant (p=0.0089), DURRAN was highly 
significant (p<0.0001).   
 
12.4  Time from close to submission for first reportings of results 
Of the 52 publication records used in the analysis of the whole set the time from close to 
submission was negative for 1 and positive for 51. Therefore no analysis was performed for 
negative responses. 
 
Analysis of positive responses 
Not surprisingly all variables significant in the analysis of the whole set remained so when the one 
negative response was removed. 
 
 
12.5  Time from close to publication for first reportings of results 
Of the 170 publication records used in the analysis of the whole set the time from close to 
publication was negative for 16 and positive for 154. 
 
Analysis of negative responses 
Only one variable was found to be a significant predictor of a longer time from close to 
publication; a shorter duration of randomization period (DURRAN) (p=0.0412). 
 
Analysis of positive responses 
The only variable significant in the analysis of the whole set and now not so is duration of 
randomization period (DURRAN) (p=0.1238).  
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12.6  Time from close to submission for all mentions 
Of the 209 publication records used in the analysis of the whole set the time from close to 
submission was negative for 14 and positive for 195. 
 
Analysis of negative responses 
None of the variables significant in the analysis of the whole set remain so.  
 
Analysis of positive responses 
All variables remain in the model with the exception of duration of randomization period 
(DURRAN) (p=0.1197). 
 
12.7  Time from close to publication for all mentions 
Of the 581 publication records used in the analysis of the whole set the time from close to 
publication was negative for 46 and positive for 535. 
 
Analysis of negative responses 
Four variables remain significant predictors of a longer time to publication. Three of these are only 
of borderline or moderate significance and act in the opposite direction. These are that clinical 
significance is reported (CLNSG) (p=0.0440), a clear indication is not given as to whether the 
main questions in the paper are answered in that paper (ANSWER) (p=0.0418) and if reported in 
articles which mention fewer trials (NTREP) (p=0.0239). The fourth variable, shorter duration of 
randomization period (DURRAN) is highly significant (p=0.0002) and acts in the same direction as 
it does in the analysis of the whole set. 
 
Analysis of positive responses 
Five variables significant in the analysis of the whole set are no longer so. These are; duration of 
randomization period (DURRAN) (p=0.5137),  number of randomizations mentioned in article 
(NRREP) (p=0.2168), impact factor of journal (IMPACT) (p=0.1386), published in full in a 
language other than English versus English (ENGLISH) (p=0.0698) and reported as a meeting 
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abstract versus as a journal article or book chapter (PUBTYPE) (p=0.0802). NRREP, IMPACT, 
ENGLISH and PUBTYPE were all of only moderate significance in the analysis of the whole set 
(p= 0.0362, 0.0128, 0.0349 and 0.0316 respectively). However, DURRAN was highly significant 
(p=0.0008). Of the variables remaining in the model, all act in the same direction as in the whole 
set analysis.  
 
12.8  Time from close to submission for all reportings of results 
Of the 129 publication records used in the analysis of the whole set the time from close to 
submission was negative for one and positive for 128. Therefore no analysis of negative responses 
was undertaken. 
 
Analysis of positive responses 
Not surprisingly all variables significant in the analysis of the whole set remained so when the one 
negative response was removed. 
 
12.9  Time from close to publication for all reportings of results 
Of the 129 publication records used in the analysis of the whole set the time from close to 
publication was negative for 20 and positive for 352.  
 
Analysis of negative responses 
Two variables remain significant predictors of a longer time to publication. These are; that an 
indication is given as to whether the main questions as stated in the article are answered in the 
article (ANSWER) (p<0.0001) and degree of statistical significance (LOGPEST) (p=0.0412), the 
latter acting in the opposite direction to its effect in the analysis of the whole set.  
 
Analysis of positive responses 
Only one variable is no longer significant, whether an indication is given as to whether the main 
questions as stated in the article are answered in the article (ANSWER) (p=0.0710).  
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12.10  Conclusions 
The group of randomizations which are mentioned before closure are clearly atypical. Their 
removal generally leads to one or more variables becoming no longer significant. Two analyses of 
the whole set contained only one negative response, those of time from close to submission for the 
first reporting of results and for all results. In both cases its removal made minimal difference to 
the model. 
 
Of the other six whole set analyses, five contained variable DURRAN. This variable appears to be 
acting as a surrogate for whether or not the response is negative or positive, most notably in the 
analyses of time from close to publication for first mentions and for all mentions. The set of all 
mentions was taken and a variable created to indicate those publication records with date of 
publication prior to that of closure. The correlation of this indicator with DURRAN was found to 
be moderately high, ρ=0.32775 (p<0.0001 using the 582/610 observations for which start and close 
date of accrual period and date of publication are known), supporting this theory. 
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13  WHICH FACTORS AFFECT THE THREE TIME PERIODS? – CONCLUSIONS 
 
13.1  Introduction 
This chapter begins by summarizing the findings of the twelve ‘How long?’ analyses, in tabular 
form. This facilitates a comparison of factors affecting a particular time period response, between 
the ‘all records’, ‘all results’, ‘first mentions’ and ‘first results’ analyses, or for a particular dataset 
a comparison of the factors affecting the three time periods analysed. This is followed by a written 
description of the key findings, with some suggestions as to why these may be important factors 
and implications, i.e. the possibility of introducing bias when identifying randomized comparisons 
for inclusion in meta-analyses. Finally, the findings of the three ‘first results’ analyses are 
compared with results of other similar studies identified from a literature search.  
 
13.2  Table summarizing the findings from the twelve ‘How long?’ analyses 
Table 13.1 summarises the significant variables in each of the twelve regressions.  
Unchanging trial characteristics taken from the definitive record are given first, followed by results 
variables, followed by variables to do with the article, followed by interactions. 
Key
 
ANSWER main questions answered  
    (Yes, No, X =not reported) 
ARMS    number of arms 
CGROUP country group of trialists  
    (America, Europe, Other) 
CLNSG  clinical significance  
(Yes, No, Possibly,  
X=not reported) 
DEVLPNG  conducted in a ‘developing’ 
country 
DURRAN   duration of randomization 
ENGLISH published as an Abstract in 
English rather than in full  
EQUIV  equivalence trial 
FIRSTL   relapse/refractory as opposed to  
     first-line treatment 
FUNDG funding source 
  (Government, Charity) 
IMPACT impact factor 
INTERNL international participation  
(Yes, Limited, No) 
JGROUP country group of publisher 
(America, Europe, Other) 
      
LOGAUTH  log 10 (number of co-authors) 
LOGPEST    spacing between log e (typical 
p-value) and that of the non-
significant/not reported 
category 
LOGNTREP log 10 (number of trials 
reported) 
MULTIC multi-centre participation  
(Yes, Limited, No) 
NCLOSE close date of accrual period 
NOIMPACT no impact factor associated 
NOQ     number of questions 
NRAND     number of randomizations 
NRREP number of randomizations 
reported 
NSTART  number of trials reported 
POSNG     direction of results  
(+, - , Null, Opposite,  
X=not reported) 
PRESENTD presented at a major meeting 
PUBTYPE Journal, Book or Meeting 
abstract
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n number of observations used in the final model out of total number for which the response variable 
is present  
p number of variables in the final model including all indicator variables used to express a categorical 
variable and interactions 
↑ explanatory variable for which an increase, in the case of a continuous variable, or belonging to that 
class, in the case of a categorical variable, corresponds to an increase in the response variable 
↓ explanatory variable for which a decrease, the case of a continuous variable, or not belonging to 
that class, in the case of a categorical variable, corresponds to an increase in the response variable 
↑↑, ↓↓  class having the greatest effect for a categorical variable with three categories 
* interaction  between two main effects 
 
 
Dataset 
Response 
variable 
All mentions All results 1st mentions 1st results 
 
Close to 
submission ↑ 
(TCLREC) 
n=209/209 p=6 
 
DURRAN ↓ 
DEVLPNG ↑ 
 
 
LOGPEST ↑ 
 
 
IMPACT ↓ 
LOGNTREP ↑ 
NRREP ↓ 
n=129/129 p=5 
 
NOQ ↑ 
 
 
 
LOGPEST ↑ 
POSNG (X↑ vs. +,-,F,O) 
 
 
PRESENTD ↓ 
IMPACT ↓ 
 
n=63/63 p=4 
 
NRAND ↓ 
DURRAN ↓ 
CGROUP (E,O ↑ vs. A) 
DEVLPNG ↑ 
 
 
n=52/52 p=7 
 
NCLOSE ↓ 
MULTIC (Y,L ↑ vs. N) 
CGROUP  
(O ↑↑ vs. E ↑ vs A) 
 
POSNG  
(-↓↓vs+,F↓ vs. O,X) 
 
IMPACT ↑ 
 
Receipt to 
publication ↑ 
(TRECPUB) 
n=195/218 p=6 
 
NSTART ↑ 
DURRAN ↑ 
CGROUP(O,A↑ vs. E) 
 
 
 
JGROUP (A,E vs. O ↓) 
NRREP ↓ 
LOGAUTH ↑ 
n=121/137 p=8 
 
DURRAN ↑ 
MULTIC (Y,L ↑ vs. N) 
INTERNL (Y↓ vs. L,N) 
 
ANSWER (Y↑ vs. N,X) 
 
JGROUP 
 (A vs. E ↓vs. O↓↓) 
 
INTERNL Y* IMPACT↑ 
n=67/72 p=7 
 
NRAND ↓ 
 
CLNSG  
(Y,N ↓ vs. P,X) 
 
JGROUP (O↓ vs. A,E) 
NRREP ↓  
 
CGROUP O,E * 
DURRAN ↑ 
n=49/60 p=6 
 
FUNDG (G vs. G+C↑) 
 
 
 
CLNSG  
(Y↓ vs. N↓↓vs. P,X) 
 
PRESENTD ↑ 
NTREP ↑ 
NRREP ↓ 
 
 
Close to 
publication ↑ 
(TCLPUB) 
n=581/582 p=16 
 
NSTART ↓ 
DURRAN ↓ 
MULTIC  (Y ↑ vs. L,N) 
CGROUP (O,Avs.E ↓) 
DEVLPNG ↑ 
 
CLNSG  
(Y↑↑ vs.X↑ vs. N,P) 
ANSWER (Y,N ↑ vs. X) 
 
 
PRESENTD ↓ 
IMPACT ↓ 
PUBTYPE (M↓ vs. J,B) 
ENGLISH (A↓ vs. E) 
NTREP ↑ 
NRREP ↓ 
 
CGROUP E,O * 
MULTIC N,L↑ 
n=372/372 p=9 
 
NCLOSE ↓ 
 
 
 
 
LOGPEST ↑ 
POSNG (-↑ vs. +,F,O,X) 
ANSWER (Y,N ↑ vs. X) 
 
 
PRESENTD ↓ 
NTREP ↑ 
 
 
 
 
LOGPEST * POSNG + ↓ 
LOGPEST * POSNG - ↓ 
 
n=195/195 p=9 
 
NSTART ↓ 
DURRAN ↓ 
CGROUP (O ↑vs. A,E) 
DEVLPNG ↑ 
EQUIV ↓ 
 
ANSWER (Y,N ↑ vs. X) 
 
 
 
 
PRESENTD ↓ 
IMPACT ↓ 
NTREP ↑ 
n=170/170 p=10 
 
DURRAN ↓ 
 
 
 
 
LOGPEST ↓ 
CLNSG (Y,N ↓ vs. X,P) 
POSNG (F ↓vs. +,-,O,X) 
 
 
IMPACT↓ 
NOIMPACT ↓ 
 
 
 
 
CGROUP E*IMPACT ↑ 
CGROUP O*POSNG F↑ 
 
Table 13.1 Summary of the findings of the twelve ‘How long?’ analyses 
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13.3  Implications for the identification of randomized comparisons for inclusion in meta-
analyses 
The output from the twelve regressions, using the final model in each case, is given in Appendices 
VIII (‘first mentions’ and ‘first results’ analyses) and XV and XVIII (analyses incorporating 
repeated measures), and the findings were summarized in Chapters 6 and 11, quoting the R2 value 
for each independence model, and the p-value for each variable in all models, independence and 
those incorporating repeated measures. In this section the key findings are discussed, with some 
suggestions as to why these may be important factors. In Table 13.1 the significant variables are 
given in an order such that those to do with the randomization are given first, followed by results 
variables, and then those to do with publication. Terms included in interactions are mentioned last.  
 
It can be seen that there are approximately two and a half to three times as much data for the ‘time 
from close to publication’ analyses than for those investigating the other two time periods. Date of 
submission/receipt of article is only available for a subset of particular journals and for no books or 
meeting abstracts.  
 
Since both the number of observations (n) and the number of variables (p) used vary between the 
twelve analyses it is interesting to look at the ratio of n to p. In four analyses the number of 
observations is between 30 and 41 times that of the number of variables. These are all three of the 
‘all mentions’ analyses plus the analysis of time from close to publication for all reportings of 
results. For five analyses this ratio is greater than 15 but less than 30. These are the analyses of  
time from close to submission and time from receipt to publication for all reportings of results, time 
from close to submission and time from close to publication for first mentions, and time from close 
to publication for first reportings of results. However, for the analyses of time from receipt to 
publication for both first mentions and first reportings of results the ratio is approximately 10, and 
for that of close to publication for first reportings of results the ratio is just over 7. 
 
For the final models for all four analyses of time from close of randomization to submission and for 
three of the four analyses of time from close to publication, relevant observations were excluded 
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solely due to missing values for the response variable. In the analysis of time from close to 
publication for all mentions, only one observation was excluded due to a missing value for one of 
the chosen explanatory variables. However, for each of the four ‘time from receipt to publication’ 
analyses a considerable number of records, for which the response variable was present, had to be 
omitted due to missing values for one or more of the chosen explanatory variables. The numbers 
and proportions of observations omitted for this reason are as follows: ‘all mentions’ 23/218=11%, 
‘all results’ 16/137=12%, ‘first mentions’ 5/72=7% and ‘first results’ 11/60=18%. This could 
indicate that the models developed for the time from receipt to publication analyses are less stable 
than those developed for analyses of the other two time periods.  
 
Also, the date of submission/receipt used is that for the journal in which the article appears. In 
some cases an article was submitted to, and rejected by, other journals before finally being 
accepted. Since it is likely that the more prestigious journal is approached first, and that this is 
likely to have a high impact factor, it is to be expected that if impact factor is significant, then the 
time from close to submission (and to publication) will be longer for journals with no or a low 
impact factor.  
 
It is not easy to predict the direction in which variables may affect the outcome. For example 
trialists may be keen to publish a randomization with a significant result. However, a significant 
result may not be achieved for several years (if ever), when the event rate is small. Similarly, a 
large multi-centre or international trial may be considered worthy of swift publication. However 
this may mean that the agreement of many co-authors or working party members must be obtained 
before a manuscript is submitted, which could slow down the process.  
 
13.4  Conclusions for the first reporting of results of each randomization 
Records are counted as reporting results if any indication of the type of result (e.g. survival), 
statistical significance, clinical significance or direction of results, is given, however brief. 
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Time from close to submission for the first publication of results can be considered an indication of 
how keen the trialists are to publish the results of their work. Factors associated with a longer time 
from close to submission are:  
• Randomizations are from early trials 
• Involving multi-centre participation  
• Conducted in countries other than the US, with those conducted outside both North 
America and Europe taking still longer.   
• Direction of results is opposite (both a positive and a negative result are reported) or not 
reported. Negative results are submitted fastest, followed by positive and null results.  
• Published in journals with a high impact factor  
 
A surprising finding is that results in favour of the standard or control arm, were submitted more 
quickly than all others, including those clearly in favour of the experimental arm. However this was 
not found to be significant in the analysis of time from close to publication for first reportings of 
results, and indeed when extended to the analysis of time from close to publication for all 
reportings of results, negative results were found to have a longer time to publication than all 
others. This indicates that although trialists may be keen to publish their negative findings, journal 
editors may be less so.  
 
The fact that time from close to submission was longer for randomizations with multi-centre 
participation is to be expected, since the agreement of several people on details of the article to be 
submitted is likely to be necessary. The finding that time to submission was longer for articles 
published in journals with a high impact factor was surprising. Initially the reason for this was 
thought to be that results are often first reported as meeting abstracts, many of which do not have 
an impact factor, and that for analysis purposes where the impact factor is missing it has been set to 
zero. However this cannot be so since the date of submission/receipt is not available for any 
meeting abstracts. 
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Time from receipt of article to publication is an indication of how eager the journal is to publish the 
results of a randomization. Factors associated with a delay in time from receipt of article by the 
publisher to actual publication of first results are: 
• Funded by charity as well as Government money 
• No clear indication is given as to whether results are clinically significant or not. (Those 
clearly not clinically significant are published quickest, followed by those that clearly are 
clinically significant.) 
• Presented at a major meeting 
• Reported in articles that mention a greater number of trials 
• Reported in articles that mention fewer randomizations 
 
The time from close to publication, the sum of the above two time periods, for the first publication 
of results, is very important, since this is the delay between obtaining the results of a randomized 
comparison and making them widely available, through publication, to the clinicians who treat 
patients, and who may change their practices as a result. Factors associated with longer delay from 
close to publication are: 
Main effects: 
• Shorter duration of accrual period  
• Results have larger p-values associated with them 
• No clear indication is given as to whether the results are clinically significant or not 
• Reported in a journal with an impact factor associated with it  
Interactions: 
• Conducted in a European country and published in a journal with a higher impact factor 
• Conducted outside Europe and published in a journal with a lower impact factor 
• Conducted outside North America and Europe and results are null   
• Conducted in North America or Europe and results are not null  
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The findings to do with impact factor are interesting. As expected, the time from close to 
publication was longer when results were published in a journal with an impact factor associated 
with it. This is because the group of journals without an impact factor includes many meeting 
abstracts and all book chapters, and it is common for results of a randomization to be reported as a 
meeting abstract prior to publication as a full paper in a journal. For non-European trials, the lower 
the impact factor the longer the time to publication. This is also as expected since it is common for 
an article to be submitted to a prestigious journal, with a high impact factor, rejected and then re-
submitted to a less prestigious journal, with a lower impact factor. However, surprisingly, it was 
found that for European trials, a longer time from close of randomization was associated with 
publication in a high impact factor journal. One possible explanation for this is that many of the 
higher impact factor journals are American (as described in Section 4.4), and there may be a 
tendency towards accepting articles which report results of American trials. 
 
The findings to do with the nature of the results reported are important. The first indicates that 
results with smaller p-values associated with them are made available more quickly than those that 
are less striking. However this is countered by the second, which is that null results (where no clear 
benefit of either the experimental or the standard arm is shown) from North American and 
European trials are published more quickly than when the trial found in favour of one of the 
treatment arms.  
 
A likely explanation for this is as follows: where results are highly statistically significantly in 
favour of a particular randomization arm, the trialists will be keen to publish. Where there is clearly 
no difference between the outcomes, there is no reason to delay publication. However, if the 
outcome in one trial arm is better than that in the other, and this result is almost statistically 
significant, the trialists will wish to delay publication in the hope that the  p-value will go below 
0.05.  
 
An alternative explanation of these two findings is that this may be due to two differing attitudes of 
trialists. One group of trialists may value a null result and seek to publish it, going on to re-publish 
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the results after a longer follow-up period, by which time there may well be a sufficient number of 
events to achieve statistical significance. The other may only publish if, and when, statistical 
significance is reached. 
 
It is of some concern that null results from randomizations conducted outside North America and 
Europe are taking a longer time to publish than others. 
 
13.5  Conclusions for the first mention of each randomization 
The first mention of a randomization often does not include any results. For example, a paper 
publishing detailed results of a trial may also refer briefly to a subsequent trial that is currently 
open or in its planning stages. However, provided it was clear that this new trial is randomized, a 
brief mention such as this would be sufficient for the purposes of those involved in identifying 
randomizations for inclusion in meta-analyses. The time periods ‘close to submission’ and ‘receipt 
to publication’ are less useful when looking at first mentions, as opposed to first publication of 
results, since briefly mentioning a new trial is not a motivation for either the trialists or the 
publisher to publish the report quickly. 
 
The factors likely to increase time from close to submission for first mentions are as follows: 
• Trial comprises fewer randomizations 
• Shorter duration of accrual period  
• Conducted outside North America  
• Conducted in a ‘developing’ country 
 
The factors likely to increase time from receipt to publication, for first mentions are: 
Main effects: 
• Trial comprises fewer randomizations  
• No clear indication is given of whether results are clinically significant or not 
• Published in a North American or European journal 
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• Reported in an article that mentions fewer randomizations 
Interaction: 
• For trials conducted outside North America, longer duration of accrual period 
 
However, time from close to publication is very important, since this is the delay between the 
randomization closing and its availability for identification and inclusion in meta-analyses. 
The factors likely to increase this delay are as follows: 
• Earlier randomizations 
• Shorter duration of accrual period  
• Not an equivalence trial 
• Conducted in a ‘developing’ country 
• Conducted outside North America and Europe (of borderline significance, once 
‘developing’/ ’developed’ country is taken into account) 
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper 
• Not presented at a major meeting 
• Reported in a journal with a low or no impact factor 
• Reported in articles which mention a greater number of trials 
 
A possible explanation as to why the time from close to publication is shorter for equivalence trials 
is that a longer time is needed to obtain enough events to demonstrate the superiority of one 
treatment arm over the other than to demonstrate no significant difference in outcome between 
treatment arms. This variable did not remain in the reduced set of significant predictors for the 
‘time from close to publication for first results’ analysis, although the reason may be that there 
were other variables that had a greater effect.    
 
Again, it is worth noting that the time to publication is longer for randomizations conducted in 
‘developing’ countries and also in countries other than North America and Europe. It is important 
that these randomizations are not excluded from any meta-analyses for which they are eligible. 
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A possible reason for randomizations reported in articles which mention a greater number of trials 
leading to a longer time from close of randomization to publication is that the close dates of the 
randomizations are likely to span a wider time period and so include some earlier dates. 
 
Note that since a brief mention of a new trial may occur when the trial is still open, or even before 
it is open for accrual, it is reasonable to expect some negative ‘close to publication’ time periods.   
 
It is encouraging to note that the results of more recent randomizations are being reported more 
quickly than was the case with earlier trials, and also that they are first mentioned more quickly and 
so can be identified sooner after closure. 
 
13.6  Conclusions for all reportings of results of each randomization  
Of the three time periods, the most straightforward to interpret, when looking at all reportings of 
results, is ‘time from receipt to publication’. The results of a randomization may be reported 
several times, for example shortly after closure, and after follow-up periods of various lengths. 
When looking at ‘time from close to publication’ (or ‘from close to submission’) a high value of 
the response variable may indicate that the results of a randomization were slow to be published 
because they were not considered important, or alternatively, that they were considered so 
important that they were re-analysed and updated many years after the randomization closed. A 
third possibility is that a randomization may not yield statistically significant results to begin with, 
but later when there have been more events, a level of statistical significance is achieved. Therefore 
it is not always possible to know whether the time period response variable is affected by the 
explanatory variables or whether it is the other way around. All that is known is that there is an 
association between the two.  
 
Factors associated with a longer time from close to submission for all reportings of results are: 
• Greater number of questions 
• Results with smaller p-values associated with them 
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• Direction of results is not reported 
• Not presented at a major meeting 
• From a publication with a low or no impact factor 
 
It is interesting to note that the two significant trial characteristics common to the ‘first results’ and 
‘all results’ analyses have opposite effects. For the first results, the higher the impact factor of the 
journal the longer the time from close to submission. However, when including all reportings of 
results, a lower impact is associated with a longer time from close to submission. Since only 
journal articles are used in this analysis, due to date of submission/receipt of article being unknown 
for all meeting abstracts (and book chapters), the reason for this finding is unclear.   
 
The second significant predictor of time from close to submission common to the two analyses is 
the direction of results. In the ‘first results’ analysis, negative results were submitted most quickly, 
followed by positive and null results, with opposite results (i.e. where one main result is in a 
positive direction and the other in a negative direction) and those where the direction of results is 
not reported, having a longer time to submission. When all reports of results are included, again 
those results where direction is not stated have a longer time to submission, but there is no 
significant difference in the time to submission for results where direction is stated. 
 
Factors associated with a longer time from receipt to publication for all records containing results 
are:  
Main effects: 
• Longer duration of accrual period 
• Multi-centre participation 
• The main questions as stated in the paper are answered in the paper 
• Published in a North American journal, followed by European journal, with journals from 
elsewhere being the quickest to publish. 
• Limited international or single-country as opposed to truly international participation  
Interaction: 
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• However, truly international trials published in a journals with a high impact factor also 
have a longer time to publication. For journals with a non-zero impact factor of less than 8, 
international trials have a shorter time to publication than others. For those with an impact 
factor greater than 8, the time to publication is increased. A possible explanation for this is 
that American journals may be more keen to publish American trials than those conducted 
elsewhere, and many of the higher impact journals are American (as was described in 
Section 4.4.).  Also international trials are more likely to be conducted outside the US. 
Therefore a journal with a higher impact factor is likely to publish an international trial less 
quickly. 
 
None of the trial characteristics found to be significant predictors of time from receipt to 
publication for first results were also significant when all reportings of results were included. 
 
Factors associated with a longer time from close to publication, for all records reporting results are: 
Main effects: 
• Earlier randomization 
• An indication is given as to whether the main questions in the paper are answered in that 
paper  
• Not reported at a major scientific meeting  
• Reported in articles which mention a greater number of trials 
• Direction of results is negative 
• Results with smaller p-values 
Interaction: 
• Results clearly in favour of either the experimental or the standard arm, and the associated  
p-values are larger, the former having a slightly greater effect than the latter.  
 
In the case of results in favour of the standard arm the effect of the interaction is in the opposite 
direction of that of the main term. A negative result only leads to a delay in publication if it is 
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significant only at the p=0.05 level or if significance is not achieved. Otherwise the time to 
publication is shortened. 
 
The significant predictors of time from close to publication for first results that were also 
significant when all results were included are statistical significance of results and direction of 
results. For the set of first reportings of results, as has already been discussed, results with larger p-
values attached to them had a longer time from close to publication, as did non-null results, as 
might be expected. When all results are included in the analysis, the effect of statistical significance 
is similar, in that for clearly positive or negative results those with larger p-values associated with 
them have a longer time to publication. 
 
13.7  Conclusions for all mentions of each randomization 
Variables found to be associated with a longer time from close of randomization to submission are: 
• Shorter duration of accrual period 
• Conducted in a ‘developing’ country 
• Results with smaller p-values associated with them 
• Reported in a publication with a low or no impact factor  
• Published in an article which mentions a greater number of trials 
• Published in an article which mentions fewer randomizations 
 
 
Two of the significant predictors of a longer time from close to submission for first mentions 
remained significant when all mentions were included. These are a shorter duration of accrual 
period and if the trial was conducted in a ‘developing’ country. These two factors are also 
significant predictors of time from close of randomization to actual publication for both first and all 
mentions. The importance of the latter has already been discussed. The reason for the former is 
unclear. 
 
Factors associated with a longer time from submission/receipt to publication are: 
• More recent trials 
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• Longer duration of accrual period 
• Conducted outside Europe  
• Published in a North American or European journal 
• Reported in articles which mention fewer randomizations 
• Larger number of co-authors 
 
Three of the significant predictors of a longer time from receipt to publication in the ‘first 
mentions’ analysis are also significant in the ‘all mentions’ analysis. These are being published in 
an American or European journal, being reported in an article which mentions a fewer number of 
randomizations and, for trials conducted outside North America, a longer duration of accrual 
period.  
 
Factors associated with a longer time from close of randomization to publication of article are: 
Main effects: 
• Earlier trials 
• Shorter duration of accrual period 
• Conducted in a ‘developing’ country  
• Results clearly reported as clinically significant, followed by those where clinical 
significance is not reported. Results clearly not or only possibly clinically significant were 
published quickest. 
• A clear indication is given as to whether the main questions in the paper are answered in 
that paper  
• Not presented at a major meeting 
• Published in full in the English language. 
• Reported in articles which mention a greater number of trials 
• Reported in articles which mention a smaller number of randomizations 
• Reported in a publication with a low or no impact factor 
• Reported in a journal article or book chapter as opposed to a meeting abstract 
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• Conducted outside Europe  
• Participation of five or more centres 
Interaction: 
• However, for trials conducted outside North America, the participation of less than five 
centres also acts to delay publication 
 
This is the only analysis where publication type, i.e. whether reported in a journal article, book 
chapter or meeting abstract was found to be significant. Since time to publication is shorter for 
reportings in meeting abstracts this supports the case that time-consuming hand-searching of 
meeting abstract books is a worthwhile process for trial identification. However, publication type 
was not significant in either the ‘first mentions’ or ‘first results’ analyses of time from close to 
publication. 
 
All but one of the nine significant predictors of a longer time from close to publication for first 
mentions are also significant for the analysis using all mentions.  
 
Seven of these affect the response in the same direction for the two analyses. These are: an earlier 
start date of the accrual period, a shorter duration of accrual period, trial conducted in a 
‘developing’ country, if the article clearly states whether or not the main questions of the 
randomization are answered in the article, if the findings have not been already presented at a 
major scientific meeting, if the article is published in a journal with a lower impact factor, and if 
the article mentions a larger number of trials.  
 
In addition, the country group of trialists is also significant in the two analyses. For the first 
mentions, randomizations conducted by trialists in North America or Europe had a longer time to 
publication than those run in other countries. In the ‘all mentions’ analysis randomizations from 
North American and other non-European trials were found to have a longer time to publication than 
those conducted in Europe. In addition, for trials conducted outside North America, the 
participation of less than five centres also leads to a delay in publication. 
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13.8  Studies of ‘pipeline’ bias identified from a literature search 
As was described in Section 2.5, several other studies of ‘pipeline bias’ were identified. 
[Liebeskind et al (1999), Misakian and Bero (1998), Cheng et al (1998), Stern and Simes (1997), 
Handysides (1996), Dickersin and Min (1993), Chew (1991) and Ioannidis (1998)] These, plus this 
current study, are summarised as a table in Appendix XIX.  
 
 
 
 
XVII 
 
13.9  Differences between this project and the other studies being compared 
Before comparing the findings of this project with those of the other studies, it is necessary to note 
three important differences: 
 
(i) the definition of statistical significance 
In this thesis two variables are used to specify statistical significance. LOGPEST is a continuous 
variable, the magnitude of the distance of log e (a typical value of the p-value for the category to 
which the result belongs) from that for the ‘non-significant/not reported’ category. The advantage 
of the implementation of a continuous variable to represent statistical significance is that the degree 
of statistical significance of the results, as opposed to merely ‘statistically significant versus non-
significant’ is built in. This was described in detail in Section 4.2.1. LOGPNR is used to specify 
whether or not any indication of the p-values associated with results is given in the article. 
Together the two variables specify the degree of statistical significance of the results, and also 
whether a value of zero for LOGPEST means ‘non-significant’ or ‘not reported’. A third variable, 
POSNG, specifies the direction of the results, i.e. positive, negative, null (flat), opposite (one 
positive, the other negative) and not reported.  
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In all the analyses performed, where LOGPEST and POSNG were found to be either significant or 
non-significant, but only eliminated at p<0.2, the interaction between LOGPEST and the 
categories of POSNG were tried in the model, as well as the main effects. 
In three of the other studies, Liebeskind et al (1999), Misakian and Bero (1998) and Ioannidis 
(1998), one variable is used in a two-dimensional capacity to specify both statistical significance 
and direction. In Cheng et al (1998) and Dickersin and Min (1993) different definitions are used 
again. 
 
In this thesis statistical significance and direction of results are two distinct one-dimensional 
variables. The only ‘two dimensional’ results variable used is ‘clinical significance’. This combines 
the direction of the result with the ‘strength of the impression given by the text’, in the opinion of 
the authors, regardless of any p-values reported. If the general tone of the paper indicated that the 
results were in favour of the experimental arm, or in the case of an equivalence trial, the 
experimental arm was at least as good as the standard arm, then the findings are classed as 
‘clinically significant’. If the impression given was that this was clearly not so, then the findings 
are classed as ‘not clinically significant’. There are also ‘possibly clinically significant’ and ‘not 
reported’ categories. The definition of ‘significance’ as “judged by investigator to be either 
statistically significant or ‘of great importance’ ” used by Dickersin and Min (1993) is similar to 
that of ‘clinical significance’ used here, in as much as it a measure of how important the trialists 
view their findings.  
 
(ii) the response variable in question 
This project analysed four datasets: ‘all mentions’, ‘all reportings of results’, ‘first mentions’ and 
‘first reportings of results’. It is the ‘first reporting of results’ that is the focus of the other studies 
found, and therefore compared here. In this project the main response variable analysed is the time 
from the close of randomization (i.e. of the accrual period) to first publication. The other two 
response variables are ‘time from close of randomization to submission’, and ‘time from receipt by 
accepting journal to publication’.  
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In the other studies, time to publication is measured from varying starting points. Liebeskind et al 
(1999) and Ioannides (1998) used the start of the accrual period to publication, Misakian and Bero 
(1998) used the year funding began to year of publication, Stern and Simes (1997) used time from 
approval by ethics committee to publication. 
 
(iii) the number of explanatory variables, in addition to statistical significance and direction of 
results, tried in the analysis 
It is impossible to know all of the variables tried in the other studies. Variables may well have been 
tried in the model, found to be non-significant and not mentioned in the report. However, another 
possibility is that a larger number of variables were tried in this project, some of which were found 
to be more significant than those expressing statistical significance and direction of results, in 
which case statistical significance and direction were dropped from the model. 
 
13.10  A comparison of the findings of this project with those of other studies 
In the light of the above points, the findings of this thesis can be compared with those of other 
similar studies identified.  The terminology used throughout this thesis will be used when referring 
to all studies, for consistency. 
 
From the published studies there is a common theme: time to publication was shorter for 
statistically significant positive results than for statistically significant negative results, with non-
significant results having the longest time to publication.  
 
Lieberskind et al (1999) found that time to publication was shorter for statistically significant 
positive results than for statistically significant negative and null results. However this difference 
was not statistically significant (p=0.079). Misakian and Bero (1998) found that the time to 
publication was statistically significantly shorter for statistically significant results than for non-
significant results (p=0.007). In this study the direction of results was not a factor. Stern and Simes 
(1997), similarly, reported that statistically significant positive results were published more quickly 
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than clearly non-significant results, with those of borderline significance having the longest time to 
publication. Ioannides (1998) found that time to publication was shorter for statistically significant 
positive results than for statistically significant negative results (p<0.001).  
 
The findings of this thesis were similar to the above in that the more statistically significant the 
results, the shorter time to publication (p=0.0153). However, it was also found that null results 
were published more quickly than others (p=0.0127). As was discussed in Section 13.4, a possible 
explanation for these findings is as follows: where results are highly statistically significant in 
favour of a particular treatment arm, the trialists will be keen to publish as soon as possible. Where 
there is clearly no difference in the outcomes of the two arms, there is no reason to delay 
publication. However, if the outcome in one trial arm is better than that of the other, and this result 
is almost statistically significant, the trialist will wish to delay publication in the hope that 
statistical significance will be achieved. Ioannidis (1998) points out that ‘long-protracted trials 
often had low event rates and failed to reach statistical significance, while trials that were 
terminated early had significant results’. This thesis found that although generally null results were 
published faster than others, null results from trials conducted outside North America and Europe 
had a far longer time to publication (p=0.0023). Unlike Ioannidis’ finding, this thesis found that a 
shorter duration of accrual is associated with a delayed first publication of results (p=0.0002). 
However this could be complicated by the fact that some randomizations are ‘serial’ as opposed to 
‘separate’. (This was discussed in Section 7.5.) 
 
Prompted by the above comment by Ioannides, the correlation between duration of accrual period 
(DURRAN) and degree of statistical significance (LOGPEST), and that between ‘decline in 
interest in the randomization’, measured by ‘time to accrue the second half of the patients minus 
time to accrue the first half’ (WANE) and LOGPEST were obtained for first reportings of results. 
Both have low values and neither is statistically significant. In concordance with Ioannidis’ finding, 
the correlation between DURRAN and LOGPEST is negative (ρ= -0.11440, p=0.1374 based on the 
170/188 first reportings of results for which duration of accrual period is known, degree of 
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statistical significance being known for all 188.) i.e. a shorter accrual period is associated with a 
higher degree of statistical significance. Surprisingly, the correlation between WANE and 
LOGPEST is positive ρ=0.20378, i.e. a decline in interest is associated with a higher degree of 
statistical significance, although this is of only borderline statistical significance (p=0.0569) and 
based only on the 88/188 first reportings of results for which the former is known.  
 
This thesis also found that if results were either clearly ‘clinically significant’ or ‘not clinically 
significant’ then the time to publication is shorter than if no clear impression is given. 
 
As in this thesis, a number of the studies, Liebeskind et al (1999), Misakian and Bero (1998), 
Cheng et al (1998), Stern and Simes (1997) and Ioannides (1998), collected data on sample size. 
This is not mentioned as a significant predictor of time to publication in any of them, with the 
exception of Misakian and Bero (1998) and then only when univariate analysis was used and 
animal studies included (p=0.03). Similarly, in this project, number of patients accrued was not a 
significant predictor for any of the three time periods modelled. 
 
Ioannides (1998) reports that randomizations with statistically significant positive results were 
submitted for publication significantly more rapidly after completion than were those with 
statistically negative results (p=0.001). This project found the opposite i.e. that randomizations 
with negative results were submitted for publication faster than those with either positive or null 
results, with opposite (i.e. one main result positive, the other negative) and those where the 
direction of the results is unspecified having the longest time to submission (p=0.0147 and 
p=0.0107 respectively). Of course, it could be argued that those results where direction is not 
specified are more likely to be negative, and that this could weaken the finding. It was also found 
that statistical significance was not a statistically significant predictor of time to submission. 
However, if some of the other significant variables had been omitted from the analysis, this may 
not have been the case. 
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Ioannides (1998) also found that the time from submission/receipt to publication was shorter for 
statistically significant positive trials than for statistically significant negative trials (p=0.04). This 
project did not find either statistical significance or direction of result to be statistically significant 
predictors of time from receipt to publication.  However, it did find that results clearly reported as 
not ‘clinically significant’ are published faster than those that are, with those for which no 
impression of clinical significance is conveyed taking longest (p=0.0056 and p=0.0040 
respectively), in contrast to Ioannides’ findings.  
 
Chew (1991), in the study of the eventual publication of papers rejected by one particular journal, 
the American Journal of Roentgenology (AJR), found that the time from rejection by the AJR to 
publication elsewhere was longer for papers published in non-US journals, and that most of the 
journals of eventual publication had lower impact factors than the AJR. Although the results of this 
project cannot be compared directly, it is interesting to note that those articles eventually published 
in a journal with a high impact factor were found to have a longer time to submission (p=0.0242). 
For European trials, the time from close to publication was also longer (p=0.0062), but generally 
eventual publication in a high impact factor journal led to a shorter time to publication. The latter 
agrees with Chew’s findings. Not surprisingly time from close to publication was shorter for 
articles in publications without an impact factor associated with them, which include some meeting 
abstract books and all book chapters as well as some journals.  
 
13.11  Conclusions 
In agreement with the other studies identified, it was found that a higher degree of statistical 
significance leads to a shorter time to publication. However, unlike the findings of most of the 
other studies, it was also found that the direction of results was not a significant predictor of time to 
publication, with the exception of null results which are generally published more quickly than 
others, except for null results from trials conducted outside North America and Europe which are 
published more slowly. In addition, an important factor was found to be the importance the trialists 
attach to their results, irrespective of the direction of those results. This thesis also found, in 
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contrast to the published studies, that randomizations which found in favour of the standard or 
control arm were submitted faster than all others, including those clearly in favour of the 
experimental arm, although they were not actually published faster.  
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14  OTHER INVESTIGATIONS I: WHICH TRIAL CHARACTERISTICS AFFECT  
(a) WHETHER A RANDOMIZATION IS EVER MENTIONED IN AN ARTICLE AND  
(b) WHETHER THE RESULTS OF THAT RANDOMIZATION ARE EVER REPORTED?  
 
14.1  Introduction 
As was discussed in 2.4 the two main questions addressed in this thesis are: 
• Which factors affect how long the searching process should continue in order to identify all 
trials through publication? 
• How wide does the search need to be? 
 
The first of these has been thoroughly investigated and reported in this thesis. Important aspects of 
the second are discussed in this chapter and Chapter 16 but will be the subject of future research.  
 
Issues addressed are: 
• why some randomizations are never mentioned in any article 
• why the results of some randomizations are never reported 
• why some randomizations are mentioned in more articles than others 
• why the results of some randomizations are published more frequently than those of others 
 
A large proportion of the time spent on this project went into the collection and checking of the 
data. These same data, with some manipulation, could be used to answer other questions. Other 
aspects, not investigated here, could include, for example: 
• which characteristics of randomizations result in publication in the most prestigious 
journals 
• why some randomizations are published as abstracts, but never reach publication as full 
journal articles  
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14.2  Data used for the analyses 
The ‘definitive records’ dataset was used for the analyses in this chapter. This means that only 
variables which remain unchanged over time have been included.  Data specific to an individual 
publication, such as results at a point in time, have not been used. These analyses do not involve 
repeated measures since the ‘definitive records’ dataset comprises 243 records, one for each 
randomization, using an amalgamation of the data from all available sources.  
 
The LOGISTIC procedure in SAS was used to perform logistic regression. The algorithm for the 
program and some SAS commands for this are given in Appendix XX.  
 
Variables not included in the analyses 
As with the ‘How long?’ analyses, variables with missing values for more than 25% of 
observations are not included in the analyses. The justification for this is that a variable available 
for a small proportion of the observations is unlikely to affect the response variable to any degree. 
Variables omitted for this reason are: 
• Funding source (FUNDG) (34% missing) 
• Method of randomization (in order of reliability: by central computer, by notification to a 
central office, or by a sealed envelope method) (RANDMETH) (81% missing) 
• Timing of late randomization (done at the correct stage or done too early) (RANDTIME) 
(72% missing) 
• Randomization design used (simple randomization, block randomization or minimization 
of imbalance) (RDESIGN) (95% missing) 
• Whether or not any attempt was made to balance patient characteristics between 
randomization arms (BALANCED) (61% missing) 
• Risk group eligibility (RISK) (41% missing) 
• Whether the target number of patients was reached (TARGET) (85% missing)  
• Whether the target number of centres was reached (CTARGET) (27% missing) 
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• Whether it took longer to accrue the second half of the patients than the first (WANE) 
(57% missing) 
 
One variable was collected but not considered reliable enough for inclusion in the analyses: 
• Whether the two main questions of the trial were ever answered in any publication 
(ANSEVER) 
The reason for the unreliability of the variable is that the main questions (e.g. survival, disease-free 
survival, relapse in a particular site) were taken from the trial protocol where available and failing 
that from the articles themselves. However, when the main questions for the group of 
randomizations, for which there was information from both the trial protocol and the articles were 
investigated, it became clear that the main questions from the two sources often were discrepant. 
Therefore, if this variable had been included in the analyses, it may have introduced bias between 
the group of randomizations for which the trial protocol (see Appendix II) is available, and the 
group for which it is not. 
 
Another variable not used is: 
• Trial category (e.g. induction treatments, central nervous system prophylaxis, maintenance 
duration, bone marrow transplant) (TRCAT) 
It was decided that, with eleven categories, it was impractical to use this variable. Instead, various 
combinations of the categories were used to form two new variables. These are: 
• Treatment type (chemotherapy, radiotherapy, immunotherapy, transplant and antibiotic) 
(TXCHEMO) 
• First-line treatment or relapse/refractory (FIRSTL) 
 
Variables included in the analyses 
A backwards elimination process is used for the initial stage of each analysis. As with the ‘How 
long?’ analyses, all variables having no, or very few missing values are put into the model. The 
regression is run and the least significant variable is then dropped. This process is then repeated 
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until a reduced set of significant variables (each with p<0.05) remains. Other variables can then be 
added to the model one-by-one to see if they, too, remain in at p<0.05. 
 
Variables with no, or very few, missing values were included at the initial stage of the analysis. 
Such continuous variables are; 
• Number of randomizations that make up the trial (NRAND) (0% missing) 
• Number of randomization arms (ARMS) (0% missing) 
• Start date of randomization (NSTART) (5% missing) 
 
Categorical variables used in the initial stage of the analysis are: 
• Age group eligibility (children or both children and adults) (AC) (3% missing) 
• Country group of trialists (North America, Europe or Other) (CGROUP) (0% missing) 
• ‘Developing’ country or ‘developed’ (DEVLPNG) (0% missing) 
• Equivalence trial or not (EQUIV) (0% missing) 
• First-line or relapse/refractory treatment (FIRSTL) (5% missing) 
• Multi-centre, multi-centre(limited) or single-centre participation (MULTIC) (1% missing) 
• Treatment type (a frequency table was produced, which to indicated that radiotherapy vs. 
immunotherapy vs. the rest should be tried) (TXCHEMO) (3% missing) 
 
Continuous variables with too many missing values to be included in the initial regression are: 
• Close date of randomization (NCLOSE) (10% missing) 
• Duration of accrual period (DURRAN) (10% missing) 
• log 10 (number of patients accrued) (LOGSIZE) (13% missing) 
 
A categorical variable with too many missing values to be included in the initial regression is: 
• International, international-limited or single-country participation (INTERNL) (12% 
missing) 
 
Another variable to be tried at a later stage is: 
204 
• Number of questions (NOQ) (0% missing) 
This is very highly correlated with ARMS (ρ=0.94), and so is tried in place of ARMS at the point 
where ARMS is to be dropped as the least significant variable remaining in the model. If ARMS 
remains in the reduced set of significant variables, NOQ is tried in its place to see whether or not 
this improved the fit of the model. Similarly NCLOSE is highly correlated with NSTART (again 
ρ=0.97), and so a similar method is used. 
 
Any variable, either included in the reduced set of significant variables at any stage, or eliminated 
at p<0.2, is tried again at the end of the process. Variables highly correlated with any variable in 
the model (ρ>0.3) are also tried in place of that variable to see if a better fit to the data can be 
found. 
 
Interaction terms 
Once the best fitting main effects model is found, interaction terms are tried. 
Interactions which may have an effect are: 
• Country group of trialist and duration of accrual period 
• Country group of trialist and number of patients accrued 
• North American trial with five or more centres participating 
• Single-centre trial conducted outside North America and Europe 
• Truly international trial, conducted in the US 
• Single-country trial, conducted outside North America and Europe 
• Conducted in a ‘developing’ country and number of patients accrued 
• Truly international trial conducted in a ‘developed’ country 
• Single-country participation in a trial conducted in a ‘developing’ country 
• Multi-centre trial conducted in a ‘developed’ country 
• Single-centre trial conducted in a ‘developing’ country 
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Interaction terms will only be tried if both main effects are either statistically significant or were 
eliminated from the model with p<0.2. Otherwise the interaction is unlikely to affect the response 
variable in question. 
 
14.3  Which trial characteristics affect whether a randomization is ever mentioned in an 
article?  
Selecting the model that best fits the data 
Due to missing data for some variables, there were two possible models to choose from. The 
probability modelled is for the response ‘mentioned’. 
 
Model 1: 
Explanatory variables: 
• Start date of accrual period     (NSTART) p=0.0011 
• Relapse/refractory vs. first line treatment   (FIRSTL)  p=0.0101 
• Conducted in a ‘developing’ country vs. ‘developed’ (DEVLPNG)  p=0.0055  
• Duration of accrual period     (DURRAN) p=0.0420 
n = 209/243 observations were used 
Residual SS= -2 log L = 115.105 
Residual df =205 
 
Model 2: 
Explanatory variables: 
• Start date of accrual period     (NSTART) p=0.0038 
• Conducted in a ‘developing’ country vs. ‘developed’ (DEVLPNG)  p=0.0057 
• log 10 (number of patients accrued)    (LOGSIZE) p=0.0003 
n = 200/243 observations were used 
Residual SS= -2 log L = 69.863 
Residual df =197 
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Since the two models in question are not nested and missing values mean that they may be using 
different observations, it was necessary to apply the methods described in Section 5.3.3 to select 
the model that best fits the data. Both models were run using (i) common observation only and (ii) 
using all 243 observations, but replacing all missing values for a variable by the mean. Both 
methods gave the same conclusion, that Model 2 has a smaller value for -2 log L than Model 1, and 
so is a better fit to the data. 
 
Interpreting the results of the chosen model 
The output for the chosen model is given as Table 14.1. 
The LOGISTIC Procedure  
                         Number of Observations        200              
 
                                 Response Profile 
                        Ordered                      Total 
                          Value       MENTND     Frequency 
  
                              1            1           186 
                              2            0            14 
  
                         Probability modeled is MENTND=1. 
  
 NOTE: 43 observations were deleted due to missing values for the response or  
       explanatory variables. 
  
                             Model Convergence Status 
                  Convergence criterion (GCONV=1E-8) satisfied.           
  
                              Model Fit Statistics 
                                                   Intercept 
                                    Intercept         and    
                     Criterion        Only        Covariates 
  
                     AIC              103.456         77.863 
                     SC               106.754         91.057 
                     -2 Log L         101.456         69.863 
  
                    Analysis of Maximum Likelihood Estimates 
   
                                 Standard         Wald 
   Parameter     DF   Estimate      Error   Chi-Square   Pr > ChiSq   Exp(Est) 
  
   Intercept      1     0.0103     2.0455       0.0000       0.9960      1.010 
   NSTART         1   -0.00054   0.000186       8.3799       0.0038      0.999 
   DEVLPNG   0    1     1.2853     0.4649       7.6445       0.0057      3.616 
   LOGSIZE        1     2.9060     0.8036      13.0782       0.0003     18.284 
   
                              Odds Ratio Estimates 
                                          
                                     Point          95% Wald 
                Effect            Estimate      Confidence Limits 
  
                NSTART               0.999       0.999       1.000 
                DEVLPNG 0 vs. 1     13.074       2.114      80.875 
                LOGSIZE             18.284       3.785      88.320 
  
Note  
DEVLPNG=0 denotes a ‘developed’ country 
DEVLPNG=1 denotes a ‘developing’ country 
 
Table 14.1 Output from the ‘ever-mentioned/never mentioned’ logistic regression analyses 
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14.3.1 Method for calculating an odds ratio (OR) 
The general case 
If     p = the probability of an event occurring, given a particular characteristic 
then    1 – p = the probability that it does not occur, given that characteristic. 
and the odds it occurring, given that characteristic are  p / (1 - p) 
and  logit (p) = log [p / (1 - p)] = (α
  
+ β1x1 + … + βmxm), for a model with m explanatory 
variables. 
 
Similarly,  
if     p' = the probability of an event occurring, without that characteristic 
then    1 – p' = the probability that it does not occur, without that characteristic 
and the odds it occurring, without that characteristic are  p' / (1 - p') 
and  logit (p') = log [p' / (1 - p')] = (α
  
+ β1x1' + … + βmxm '), say. 
 
Therefore, the odds ratio (OR)  for the event occurring, characteristic present: not present is 
OR =   p / (1 - p) 
            p' / (1 - p')  
 
log (OR)  =  log [p / (1 - p)] - log [p' / (1 - p')] 
    = (α
  
+ β1x1 + … + βmxm) - (α  + β1x1' + … + βmxm ') 
If the characteristic that differs between the two groups is xj and all other variables are the same 
i.e. if xi' = xi for all i ≠ j, then 
log (OR)  = βj (xj – xj') 
So OR     = exp [βj (xj – xj')] 
 
Application to these data 
Let   p = the probability that a randomization conducted in a developed country is ever mentioned 
                in an article 
and   p' = the probability that a randomization conducted in a developing country is ever  
                mentioned in an article 
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In this analysis the only categorical variable in the model is whether the trial was conducted in a 
‘developed’ or a ‘developing’ country (DEVLPNG). 
Let variable DEVLPNG = x1 = 1 if randomization was conducted in a ‘developed’ country. 
Let variable DEVLPNG = x1'  = -1 if randomization was conducted in a ‘developing’ country. 
OR     = exp [β1 (x1  -   x1')] = exp 2β 
 
From Table 14.1 it can be seen that β1 = 1.2853, x1  =1 and x1' = -1 and that the odds ratio is 13.074. 
 
To test the fit of the model: 
χ2 = 69.863 with 196 df,  p= 0.9999  
i.e. the model is an excellent fit to the data. 
 
Summary 
Dependent variable: Randomization ever mentioned/never mentioned, in a publication 
Independent variables: Conducted in a ‘developed’/ ‘developing’ country  
Continuous covariates: Start date of accrual period 
   log 10 (number of patients accrued) 
Fitted constants for odds of being mentioned 
Overall constant    1.010 
‘Developed’/’developing’ country   χ2 = 7.6445, df=1, p-value= 0.0057 
 ‘Developed’   3.616 
 ‘Developing’   0.277 
Start date of accrual period  0.999  χ2 = 8.3799, df=1, p-value = 0.0038 
log 10 (number of patients accrued)        18.284  χ2 = 13.0782, df=1, p-value = 0.0003 
 
Therefore: 
• The odds ratio for a randomization ever being mentioned in an article if conducted in a 
‘developed’ country to if conducted in a ‘developing’ country is 13.074. 
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• The odds ratio of being mentioned for any start date of accrual period vs. the day before is 
0.999 i.e. the odds that a randomization is ever mentioned is slightly greater for earlier than 
for more recent trials, as would be expected.  
• The odds of ever being mentioned are greater for randomizations which accrued a greater 
number of patients. The odds ratio for a difference in log 10 (number of patients accrued) of 
1.0. i.e. for a tenfold increase in the number of patients accrued, is 18.284. 
 
14.4  Which trial characteristics affect whether the results of a randomization are ever 
reported?  
Interpreting the model 
The output is given as Table 14.2. 
 
                          Number of Observations        231 
 
                                 Response Profile 
                        Ordered                      Total 
                          Value       RESPUB     Frequency 
  
                              1            1           177 
                              2            0            54 
  
                         Probability modeled is RESPUB=1. 
   
NOTE: 12 observations were deleted due to missing values for the response or  
       explanatory variables. 
  
                             Model Convergence Status 
                  Convergence criterion (GCONV=1E-8) satisfied.           
  
                            Model Fit Statistics 
                                                   Intercept 
                                    Intercept         and    
                     Criterion        Only        Covariates 
  
                     AIC              253.230        237.057 
                     SC               256.672        247.384 
                     -2 Log L         251.230        231.057 
   
                    Analysis of Maximum Likelihood Estimates 
   
                                 Standard         Wald 
   Parameter     DF   Estimate      Error   Chi-Square   Pr > ChiSq   Exp(Est) 
  
   Intercept      1     1.9220     0.6322       9.2413       0.0024      6.834 
   DEVLPNG   0    1     1.0273     0.3001      11.7136       0.0006      2.793 
   NSTART         1   -0.00023   0.000081       7.9034       0.0049      1.000 
    
                                Odds Ratio Estimates 
                                          
                                     Point          95% Wald 
                Effect            Estimate      Confidence Limits 
  
                DEVLPNG 0 vs. 1      7.803       2.406      25.306 
                NSTART               1.000       1.000       1.000 
 
Table 14.2 Output from the ‘results ever reported/never reported’ logistic regression analysis 
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The probability modelled is for the response ‘results reported’. 
Explanatory variables: 
• Conducted in a ‘developing’ country vs. ‘developed’ (DEVLPNG)  p=0.0006 
• Start date of accrual period     (NSTART) p=0.0049 
n = 231/243 observations were used 
Residual SS= -2 log L = 231.057 
Residual df =228 
 
From Table 14.2 it can be seen that the odds ratio for the results of a randomization ever being 
reported in an article for randomizations conducted in a ‘developed’ country versus those 
conducted in a  ‘developing’ country is 7.803. 
 
To test the fit of the model: 
χ2 = 231.057 with 228 df,  p=0.4495  
So the model is a fairly good fit to the data. 
 
Summary 
Dependent variable: Results of randomization ever reported / never reported 
Independent variables: Conducted in a ‘developed’/ ‘developing’ country  
Continuous covariate: Start date of accrual period 
Fitted constants for odds of being mentioned 
Overall constant    6.834 
‘Developed’/’developing’ country   χ2 = 11.7136, df=1, p-value = 0.0006  
‘Developed’   2.793 
 ‘Developing’   0.358 
Start date of accrual period  1.000  χ2 = 7.9034, df=1, p-value= 0.0049 
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Therefore: 
• The odds ratio for a randomization ever being mentioned in an article if conducted in a 
‘developed’ country to if conducted in a ‘developing’ country is 7.803. 
• The odds ratio of being mentioned for any start date of accrual period vs. the day before is 
very slightly less than 1.000, so the odds that a randomization is ever mentioned is slightly 
greater for earlier than for more recent trials.  
 
The model fits the data fairly well. However it contains only two explanatory variables. All other 
unchanging, ‘definitive records’ variables were tried and no others were found to be significant.  
 
A possible explanation for this is that the nature of the results of the randomization probably has a 
great effect on whether they are published. Therefore new variables must be created to do with 
statistical significance, direction of results, clinical significance and whether the main questions of 
the randomization were ever answered. So far each reporting of results contains data specific to a 
particular publication. The next step would be to create fields to be added to the definitive record 
for each randomization. For example, statistical significance of the most statistically significant 
result ever obtained for each randomization.  
 
In order to have this information for unpublished randomizations, it would be necessary to contact 
the trialists, and in order to avoid bias, it would be necessary to do the same for all published 
randomizations also. This would involve designing and sending out a questionnaire asking for at 
least the following information: 
• The main questions being asked in each randomization e.g. survival, rate of relapse in a 
specific site etc. 
• Whether the answers to the questions have ever been published 
• Data on statistical significance, direction of results and clinical significance that can be 
used as a ‘definitive result’, for example n years after the randomization opened or closed 
• If the randomization has remained unpublished, the reasons for this. Was it never 
analysed?  Was it analysed, but its findings not considered worth reporting? 
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These data could then be added to the definitive record for each randomization and each new 
variable tried in the logistic regression, in order to obtain a better fitting model. It is intended that 
this should be undertaken in the future. 
 
14.5  Conclusions 
Earlier randomizations conducted in a ‘developed’ country are more likely both to have been 
mentioned in an article, and to have had their findings published, than those without these 
characteristics. If, in addition, a large number of patients was accrued, the likelihood of having 
been mentioned is even greater, although this latter trial characteristic does not increase the 
probability that the results of the randomization have been reported. 
 
Although it may seem that earlier randomizations must necessarily have a greater chance of having 
been published, it should be remembered that all randomizations included in this project began 
prior to 1 January l988, and all articles relating to these, published prior to 1 January 2000 and 
identified by the cut-off date for analysis, 28 November 2000, allowing ample time for the accrual 
and follow-up periods and the publication process. 
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15  OTHER INVESTIGATIONS II: AN INVESTIGATION INTO WHICH TRIAL 
CHARACTERISTICS AFFECT (a) THE FREQUENCY OF MENTIONS OF A 
RANDOMIZATION AND (b) THE FREQUENCY OF REPORTING OF THE RESULTS 
OF A RANDOMIZATION? 
 
15.1  Introduction 
This chapter deals with the second ‘How wide?’ question, seeking to discover which trial 
characteristics affect frequency of publication. 
 
15.2  Data used for the analyses 
As with the analyses with response variable ‘mentioned/not mentioned’ and ‘results reported/not 
reported’, the ‘definitive records’ dataset is used for investigating which trial characteristics affect 
‘frequency of mentions’(NMENT) and ‘frequency of reporting of results’ (NRES). There is one 
record for each randomization, whether published or unpublished. Again, the only variables tried 
are those which do not change over time, which were described in detail in Section 14.2. The 
number of articles in which the randomization has been mentioned, and the number of articles in 
which its results have been reported are also attached to the definitive record.  
 
The date at which the data to be analysed were frozen was 28 November 2000. Two new variables, 
STARTCUT and CLOSECUT were created. These are the time periods from the start of the 
accrual period for a randomization until the cut-off date of 28 November 2000 and from the close 
of the accrual period until the cut-off date respectively. The start date of the accrual period was 
chosen for use in the ‘frequency of mentions’ analysis so that mentions of a randomization before 
that randomization closed fall within the time period. For the ‘frequency of reporting of results’ 
analysis, the close date of the accrual period was used. 
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15.3  Which trial characteristics affect the frequency of mentions of a randomization? 
Choosing an appropriate model 
To check whether a Poisson regression model is suitable for the ‘frequency of mentions’ analysis, 
an ordinary linear regression was run with the response variable 
√(NMENT/STARTCUT) =  α +∑
=
p
j 1
βj  xj 
where xj ,  j=1 …  p  are explanatory variables,  
and α and βj , j=1 …  p are parameter estimates 
 
√(NMENT/STARTCUT) is the variance stabilizing transformation. If the variable, NMENT, has a 
Poisson distribution, the plot of residuals against fitted values forms a random pattern, and that of 
residuals against normal scores an approximately straight line. If, however, the plot of residuals 
against fitted values produces a wedge-shaped pattern, this would indicate overdispersion, i.e. that 
the mean has a distribution with the variance increasing more rapidly than the mean, as the mean 
increases. In such a case, the assumption of the Poisson model,  
 variance = mean  = µ 
is not satisfied. 
Instead, the negative binomial model, with relationship between the mean and variance, 
 variance = µ + kµ2 ,  where k = scale factor 
should be used.  
 
The explanatory variables, used in this preliminary investigation, were any of the ‘definitive 
records’ variables significant in either the ‘time from close to publication for all mentions’ analysis 
or the ‘ever mentioned/never mentioned’ logistic regression. These are date of start of accrual 
period (NSTART), duration of accrual period (DURRAN), country group of trialists (CGROUP), 
whether or not the randomization was conducted in a ‘developing’ country (DEVLPNG), degree of 
multi-centre participation (MULTIC), log10 (number of patients accrued) LOGSIZE and whether 
first-line or relapse treatment (FIRSTL). 
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The diagnostic plots obtained are given as Figures 15.1 and 15.2. 
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Figure 15.1 Modelling frequency of mentions using ordinary linear regression with the variance stabilizing 
transformation. Standardised residuals vs. fitted values 
 
 
In Figure 15.1, the top half of the plot of standardised residuals against fitted values shows a 
random pattern, indicating that ‘frequency of mentions’ does have a Poisson distribution. The 
diagonal line in the lower half of the plot may be thought to indicate the opposite. However this is 
misleading for the reason that the response variable, ‘frequency of mentions’ (NMENT), is an 
integer, with lowest possible value zero.  
For any observation yi,  
residual εi = yi – fitted value  
                  = yi –  (αi +∑
=
p
j 1
βij  xij) 
Therefore, for those observations for which yi = 0, i.e. for those randomizations never published,  
εi = – fitted value  
    = – (αi +∑
=
p
j 1
βij  xij) 
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These observations form the diagonal line in the lower half of the plot. Since yi cannot take a value 
lower than zero, it is not possible for any residuals to lie beneath this line. Therefore the lower half 
of the plot cannot be used to determine the suitability of the Poisson model.  
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Figure 15.2 Modelling frequency of mentions using ordinary linear regression with the variance stabilizing 
transformation. Residuals vs. their normal scores 
 
 
In Figure 15.2 the plot of residuals versus normal scores, with the exception of one observation 
(bottom left-hand corner), also suggests that the Poisson model may be appropriate. 
 
Both the Poisson and negative binomial models are now applied, using a log link, and the results 
compared: 
log (NMENT/STARTCUT) =   α +∑
=
p
j 1
βj  xj 
           log NMENT  =   α +∑
=
p
j 1
βj  xj   -  log (STARTCUT) 
The same set of explanatory variables was used initially, with a backwards elimination process, 
dropping the least significant each time, until a reduced set of significant variables was obtained. 
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Other ‘definitive records’ variables were then added in, one by one, until the best-fitting model was 
found.  
 
Interactions between country group of trialists (CGROUP) and whether multi-centre participation 
took place (MULTIC), whether there was international participation (INTERNL), and size of trial 
(LOGSIZE) were tried, as were those between whether conducted in a ‘developing’ country 
(DEVLPNG) with MULTIC, INTERNL and LOGSIZE respectively. None were found to be 
significant.  
  
The algorithm for the program and some SAS commands used to perform the negative binomial 
and Poisson regressions are given in Appendix XX, and the output for the final models obtained are 
in Appendix XXI. The findings are summarized below: 
 
Summary of findings 
1. Using the negative binomial model 
The following trial characteristics lead to a randomization being mentioned in a greater number of 
articles: 
• Later start date of accrual period (NSTART) P(<0.0001) 
• Conducted in a ‘developed’ country (DEVLPNG) (p=0.0028) 
• Single-centre participation (MULTIC) (p=0.0006) 
• Greater number of patients accrued (LOGSIZE) (p<0.0001) 
• Equivalence trial (EQUIV) (p=0.0183) 
• First-line treatment as opposed to treatment for relapse/refractory disease (FIRSTL) 
(p=0.0079) 
• Conducted in North America (CGROUP) (p=0.0165)  
 
Deviance=185.3164, 180 df 
Deviance/ df = 1.0295 
This is based on 188/243 of the randomizations. 
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The scale factor (negative binomial dispersion parameter) was estimated by maximum likelihood. 
k=0.0214, standard error of k=0.0363. 
 
Diagnostic plots are given as Figures 15.3 and 15.4. The residuals used are the Pearson (χ2) 
residuals for identifying poorly fitted observations.  
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Figure 15.3 Modelling frequency of mentions using a negative binomial regression. Standardised residuals 
vs. fitted values 
 
With the exception of one outlying observation (top left hand corner) Figure 15.3 shows a fairly 
random spread, indicating a constant variance. The series of parallel lines are due to the discrete 
nature of the response variable. 
 
Outlying observation 
The outlying observation, with standardised residual of 3.41, is record 349 from the ‘definitive 
records’ database, the randomization 1209. This is from a single randomization trial, ALL-REZ-
BFM-85, (trial 1209), which was run by the BFM children group in Germany, for the short period 
April 1985-March 1986. It was a post-relapse randomization, which involved multi-centre 
participation and accrued 46 patients.  The two treatment arms were high dose methotrexate 
infused over a short period versus intermediate dose methotrexate over a longer period, both 
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followed by folinic acid, and it is not thought to be an equivalence trial. It was mentioned in four 
articles, more frequently than might be expected. 
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Figure 15.4 Modelling frequency of mentions using a negative binomial regression. Residuals vs. their 
Normal scores 
 
Figure 15.4 shows a fairly straight line, indicating a normal distribution. 
 
2. Using the Poisson model 
Output from the Poisson regression is very similar. 
The following trial characteristics lead to a randomization being mentioned in a greater number of 
articles: 
• Later start date of accrual period (NSTART) (p<0.0001) 
• Conducted in a ‘developed’ country (DEVLPNG) (p=0.0025) 
• Single-centre participation (MULTIC) (p=0.0004) 
• Greater number of patients accrued (LOGSIZE) (p<0.0001) 
• Equivalence trial (EQUIV) (p=0.0137) 
• First-line treatment as opposed to treatment for relapse/refractory disease (FIRSTL) 
(p=0.0067) 
• Conducted in North America (CGROUP) (p=0.0131)  
220 
Deviance=196.2034, 180 df 
Deviance/df =1.0900 
This is based on 188/243 of the randomizations. 
The diagnostic plots given as Figures 15.5 and 15.6. 
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Figure 15.5 Modelling frequency of mentions using a Poisson regression. Standardised residuals 
vs. fitted values 
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Figure 15.6 Modelling frequency of mentions using a Poisson regression. Residuals vs. their normal scores 
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Clearly, the diagnostic plots from the Poisson regression (Figures 15.5 and 15.6) are very similar to 
those from the negative binomial model (Figures 15.3 and 15.4). The outlier in Figures 15.3 and 
15.5 is the same observation, and has already been discussed. 
 
Conclusion 
The same variables were found to be significant using either model, and the p-values associated 
with them did not differ much, but were slightly smaller with the negative binomial model than 
with the Poisson model. The deviance was slightly smaller when the former was used (185.3164 as 
opposed to 196.2034 for the same number of degrees of freedom 180).  
 
The value of k, the scale factor in the negative binomial regression is small (0.0214). The largest 
number of mentions for any randomization is 13. The randomization in question is 3107, SJCRH 
X, which was discussed in Section 1.4. From Figure 15.3 it can be seen that the largest fitted value 
is approximately 7.5, that for randomization 3107. 
Since variance = µ + kµ2,  the greatest value that the variance can take is approximately  
7.5 + 0.0214 × 7.52 = 8.7, which is not much greater than the mean. 
 
For these reasons it is immaterial which of the two models is used. 
 
15.4  Which trial characteristics affect the frequency of reporting of the results of a 
randomization?  
Choosing an appropriate model 
Again the suitability of the Poisson regression model was tested by use of the variance stabilizing 
transformation, 
√(NRES/CLOSECUT) =  α +∑
=
p
j 1
βj  xj 
where xj , ,j=1 …  p are explanatory variables 
and α and βj , j=1 …  p are parameter estimates. 
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The only ‘definitive records’ explanatory variable in the ‘time from close to publication’ analysis 
for all reportings of results was date of close of accrual period (NCLOSE). Date of start of accrual 
period (NSTART), which is highly correlated with NCLOSE,  and whether or not conducted in a 
‘developing’ country (DEVLPNG) were the only significant variables in the ‘results published/not 
published’ logistic regression analysis. For the purpose of this preliminary investigation, NCLOSE 
and DEVLPNG were used, plus other variables considered likely to affect the response, i.e. those 
tried in the ‘frequency of mentions’ preliminary investigation. Since NSTART is highly correlated 
with NCLOSE, the former was not included. 
 
The diagnostic plots obtained are given as Figures 15.7 and 15.8. 
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Figure 15.7 Modelling frequency of reporting of results using ordinary linear regression with the variance 
stabilizing transformation. Standardised residuals vs. their fitted values 
 
 
For the same reason as with the preliminary investigation for the ‘frequency of mentions’ analysis, 
the lower half of the plot of standardised residuals versus fitted values (Figure 15.7) should not be 
used to assess whether the distribution is wedge-shaped. The upper half indicates that it is not, and 
that a Poisson model is therefore suitable. The same negative residuals are responsible for the kink 
in an otherwise fairly straight line in the plot of residuals versus their normal scores (Figure 15.8). 
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Figure 15.8 Modelling frequency of reporting of results using ordinary linear regression with the variance 
stabilizing transformation. Residuals vs. their normal scores 
 
 
Again, both the negative binomial and Poisson regressions were run. For this analysis the results 
obtained in the two ways were identical. When the former was used, the dispersion parameter was 
estimated to be zero. This should be treated with caution since the model did not converge. 
However, since the results were identical when the Poisson model was used, and there were no 
convergence problems with this latter model, the results are confirmed. 
 
Summary of findings 
The following trial characteristics lead to the results of a randomization being reported in a greater 
number of articles: 
• Later close date of accrual period (NCLOSE) (p<0.0001) 
• Conducted in a ‘developed’ country (DEVLPNG) (p=0.0004) 
• Single-centre participation (MULTIC) (p<0.0001) 
• Number of patients accrued (LOGSIZE) (p<0.0006) 
• Treatment type: immunotherapy or radiotherapy as opposed to chemotherapy or antibiotic 
(TXCHEMO) (p=0.0031) 
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Deviance=193.6045 182 df 
Deviance/df=1.0638 
This is based on 188/243 of the randomizations. 
 
The diagnostic plots are given as Figures 15.9 and 15.10. 
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Figure 15.9 Modelling frequency of reporting of results using either the negative binomial or Poisson 
regression. Standardised residuals vs. fitted values 
 
 
Again, the plot of standardised residuals versus fitted values (Figure 15.9) gives a random spread, 
and the plot of residuals versus their normal scores (Figure 15.10) is fairly straight, indicating the 
model is a good fit to the data. 
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Figure 15.10 Modelling frequency of reporting of results using either the negative binomial or Poisson 
regression. Residuals vs. their normal scores 
 
 
15.5  Conclusions 
Several of the trial characteristics associated with a higher frequency of mentions are also 
associated with a higher frequency of reporting of results. These are, as may be expected, 
randomizations from trials conducted in ‘developed’ countries and those accruing a larger number 
of patients. Surprisingly, in both analyses, single-centre, as opposed to multi-centre, participation 
also leads to a greater frequency of publication. A possible explanation for this is that there are 
likely to be fewer co-authors of reports of results from single-centre randomizations and so the 
agreement of fewer people would be necessary in order for articles to be submitted. Later start date 
of accrual period was significant in the ‘frequency of mentions’ analysis, as was later close date of 
accrual period in the ‘frequency of reporting results’ analysis. These variables are very highly 
correlated (ρ=0.97), and both imply, encouragingly, that more recent randomizations are published 
more widely than earlier randomizations. 
 
In addition, randomizations between treatments for first-line therapy tend to be mentioned in more 
articles than those for relapse/refractory disease, as do randomizations conducted in North America 
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and equivalence trials. However these factors do not affect the frequency of reporting results. 
Results from immunotherapy and radiotherapy trials were reported more frequently than those 
from chemotherapy or antibiotic trials, although there was no difference in the number of times 
mentioned. 
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16  UPDATE 
 
16.1  Introduction 
This short chapter summarises new data found since the analyses were run.  
 
16.2  Data 
In recent years, attempts have been made to update the list of randomized trials for the overview 
(meta-analysis), but these attempts have not yet been as comprehensive or systematic as the earlier 
searching which formed the basis for the list of trials used in this thesis.  
 
The last comprehensive search of MEDLINE and EMBASE was done on 6 September 1999. After 
then, the processing of publications on two treatment questions only was continuously updated. 
These were central nervous system treatment and duration of therapy, which were topics for 
overviews and collaborative meetings. Searches were done targeting these specific types of 
treatment only, but if other trials were found by chance, they too were added to the database. On 28 
November 2000 the Cancer Overviews Group decided that there would be no systematic update of 
the ALL database within the next 12 months. Therefore all analyses reported here have used the 
data frozen at that point. 
 
The trial lists were checked for the last time on 1 June 2002 and showed that this fairly limited 
searching has not found any additional trials or randomizations starting prior to 1 January 1988. 
However, seven additional articles, published before 1 January 2000, relating to randomizations 
already identified had been found. Also, it had become apparent that one randomization had been 
registered twice, with two different ID numbers and under two different groups of trialists. 
 
A summary of the seven new articles found: 
 
1. Schrappe et al (1998) published in Klinische Padiatrie, is a report by the BFM group (Group 
12), describing four of their trials: ALL-BFM- 81, ALL-BFM-83, ALL-BFM-86 and ALL-BFM-
90.The last two digits of the trial name indicate the year the trial opened. The latter is ineligible for 
228 
inclusion in this study since the entry period started after 1 January 1988. The report demonstrates 
the efficiency of CNS-directed chemotherapy with or without reduced cranial radiotherapy in 
preventing CNS relapse. It is published in full in English with the abstract in German also. (The 
other six articles are published only in English.) ALL-BFM-81 (1204) contains two 
randomizations; maintenance duration (1204) and CNS prophylaxis; radiotherapy versus 
chemotherapy (intravenous methotrexate) (1205). ALL-BFM-83 (1206) consists of three 
randomizations; maintenance duration (1206), late/second reinduction block versus control (1207), 
and two doses of radiotherapy for CNS prophylaxis (1208). ALL-BFM-86 (1211) has one 
randomization (1211); intensification block versus not during maintenance treatment. 1211 had 
been reported in one other article, the others in several. 
 
2. Freeman et al (1997) in Medical and Pediatric Oncology, describes the US Cancer and 
Leukemia Group B (CALGB) trial CLB 7611 (1416). This trial has a single randomization (1416) 
for CNS prophylaxis treatment; cranial irradiation versus chemotherapy in the form of intravenous 
methotrexate. Again this randomization, open between 1976 and 1979, had already been reported 
many times. 
 
3. Miller et al (1981) is technically a book reference, although Haematology and Blood 
Transfusion, in which the article is published, is similar to a journal. This reports trial CCG-141 
(1612) by the Children’s Cancer Group (CCG) (Group 16).  This has two randomizations, between 
two induction and consolidation treatments (1612) and between three maintenance treatments 
(1615). The maintenance treatments are, after three years, to stop treatment, to have a further 4-
week block of treatment or to continue maintenance for another two years. Again several articles 
reporting each randomization had already been found. 
 
4. Miller (1981) was published in the book Cancer: Achievements, Challenges and Prospects for 
the 1980’s. Again the trial reported is CCG-141. 
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5. Gelber et al (1993), published in Cancer, is entitled ‘Central Nervous System Treatment in 
Childhood Acute Lymphoblastic Leukemia’. It reports four trials, each comprising a single 
randomization, run by the Dana Farber Cancer Institute (DFCI), (Group 17). DFCI 73001 (1701) 
compares three induction treatments, DFCI 77001 (1702) compares two consolidation treatments, 
DFCI 80001 (1703) is between two intensification blocks and DFCI 81001(1704) compares a pre-
induction treatment against a control. In each case the first two digits of the trial name indicate the 
year the accrual period began. Again all four randomizations have been published in other articles, 
1703 in only one other. 
 
6. Koizumi et al (1997) reports some of the randomizations belonging to four trials conducted by 
The Japanese Children’s Cancer and Leukaemia Group (Group 26) in Medical and Pediatric 
Oncology. In each case the first two digits of the trial name indicate the year the trial began. 
JCCLSG S-811 (2601) compares two maintenance treatments for standard risk patients and 
JCCLSG H-811 (2602) two maintenance treatments for high risk patients (not reported in this 
article). JCCLSG I-841 (2603) contains two randomizations; 2603 is between two induction and 
maintenance regimens for intermediate risk patients (not reported in this article), one of which 
includes cranial irradiation, and 2604 is a two-arm induction randomization for low-risk patients. 
JCCLSG L-874 (2606) comprises three randomizations. 2606 is a CNS prophylaxis randomization 
for low risk patients, between cranial irradiation and chemotherapy (methotrexate + leucovorin 
rescue) and JCCLSG I-874 (2607) is a similar randomization for intermediate risk patients. 
JCCLSG H-874 (2608) is between two intensification treatments for high risk patients (not 
reported in this article). The fourth trial JCCLSG-911 is ineligible for inclusion since it opened 
after 1 January 1988. Again, other articles for all randomizations have already been found, 
although only one other each for randomizations 2602 and 2605.  
 
7. Nishimura (1993) mentions four trials run by the Tokyo Children’s Cancer Study Group, Japan 
(Group 127) in Cancer Chemotherapy: Challenges for the Future. Two are eligible for inclusion in 
these data. Again the first two digits specify the year the trial began. The first of these is TCCSG 
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84-11 (12701), which has two randomizations; TCCSG L84-11 SR (12701) and TCCSG L84-11 
HR (12702), CNS prophylaxis randomizations of chemotherapy with intravenous and intrathecal 
methotrexate versus control for standard and high risk patients respectively. The other trial is 
TCLSG L81-10 (12703) for standard risk patients, which randomizes between two doses of cranial 
irradiation (12703) and between two consolidation and randomization treatments. The other two 
trials reported; TCCSG L-89-12 and L92-13 began too late to be eligible for inclusion. Two other 
articles reporting randomization 12701 have been found, and one other for the other three 
randomizations of interest. 
 
To summarise; all the randomizations reported in the seven newly found articles have also been 
reported elsewhere. All seven articles are concerned, at least in part, with one or both of the two 
questions addressed for the last ALL Collaborative Overview, namely CNS therapy and duration of 
maintenance treatment. Four articles (1,2,6 and 7) mention randomizations between CNS 
prophylaxis treatments. Article 5 reports trials that do not randomize between CNS treatments, but 
nonetheless focuses on CNS treatments. Articles 1, 3 and 4 mention randomizations between 
maintenance treatments of differing duration.  
 
The randomization which has been included twice is from the POG7623/SWOG7623/AlinC trial 
(2902 and 3218). It is under the Pediatric Group (POG) (Group 29) as randomization 2903, 
between two combined induction, consolidation and maintenance treatments, one of which 
involves cranial irradiation. It is also under the Southwest Oncology Group (SWOG) as a trial with 
a single randomization between two CNS treatments; cranial irradiation plus chemotherapy with 
methotrexate versus more methotrexate. Instead of two randomizations reported in one and two 
articles respectively, this should be considered as one randomization reported in three articles, 
publications 177 [van Eys et al (1989b)], 251 [Wells et al (1983)] and 252 [Whitt et al (1984)].  
 
Since 257 articles have been included in the data analysed, the small amount of additional data 
(less than 3%) should not affect the results reported. 
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17  SUMMARY OF THE MAIN CONCLUSIONS 
 
17.1  Introduction  
This final chapter summarises the main findings of this thesis i.e. the chief factors leading to 
publication bias and the importance of these to meta-analysts. 
 
17.2  The ‘How long?’ analyses 
Of the twelve ‘How long’ analyses reported here, the most informative are those of time from close 
to publication for the first reporting of results and for the first mention of each randomization.  
 
The first is important since this is the delay between the close of the randomization and making the 
results widely available through publication to clinicians treating patients, who may change their 
practices as a result of what they read. This analysis showed that results with smaller p-values 
associated with them are first published more quickly than those with larger p-values. This is in 
concordance with other similar studies conducted. It was also found that null results (where the 
trial found in favour of neither treatment arm) are generally first published faster than those in 
favour of either the experimental arm or the standard (control) arm, but that null results from trials 
conducted outside North America and Europe had a longer time to first reporting of results. It is 
pleasing to note that this project did not find direction of results (i.e. whether in favour of the 
experimental or the standard arm) to be a significant predictor of time to first reporting of results. 
This was not the case with most of the other studies. It was also found that if the trialists indicated, 
in an article, that that they considered results of their randomization were either clearly in favour of 
the experimental treatment arm, or that this was clearly not so, the time from close to publication 
was shorter than if no clear impression was given, irrespective of the p-values associated with the 
results. This demonstrates that the importance the trialists attach to their results and the motivation 
of the trialists to publish also influence time to publication.  
 
Surprisingly, and in contrast to the findings of the published studies, it was found that results in 
favour of the standard or control arm, were submitted more quickly than all others, including those 
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clearly in favour of the experimental arm. Since this was not found to be significant in the analysis 
of time from close to publication for first reportings of results, this may indicate that although 
trialists may be keen to publish their negative findings, journal editors may be less so.  
 
The second analysis showed that neither statistical significance nor direction of results are 
significant predictors of the time from close to publication, for the first mention of a randomization. 
This should be reassuring for those involved in identifying randomizations for inclusion in meta-
analyses. This analysis also found that time from close to first mention was longer for 
randomizations conducted by ‘developing’ countries.  
 
When the analyses of time from close to publication (and from close to submission) were re-run 
omitting records relating to reportings of randomizations prior to closure, typically the model 
changed significantly. It appears that duration of randomization is acting as a surrogate for whether 
or not the randomization is mentioned prior to closure. It is intended that this interesting finding 
will be investgated fully in future.   
 
 
17.3  The ‘How wide? analyses 
Turning to the ‘How wide?’ analyses; neither statistical significance, direction of results nor any 
other variable associated with a particular publication is used in these analyses, only those variables 
unchanging over time have been included. It was found that the results of randomizations 
conducted in ‘developing’ countries were less likely to have ever been reported and that these 
trials, and smaller trials, were less likely to have ever been mentioned in an article. These 
characteristics, together with those of multicentre participation and recent occurrence, are also 
associated with both a lower frequency of mentions, and also a lower frequency of reporting of 
results. 
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17.4  Overall conclusion 
The overall conclusion, therefore, is that there is evidence of ‘pipeline bias’ in the reporting of 
results in that highly statistically significant results are published faster than others, but this is not a 
problem for those wishing only to identify randomized trials for inclusion in meta-analyses. The 
geographic location of randomized trials was, however, found to be an important predictor of 
whether a randomization was ever mentioned in an article, frequency of mentions and of the time 
to publication. It may be worth going to extra lengths to track down the smaller trials conducted in 
countries outside North America and Europe in order to avoid selection bias when identifying 
randomized trials for inclusion in meta-analyses. 
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APPENDICES 
 
APPENDIX I: SUMMARY OF TRIALS, RANDOMIZATIONS AND ARTICLES USED AS A SOURCE OF DATA 
 
Trial group number and name     Trial      Rand     Question                Accrual period              Size  No. Articles  Publication IDs (see key)     
 
11 AIEOP, Italy 
AIEOP 7901/7902  1101 1101 duration   early 81 – summer 83 177 1 30     
AIEOP 7903   1102 1102  combination early 79 - summer 81 210 1 30 
Second CR   1103 1103  post-relapse May 80 - Jun 83  84 1 31 
 
12 BFM – children Group, Germany 
ALL-BFM-76   1201 1201 intensification  Oct 76 - Mar 79    158 4 33 32 37 48 
ALL-BFM-79   1202 1202 intensification  1 Apr 79 – Mar 81 199 4 34 32 37 48 
ALL-BFM-79   1203 1203 intensification 1 Apr 79 – 31 Mar 81  126 4 34 32 37 48 
ALL-BFM-81   1204 1204 duration  1 Apr 81 – 30 Sep 83  395 7 35 34 32 37 46 48 38 
ALL-BFM-81   1205 1205 CNS prophylaxis 1 Apr 81 – 30 Sep 83  277 6 35 32 46 47 48 38 
ALL-BFM-83   1206 1206 duration  1983 – Sep 86  351 6 35 32 41 47 48 281 
ALL-BFM-83   1206 1207 intensification 1983 – Sep 86  126 3 32 41 46 
ALL-BFM-83   1206 1208 CNS prophylaxis late 1983- Sep 86  143 4 32 46 47 48 
ALL-REZ-BFM-85  1209 1209 post-relapse Apr 85 – 31 Mar 86  46 4 40 42 43 44 
ALL-BFM-??   1210 1210 immunotherapy 1982 - ?   ? 0 
ALL-BFM-86   1211 1211 intensification Oct 86 – Mar 90  128 1 45 
ALL-REZ-BFM-87  1215 1215 post-relapse spring 87 – end 88 41 0 
 
13 Bombay, India 
Bombay TAT TMC 1  1301 1301 maintenance Jul 79 – Dec 80   ? 0 
 
14 Cancer and Leukemia Group B (CALGB), USA 
ALGB 1965   1401 1401 maintenance 1960s   116 1 50 
ALGB 6601   1402 1402 intensification 1966 - 68  267 3 51 52 53 
ALGB 6601   1402 1403  maintenance 1966 - 68   211 3 51 52 53 
ALGB 6601   1402 1499 intensification 1966 - ?   ? 2 52 53 
ALGB  6801   1404 1404 induction Feb 68 – Feb 71  514 5 51 52 53 55 282 
ALGB  6801   1404 1405 intensification Feb 68 – Feb 71  225 7 51 52 53 54 55 60 282 
ALGB  6801   1404 1406 maintenance Feb 68 – Feb 71  339 5 51 52 53 55 282 
ALGB  6801   1404 1498 duration  1973 - ?   ? 1 53
260 
CLB 7111   1407 1407  induction 5 Feb 71 – 18 Mar 74 646 5 52 56 57 61 5 
CLB 7111   1407 1408 CNS prophylaxis  5 Feb 71 – 18 Mar 74 467 7 52 54 56 57 60 58 61 
CLB 7111   1407 1409 maintenance  12 Jul 71 – Mar 74 493 4 52 56 58 61 
CLB 7112 relapse  1410 1410 post-relapse 1971 – 71   88 2 57 59 
CLB 7112 relapse  1410 1411 post-relapse 1971 – 71  45 2 57 59 
CLB 7211 relapse  1412 1412 post-relapse  1972 – 72  135 2 57 59 
CLB 7211 relapse  1412 1413 post-relapse  1972 – 72  91 2 57 59 
CLB 7411   1414 1414 CNS prophylaxis 1974 –77   339 3 54 57 60 
CLB 7411   1414 1415 maintenance  1974 – 77  339 1 57 
CLB 7611   1416 1416 CNS prophylaxis 12 Nov 76 – late 79 506 8 54 57 60 62 63 64 72 280 
CLB 7611R   1417 1417 intensification  Jan 80 – 81   ? 1 72 
CLB 7811, relapse  1418 1418 post-relapse  Dec 78 – Nov 79  ? 0 
CLB 6911 4-way   1423 1423 post-relapse  Mar 69 – Feb 70   ? 2 69 56 
CLB 6911 4-way   1423 1424 post-relapse  Feb 70 – Sep 70   ? 2 69 56 
CLB 6911 4-way   1423 1425 maintenance  Mar 69 – Sep 70  87 1 69 
ALGB ????   1428 1428 post-relapse  1960s   57 1 71 
ALGB ????   1428 1497 maintenance  1960s   19 1 71 
CALGB 6611   1429 1429 unknown 1966 - ?   96 1 288 
CALGB 6611   1429 1496 maintenance  1966 - ?   ? 1    288 
 
16 Children’s Cancer Group  (CCG), USA 
CCG-101   1601 1601 CNS prophylaxis  Jun 72 – summer 74 590 9 111 112 113 114 115 116 117 118 119 
CCG-101   1601 1602 duration  autumn 75 - summer 78 244 6 75 80 111 112 115 116 
CCG-105   1603 1603 combination  May 83 – Apr 89  1606 4 78 82 84 85 
CCG-105   1603 1604 CNS prophylaxis May 83 – Apr 89   1389 6 78 79 81 82 84 85 
CCG-106 - 3 arm   1605 1605 combination  May 83 – Nov 84  214 5 86 87 88 89 90 
CCG-106 - 3 arm   1605 1606 combination  8 Nov 84 – Mar 87 328 4 86 87 88 89 
CCG-121   1607 1607 post-relapse  Jan 82 – Dec 85  119 0 
CCG-123 - first stratum 3-way 1608 1608 combination  Apr 83 – Nov 85  260 5 89 91 92 93 276 
CCG-123 - first stratum 3-way 1608 1609 combination  Nov 85 – Dec 85   14 4 93 91 92 276 
CCG-123 - first stratum 3-way 1608 1610 combination  Dec 85 – Apr 87  183 4 93 91 92 276 
CCG-123 - first stratum 3-way 1608 1635 combination  Apr 87 – Apr 89  209 4 93 91 92 276 
CCG-123 - first stratum 3-way 1608 1636 combination  Apr 83 – Oct 85  272 4 93 91 92 276 
CCG-139   1611 1611 combination  autumn 83 – Jan 89 148 2 94 95 
CCG-141   1612 1612 combination  Feb 75 – spring 77 306 5 77 89 96 108 114 
CCG-141   1612 1615 maintenance  Mar 78 – Jun 80  287 6 77 89 96 97 98 108 
CCG-141   1612 1698 CNS prophylaxis 1975 - ?   ? 1 97 
CCG-141A I   1613 1613 intensification  spring 77 – summer 78 366 2 77 97
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CCG-141A I   1613 1614 maintenance  spring 78 – summer 301 1 108 
CCG-143   1616 1616 CNS prophylaxis  Aug 74 – spring 75 179 3 111 112 113 
CCG-143   1617  1617 duration  autumn 77 – summer 78  72 4 75 80 111 112 
CCG-161   1618 1618 CNS prophylaxis 1 Apr 78 – autumn 82  529 4 97 101 99 100 
CCG-161   1618 1619 maintenance  1 Apr 78 – May 83 625 5 97 101 99 100 108 
CCG-161   1618 1621 duration  1980 – 85  285 8 77 90 100 101 102 103 99 75 
CCG-162   1622 1622 maintenance  1 Apr 78 – autumn 81 1058 3 97 101 110 
CCG-162   1622 1624 duration  1980 – Nov 84  716 5 90 101 102 103 75 
CCG-162A   1623 1623 maintenance  Jun 81 – Feb 83  541 0 
CCG-163D   1625 1625 maintenance  1 Apr 78 – Apr 81  321 4 89 101 102 97 
CCG-163D   1625 1626 duration  1981 – 85  120 5 90 101 102 103 75  
CCG-171   1627 1627  post-relapse  Apr 79 – Feb 82   97 0 
CCG - relapse   1633 1633  post-relapse  1970s   164 1 104 
CCG - relapse   1633 1640  post-relapse  1970s   50 1 104 
Relapsed Patients in New CR 1634 1634 post-relapse  1980s (?)  50 1 105 
CCG 1970a   1637 1637 maintenance  1970 – 71  350 1 106 
CCG 1970a   1637 1638 maintenance  1970 – 71  153 1 106 
CCG-098   1639 1639 post-relapse May 86 -  Mar 88  49 1 120 
CCG - (1967)   1645 1645 duration  1967 – 1967  15 1 107 
CCG - (1967)   1645 1699 unknown  1963 – 67  165 1 107 
CCG-144   1652 1652 unknown 1984 – 88  ? 0 
 
17 Dana Farber Cancer Institute (DFCI), USA 
DFCI 73001   1701 1701 induction  May 73 – Dec 74  45 3 121 122 126 
DFCI 77001   1702 1702 intensification  1 Jun 77 – Oct 79  64 2 123 126 
DFCI 80001   1703 1703 intensification  1 Jan 80 – 31 Dec 80 22 1 126 
DFCI 81001pre-induction  1704 1704 induction  May 81 – Dec 83  77 6 124 126 127 128 129 38 
DFCI 85001   1705 1705 induction  spring 85 - Dec 87 210 0 
DFCI 87001 pre-induction  1706 1706 induction  Oct 87 - 91   ? 0 
DFCI 87001 pre-induction  1706 1707 maintenance  Nov 87  - summer 91 353 1 130 
DFCI 87001 pre-induction  1706 1708 CNS prophylaxis Nov 87 – Jul 91  109 2 130 131 
SFCC ???   1709 1709 CNS prophylaxis Jul 72 – 197?  20 1 125 
 
18 Dutch Childhood Leukaemia Study Group, The Netherlands 
DCLSG-ALL-V/EORTC 99801 1801 1801 induction  4 May 79 – Dec 82 240 3 132 133 134 
 
19 European Organisation for Research on Treatment of Cancer (EORTC) 
EORTC 58741   1901 1901 intensification  May 71 – Jan 79  224 1 135
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EORTC 58741   1901 1902 immunotherapy  autumn 72 – spring 80 123 1 135 
EORTC 58791   1903 1903 induction  May 80 – Dec 85  108 3 136 137 138 
EORTC 58791   1903 1904 intensification  1980 – 88  82 3 136 137 138 
EORTC 58831   1905 1905 intensification  Jul 83 – summer 89 388 1 139 
EORTC 58832   1906 1906 CNS prophylaxis  Jul 83 – end 88  191 2 142 143 
EORTC ????   1912 1912 miscellaneous  1980s (?)  51 1 141 
 
20 French ALL Cooperative Group (FRALLE) / French Society of Pediatric Hematology (SHIP), France 
FRALLE 87   2004 2004 CNS prophylaxis summer 87- early 89 188 1 147 
FRALLE 83 LR   2005 2001 duration  Jun 83  - Apr 87  66 2 144 145 
FRALLE 83 LR   2005 2005 induction  Jun 83 – Apr 87  113 1 145 
FRALLE 83 IR   2006 2002 combination  1983 – 87  250 1 146 
FRALLE 83 IR   2006 2003 testicular XRT 1983 – 86  63 1 144 
FRALLE 83 IR   2006 2006 induction  1983 - 87   ? 0 
 
21 GATLA, Argentina 
GATLA 72   2101 2101 intensification  Oct 72 – Dec 75  465 2 148 284 
GATLA 72   2101 2102 maintenance  Oct 72 – Dec 75  465 2 148 284 
GATLA 72   2101 2103 immunotherapy  1972 - 75   ? 1 148 
GATLA 1 LLA-79  2104 2104 immunotherapy Jan  79 – Jan 84  602 1 284 
GATLA 7 LLA-87  2105 2105 maintenance  Jul 87 – Dec 89  272 2 150 284 
Protocol 1-ALL-76  2198 2197 immunotherapy  Jan 76 – Dec 78  336 1 284 
Protocol 1-ALL-76  2198 2198 maintenance  Jan 76 – Dec 78  336 1 284 
Protocol 11-ALL-67  2199 2199 maintenance  Nov 67 – Sep 70  38 1 284 
 
22 Great Ormond Street Hospital, London, UK 
GOS-79    2201 2201 maintenance  Jun 79 - Dec 82  144 1 152 
 
23 Gunma University, Japan 
Japan KLSG 1   2301 2301 immunotherapy  Mar 79 – Jul 81   15 1 153 
 
24 Cooperative Acute Lymphoblastic Leukaemia Group (COALL), Germany 
COALL 80   2401 2401 maintenance  Nov 78 – Nov 82  105 2 155 154 
COALL 80   2401 2402 maintenance  Nov 78 – Nov 82  39 2 154 155 
COALL 85/89   2403 2403 intensification  1 Jan 85 – end 87  143 4 156 157 158 159 
COALL 85/89   2403 2404 intensification  1 Jan 85 – spring 90 58 4 157 158 159 156 
COALL 82   2405 2405 intensification  1982 – Nov 83   ? 1 155
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25 Instituto Nacional de Enfermedades Neoplasicas (INEN), Peru 
INEN-7902   2502 2502 maintenance  Jan 79 – summer 83 48 0 
INEN-P83   2503 2503 CNS prophylaxis Jan 83 – summer 85 59 0 
INEN-P85   2504 2504 CNS prophylaxis summer 85 – summer 88 73 0 
 
26 Japanese Children’s Cancer and Leukaemia Group, Japan 
JCCLSG S-811   2601 2601 maintenance  late 80 – early 84  115 6 160 161 162 163 166 83 
JCCLSG H-811   2602 2602 maintenance  early 81 – summer 82  88 1 83 
JCCLSG I-841   2603 2603 combination  early 84 - spring 87 78 2 164 83 
JCCLSG I-841   2603 2604 induction  early 84 – summer 87 66 3 164 166 83 
JCCLSG H-851   2605 2605 maintenance  late 84 – summer 87 93 1 83 
JCCLSG 874   2606 2606 CNS prophylaxis April 87 – early 91  87 3 166 76 83 
JCCLSG 874   2606 2607 CNS prophylaxis April 87 – autumn 91 114 4 165 166 76 83 
JCCLSG 874   2606 2608 intensification  April 87 – Dec 90 164 3 166 76 83 
 
27 Medical Research Council, UK 
UKALL I   2701 2701 CNS prophylaxis Aug 70 - Jan 72   26 4 1 12 4 5 
UKALL I   2701 2702 duration  start 72  - Autumn 73 82 4 15 4 1 2 
UKALL II   2703 2703 CNS prophylaxis 1 Jan 72 – Dec 72 39 2 12 3 
UKALL II   2703 2704 maintenance  1 Jan 72 – Mar 73 185 2 12 3 
UKALL II   2703 2705 duration  Autumn 73 – summer 75 207 3 15 12 3 
UKALL III   2706 2706 maintenance 1 Sep 73 – 12 Nov 74 135 1 16 
UKALL III   2706 2707 maintenance  autumn 74 – Dec 75 110 1 16 
UKALL III   2706 2708 duration  summer 75 - Dec 77 249 2 15 16 
UKALL IV   2709 2709 induction  start 75 – start 78  431 1 18 
UKALL IV   2709 2710 maintenance early 75 – Dec 77  336 1 18 
UKALL V   2711 2711 CNS prophylaxis Jan 76 – summer 79 334 1 9 
UKALL V   2711 2712 maintenance  autumn 75 – summer 79  524 4 9 18 15 285 
UKALL V   2711 2713 duration  late 77 – summer 81 305 4 9 18 15 285 
UKALL VI (children)  2714 2714 intensification  summer 77 – spring 80 219 2 17 18 
UKALL VI (children)  2714 2716  CNS prophylaxis 1 Jan 78 – Nov 78 62 0 
UKALL VI (children)  2714 2718 CNS prophylaxis Nov 78 – spring 80 25 0 
UKALL VI (children)  2714 2720 testicular XRT 1 Jan 78 - spring 80  73 1 17 
UKALL VII   2722 2722 induction  1 Mar 79 – Mar 80  82 1 14 
UKALL VII   2722 2723 CNS prophylaxis 1 Mar 79 – Mar 80 82 2 13 14 
UKALL VII   2722 2724 CNS prophylaxis 1 Mar 79 – Mar 80 82 1 14 
UKALL VII   2722 2725 testicular XRT 1 Mar 79 – Mar 80 43 2 14 17 
UKALL VII   2722 2726 maintenance  1 Mar 79 – Mar 80 82 2 13 14
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UKALL VIII   2727 2727 induction  1 Sep 81 – 31Dec 84 630 5 21 22 8 18 19 
UKALL VIII   2727 2728 duration  Feb 83 – early 87  408 6 20 21 22 18 19 8 
UKALL X   2730 2730 intensification  Jan 85 – Sep 90  1171 6 23 10 11 18 24 283 
MRC meningeal   2740 2740 post-relapse  1970s (?)     38 2 28 29 
MRC Concord Trial  2741 2741 intensification  Jan 69 – Aug 70  122 1 277 
 
28 US National Cancer Institute, USA 
NCI-immuno   2801 2801 immunotherapy  1970’s (?)  49 1 167 
NCI 72-1   2802 2802 CNS prophylaxis 1971 - 74   32 2 168 169 
NCI 77-02   2803 2803  combination  Feb 80 – Dec 83  181 3 172 170 171 
NCI-82-C-199   2804 2804 maintenance  Nov 82 – Apr 86  ? 0 
NCI-84-C-153A/CCG-144 2805 2805 CNS prophylaxis Jun 84 – Nov 88  181 1 172 
 
29 Pediatric Oncology Group (POG), USA 
POG 7420 / SWOG 7420/ALinC11 2901 2901 combination  10 Sep 74 – 29 Oct 76 408 2 175 176 
POG 7623 / SWOG 7623/ALinC12 2902 2902 maintenance late 76 – end 80  434 1 177 
POG 7623 / SWOG 7623/ALinC12 2902 2903 combination  late 76 - late 80  430 1 179 
POG 7623 / SWOG 7623/ALinC12 2902 2904 miscellaneous autumn 80 – summer 81 126 1 181 
POG 7837   2905 2905 combination  Apr 79 – Mar 81  59 3 182 183 204 
POG 7866   2906 2907 combination  Mar 79 – Sep 79   ? 0 
POG 7866   2906 2917 combination  Mar 79 – Feb 80   ? 0 
POG 8035 / POG 8036/ALinC13 2908 2908 combination  Jun 81 – Jan 86  1504 5 184 185 186 187 204 
POG 8698   2911 2911 intensification  Feb 86 – 1988  20 0 
POG 8704   2913 2913 maintenance  May 87 – Jan 91  363 2 192 204 
POG 8710 / SIMAL 5  2914 2914 post-relapse Dec 87 -   277 1 188 
POG 8602 / ALinC 14  2918 2918 intensification  Feb 86 – Aug 86   ? 7 192 193 194 189 190 191 204 
POG 8602 / ALinC 14  2918 2919 intensification  Aug 86 – May 87  ? 7 190 191 192 193 204 189 194 
POG 8602 / ALinC 14  2918 2920 intensification  May 87 – Jan 88  ? 7 190 191 192 193 204 189 194 
POG 8602 / ALinC 14  2918 2922 intensification  Feb 86 – Aug 86   ? 7 192 189 191 190 193 194 204 
POG 8602 / ALinC 14  2918 2923 intensification  Aug 86 – May 87  428 8 279 190 191 192 193 189 194 204 
POG 8602 / ALinC 14  2918 2924 intensification  May 87 – Jan 88   ? 7 189 191 192 193 194 190 204 
POG 8602 / ALinC 14  2918 2926 intensification  Feb 86 – Aug 86   ? 7 192 189 191 190 194 193 204 
POG 8602 / ALinC 14  2918 2927 intensification  May 87 – 1991  ? 7 193 189 190 191 192 194 204 
POG 8304   2928 2928 post-relapse  Apr 83 – Nov 89  104 2 195 196 
POG 8303   2929 2929  post-relapse  Apr 83 – Dec 87  258 1 197 
POG 7834   2930 2930  post-relapse  Jan 79 – Apr 83  113 1 205 
POG 7712   2933 2933 post-relapse Jun 78 – Nov 82  87 2 174 198 
POG 7818   2934 2934  post-relapse Aug 79 – Aug 81  67 1 199
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POG 7919   2935 2935 post-relapse  Jul 79 – Feb 82  74 1 200 
POG 8022   2936 2936  post-relapse Mar 81 – Jul 83  43 1 206 
POG 8594   2939 2939 post-relapse  Oct 85 – Dec 87  19 1 201 
POG CNS 1   2952 2952 CNS prophylaxis  1960s (?)  31 1 203 
POG CNS 2   2953 2953 CNS prophylaxis 1960s (?)  31 1 203 
 
30 St Joseph’s Hospital, Phoenix, USA 
NCI-D79-053-088  3001 3001 post-relapse  Mar 79 – Jan 80  ? 0  
 
31 St Jude Children’s Research Hospital, Memphis, USA 
St Jude IV   3101 3101 maintenance  summer 65 – summer 67 42 3 207 209 210 
St Jude VI   3103 3102 CNS prophylaxis Jul 68 – May 70  94 7 209 210 214 215 211 212 213 
St Jude VI   3103 3103 intensification  Jul 68 – May 70  94 4 209 210 215 213 
St Jude VI   3103 3124 CNS prophylaxis Jul 68 – summer 70 49 7 209 210 211 212 213 214 215 
St Jude VII   3104 3104 CNS prophylaxis May 70 – early 72 94 5 209 214 215 216 210  
St Jude VII   3104 3105 maintenance  May 70 – early 72 94 4 209 215 216 210 
St Jude VII   3104 3125 CNS prophylaxis May 70 – early 72 47 5 209 210 214 215 216 
SJCRH VIII   3106 3106 maintenance  Jan 72 – May 73  79 6 209 215 217 218 210 219 
SJCRH VIII   3106 3113 maintenance  May 73 – Nov 75  149 3 215 218 219 
SJCRH X   3107 3107 combination  May 79 – Jan 84   309 13 220 221 222 223 224 225 226 227  
              228 229 230 231 235 
SJCRH XI   3108 3108 maintenance  Feb 84 – Sep 88  108 6 232 233 234 235 236 237 
SJCRH XI   3108 3109 maintenance  Feb 84 – Sep 88  233 6 233 235 236 234 237 232 
SJCRH R VIII   3112 3112 post-relapse  Sep 79 - 1982   ? 0 
SJCRH TOT IX   3114 3114 combination  autumn 75 – May 79 256 2 227 238 
SJCRH TOT IX   3114 3116 combination  late 75 – May 79  27 2 227 238 
St Jude V   3115 3115 duration  end 67 – summer 68 20 3 209 210 239 
St Jude P. carinii   3117 3117 miscellaneous  Oct 74 – Oct 76  136 1 241 
 
32 Southwest Oncology Group (SWOG), USA 
SWOG 690/691 / ALinC 9 3201 3201 induction  Jul 71 – Mar 73  226 1 242 
SWOG 690/691 / ALinC 9 3201 3202 CNS prophylaxis Jul 71 – Mar 73  194 2 243 244 
SWOG 690/691 / ALinC 9 3201 3203 maintenance  Jul 71 – Mar 73  ? 1 242 
SWOG 7220 / ALinC 10  3204 3204 induction  Feb 73 – Aug 73  73 1 245 
SWOG 7220 / ALinC 10  3204 3205 maintenance  Feb 73 – Aug 74  154 1 246 
SWOG ????   3206 3206 induction  Jul 67 – Nov 69  19 1 247 
SWOG 8612   3214 3214 post-relapse  Dec 86 - ?  ? 0 
SWOG 663/664 / ALinC 6 3215 3215 induction  1965 – 67  68 1 250
266 
SWOG 663/664 / ALinC 6 3215 3216 maintenance  Oct 65 – Jun 67  68 1 250 
SWOG 7420   3217 3217 CNS prophylaxis 1 Oct 74 – 1978  ? 2 251 252 
SWOG 7623 / ALinC 12  3218 3218 CNS prophylaxis 1976 – 1 Jun 78  357 2 251 252 
 
33 Wroclaw, Poland 
Poland    3301 3301 immunotherapy  1970s    37 1 253 
 
34 Jena University, Germany 
ALL VII 81   3401 3401 CNS prophylaxis spring 83 – spring 86 244 2 254 255 
ALL VII 81   3401 3403 CNS prophylaxis spring 86 – early 88 98 1 255 
ALL VII 81   3401 3405 unknown  Jul 83 – Dec 83  30 0 
ALL VII 81   3402 3402 maintenance  1 Sep 81 – 31 Dec 87 381 3 254 255 256 
 
35 PETHEMA, Spain 
LAL 7/78   3501 3501 CNS prophylaxis Apr 78 – Dec 83  65 5 259 257 258 286 287 
LAL 7/78   3501 3502 CNS prophylaxis Apr 78 – Dec 83  22 5 258 259 257 286 287 
LAL 17/84   3503 3503 CNS prophylaxis Oct 83 – early 90  124 3 260 286 287 
LAL 17/84   3503 3504 CNS prophylaxis spring 84 – early 89 130 3 260 286 287 
 
36 Institut de Cancerologie et d’Immunogenetique (INSERM), France 
ICIG-ALL 9   3601 3601 immunotherapy  1970 -    22 2 261 262 
ICIG-ALL 10   3602 3602 immunotherapy  1970 -    14 2 261 262 
ICIG pilot   3603 3603 immunotherapy  1962 -    30 3 263 264 265 
 
84 Memorial and Sloan Kettering Cancer Centre (MSKCC), USA 
MSK-NY-II   8401 8401 induction  Nov 86 – Feb 91  44 1 266 
 
125 Vienna, St Anna Kinderspital, Austria 
Austrian-BFM-86  12501 12501 maintenance  autumn 86 – spring 89 10 0 
 
127 Tokyo Children’s Cancer Study Group, Japan 
TCSLG L84-11   12701 12701 CNS prophylaxis spring 84 – Feb 89 190 2 267 268 
TCSLG L84-11   12701 12702 CNS prophylaxis Jun 84 – Feb 89  263 1 267 
TCLSG L81-10   12703 12703 CNS prophylaxis early 80 – spring 84 68 1 267 
TCLSG L81-10   12703 12704 combination  1981 – 84   1 267  
 
305 Australasian Childhood Leukaemia Study Group 
ANZCCSG ALL V  30501 30501 maintenance  1986 - 92  600 1 169 
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338 Brazilian Cooperative ALL Group, Brazil 
GBTLI-80   33802 33802 CNS prophylaxis Jul 80 – Jul 82  203 1 270 
GBTLI-82   33803 33803 maintenance  Aug 82 – Jul 85  360 1 270 
 
341 Israel National Study, Israel 
INS 84    34101 34101 CNS prophylaxis autumn 84 – summer 89 75 2 272 273 
INS 84    34101 34102 induction  late 84 – spring 87 13 0 
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APPENDIX II: TRIAL PROTOCOLS USED AS A DATA SOURCE 
 
In addition to the Cancer Overviews Group’s trial listings, which are available for all 
randomizations, and the articles referenced, additional data were obtained for some randomizations 
using the electronic trial protocol database, Clinprot, and/or the hard copy of the protocol in full. 
 
Trials for which this additional information was available are listed below: 
 
Key 
C=clinprot  
P=trial protocol in full 
E=EORTC Handbook 
 
Trial name Trial ID Randomization IDs Additional  
data source 
Bombay TAT TMC 1 1301 1301 C 
CLB 7611  1416 1416 C 
CLB 7611R  1417 1417 C 
CLB 7811, relapse 1418 1418 C 
CCG-105 1603 1603 1604 C 
CCG-106 - 3 arm 1605 1605 1606 C 
CCG-121 1607 1607 C 
CCG-123 - first stratum 3-way 1608 1608 1609 1610 1635 1636 C 
CCG-139  1611 1611 C 
CCG-161 1618 1618 C 
CCG-162 1622 1622 1624 C 
CCG-162A 1623 1623 C 
CCG-163d  1625 1625 1626 C 
CCG-171  1627 1627 C 
CCG-098  1639 1639 C 
DFCI 81001pre-induction 1704 1704 C 
DFCI 85001 1705 1705 C 
DFCI 87001 pre-induction  1706 1706 1707 1708  C 
DCLSG-ALL-V/EORTC 99801 1801 1801 E 
EORTC 58741  1901 1901 1902 C P 
EORTC 58791  1903 1903 1904 C 
EORTC 58831  1905 1905 C E 
EORTC 58832  1906 1906 C E 
FRALLE 87 2004 2004 P 
GATLA 72 (1 ALL 72) 2101 2101 2102 P 
GATLA 1 LLA  79 2104 2104 C P 
GATLA 7 LLA-87 2105 2105 P 
Japan KLSG 1  2301 2301 C 
COALL 80 2401 2401 2402 C 
INEN-7902  2502 2502 C 
UKALL I 2701 2701 2702 P 
UKALL II 2703 2703 2704 2705 P 
UKALL III  2706 2706 P 
UKALL IV 2709 2709 2710 P 
UKALL V 2711 2712 P 
UKALL VI (children)  2714 2714 2716 2718 2720 P 
UKALL VII 2722 2722 2723 2724 2725 2726  P 
UKALL VIII 2727 2727 P 
UKALL X 2730 2730  P 
MRC meningeal  2740 2740 P 
NCI-77-02  2803 2803 C 
NCI-82-C-199  2804 2804 C 
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NCI-84-C-153A/CCG-144 2805 2805 C 
POG 7837  2905 2905 C 
POG 7866 2906 2907 2917 C 
POG 8035 / POG 8036 / ALinC 13 2908 2908 C 
POG 8698  2911 2911 C 
POG 8704  2913 2913 C 
POG 8710 / SIMAL 5  2914 2914 C 
POG 8602 / AlinC 14  2918 2918 2919 2920 2922 2923 
2924 2926 2927 
C 
POG 8304  2928 2928 C 
POG 8303  2929 2929 C 
POG 7834  2930 2930 C 
POG 7712  2933 2933 C 
POG 7818  2934 2934 C 
POG 7919  2935 2935 C 
POG 8022  2936 2936 C 
POG 8594  2939 2939 C 
NCI-D79-053-088 3001 3001 C 
SJCRH X  3107 3107 C 
SJCRH XI  3108 3108 3109 C 
SJCRH R VIII  3112 3112 C 
SWOG 8612  3214 3214 C 
Austrian-BFM-86 12501 12501 P 
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APPENDIX III: ALGORITHM FOR THE MAIN DATA MANAGEMENT PROGRAM (JMAIN.SAS) 
 
Note: For many of categorical variables the codes used were added as needed without much pre-planning. In 
order for this information to be useful, new variables must be introduced to combine categories broadly and 
more meaningfully. The majority of the new variables created in this program are for this purpose. 
 
Read in data 
• Read in data from text file JANALYSIS.TXT 
 
Set up option to select dataset from all records/all results/first mentions/first results 
• Set up option for use in dealing with first mentions or first reportings of results, where records which tie 
(see Section 5.3.1) are replaced by special records containing data from both/all tying records. This is to 
be ‘switched off’ when dealing with all records or all records which contain results. 
 
Operations on the ‘initial dataset’, applicable to both definitive and publication records 
• Exclude the following: i) Records resulting from review articles, duplications, randomizations that failed 
to open or recruit any patients and those that were not properly randomized (e.g. if the treatment 
allocation was by date of birth) or not randomized at all. These are identifiable using the notes codes. 
ii)Randomizations which are known to be open to adults only 
• Create numerical date variables, for use in the calculations, for date fields in both definitive records and 
publication records, i.e. start and close dates of the accrual period and the official (planned) start and 
close dates of the trial. 
• Create a year only variable for start and close dates of the accrual period, for use with graphs. 
• Convert numerical unknowns into missing values. e.g. where ‘number of randomization arms’ = 99. 
• Create new variables to distinguish between the following: 
o Randomization process takes place at the correct time versus not. 
o Methods of randomization: central computer versus notification to central office versus sealed 
envelope method 
o Randomization designs used: simple versus block versus minimisation of imbalance. 
o A form of balancing has been used versus not. 
• For dichotomous variables set blanks to zero. This applies to equivalence trial, planned method of 
follow-up indicated, actual method of follow-up indicated, subgroup results reported, reported at a 
meeting, other eligibility criteria stated, baseline characteristics given. 
• Create new variable (transformation): log 10 (number of patients) 
• Create new variable (calculation): Duration of accrual period = close date – start date 
• Create new variable for whether a randomization is for children only, adults only or both adults and 
children, using the lowest and highest age eligible. If highest age <25 then randomization is for children 
only, if lowest age >13 then randomization is for adults only. Randomizations in the latter group should 
have been excluded already, but this serves as an additional check. If neither the highest nor lowest age 
is given, then the age eligibility is unknown. Otherwise assume the randomization is open to both adults 
and children. 
• Create new variable to combine categories in order to get the following: 
o Broad eligibility risk groups: any, low, low-standard, standard, standard-high and high. 
o Broad categories for type of trial: induction, central nervous system prophylaxis, intensification, 
maintenance, combination of more than one of these, duration of treatment, testicular radiotherapy, 
bone marrow transplant, immunotherapy, post-relapse treatment, miscellaneous (e.g. antibiotic, 
cardio-protective, unclear). 
o Combine the latter in two ways: 
 Whether the randomization includes a transplant arm, a radiotherapy arm, an immunotherapy 
arm, only chemotherapy treatments, antibiotic treatments, other or unknown. 
 First line therapy versus relapse/refractory versus other/unknown. 
• Use the first three digits of the trial/randomization ID to split the country group of trialists into  
o Europe, North America and Other 
o ‘Developing’ or ‘developed’ country 
• Create new variable to calculate whether the target number of patients has been reached using ‘number 
of patients accrued’ and ‘planned size’ 
• Create new variable to split into single-centre, multi-centre (limited), i.e. at least 2 but less than 5, and 
multi-centre participation, i.e. 5 or more. 
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• Similarly, for what the participation was planned to be (but not necessarily achieved): create new 
variable to split into single-centre, multi-centre (limited), and multi-centre. 
• Create new variable, using the above two new variables with categories single-centre, limited and multi-
centre, to decide whether the target number of centres was reached 
• Create new variable to specify whether participation was single-country, limited (a few adjacent 
countries took part) or international. 
• Set cut-off for date of start of randomization as 1/1/88 
 
Identify all randomizations which started after cut-off date, for exclusion.  
Start date is known for all definitive records. Using the randomization ID these can then be excluded from 
the set of publication records, where the start date is not always known. 
• Create  new temporary dataset for definitive records  
• Take the initial dataset 
• Delete all records with a non-zero publication ID number (these are the publication records) 
• Select records where start date is after 1/1/88 and sort by randomization ID. 
• Count the number of publication records for each randomization. This count to be attached to the 
definitive record later 
 
Create permanent dataset for definitive records  
• Take the initial dataset 
• Delete all records with a non-zero publication ID number (the publication records) 
• Delete records for randomizations which began after 1/1/88.  
• Sort records by randomization ID 
• Merge with the count of publication records and with the small permanent dataset 
LEUKJR.QUESTION, created using the program QUESTIONS.SAS. This contains the definitive main 
questions and whether ever answered in any paper. 
• If the number of publications is missing, set to zero. 
• Remove dates that are too inaccurate to be useful i.e. those with qualifier 3 (decade alone is known) and 
4 (even decade is estimated). Do this for planned start and close dates of trial, actual start and close dates 
of randomization accrual period. Remember to do this for all date forms i.e. character dates, those in 
numerical form and year only dates where applicable. Also duration of randomization period must be set 
to ‘missing’ if either start or close date of accrual period has qualifier 3 or 4. Also remove synthetic dates 
(qualifier 5) for date of randomization of first, middle and last patient, since these are only used to 
calculate intervals and were found be very inaccurate, when compared to the start and close date of 
accrual period. 
• Create new variables only applicable to the definitive records: 
o Time from accrual of first patient to accrual of middle patient (1) 
o Time from accrual of middle patient to accrual of last patient (2) 
o Indication of wane of interest in randomization = (2) – (1) 
• Where number of questions is unknown, calculate using number of randomization arms. For a 
randomization with n arms, number of questions = 1 + 2 + … + (n-1) = n(n-1)/2 
• Sort records by randomization ID 
 
Create permanent dataset for publication records 
• Take the initial dataset 
• Delete all records with publication ID number = 0 (the definitive records) 
• Remove inaccurate dates, as described previously. Do this for planned open and close date of trial, actual 
start and close dates of randomization accrual period, duration of randomization, if one or both of the 
start and close dates are inaccurate, cut-off date for analysis, dates of receipt, acceptance and publication 
of article. Again, remember to do this for character, numeric and year only date forms where applicable. 
• Create new variables which are only applicable to the publication records: 
o Numerical dates of receipt, acceptance and publication of article. 
o Combine categories to obtain the following new variables: 
 Publication type i.e. journal article, book chapter or meeting abstract 
 Whether published in full in the English language or as an abstract in English with the full 
paper in another language 
• Using the journal code (in conjunction with the publication type in the case of meeting abstracts) attach 
the following information: 
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o Full name of journal 
o Impact factor (taken from Journal Citation Reports – 1995 Science Edition) 
• Create further new variables which are only applicable to the publication records: 
o Specify whether a journal/book/abstract has no impact factor associated with it, and if so, set the 
impact factor to zero. 
o Merge in  number of co-authors for each article. 
o Transformation of above, log 10 (number of co-authors) 
o Alternative number of co-authors, same as number of co-authors, but setting n=30 (approximate size 
of working party) for articles by the MRC Working Party 
o Transformation of above, log 10 (alternative number of co-authors)  
o Using the journal code, specify whether the country group of publication is Europe, North America, 
Other or Unknown. 
o Country group of trialists is same as that of publisher versus not 
o New time variables to do with articles only: 
 Time from receipt of article to acceptance for publication 
 Time from acceptance to publication 
 Time from submission/receipt to publication  
o Broad main question and answer categories, in order of importance: 1=survival (or disease-related 
deaths), 2=Event-free survival (EFS) (including disease-free survival (DFS)), 3=treatment-related 
deaths, 4=achieving remission, 5=any relapse (Note: 3, 4 and 5 are ranked equal), 6=specific site 
relapses, 7=toxicity, 8=other. Classify main questions and main results in this way.  
o Statistical technique categories for coding the two main results in order of merit: Cox regression (an 
advanced form of longitudinal), longitudinal (survival analysis), cross-sectional, other 
o New variable, overall statistical technique, taking the ‘better’ of the two main techniques stated, 
using the hierarchy above. 
o Whether the main questions stated in a paper have been answered in that paper. For each of the two 
main questions: if main question category is blank, then whether answered must also be blank. 
Otherwise whether answered must be classified as yes/partly/no/unclear 
o New variable whether overall the two main questions in the paper have been answered in it. If both 
have been answered, or if there was only one main question and it was answered then overall 
answered =yes. If answered is blank for both, then overall answered=not reported. Otherwise overall 
answered=no. 
o New variable for statistical significance of the best of the two main results: The possible categories 
for the two results are, ranked in order: 3 star (p<0.001), 2 star (p<0.01) 1 star (p<0.05 or 
significance level not stated but known to be statistically significant), ½ star (no p-value stated but 
possibly statistically significant), 0 star (p>0.05 or said to be not statistically significant). The 
overall statistical significance for the record is defined as the more significant of the two.  
If the star category is blank (statistical significance is not reported), set to 0 star. 
o New variable, a transformation of the above: Take a typical p-value for each of the above categories 
and take minus the logarithm of it.  
category    typical value - log e (typical value)       spacing ( i.e. distance of value from that 
                                                                                                         for not stated/non-sig. category)  
3 star  0.001  -6.9   5 
2 star  0.01  -4.6   2.7 
1 star  0.05  -3.0   1.1 
½ star  0.075  -2.6   0.7 
0 star  0.15  -1.9   0 
o New variable to indicate where statistical significance is not reported. 
o New variable for overall clinical significance for the two main results: 
If either is clinically significant then overall clinical significance = yes 
Otherwise, if either is possibly clinically significant then overall clinical significance = 
possibly 
Otherwise if either is not clinically significant or if it is too early to tell, then overall 
clinical significance=no. 
If clinical significance is blank for both results, then clinical significance= not reported. 
o New variable to specify overall direction of results: 
If both are positive then overall direction=positive 
If both are negative the overall direction=negative 
If both are null then overall direction=null 
If one is positive and the other is null or unknown then overall direction=positive 
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If one is negative and the other is null or unknown then overall direction=negative 
If one is null and the other is unknown then overall direction=null 
If one is positive and the other is negative then the overall direction=opposite 
If both are blank then overall direction=not reported 
o New variable to specify whether record contains result(s): 
If result (e.g. survival), type of result (e.g. median), statistical technique used, statistical 
significance, clinical significance and direction are all blank for both results, then record 
does not report results. Otherwise it does. 
• For each publication ID, specify: 
o Number of trials reported 
o Number of randomizations reported 
Note: For the special records which replace tied records the publication ID will be missing. Specify 
for each special record number the number of trials and randomizations. 
o Create new transformed variable log 10 (number of trials reported) 
• Sort records by randomization ID and output to form permanent dataset. 
 
To create a permanent ‘merged dataset’ 
The publication records data and the definitive records data are merged so that the most accurate information, 
stored as the definitive record, is used for fields that will not change over time (e.g. start and close dates of 
randomization period, number of patients accrued) and the publication record is used for data specific to a 
particular article (e.g. results, details of the journal). 
• Take the permanent definitive records dataset 
• Where a variable is present in both the publication records dataset and in the definitive records dataset, 
rename it in the definitive records dataset. 
• Remove the definitive records for those randomizations which have no publication records (i.e. which 
remain unpublished) 
• Take the permanent publication records dataset 
• Drop the definitive record version of the following variables: record number, trial ID, publication ID, 
centre number (i.e. group of trialists), country group, ‘developing’/’developed’, cut-off date of 1/1/88. 
These are necessarily identical in the definitive and publication records.  
• Replace in the publication records dataset all variables for which there is a definitive records version 
with the latter 
• Create calculated time variables which use data from both the definitive record (close date of accrual 
period) and publication records (dates relating to the article) in the calculation: 
o Time from close of randomization to submission/receipt of article 
o Time from close  of randomization to publication of article 
o Where not given, calculate an estimate of the median length of follow-up, using cut off date for 
analysis –  ½ (start date + close date) 
This can only be used if the type of result median, mean or average. 
o Similarly, calculate time from cut-off date for analysis to submission of article using  
Date article received – cut off date for analysis 
=Date article received – [½ (start date + close date) + number of days on follow-up] 
 
For each randomization, to attach an ‘order of publication’ number to each of the publication records 
Form a new permanent dataset: 
• Take the merged dataset 
• Sort by randomization ID, and within that by date of publication 
• Count the number of records for each randomization and attach this as a variable to the merged dataset, 
merging by randomization ID 
• Store as a new permanent dataset 
• If a record is the first for a randomization, set the order number to 0 
• Add 1 to the order number 
 
For each randomization, to attach an ‘order of publication’ number to each of the publication records 
that contains results 
Form a new permanent dataset: 
Take the merged dataset, selecting only those records that contain results. Repeat steps in Italics.  
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APPENDIX IV: COMPLETE VARIABLE LIST 
(a) SHORT FORM IN ALPHABETICAL ORDER (b) IN LOGICAL ORDER 
 
Note: X* denotes two variables X1 and X2 relating to the 2 main questions or 2 main results collected 
 
(a) In alphabetical order 
 
AC   age eligibility 
ALLORDER order of mention for a randomization  
ANSEVER definitive main questions ever answered? 
ANSWER main questions in paper answered in paper? 
ARMS   number of arms 
AUTHMRC number of authors where given, or set to approximate size of Working Party where 
authorship of MRC trials is attributed to Working Party  
AUTHORS number of authors 
BALANCED  balancing used in randomization? 
CANS*  definitive main questions from clinprot/protocol  
CENTRE centre i.e. trialists’ ID assigned by COG 
CGROUP  country group of trialists 
CLNSG  clinical significance of best of 2 main results 
CQUEST* main definitive questions from clinprot/protocol  
CTARGET  target number of centres reached? 
DEVLPNG trial conducted in a ‘developing’ country 
DURRAN  duration of randomization period (days) 
ENGLISH published in English language? 
EQUIV   equivalence trial? 
FIRSTL  first-line or relapse/refractory therapy? 
FUNDG  funding source 
FUPDAYS length of follow-up period from close of randomization (days) 
IMPACT  impact factor of journal 
INTERNL  degree of international participation 
JGROUP country group of publisher 
LOGAUTH log 10 (AUTHORS) 
LOGMRC log 10 (AUTHMRC) 
LOGNTREP log 10 (NTREP) 
LOGPEST measure of statistical significance of best of 2 main results [distance of log e (typical p-
value for category) from that for non-significant/not reported category] 
LOGPNR p-values not reported? 
LOGSIZE  log 10 (NOPAT) 
MENTND randomization ever/never mentioned in an article?  
MULTIC degree of multi-centre participation  
NACCP  date accepted for publication 
NCLOSE close date of accrual period 
NDPUB  date published 
NOIMPACT  no impact factor associated with article? 
NOPAT  number of patients randomized 
NOQ  number of questions 
NMENT frequency of mentions of a randomization 
NRAND number of randomizations 
NRECDP date submitted/received for publication 
NRES  frequency of reporting of results of a randomization 
NRREP  number of randomizations mentioned in article 
NTREP  number of trials mentioned in article 
NSTART start date of accrual period 
PANS *  definitive main question from or articles 
POSNG  direction of 2 main results 
PQUEST* definitive main questions from papers 
PRESENTD  presented at meeting? 
PUBID  publication ID 
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PUBTYPE publication type: journal article/book chapter/meeting abstract 
QCAT*   main questions in paper 
RANDMETH method of randomization used 
RANDTIME timing of late randomization  
RANID   randomization ID assigned by COG 
RCAT*   main results in paper 
RCOUNT number of publications for each randomization 
RDESIGN randomization design used 
RESORDER order of reporting of results for a randomization 
RESPUB results of randomization ever/never reported in an article 
RESULTS record contains results? 
RISK  risk group eligibility 
SGROUP country group of publisher same as that of trialists? 
SUBGRP subgroup results reported? 
TARGET target number of patients reached? 
TCLPUB time from close of randomization to publication (days) 
TCLREC time from close of randomization to submission for publication (days) 
TECH  type of statistical technique used 
TRCAT  trial category 
TRECPUB time from receipt by publisher to publication (days) 
TRID  trial ID assigned by COG 
TXCHEMO type of treatment 
WANE   accrual time of 2nd half of patients minus accrual time of 1st half of patients (days) 
 
 
(b) In logical order 
 
Continuous variables which do not change over time 
 
NRAND number of randomizations 
Missing for 0/149 (0%) trials 
 
ARMS  number of arms  
Missing for 0/243 (0%) randomizations 
 
NOQ  number of questions (in definitive record only)  
Missing for 0/243 (0%) randomizations 
 
NOPAT  number of patients randomized 
   Missing for 31/243 (13%) randomizations 
   
LOGSIZE log 10 (NOPAT) 
   Missing for 31/243 (13%) randomizations 
 
NSTART start date of accrual period  
(START (date format) and STARTYR (discrete years) are different forms of the 
 same variable) 
  Missing for 12/243 (5%) randomizations 
 
NCLOSE close date of accrual period  
(CLOSE (date format) and CLOSEYR (discrete years) are different forms of the 
 same variable) 
  Missing for 24/243 (10%) randomizations 
 
DURRAN duration of randomization period (days) 
   Missing for 24/243 (10%) randomizations 
 
WANE  accrual time of 2nd half of patients minus accrual time of 1st half of patients 
   Missing for 138/243 (57%) randomizations 
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Dichotomous variables which do not change over time and their categories 
 
DEVLPNG trial conducted in a ‘developing’ country? 
   1=yes 
   0=no 
    Missing for 0/149 (0%) trials 
 
EQUIV  equivalence trial?  
1=yes 
0=no or not known 
Missing for 0/243 (0%) randomizations 
 
 
Categorical variables which do not change over time and their categories 
 
FUNDG  funding source 
1=Government 
2=drug company 
3=charity 
4=Government + charity 
5=Government + drug company + charity 
Missing for 65/149 (44%) trials 
 
TRCAT  trial category 
1=induction 
2=CNS prophylaxis 
3=intensification 
4=maintenance 
5=combination (induction/intensification/maintenance) 
6=duration of treatment 
7=testicular radiotherapy 
8=bone marrow transplant 
9=immunotherapy 
10=treatment after relapse 
11=miscellaneous e.g. antibiotic, cardio protection 
Missing for 4/243 (2% randomizations) 
 
TXCHEMO type of treatment 
C=chemotherapy only 
T=transplant 
R=radiotherapy 
I=immunotherapy 
A=antibiotic 
O=other 
Missing for 7/243 (3% randomizations) 
 
FIRSTL  first-line or relapse/refractory therapy? 
1=first-line treatment 
2=relapse/refractory 
Missing for 13/243 (5%) randomizations 
 
CQUEST1, CQUEST2, PQUEST1, PQUEST2  
definitive main questions from clinprot/protocol and papers respectively  
These only apply to the definitive record 
 
Definitions:  
Event Free Survival (EFS) = time from diagnosis until induction death/failure, CR death or 1st  
       relapse 
Disease-free survival (DFS) =  time from achieving complete remission to relapse/death 
These are ranked in order with the exception that 3,4 &5 are of equal rank: 
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1=survival 
2=EFS (including DFS) 
3=treatment-related deaths 
4=achieving CR 
5=any relapse 
6=specific relapse sites 
7=toxicity 
8=other  
Missing for 164/243 (67%), 173/243 (71%), 55/243 (23%) and 94/243 (39%) 
randomizations respectively 
 
AC  age eligibility 
B=both adults and children 
C=children  
Missing for 6/243 (2%) randomizations 
 
RISK   risk group eligibility 
0=any 
1=low 
2=low-standard 
3=standard 
4=standard-high 
5=high 
Missing for 100/243 (41%) randomizations 
 
TARGET  target number of patients reached? 
Y=yes 
N=no 
Missing for 206/243 (85%) randomizations 
 
MULTIC degree of multi-centre participation 
Y=yes i.e. >5 
L=limited i.e. 2-5 
N=no i.e. 1 
Missing for 3/243 (1%) randomizations 
 
CTARGET  target number of centres reached? 
Y=yes 
N=no 
Missing for 66/243 (27%) randomizations 
 
INTERNL  degree of international participation 
N=no 
L=limited 
Y=yes 
Missing for 30/243 (12%) randomizations 
 
CGROUP country group of trialists 
E=Europe 
A=North America 
O=other 
Missing for 0/149 (0%) trials 
 
RANDTIME timing of late randomization  
Y=late randomization done at correct time 
N=late randomization done too early 
Missing for 176/243 (72%) randomizations, although only applicable to a small 
proportion of randomizations 
280 
RANDMETH method of randomization used 
C=central computer 
N=notification to central office 
E=sealed envelopes 
Missing for 196/243 (81%) randomizations 
 
RDESIGN  randomization design used 
S=simple randomization 
B=block randomization 
M=minimisation of imbalance 
Missing for 230/243 (95%) randomizations 
 
BALANCED  balancing used in randomization? 
Y=some attempt made to balance 
N=not balanced 
  Missing for 149/243 (61%) randomizations 
 
CANS1, CANS2, PANS1 and PANS2 
definitive main question from clinprot/protocol or papers respectively ever answered (in 
any paper)? 
Note: Only applicable to the definitive record 
   Y=yes 
   N=no 
Missing for 164/243 (67%), 173/243 (71%), 55/243 (23%) and 95/243 (39%) 
randomizations respectively 
 
  
Continuous variable only usable in definitive records dataset but can change 
 
RCOUNT  number of publications for each randomization 
   Missing for 0/243 (0%) randomizations 
 
 
Continuous variables specific to a publication 
 
These are only present in publication records, not the definitive record. 
 
FUPDAYS  length of follow-up period from close of randomization (days) 
   Missing for 228/394 (58%) publication records containing results 
 
LOGPEST  measure of statistical significance of best of 2 main results (distance of log e (typical p- 
  value for category) from that for non-significant/not reported category) 
Note: This is an ordered categorical variable, but it will be used as if continuous 
0 =if not statistically significant or not reported 
0.7=if possibly statistically significant 
1.1=if statistically significant p<0.05 
2.7=if statistically significant p<0.01 
5=if statistically significant p<0.001 
  Missing for 0/610 (0%) publication records 
 
IMPACT  impact factor of journal - 1995 version 
0=n/a or n/k  
  Missing for 0/257 (0%) articles 
 
NRECD   date submitted/received for publication 
  Note: RECDP is the same variable in date format. 
  Missing for 175/257 (68%) articles 
 
 
NACCP   date accepted for publication 
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Note: ACCP is the same variable in date format. 
  Missing for 168/257 (65%) articles 
 
NDPUB   date published 
Note:  DPUB is the same variable in date format and YPUB (discrete years) the format to  
produce graphs. 
  Missing for 0/257 (0%) articles 
 
NTREP   number of trials mentioned in article 
   Missing for 0/257 (0%) articles 
 
LOGNTREP  log10 (NTREP) 
   Missing for 0/257 (0%) articles 
 
NRREP   number of randomizations mentioned in article 
   Missing for 0/257 (0%) articles 
 
ALLORDER  order of mention for a randomization 
   Missing for 0/610 (0%) records 
 
RESORDER  order of reporting of results for a randomization 
   Missing for 0/394 (0%) records containing results 
 
AUTHORS  number of authors 
   Missing for 0/257 (0%) articles 
 
AUTHMRC  number of authors where given, and set to 30 (approximate size of a working 
party) where authorship is stated as Working Party 
   Missing for 0/257 (0%) articles 
 
LOGAUTH  log10 (AUTHORS) 
   Missing for 0/257 (0%) articles 
 
LOGMRC  log10 (AUTHMRC) 
   Missing for 0/257 (0%) articles 
 
 
Dichotomous variables specific to a publication 
 
RESULTS  record contains results? 
Y=yes 
N=no 
  Missing for 0/610 (0%) records 
 
LOGPNR p-values not reported 
   1=p-values not reported 
   0=p-values are reported 
   Missing for 0/610 (0%) records 
 
SUBGRP  subgroup results reported? 
1=subgroup results reported 
0=not reported or not noted 
  Missing for 0/610 (0%) records 
 
PRESENTD  presented at meeting? 
1=yes 
0=not known 
  Missing for 0/257 (0%) articles 
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NOIMPACT  no impact factor associated with journal/book/abstract 
   1=no impact factor associated 
   0=is an associated impact factor 
   Missing for 0/257 (0%) articles 
 
 
Categorical variables specific to a publication 
 
QCAT1, QCAT2 main questions 1 and 2 in paper 
  Coding as *QUEST* 
   Missing for 361/610 (59%) and 491/610 (80%) publication records respectively 
 
RCAT1, RCAT2 main results 1 and 2 in paper 
Coding as *QUEST* 
Missing for 36/394 (9%) and 146/394 (37%) publication records containing 
results respectively 
 
TECH   type of statistical technique used) 
L=longitudinal (survival analysis method) 
X=Cox-regression (an advanced form of L) 
C=cross-sectional method 
O=other 
  Missing for 193/394 (49%) publication records containing results 
 
POSNG  direction of two main results  
1=positive 
-1=negative 
0=null 
2=opposite   
3=not reported 
  Missing for 0/610 (0%) publication records 
 
CLNSG  clinical significance of best of 2 main results 
Y=clinically significant 
P=possible clinically significant 
N=not clinically significant 
X=not reported 
  Missing for 0/610 (0%) publication records 
 
ANSWER  both main questions in paper answered in same paper? 
   Y=main question(s) answered 
   N=main questions(s) not answered 
   X=not reported 
   Missing for 0/610 (0%) publication records 
 
PUBTYPE type of article 
1=journal 
2=book 
3=meeting paper 
  Missing for 0/257 (0%) articles 
 
ENGLISH  published in English language? 
E=full English 
A=abstract English full other 
  Missing for 0/257 (0%) articles 
 
 
 
JGROUP  country group of journal publisher 
E=Europe 
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A=North America 
O=other 
  Missing for 17/257 (7%) journals 
 
SGROUP  country group of publisher same as that of trialists? 
Y=yes 
N=no 
  Missing for 17/257 (7%) journals 
 
 
Continuous time periods used as response variables 
 
TCLREC  time from close of randomization to receipt of article by publisher (days) 
   Missing for 401/610 (66%) publication records 
 
TRECPUB  time from receipt by journal to publication (days) 
   Missing for 392/610 (64% publication records 
   
TCLPUB  time from close of randomization to publication (days) 
   Missing for 28/610 (5%) publication records 
 
 
Other continuous response variables 
 
NMENT frequency of mentions 
   Missing for 0/243 (0%) randomizations 
 
NRES   frequency of reporting of results 
                              Missing for 0/243 (0%) randomizations 
 
 
Dichotomous response variables 
 
MENTND whether randomization ever mentioned in an article 
   Missing for 0/243 (0%) randomizations 
 
RESPUB  whether results of randomization ever published in an article 
   Missing for 0/243 (0%) randomizations 
 
 
Categorical grouping variables  
 
RANID  randomization ID assigned by COG 
   Missing for 0/243 (0%) randomizations 
 
TRID   trial ID assigned by COG 
   Missing for 0/149 (0%) trials 
 
CENTRE  centre i.e. trialists ID assigned by COG 
   Missing for 0/149 (0%) trials 
 
PUBID   publication ID applicable to publication records only 
   Missing for 0/257 (0%) articles 
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APPENDIX V: CONTINUOUS EXPLANATORY AND RESPONSE VARIABLES: 
                                   MEAN, STANDARD DEVIATION, RANGE 
 
Variable n/N Mean Standard 
deviation 
Minimum Maximum 
Explanatory      
ARMS 243/243 2.321 0.736 2 8 
AUTHORS 257/257 7.584 5.301 1 42 
AUTHMRC 257/257 8.241 6.310 1 42 
DURRAN 219/243 1010.580 577.076 0 2922 
FUPDAYS 166/394 1762.292 1027.763 6 5478 
IMPACT 257/257 3.991 5.574 0 22.412 
LOGAUTH 257/257 0.780 0.313 0 1.623 
LOGMRC 257/257 0.805 0.326 0 1.623 
LOGNTREP 257/257 0.106 0.205 0 0.778 
LOGPEST 610/610 0.516 1.208 0 5 
LOGSIZE 212/243 2.108 0.446 1.000 3.206 
NCLOSE 219/243 7862.667 2377.951 2709 11869 
NOPAT 212/243 209.057 236.698 10 1606 
NOQ 243/243 1.782 2.356 1 28 
NRAND 149/149 1.644 1.103 1 10 
NRREP 257/257 2.374 2.031 1 11 
NSTART 231/243 6752.113 2249.953 911 10210 
NTREP 257/257 1.475 1.031 1 6 
WANE 105/243 28.390 141.293 -360 375 
      
Response      
NMENT 243/243 2.510 2.179 0 13 
NRES 243/243 1.621 1.531 0 8 
TCLPUB 582/610 1792.938 1516.016 -1679 10150 
TCLREC 209/610 1923.407 1640.573 -1113 9503 
TRECPUB 218/610 300.417 164.380 18 859 
 
 
N = total number of trials, randomizations, articles or publication records, (whichever is  
       appropriate for the variable in question) 
 
n  = number of observations present for variable and used in the calculation of the mean and  
       standard deviation 
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APPENDIX VI: JOURNALS: NUMBER OF ARTICLES USED AND IMPACT FACTOR 
 
 --------------------------- Publication type=Journal --------------------------- 
  
                                                            Number 
                                                              of       Impact 
     Publication                                           articles    factor 
  
     Acta Paediatrica Japonica                                 1        0.000 
     Acta Therapeutica                                         1        0.071 
     American Journal of Clinical Oncology                     1        0.754 
     American Journal of Diseases of Children                  2        1.433 
     American Journal of Medicine                              1        3.749 
     American Journal of Pediatric Hematology/Oncology         5        1.271 
     Anales Espanoles de Pediatria                             2        0.000 
     Annals of Oncology                                        1        2.256 
     Archivum Immunologiae et Therapiae Experimentalis         1        0.000 
     Archives of Disease in Childhood                          4        1.582 
     Archives of Internal Medicine                             1        4.166 
     Archives of Neurology                                     1        4.260 
     Biomedicine                                               1        0.000 
     Blood                                                    13        8.569 
     British Journal of Cancer                                 1        3.449 
     British Journal of Haematology                            3        2.616 
     British Medical Journal                                   9        4.549 
     Cancer                                                   30        2.864 
     Cancer Chemotherapy Reports                               1        0.000 
     Cancer Clinical Trials                                    1        0.000 
     Cancer Drug Delivery                                      1        0.000 
     Cancer Research                                           4        8.206 
     Cancer Treatment Reviews                                  1        3.106 
     European Journal of Pediatrics                            2        1.073 
     Haematology and Blood Transfusion                        19        0.000 
     International Journal of Pediatric Hematology/Oncology    2        0.000 
     International Journal of Radiation Oncology Biology  
       Physics                 3        2.484 
     International Journal of Hematology                       3        0.636 
     Investigational New Drugs                                 1        0.495 
     Japanese Journal of Clinical Haematology                  1        0.000 
     Journal of Cancer Research and Clinical Oncology          1        1.459 
     Journal of Clinical Oncology                             24        6.922 
     Journal of Clinical Pathology                             1        0.000 
     Journal of Pediatric Psychology                           1        0.000 
     Klinische Padiatrie                                       4        0.280 
     Lancet                                                   12       17.490 
     Leukemia                                                  7        2.350 
     Medical and Pediatric Oncology                           12        1.543 
     Neoplasia                                                 1        0.000 
     Neurotoxicity                                             1        1.363 
     New England Journal of Medicine                          10       22.412 
     Pediatric Hematology and Oncology                         2        0.425 
     Seminars in Hematology                                    1        2.095 
     Tijdschr Kindergeneesk                                    1        0.000 
  
                                      N = 44 
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 ---------------------------- Publication type=Book ----------------------------- 
  
                                                            Number 
                                                              of       Impact 
     Publication                                           articles    factor 
  
     Adjuvant Therapy of Cancer                                2          0   
     Central Nervous System Leukaemia                          1          0   
     Immunotherapy of Cancer: Present Status of Trials in Man  1          0   
     Leukemia Research: Advances in Cell Biology and Treatment 3          0   
     Leukemia                                                  1          0   
     Recent Advances in Leukaemia and Lymphoma                 1          0   
     Unifying Concepts of Leukaemia Bibliotheca Haematologica  1          0   
     William Dameshek and Frederick Gunz’s Leukaemia           1          0   
  
                                      N = 8 
  
  
 -------------------- Publication type=Meeting abstract book -------------------- 
  
                                                            Number 
                                                              of       Impact 
     Publication                                           articles    factor 
  
     Blood: Abstracts of American Society of Haematology (ASH) 4        8.569 
     British Journal of Haematology: British Society of  
       Haematology (BSH) and European Hematology Association  
       (EHA) Abstracts               1        2.616 
     European Conference on Clinical Oncology (ECCO)           1        2.095 
     Haematologica: Abstracts of the European Hematology 
       Association (EHA)              3        1.200 
     International Workshop on ALL: Assesment of Progress  
       and Future Directions               1        0.000 
     International Journal of Radiation Oncology Biology 
       Physics: Abstracts               1        2.484 
     Leukaemia Research: Scientific Program of Abstracts       1        1.179 
     Medical and Pediatric Oncology: International Society of 
       Pediatric Oncology (SIOP) Abstracts                     6        1.543 
     Proceedings of the American Association for Cancer  
       Research (AACR)                                         7        0.000 
     Proceedings of the American Association for Cancer  
       Research (AACR) and the American Society of Clinical  
       Oncology (ASCO)                                         1        0.000 
     Proceedings of the American Society of Clinical  
       Oncology (ASCO)                                        25        0.000 
  
                                      N = 11 
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APPENDIX VII: SUMMARY OF THE VARIABLES  
USED IN THE TWELVE ‘HOW LONG?’ ANALYSES  
1st mentions 1st results All mentions All results Analysis 
T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 
Initial 
variables 
            
Categorical 
            
CGROUP ● 1 ● 1# ● 2 ● 1  ● 1 ● 1 ● 2 ●2#   ●4# 
FUNDG  ●(22)  ●(15) ●(18) ●(23) ●   ●(14)   
MULTIC ● 2 ● 3 #  ● 2   ●2# ● 2 ●3# ● 2 ●2  
INTERNL ●2(8)# ●1(13)# ● 2#   ●3# ● 1 ● 3  ● 1 ●3  
CTARGET ●(19) ●(21) ●(18)         ●(9) 
TXCHEMO ●  2 ● 1 ● 3  ● 4 ●  3 ●2○ ● 1 ● 3   ● 3 
FIRSTL ● ● ●   ● ●  ●# ●  ● # 
EQUIV   ●   ●   ● #   ● # 
AC ● #      ● #     ● 
RESULTS  ● ●     ● # ●    
CLNSG †    ●2(25)# ●3(25)     ●1(18) ●3(18)# ●3(16) 
POSNG †    ●2 ●2 ●3(11)    ●1#(11)  ●3(12) 
ANSWER †           ●#(22)  
PUBTYPE   ●1          
JGROUP ● 3 ● 1 ● 2 ● 1 ● 3 ●3# ●3# ●1#   ●1  
SGROUP ● ●  ●    ●  ● # ● ●# 
PRESENTD ● ● ● ● ● # ● ● ● ● ● ● ● 
SUBGRP    ● ● #   ● #   ●#  
ENGLISH    ●     ● ●#○  ● 
             
Continuous             
NRAND ● ● ● ● ● ● ● ● ● ● ● ● 
ARMS ● ● ● ● ● ● ● ● ● ● ● ● 
NOQ ● ● ● ● ● ● ● ● ● ● ● ● 
NSTART ● ● ● ● ● ● ● ● ● ● ● ● 
NCLOSE ● ● ● ● ●(13) ● ● ● ● ● ● ● 
DURRAN ● ●(13) ● ● ●(13) ● ● ● ● ● ● ● 
LOGSIZE ● ● ● ● ●(12) ● ●(11) ●(12) ● ● ● ● 
LOGPEST †    ● ●(12) ●(13)    ● (11) ● (11) ●(12) 
IMPACT † ● (16) ● (18) ● ● ●(13)  ● (9) ●(10)  ● (7) ● (9)  
             
2nd stage 
variables 
            
DEVLPNG ● ● ● ● ● ● ● ● ● ● ● ● 
LOGPEST ● ● ● ● ● # ● ● ● ● # ● ● ● 
LOGPNR ● # ● ● ● ● # ● # ● ● ● # ● ● # ● # 
CLNSG ● 3 ● 1 ● 8# ● 3# ● 4 ● 1 ● 5# ● 6 ●2# ● 7 ● 6 ● 8 
POSNG ● 1 ● 1# ● 2 ● 3 ● 4 ● 2 ●7 #  ●5# ● 6#  ● 2 
ANSWER ● 2 ● 1 ● 2 ● 1 ●2 ● 2 ● 1 ● 1 ● 2 ● 1 ● 1 ●1 
PUBTYPE      ●1   ●1   ●1 
IMPACT ● ● ● ● ● ● ● ● ● # ● ● ● 
NOIMPACT ● ● # ● ● ● ● ● ● ● # ● ● # ● 
NTREP ● ● ● ● ● ● ● ● ● ● ● ● 
NRREP ● ● ● ● ● ● ● ● ● ● ● ● 
AUTHORS ● ● ● ● ● ● ● ● ● ● ● ● 
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1st mentions 
 
1st results All mentions All results Analysis 
T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 
Interactions 
 
            
CGROUP * INTERNL 
 
 ● 123      ● 13  ●1   
CGROUP * MULTIC  
 
   ● 145   ● 13 ● 14 ● 12 ●1   
CGROUP *DURRAN 
 
●1 ●1 ●1 ●1  ●1 ●1 ●1 ●1    
CGROUP * LOGSIZE 
 
      ●12  ●12    
CGROUP * LOGPEST 
 
     ●124 ●13      
CGROUP * CLNSG 
 
 ● 1 ● 1   ● 1   ● 12    
CGROUP * POSNG 
 
 ● 1  ● 1  ● 123       
CGROUP * JGROUP 
 
●1 ●1 ●1     ●1     
CGROUP * IMPACT 
 
  ● 1 ● 1  ● 123 ● 1 ● 1     
DEVLPNG * MULTIC 
 
       ●1     
DEVLPNG * INTERNL 
 
       ●1     
DEVLPNG * IMPACT 
 
  ●1          
INTERNL * LOGPEST 
 
         ●12   
INTERNL *CLNSG 
 
 ●1         ●12   
INTERNL * POSNG 
 
 ● 1        ● 1   
INTERNL * IMPACT 
 
       ●1  ●1 ●1  
MULTIC * LOGPEST 
 
      ●12   ● 12   
MULTIC * CLNSG 
 
        ● 12 ● 13   
MULTIC * POSNG 
 
   ●1      ●1   
LOGSIZE * LOGPEST 
 
      ● 12     ● 12 
LOGSIZE *CLNSG 
 
        ● 12   ● 12 
LOGSIZE * POSNG  
 
           ● 1 
EQUIV * LOGPEST 
 
     ●1       
EQUIV * CLNSG 
 
  ●1   ●1       
EQUIV * POSNG 
 
     ●1       
LOGPEST * POSNG 
 
   ●  ●     ● ● 
CLNSG * POSNG 
 
    ●        
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Key 
 
T1 = time from close to submission (TCLREC) 
T2 = time from receipt to publication (TRECPUB) 
T3 = time from close to publication (TCLPUB) 
 
 
Notes 
 
# = box-plots of classes of a categorical variable only marginally suggest inclusion 
† = variable used in initial stage but without ‘not reported’ category 
(n) = variable missing for n% observations  
○ = only 2 observations in the I (TXCHEMO) and A (ENGLISH) categories, so these variables should probably be 
excluded 
 
 
Class combinations used for categorical variables: 
 
FUNDG   1= G+C vs. G   G=Government 
       C= charity  
 
TXCHEMO   1 = I vs. C   R vs. C  I = immunotherapy 
   2 = I vs. R , C   R = radiotherapy 
   3 = I vs. R, C , A   C = chemotherapy 
   4 = R vs. I, C   A = antibiotic 
 
MULTIC/ INTERNL  1 = Y vs. N   L vs. N  Y = yes 
   2 = Y, L vs. N   L = limited 
   3 = Y vs. L, N   N = no 
 
CGROUP/JGROUP 1 = E vs. A   O vs. A  A = North America 
   2 = O vs. A, E   E = Europe 
   3 = O,E vs. A   O = other 
   4 = E vs. A, O     
 
CLNSG    1 = Y, N vs. X, P   Y = yes 
   2 = Y vs.N,P  X vs. N,P  P = possibly 
   3 = Y, N, P vs. X   N = no 
   4 = Y vs. X   P vs. X   N vs. X X = not reported 
   5 = Y, P, X vs. N 
   6 = Y vs. N, P, X 
   7 = Y, P vs. N   X vs. N 
   8 = Y vs. X   N,P vs X 
    
CLNSG†   1 = Y vs. N   P vs. N 
   2 = Y,P vs. N 
  3 = Y vs. P,N  
 
POSNG   1 = +, O, F vs.X   - vs. X  + = positive 
   2 = +, - , O vs. X  F vs. X  -  = negative 
   3 = - vs. O,X   F, + vs. O, X  F = flat (null) 
   4 = - vs. +, F, O, X   O = opposite 
   5 = +, -, O, X vs. F   X = not reported 
   6 = X vs. +, - ,O, F 
   7 = + vs. X   - vs. X   F vs. X   O vs. X 
 
POSNG†   1 = F,-,O vs. + 
   2 = - vs. +, O, F 
   3 = +, -, O vs. F 
 
ANSWER  1 = Y vs. X   N vs. X 
   2 = Y, N vs. X 
 
PUBTYPE  1= 2 vs. 1   3 vs. 1   1 = journal article 
       2 = book chapter 
       3 = meeting abstract 
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Class combinations used in interactions 
 
CGROUP*INTERNL 
1 CGROUP=A INTERNL=Y  
2 CGROUP=E INTERNL= L, N  
3 CGROUP=O INTERNL= L, N 
 
CGROUP * MULTIC   
1 CGROUP=A MULTIC=Y, L  
2 CGROUP= E, O MULTIC=L, N 
3 CGROUP= E, O MULTIC=N  
4 CGROUP= O MULTIC=N 
5 CGROUP=E MULTIC=N  
 
CGROUP *DURRAN 
1 CGROUP=A 
 
CGROUP * LOGSIZE 
1 CGROUP=A 
2 CGROUP=E, O 
  
CGROUP * LOGPEST 
1 CGROUP=A 
2 CGROUP=O 
3 CGROUP=E,O 
4 CGROUP=E 
 
CGROUP * CLNSG 
1 CGROUP=A CLNSG=Y 
2 CGROUP=E,O CLNSG=N 
 
 
CGROUP * POSNG 
1 CGROUP=A POSNG= + 
2 CGROUP=E  
3 CGROUP=O 
 
CGROUP * JGROUP 
1  CGROUP=A   JGROUP=A 
 
CGROUP * IMPACT 
1 CGROUP=A 
2 CGROUP=E 
3 CGROUP=O 
 
DEVLPNG * INTERNL 
1 DEVLPNG=Y INTERNL=L,N 
 
 
DEVLPNG * MULTIC 
1 DEVLPNG=Y MULTIC=N 
 
 
DEVLPNG * IMPACT 
1 DEVLPNG=N 
 
 
 
 
 
 
INTERNL * LOGPEST 
1 INTERNL=Y LOGPEST 
2  INTERNL=L, N  LOGPEST 
 
INTERNL *CLNSG 
1  INTERNL=Y  CLNSG=Y 
2  INTERNL=L,N CLNSG=Y 
 
INTERNL * POSNG 
1  INTERNL=Y POSNG= + 
 
INTERNL * IMPACT 
1 INTERNL=Y 
 
MULTIC * LOGPEST 
1 MULTIC=Y, L 
2 MULTIC=N 
 
MULTIC * CLNSG 
1 MULTIC=Y, L CLNSG=Y 
2 MULTIC=L,N CLNSG=N 
3 MULTIC=N CLNSG=Y 
 
MULTIC * POSNG 
1 MULTIC=Y, L POSNG= +  
 
LOGSIZE * LOGPEST 
1 LOGSIZE ↑ 
2 LOGSIZE ↓ 
 
LOGSIZE * CLNSG 
1 CLNSG=Y 
2 CLNSG=N 
 
LOGSIZE * POSNG  
1 POSNG= +  
 
EQUIV * LOGPEST 
1 EQUIV=Y 
 
EQUIV * CLNSG 
1 EQUIV=Y CLNSG=Y 
 
EQUIV * POSNG 
1 EQUIV=Y POSNG= F, - 
 
LOGPEST * POSNG 
All categories of POSNG were tried 
 
CLNSG * POSNG 
All likely combinations of categories of CLNSG 
and POSNG were tried 
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APPENDIX VIII: OUTPUT FROM THE SIX 
‘TIME TO FIRST’ ANALYSES 
 
(I) Data used: first mentions 
Response variable: time from 
close to submission 
 
 Indicator variables 
 
 DUMCGRP =1 if CGROUP = Europe or Other 
 DUMCGRP =0 if CGROUP = America 
  
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                           Number of observations    
63 
   
 Dependent Variable: TCLREC    
  
                                        Sum of 
  Source                     DF        Squares    
Mean Square   F Value   Pr > F 
  
  Model                       4    164045500.5     
41011375.1     49.88   <.0001 
  
  Error                      58     47687433.5       
822197.1                    
  
  Corrected Total            62    211732933.9                                   
  
  
               R-Square     Coeff Var      Root 
MSE    TCLREC Mean 
  
               0.774776      64.21893      
906.7509       1411.968 
  
 
  Source                     DF    Type III SS    
Mean Square   F Value   Pr > F 
  
  DURRAN                      1    31120955.83    
31120955.83     37.85   <.0001 
  DUMCGRP                     1    21546489.68    
21546489.68     26.21   <.0001 
  NRAND                       1     5463539.54     
5463539.54      6.65   0.0125 
  DEVLPNG                     1    78954694.05    
78954694.05     96.03   <.0001 
  
                                          
Standard 
        Parameter         Estimate           
Error    t Value    Pr > |t| 
  
        Intercept      2966.907107     
457.9360691       6.48      <.0001 
        DURRAN           -1.652309       
0.2685671      -6.15      <.0001 
        DUMCGRP        1344.488454     
262.6375339       5.12      <.0001 
        NRAND          -303.309601     
117.6622343      -2.58      0.0125 
        DEVLPNG        4984.237827     
508.6250636       9.80      <.0001
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(II) Data used: first mentions 
Response variable: time from receipt to publication 
 
 Indicator variables 
 
 DUMCGRP = 1 if CGROUP = Europe or Other 
 DUMCGRP = 0 if CGROUP = America 
 
 DUMCLN = 1 if CLNSG = Yes or No 
 DUMCLN = 0 if CLNSG = Possibly or X (not reported) 
 
 DUMJGRP2 = 1 if JGROUP = Other 
 DUMJGRP2 = 0 if JGROUP = America or Europe 
 
 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                           Number of observations    72 
  
 NOTE: Due to missing values, only 59 observations can be used in this analysis. 
   
 Dependent Variable: TRECPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       7    543813.3019     77687.6146     11.44   <.0001 
  
  Error                      51    346342.8676      6791.0366                    
  
  Corrected Total            58    890156.1695                                   
 
  
               R-Square     Coeff Var      Root MSE    TRECPUB Mean 
  
               0.610919      35.69268      82.40775        230.8814 
  
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NRAND                       1     44515.1829     44515.1829      6.55   0.0135 
  DUMJGRP2                    1    168459.4320    168459.4320     24.81   <.0001 
  NRREP                       1     83170.0528     83170.0528     12.25   0.0010 
  DUMCLN                      1     40969.9666     40969.9666      6.03   0.0175 
  DUMCGRP                     1     23083.4897     23083.4897      3.40   0.0710 
  DURRAN                      1      1116.0266      1116.0266      0.16   0.6869 
  DUMCGRP*DURRAN              1     35535.6404     35535.6404      5.23   0.0263 
  
  
                                             Standard 
      Parameter              Estimate           Error    t Value    Pr > |t| 
  
      Intercept           419.0929945     50.44683513       8.31      <.0001 
      NRAND               -30.5920928     11.94876838      -2.56      0.0135 
      DUMJGRP2           -242.5832614     48.70585828      -4.98      <.0001 
      NRREP               -16.0828577      4.59565868      -3.50      0.0010 
      DUMCLN              -62.0459035     25.26087235      -2.46      0.0175 
      DUMCGRP            -109.6591559     59.47880058      -1.84      0.0710 
      DURRAN               -0.0142201      0.03507777      -0.41      0.6869 
      DUMCGRP*DURRAN        0.1186665      0.05187571       2.29      0.0263 
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(III) Data used: first mentions 
Response variable: time from close to publication 
  
 Indicator variables 
 
 DUMCGRP = 1 if CGROUP = Other 
 DUMCGRP = 0 if CGROUP = America or Europe 
 
 DUMANS = 1 if ANSWER = Yes or No 
 DUMANS = 0 if ANSWER = X (not reported) 
 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                          Number of observations    195 
   
 Dependent Variable: TCLPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       9    211892227.7     23543580.9     19.75   <.0001 
  
  Error                     185    220577998.5      1192313.5                    
  
  Corrected Total           194    432470226.2                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLPUB Mean 
  
               0.489958      86.49328      1091.931       1262.446 
 
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NSTART                      1    31716866.08    31716866.08     26.60   <.0001 
  DURRAN                      1     8498397.83     8498397.83      7.13   0.0083 
  DUMCGRP                     1     4933861.66     4933861.66      4.14   0.0434 
  PRESENTD                    1    16600239.79    16600239.79     13.92   0.0003 
  IMPACT                      1     8345380.57     8345380.57      7.00   0.0089 
  DUMANS                      1    17228289.24    17228289.24     14.45   0.0002 
  EQUIV                       1     8204363.06     8204363.06      6.88   0.0094 
  DEVLPNG                     1    21085514.19    21085514.19     17.68   <.0001 
  NTREP                       1    18899066.36    18899066.36     15.85   <.0001 
  
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      2524.418924     351.1971293       7.19      <.0001 
        NSTART           -0.200958       0.0389632      -5.16      <.0001 
        DURRAN           -0.384979       0.1441995      -2.67      0.0083 
        DUMCGRP         644.396678     316.7780204       2.03      0.0434 
        PRESENTD       -645.988106     173.1261108      -3.73      0.0003 
        IMPACT          -42.258653      15.9730486      -2.65      0.0089 
        DUMANS          643.504927     169.2879442       3.80      0.0002 
        EQUIV          -530.311866     202.1641486      -2.62      0.0094 
        DEVLPNG        1928.473752     458.5818540       4.21      <.0001 
        NTREP           244.904974      61.5138151       3.98      <.0001 
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(IV) Data used: first results 
Response variable: time from close to submission   
   
  
Indicator variables 
 
DUMMULT = 1 if MULTIC = Yes or Limited (multi-centre)     
DUMMULT = 0 if MULTIC = No (single-centre)  
  
DUMCGRP1 = 1 if CGROUP = Europe       
DUMCGRP1 = 0 if CGROUP = America or Other          
 
DUMCGRP2 = 1 if CGROUP = Other      
DUMCGRP2 = 0 if CGROUP = America or Europe     
 
DUMPN1 = 1 IF POSNG = Negative 
DUMPN1 = 0 IF POSNG = Null, Positive, Opposite or X (not reported) 
 
DUMPN2 = 1 IF POSNG = Null or Positive 
DUMPN2 = 0 IF POSNG = Negative, Opposite or X (not reported) 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                           Number of observations    52 
   
 Dependent Variable: TCLREC    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       7    18203694.72     2600527.82      5.36   0.0002 
  
  Error                      44    21361054.59      485478.51                    
  
  Corrected Total            51    39564749.31                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLREC Mean 
  
               0.460099      53.84086      696.7629       1294.115 
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NCLOSE                      1    4604740.908    4604740.908      9.48   0.0036 
  DUMMULT                     1    4002267.011    4002267.011      8.24   0.0063 
  DUMCGRP1                    1    6287727.454    6287727.454     12.95   0.0008 
  DUMCGRP2                    1    6427656.394    6427656.394     13.24   0.0007 
  IMPACT                      1    2646128.874    2646128.874      5.45   0.0242 
  DUMPN1                      1    3128268.900    3128268.900      6.44   0.0147 
  DUMPN2                      1    3454815.205    3454815.205      7.12   0.0107 
   
 Dependent Variable: TCLREC    
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      1586.189073     392.7206826       4.04      0.0002 
        NCLOSE           -0.170891       0.0554882      -3.08      0.0036 
        DUMMULT         707.071790     246.2609142       2.87      0.0063 
        DUMCGRP1       1290.393294     358.5586877       3.60      0.0008 
        DUMCGRP2       1980.913783     544.4076939       3.64      0.0007 
        IMPACT          118.940337      50.9458341       2.33      0.0242 
        DUMPN1         -910.957672     358.8650514      -2.54      0.0147 
        DUMPN2         -791.530235     296.7154113      -2.67      0.0107 
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(V) Data used: first results 
Response variable: time from receipt to publication 
 
 Indicator variables 
 
 DUMFUND = 1 if FUNDG = Government + Charity 
 DUMFUND = 0 if FUNDG = Government alone 
 
 DUMCLN1 = 1 if CLNSG = Yes 
 DUMCLN1 = 0 if CLNSG = No, Possibly or X (not reported) 
 
 DUMCLN2 = 1 if CLNSG = No 
 DUMCLN2 = 0 if CLNSG = Yes, Possibly or X (not reported) 
 
 
                                 The SAS System                                 
  
                                The GLM Procedure 
  
                           Number of observations    60 
  
 NOTE: Due to missing values, only 49 observations can be used in this analysis. 
   
 Dependent Variable: TRECPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       6    282037.7808     47006.2968      9.81   <.0001 
  
  Error                      42    201348.4641      4794.0111                    
  
  Corrected Total            48    483386.2449                                   
  
  
               R-Square     Coeff Var      Root MSE    TRECPUB Mean 
  
               0.583463      29.90745      69.23880        231.5102 
  
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  DUMFUND                     1     74239.9634     74239.9634     15.49   0.0003 
  NTREP                       1     86083.3226     86083.3226     17.96   0.0001 
  NRREP                       1    205309.3058    205309.3058     42.83   <.0001 
  PRESENTD                    1     46789.9137     46789.9137      9.76   0.0032 
  DUMCLN1                     1     40920.3761     40920.3761      8.54   0.0056 
  DUMCLN2                     1     44350.9529     44350.9529      9.25   0.0040 
  
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      282.3021900     30.48992918       9.26      <.0001 
        DUMFUND         83.1143513     21.12061988       3.94      0.0003 
        NTREP           42.2871926      9.97927196       4.24      0.0001 
        NRREP          -33.5653528      5.12904388      -6.54      <.0001 
        PRESENTD        69.8529810     22.35930692       3.12      0.0032 
        DUMCLN1        -81.6344897     27.94173628      -2.92      0.0056 
        DUMCLN2        -84.8701916     27.90314914      -3.04      0.0040
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(VI) Data used: first results 
Response variable: time from close to publication 
 
 Indicator variables 
 
 DUMCGRP1 = 1 if CGROUP = Europe 
 DUMCGRP1 = 0 if CGROUP = America or Other        
 
 DUMCGRP2 = 1 if CGROUP = Other     
 DUMCGRP2 = 0 if CGROUP = America or Europe    
 
 DUMCLN = 1 if CLNSG = Yes or No 
 DUMCLN = 0 if CLNSG = Possibly or X (not reported) 
 
 DUMDIR3 = 1 if POSNG = Null 
 DUMDIR3 = 0 if POSNG = Positive, Negative, Opposite or X (not reported) 
 
                                  The SAS System                                 
 
                                The GLM Procedure 
  
                          Number of observations    170 
   
 Dependent Variable: TCLPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                      10     70026193.2      7002619.3      9.10   <.0001 
  
  Error                     159    122324572.8       769336.9                    
  
  Corrected Total           169    192350766.0                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLPUB Mean 
  
               0.364055      66.95952      877.1185       1309.924 
  
 
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  DURRAN                      1    10960803.91    10960803.91     14.25   0.0002 
  DUMCGRP1                    1     1002867.73     1002867.73      1.30   0.2553 
  DUMCGRP2                    1       10931.17       10931.17      0.01   0.9053 
  NOIMPACT                    1    13247370.13    13247370.13     17.22   <.0001 
  DUMCLN                      1     5958769.47     5958769.47      7.75   0.0060 
  IMPACT                      1     5925128.13     5925128.13      7.70   0.0062 
  LOGPEST                     1     4625126.09     4625126.09      6.01   0.0153 
  DUMDIR3                     1     4889632.03     4889632.03      6.36   0.0127 
  DUMCGRP1*IMPACT             1     9426163.00     9426163.00     12.25   0.0006 
  DUMCGRP2*DUMDIR3            1     7409723.47     7409723.47      9.63   0.0023 
  
  
                                              Standard 
     Parameter                Estimate           Error    t Value    Pr > |t| 
  
     Intercept             2676.188113     207.1635603      12.92      <.0001 
     DURRAN                  -0.463742       0.1228607      -3.77      0.0002 
     DUMCGRP1              -215.819645     189.0285648      -1.14      0.2553 
     DUMCGRP2                32.017728     268.6058842       0.12      0.9053 
     NOIMPACT              -716.286008     172.6155531      -4.15      <.0001 
     DUMCLN                -468.630833     168.3878915      -2.78      0.0060 
     IMPACT                 -49.701284      17.9092347      -2.78      0.0062 
     LOGPEST               -143.606012      58.5691776      -2.45      0.0153 
     DUMDIR3               -434.963330     172.5332678      -2.52      0.0127 
     DUMCGRP1*IMPACT        116.108156      33.1706169       3.50      0.0006 
     DUMCGRP2*DUMDIR3      1653.784946     532.8884726       3.10      0.0023 
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APPENDIX IX: OUTPUT FROM THE SIX PRELIMINARY ANALYSES 
THAT REQUIRE INCORPORATION OF REPEATED MEASURES 
 
(I) Data used: all mentions 
Response variable: time from close to submission 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                          Number of observations    209 
   
 Dependent Variable: TCLREC    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       6    239507659.2     39917943.2     25.17   <.0001 
  
  Error                     202    320320199.2      1585743.6                    
  
  Corrected Total           208    559827858.4                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLREC Mean 
  
               0.427824      65.47045      1259.263       1923.407 
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  DURRAN                      1     26422945.4     26422945.4     16.66   <.0001 
  IMPACT                      1     17020566.1     17020566.1     10.73   0.0012 
  LOGPEST                     1     19038716.4     19038716.4     12.01   0.0006 
  DEVLPNG                     1    115291241.2    115291241.2     72.70   <.0001 
  LOGNTREP                    1     11043522.1     11043522.1      6.96   0.0090 
  NRREP                       1     36299596.6     36299596.6     22.89   <.0001 
  
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      3491.432978     337.2134594      10.35      <.0001 
        DURRAN           -0.723688       0.1772870      -4.08      <.0001 
        IMPACT         -102.299476      31.2250317      -3.28      0.0012 
        LOGPEST         248.954897      71.8486016       3.46      0.0006 
        DEVLPNG        4404.250493     516.5237941       8.53      <.0001 
        LOGNTREP       1119.731011     424.3032724       2.64      0.0090 
        NRREP          -205.378841      42.9260847      -4.78      <.0001  
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(II) Data used: all mentions 
Response variable: √(time from receipt to publication) 
 
 Indicator variables 
 
 DUMJGRP2 = 1 if JGROUP = Other 
 DUMJGRP2 = 0 if JGROUP = America or Europe 
 
 DUMCGRP1 = 1 if CGROUP = Europe 
 DUMCGRP1 = 0 if CGROUP = America or Other 
 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                          Number of observations    218 
  
 NOTE: Due to missing values, only 195 observations can be used in this analysis. 
   
 Dependent Variable: RTRECPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       6    1936.218689     322.703115     31.70   <.0001 
  
  Error                     188    1913.983806      10.180765                    
  
  Corrected Total           194    3850.202495                                   
  
  
              R-Square     Coeff Var      Root MSE    RTRECPUB Mean 
  
              0.502887      19.61802      3.190731         16.26429 
  
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NSTART                      1    297.1149815    297.1149815     29.18   <.0001 
  DUMJGRP2                    1    536.9364177    536.9364177     52.74   <.0001 
  DURRAN                      1    142.4349421    142.4349421     13.99   0.0002 
  NRREP                       1    539.1025263    539.1025263     52.95   <.0001 
  DUMCGRP1                    1    281.4252646    281.4252646     27.64   <.0001 
  LOGAUTH                     1     65.3142155     65.3142155      6.42   0.0121 
  
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      12.50450749      1.10525891      11.31      <.0001 
        NSTART          0.00058148      0.00010764       5.40      <.0001 
        DUMJGRP2      -12.83411876      1.76723713      -7.26      <.0001 
        DURRAN          0.00177204      0.00047376       3.74      0.0002 
        NRREP          -0.62203603      0.08548109      -7.28      <.0001 
        DUMCGRP1       -3.38810302      0.64441445      -5.26      <.0001 
        LOGAUTH         2.21211676      0.87336221       2.53      0.0121 
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(III) Data used: all mentions 
 Response variable: time from close to publication 
 
 Indicator variables 
 
 DUMMULT = 1 if MULTIC = Yes (multi-centre) 
 DUMMULT = 0 if MULTIC = Limited or No (single-centre) 
  
 DUMCGRP1 = 1 if CGROUP = Europe 
 DUMCGRP1 = 0 if CGROUP = America or Other 
 
 DUMCGRP2 = 1 if CGROUP = Other 
 DUMCGRP2 = 0 if CGROUP = America or Europe 
 
 DUMENG = 1 if published in full in a language other than English, with an English abstract 
 DUMENG = 0 if published in full in English 
 
 DUMCLN1 = 1 if CLNSG = Yes 
 DUMCLN1 = 0 if CLNSG = No, Possibly or X (not reported) 
 
 DUMCLN2 = 1 if CLNSG = X (not reported) 
 DUMCLN2 = 0 if CLNSG = Yes, No or Possibly 
 
 DUMANS = 1 if ANSWER = Yes or No 
 DUMANS = 0 if ANSWER = X (not reported) 
 
 PUBTYPE3 = 1 if PUBTYPE = Meeting abstract 
 PUBTYPE3 = 0 if PUBTYPE = Journal or Book 
 
 Interaction term 
 
 ICGMUL2 = 1 if non-US trial with less than 5 centres 
 ICGMUL2 = 0 otherwise  
  
                                  The SAS System                                 
 
                                The GLM Procedure 
  
                          Number of observations    582 
  
 NOTE: Due to missing values, only 581 observations can be used in this analysis. 
   
 Dependent Variable: TCLPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                      16      455689940       28480621     18.26   <.0001 
  
  Error                     564      879561623        1559506                    
  
  Corrected Total           580     1335251563                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLPUB Mean 
  
               0.341276      69.63444      1248.802       1793.368 
  
  
   
300 
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NSTART                      1    43500131.20    43500131.20     27.89   <.0001 
  DURRAN                      1    27852603.67    27852603.67     17.86   <.0001 
  DUMCGRP1                    1    20083762.47    20083762.47     12.88   0.0004 
  DUMCGRP2                    1       13376.87       13376.87      0.01   0.9262 
  DUMENG                      1    12921648.07    12921648.07      8.29   0.0041 
  PRESENTD                    1    45319683.78    45319683.78     29.06   <.0001 
  DUMCLN1                     1    13847646.75    13847646.75      8.88   0.0030 
  DUMCLN2                     1    14089452.51    14089452.51      9.03   0.0028 
  DUMANS                      1    28701395.55    28701395.55     18.40   <.0001 
  DEVLPNG                     1    41505168.94    41505168.94     26.61   <.0001 
  NTREP                       1    34515944.19    34515944.19     22.13   <.0001 
  NRREP                       1    14958164.53    14958164.53      9.59   0.0021 
  IMPACT                      1     7853063.00     7853063.00      5.04   0.0252 
  DUMMULT                     1    38602548.53    38602548.53     24.75   <.0001 
  DUMPUBT3                    1     7847942.79     7847942.79      5.03   0.0253 
  ICGMUL2                     1    18517354.16    18517354.16     11.87   0.0006 
   
 Dependent Variable: TCLPUB    
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      2344.830636     266.1429356       8.81      <.0001 
        NSTART           -0.150788       0.0285506      -5.28      <.0001 
        DURRAN           -0.439751       0.1040560      -4.23      <.0001 
        DUMCGRP1       -535.114001     149.1136359      -3.59      0.0004 
        DUMCGRP2         23.508894     253.8332300       0.09      0.9262 
        DUMENG        -1048.554597     364.2719064      -2.88      0.0041 
        PRESENTD       -637.945194     118.3405324      -5.39      <.0001 
        DUMCLN1         444.477517     149.1610371       2.98      0.0030 
        DUMCLN2         438.225404     145.7954851       3.01      0.0028 
        DUMANS          523.716816     122.0783345       4.29      <.0001 
        DEVLPNG        2182.688289     423.0914114       5.16      <.0001 
        NTREP           243.977729      51.8601645       4.70      <.0001 
        NRREP           -91.030498      29.3928265      -3.10      0.0021 
        IMPACT          -25.620568      11.4172839      -2.24      0.0252 
        DUMMULT         813.222478     163.4537804       4.98      <.0001 
        DUMPUBT3       -354.652786     158.0953317      -2.24      0.0253 
        ICGMUL2        1226.461906     355.9247439       3.45      0.0006 
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(IV) Data used: all reportings of results 
Response variable: time from close to submission 
 
 Indicator variables 
 
 DUMCLN = 1 if CLNSG = Yes, Possibly or X (not reported)  
 DUMCLN = 0 if CLNSG = No 
 
 DUMPN = 1 if POSNG = X (not reported) 
 DUMPN = 0 if POSNG = Null, Negative, Opposite or Positive 
 
 
                                  The SAS System                                 
  
                                The GLM Procedure 
  
                          Number of observations    129 
   
 Dependent Variable: TCLREC    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       6     63537508.8     10589584.8      9.71   <.0001 
  
  Error                     122    133099522.0      1090979.7                    
  
  Corrected Total           128    196637030.8                                   
  
  
               R-Square     Coeff Var      Root MSE    TCLREC Mean 
  
               0.323121      55.94419      1044.500       1867.039 
  
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NOQ                         1    12227391.26    12227391.26     11.21   0.0011 
  PRESENTD                    1    15227447.66    15227447.66     13.96   0.0003 
  IMPACT                      1     7478041.04     7478041.04      6.85   0.0100 
  LOGPEST                     1     9735783.61     9735783.61      8.92   0.0034 
  DUMCLN                      1     4888080.39     4888080.39      4.48   0.0363 
  DUMPN                       1     4370786.51     4370786.51      4.01   0.0475 
  
  
                                          Standard 
        Parameter         Estimate           Error    t Value    Pr > |t| 
  
        Intercept      1665.308430     240.1279943       6.94      <.0001 
        NOQ             106.040895      31.6748679       3.35      0.0011 
        PRESENTD       -737.627826     197.4386016      -3.74      0.0003 
        IMPACT          -83.315715      31.8230158      -2.62      0.0100 
        LOGPEST         195.050060      65.2933519       2.99      0.0034 
        DUMCLN          493.791299     233.2827338       2.12      0.0363 
        DUMPN           610.754782     305.1373789       2.00      0.0475 
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(V) Data used: all reportings of results 
Response variable: time from receipt to publication 
 
 Indicator variables 
 
 DUMMULT = 1 if MULTIC = Yes or Limited (multi-centre)   
 DUMMULT = 0 if MULTIC = No (single-centre)     
  
 DUMINT = 1 if INTERNL = Yes (international)    
 DUMINT = 0 if INTERNL = Limited or No (single-country)   
  
 DUMANS1 = 1 if ANSWER = Yes     
 DUMANS1 = 0 if ANSWER = No or X (not reported)      
   
 
 DUMJGRP1 = 1 if JGROUP = Europe 
 DUMJGRP1 = 0 if JGROUP = America or Other 
 
 DUMJGRP2 = 1 if JGROUP = Other 
 DUMJGRP2 = 0 if JGROUP = America or Europe 
 
 Interaction term 
 
 IINTIMP = 1 if truly international trial and published in a journal with a high impact 
        factor (>=6) 
 IINTIMP = 0 otherwise 
 
                                  The SAS System                                 
                                 The GLM Procedure 
  
                          Number of observations    137 
 NOTE: Due to missing values, only 121 observations can be used in this analysis. 
   
 Dependent Variable: TRECPUB    
  
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                       9    1591821.909     176869.101     13.19   <.0001 
  
  Error                     111    1488785.050      13412.478                    
  
  Corrected Total           120    3080606.959                                   
  
               R-Square     Coeff Var      Root MSE    TRECPUB Mean 
  
               0.516723      40.72208      115.8123        284.3967 
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  DUMINT                      1    192143.1012    192143.1012     14.33   0.0002 
  DUMMULT                     1    242555.8449    242555.8449     18.08   <.0001 
  DUMJGRP1                    1    338158.6972    338158.6972     25.21   <.0001 
  DUMJGRP2                    1    347074.1169    347074.1169     25.88   <.0001 
  DURRAN                      1    499587.4255    499587.4255     37.25   <.0001 
  DUMANS1                     1    114434.3629    114434.3629      8.53   0.0042 
  PRESENTD                    1     89059.0115     89059.0115      6.64   0.0113 
  IMPACT                      1     24891.2211     24891.2211      1.86   0.1759 
  DUMINT*IMPACT               1    140376.0333    140376.0333     10.47   0.0016 
  
                                            Standard 
      Parameter             Estimate           Error    t Value    Pr > |t| 
  
      Intercept          146.3566220     40.48752438       3.61      0.0005 
      DUMINT            -364.8985895     96.40827156      -3.78      0.0002 
      DUMMULT            114.8628458     27.01022549       4.25      <.0001 
      DUMJGRP1          -171.5287034     34.16103607      -5.02      <.0001 
      DUMJGRP2          -388.8656479     76.44392471      -5.09      <.0001 
      DURRAN               0.1302510      0.02134175       6.10      <.0001 
      DUMANS1             66.2695873     22.68770405       2.92      0.0042 
      PRESENTD           -63.1438472     24.50454334      -2.58      0.0113 
      IMPACT              -7.1016176      5.21301162      -1.36      0.1759 
      DUMINT*IMPACT       45.2175710     13.97704154       3.24      0.0016  
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(VI) Data used: all reportings of results 
Response variable: time from close to publication 
  
 Indicator variables 
  
 DUMCLN2 = 1 if CLNSG = No or Possibly 
 DUMCLN2 = 0 if CLNSG = Yes or X (not reported) 
 
 DUMANS = 1 if ANSWER = Yes or No 
 DUMANS = 0 if ANSWER = X (not reported) 
 
 DUMFL = 1 if FIRSTL = Treatment for relapse or refractory disease 
 DUMFL = 0 if FIRSTL = First-line treatment 
 
 DUMDIR1 = 1 if POSNG = Positive 
 DUMDIR1 = 0 if POSNG = Negative, Null, Opposite or X (not reported) 
  
 DUMDIR2 = 1 if POSNG = Negative 
 DUMDIR2 = 0 if POSNG = Positive, Null, Opposite or X (not reported) 
 
 
                                  The SAS System                                 
                                 The GLM Procedure 
 
                           Number of observations    372 
 
 NOTE: Due to missing values, only 361 observations can be used in this analysis. 
   
 Dependent Variable: TCLPUB    
                                        Sum of 
  Source                     DF        Squares    Mean Square   F Value   Pr > F 
  
  Model                      12    147092257.9     12257688.2      8.00   <.0001 
  
  Error                     348    533181438.3      1532130.6                    
  
  Corrected Total           360    680273696.2                                   
  
               R-Square     Coeff Var      Root MSE    TCLPUB Mean 
  
               0.216225      67.65727      1237.793       1829.504 
  
  Source                     DF    Type III SS    Mean Square   F Value   Pr > F 
  
  NOQ                         1     8508038.85     8508038.85      5.55   0.0190 
  NCLOSE                      1    21791464.59    21791464.59     14.22   0.0002 
  PRESENTD                    1    16226892.84    16226892.84     10.59   0.0012 
  DUMCLN2                     1    11063493.93    11063493.93      7.22   0.0076 
  DUMANS                      1    12497499.37    12497499.37      8.16   0.0045 
  DUMFL                       1    10878132.64    10878132.64      7.10   0.0081 
  NTREP                       1    11332892.08    11332892.08      7.40   0.0069 
  LOGPEST                     1    23867963.98    23867963.98     15.58   <.0001 
  DUMDIR1                     1     3986651.11     3986651.11      2.60   0.1076 
  DUMDIR2                     1     3617994.85     3617994.85      2.36   0.1253 
  LOGPEST*DUMDIR1             1    21729794.60    21729794.60     14.18   0.0002 
  LOGPEST*DUMDIR2             1    10819633.62    10819633.62      7.06   0.0082 
   
                                             Standard 
     Parameter               Estimate           Error    t Value    Pr > |t| 
  
     Intercept            2036.559165     301.8061314       6.75      <.0001 
     NOQ                    47.859027      20.3093965       2.36      0.0190 
     NCLOSE                 -0.101993       0.0270443      -3.77      0.0002 
     PRESENTD             -461.682526     141.8644709      -3.25      0.0012 
     DUMCLN2              -405.869017     151.0384910      -2.69      0.0076 
     DUMANS                416.199017     145.7261118       2.86      0.0045 
     DUMFL                 692.588037     259.9235918       2.66      0.0081 
     NTREP                 136.214422      50.0841841       2.72      0.0069 
     LOGPEST               330.632008      83.7693405       3.95      <.0001 
     DUMDIR1               276.154707     171.1970292       1.61      0.1076 
     DUMDIR2               339.431067     220.8846343       1.54      0.1253 
     LOGPEST*DUMDIR1      -390.871944     103.7897767      -3.77      0.0002 
     LOGPEST*DUMDIR2      -386.688245     145.5132636      -2.66      0.0082 
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APPENDIX X: ALGORITHMS AND SAS COMMANDS FOR THE REPEATED 
MEASURES PRELIMINARY INVESTIGATIONS AND ANALYSES 
 
(i) Algorithm for producing the correlation matrix from the residuals resulting from the  
     independence model 
 
• Use one of the two publication records datasets output at the end of the main data 
management program, JMAIN. 
If all mentions are to be used, use dataset LEUKJR.ALLRECS. Here the order of each 
record (from an article) for a particular randomization is ALLORDER 
If only records containing results are to be used, use dataset LEUKJR.RESRECS. Here the 
order of each record for a particular randomization is RESORDER 
• Run the regression as usual, outputting the residuals  
• Only keep records actually used in the regression i.e. remove those where 
one or more X variables is missing, and therefore there is no residual, RESID 
• Rename the residuals from the first publication of each randomization as RESID1, those 
from the second to RESID2 and so on up to and including RESID5.  
• Output all the residuals from the 1st publications (RESID1) and the randomization ID 
(RANID) to one dataset, all the residuals from the 2nd publications (RESID2) and RANID 
to a 2nd dataset and so on up to 5th .  
• Merge the five datasets by variable RANID producing a single dataset with five variables 
RESID1, RESID2 … RESID5 
• Obtain correlation matrix for the five variables (PROC CORR in SAS) 
 
 
(ii) Algorithm for program to calculate: correlation coefficient (ρ) for a matrix with an   
      exchangeable correlation structure,  variance inflation factor, new standard errors for 
      the parameter (β) estimates, and hence revised t-statistics and p-values for the parameter  
      estimates 
 
• For each off-diagonal correlation coefficient of the matrix obtained from the previous 
program input as variables the row position (ROW), column position (COLUMN), value of 
correlation coefficient (PIJ) and number of pairs of observations used to calculate 
correlation  coefficient (NIJ).Do this for elements above the diagonal only. (Matrix is 
symmetrical.) 
• The formula for estimating ρ is given in Section 8.7. The following SAS commands will do 
this:  
 
      (Assume the dataset used is TEMP1. Here PEST is ρ.) 
 
ZIJ=LOG(((1+PIJ)/(1-PIJ))**0.5); 
NIJM3=NIJ-3; 
NIJM3ZIJ=NIJM3*ZIJ; 
 
CUM1+NIJM3ZIJ; 
CUM2+NIJM3; 
RUN; 
 
DATA TEMP2; 
  SET TEMP1 END=FINAL; 
 
ZESTTOP=CUM1; 
ZESTBOT=CUM2; 
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IF FINAL; 
ZEST=ZESTTOP/ZESTBOT; 
PEST=(EXP(2*ZEST)-1)/(EXP(2*ZEST)+1); 
 
• Hence the variance inflation factor (VIF) (see Section 8.8) is calculated  
VIF= 1- ρ2 
• For each variable read in the variable name and the values of β and the standard error 
of β from the independence model 
For new value of SE(β), divide original value by √VIF 
For new t-value, divide β  by new value of  SE(β) 
Hence obtain new p-value. The following SAS command gives the p-value for a 2-
sided test: 
PROB_NEW = 2*(1-PROBT(ABS(T_NEW),d)); 
                  where d= residual degrees of freedom 
 
 
(iii) Algorithm for program for the preliminary investigation imposing a stationary m- 
       dependent correlation structure 
 
• As with the exchangeable correlation structure, described in Section (ii), for each off-
diagonal element of the correlation matrix formed from the residuals from the 
independence model, input as variables the row position (ROW), column position 
(COLUMN), value of correlation coefficient (PIJ) and number of observations used to 
calculate correlation  coefficient (NIJ). Do this for elements above the diagonal only.  
• Output to 1st new dataset those elements distance 1 from the diagonal i.e.(COLUMN-
ROW=1). Similarly output to 2nd dataset those elements distance 2 from the diagonal and 
so on up to 4th dataset. 
• Deal with each dataset in turn, estimating a separate correlation coefficient for elements 
distance 1,2, 3 and 4 from the diagonal, using the method described in the previous section.  
 
 
(iv) SAS commands for running the generalised estimating equation analysis  
 
The variables in the model are those for the analysis using the largest dataset, time from close to 
publication all mentions  
 
PROC GENMOD; 
  CLASS RANID ALLORDER; 
  MODEL TCLPUB = NSTART DURRAN DUMCGRP1 DUMCGRP2 DUMENG PRESENTD 
                 DUMCLN1 DUMCLN2 DUMANS DEVLPNG NTREP NRREP IMPACT 
                 DUMPUBT3 DUMMULT ICGMUL2; 
  REPEATED SUBJECT=RANID/WITHIN=ALLORDER TYPE=IND CORRW MODELSE; 
  OUTPUT OUT=TEMP1 PREDICTED=YHAT RESCHI=RESID; 
RUN; 
 
Notes 
1. RANID (randomization ID) is the clustering variable. 
    For each randomization ALLORDER is the order of publication of the article 
    (For analyses for all reportings of results, rather than all mentions, RESORDER is the order of 
    publication of the article.) 
 
 
 
2. In this example the independence correlation structure has been selected. 
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    Set TYPE to impose correlation structure required 
EXCH   = exchangeable 
MDEP(n) = stationary m-dependent with m = n 
AUTO  = autoregressive 
 
3. MODELSE produces model-based estimates of the standard error of each parameter (β)  
    estimate 
 
4. The output statement produces fitted values and residuals for use in model testing 
 
 
(v) SAS commands to run a linear mixed effects model 
 
PROC MIXED; 
  CLASS RANID ALLORDER; 
  MODEL TCLPUB = NSTART DURRAN DUMCGRP1 DUMCGRP2 DUMENG PRESENTD 
               DUMCLN1 DUMCLN2 DUMANS DEVLPNG NTREP NRREP IMPACT 
               DUMPUBT3 DUMMULT ICGMUL2/S; 
  REPEATED ALLORDER/SUBJECT=RANID TYPE=CS; 
RUN; 
 
Notes 
1. RANID (the randomization ID) is the clustering variable. For each randomization ALLORDER 
    is the order of publication of the article. 
 
2. Set TYPE to impose correlation structure required 
CS  = exchangeable 
AR(1)   = autoregressive 
TOEP(n) =  stationary m-dependent with  m=n 
   Omitting the REPEATED statement produces the independence model 
 
3. S is the command to print beta estimates and their standard errors
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APPENDIX XI: CORRELATION MATRICES FOR THE RESIDUALS FROM THE  
SIX ANALYSES THAT REQUIRE INCORPORATION OF REPEATED MEASURES 
 
                                  The SAS System                                 
                                The CORR Procedure 
 
(I) Data used: all mentions 
Response variable: time from close to submission 
 
  Variable         N 
  RESID1          63 
  RESID2          32 
  RESID3          32 
  RESID4          38    Pearson Correlation Coefficients 
  RESID5          22       Prob > |r| under H0: Rho=0      
                              Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000       0.97505       0.67907      -0.54919       0.78506 
                               <.0001        0.1380        0.3377        0.0122 
                     63             8             6             5             9 
  
   RESID2       0.97505       1.00000       0.66503       0.84975       1.00000 
                 <.0001                      0.0183        0.0002         .     
                      8            32            12            13             2 
  
   RESID3       0.67907       0.66503       1.00000       0.52495       0.89496 
                 0.1380        0.0183                      0.0655        0.0402 
                      6            12            32            13             5 
  
   RESID4      -0.54919       0.84975       0.52495       1.00000       0.72177 
                 0.3377        0.0002        0.0655                      0.1686 
                      5            13            13            38             5 
  
   RESID5       0.78506       1.00000       0.89496       0.72177       1.00000 
                 0.0122         .            0.0402        0.1686               
                      9             2             5             5            22 
 
 
(II) Data used: all mentions 
Response variable: time from receipt to publication 
 
  Variable         N  
  RESID1          59 
  RESID2          29 
  RESID3          29 
  RESID4          38   Pearson Correlation Coefficients 
  RESID5          20      Prob > |r| under H0: Rho=0  
                             Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000      -0.46045      -0.32274      -0.64546       0.73565 
                               0.2509        0.5963        0.2395        0.0595 
                     59             8             5             5             7 
  
   RESID2      -0.46045       1.00000       0.07927       0.73546      -1.00000 
                 0.2509                      0.8168        0.0042         .     
                      8            29            11            13             2 
  
   RESID3      -0.32274       0.07927       1.00000       0.93523      -0.79386 
                 0.5963        0.8168                      <.0001        0.1088 
                      5            11            29            13             5 
  
   RESID4      -0.64546       0.73546       0.93523       1.00000      -0.12197 
                 0.2395        0.0042        <.0001                      0.8451 
                      5            13            13            38             5 
  
   RESID5       0.73565      -1.00000      -0.79386      -0.12197       1.00000 
                 0.0595         .            0.1088        0.8451               
                      7             2             5             5            20 
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(III) Data used: all mentions 
Response variable: time from close to publication 
 
  Variable         N  
  RESID1         194 
  RESID2         128 
  RESID3          90 
  RESID4          68 
  RESID5          44 
                        Pearson Correlation Coefficients  
                           Prob > |r| under H0: Rho=0  
                              Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000       0.35271       0.16092       0.16406      -0.05110 
                               <.0001        0.1297        0.1813        0.7418 
                    194           128            90            68            44 
  
   RESID2       0.35271       1.00000       0.46667       0.40235       0.20546 
                 <.0001                      <.0001        0.0007        0.1809 
                    128           128            90            68            44 
  
   RESID3       0.16092       0.46667       1.00000       0.66755       0.45929 
                 0.1297        <.0001                      <.0001        0.0017 
                     90            90            90            68            44 
  
   RESID4       0.16406       0.40235       0.66755       1.00000       0.75220 
                 0.1813        0.0007        <.0001                      <.0001 
                     68            68            68            68            44 
  
   RESID5      -0.05110       0.20546       0.45929       0.75220       1.00000 
                 0.7418        0.1809        0.0017        <.0001               
                     44            44            44            44            44 
 
 
(IV) Data used: all reportings of results 
Response variable: time from close to submission 
   
  Variable         N 
  RESID1          52 
  RESID2          22 
  RESID3          23 
  RESID4          17 
  RESID5           8 
                         Pearson Correlation Coefficients  
                           Prob > |r| under H0: Rho=0  
                              Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000       0.48915       0.16009       1.00000      -0.49005 
                               0.2653        0.7970         .            0.5100 
                     52             7             5             2             4 
  
   RESID2       0.48915       1.00000        .            0.99999        .      
                 0.2653                       .            0.0026         .     
                      7            22             1             3             0 
  
   RESID3       0.16009        .            1.00000       0.89594       0.99453 
                 0.7970         .                          0.0397        0.0666 
                      5             1            23             5             3 
  
   RESID4       1.00000       0.99999       0.89594       1.00000        .      
                  .            0.0026        0.0397                       .     
                      2             3             5            17             1 
  
   RESID5      -0.49005        .            0.99453        .            1.00000 
                 0.5100         .            0.0666         .                   
                      4             0             3             1             8 
 
  
309 
(V) Data used: all reportings of results 
Response variable: time from receipt to publication 
   
  Variable         N 
  RESID1          50 
  RESID2          20 
  RESID3          23 
  RESID4          16 
  RESID5           6 
                         Pearson Correlation Coefficients  
                           Prob > |r| under H0: Rho=0  
                              Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000      -0.63539       0.21270       1.00000       1.00000 
                               0.1252        0.7312         .             .     
                     50             7             5             2             2 
  
   RESID2      -0.63539       1.00000        .           -0.97530        .      
                 0.1252                       .            0.1418         .     
                      7            20             1             3             0 
  
   RESID3       0.21270        .            1.00000       0.45448      -0.74345 
                 0.7312         .                          0.4419        0.4664 
                      5             1            23             5             3 
  
   RESID4       1.00000      -0.97530       0.45448       1.00000        .      
                  .            0.1418        0.4419                       .     
                      2             3             5            16             1 
  
   RESID5       1.00000        .           -0.74345        .            1.00000 
                  .             .            0.4664         .                   
                      2             0             3             1             6 
 
 
 
(VI) Data used: all reportings of results 
Response variable: time from close to publication 
 
  Variable         N 
  RESID1         164 
  RESID2          91 
  RESID3          54 
  RESID4          29 
  RESID5          13 
                        Pearson Correlation Coefficients  
                           Prob > |r| under H0: Rho=0  
                              Number of Observations 
   
                 RESID1        RESID2        RESID3        RESID4        RESID5 
  
   RESID1       1.00000       0.53121       0.56003       0.08945      -0.13473 
                               <.0001        <.0001        0.6445        0.6608 
                    164            91            54            29            13 
  
   RESID2       0.53121       1.00000       0.75606       0.38425      -0.10232 
                 <.0001                      <.0001        0.0396        0.7394 
                     91            91            54            29            13 
  
   RESID3       0.56003       0.75606       1.00000       0.73189       0.63482 
                 <.0001        <.0001                      <.0001        0.0198 
                     54            54            54            29            13 
  
   RESID4       0.08945       0.38425       0.73189       1.00000       0.89130 
                 0.6445        0.0396        <.0001                      <.0001 
                     29            29            29            29            13 
  
   RESID5      -0.13473      -0.10232       0.63482       0.89130       1.00000 
                 0.6608        0.7394        0.0198        <.0001               
13            13            13            13            13 
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APPENDIX XII: OUTPUT FROM EACH ANALYSIS IMPOSING  
AN EXCHANGEABLE CORRELATION STRUCTURE CALCULATED  
USING THE VARIANCE INFLATION FACTOR METHOD  
 
Key 
PEST    = estimate of correlation coefficient 
VIF   = variance inflation factor 
SQRTVIF = √ VIF 
 
(I) Data used: all mentions 
Response variable: time from close to submission 
 
__________________________________________________________________________________________ 
 
                    PEST       VIF      SQRTVIF 
 
0.76024    0.42204    0.64964 
___________________________________________________________________________________________ 
             
Obs VARIABLE    BETA     SE_OLD      T_OLD       PROB_OLD     SE_NEW      T_NEW    PROB_NEW 
  
1 INTERCPT  3491.43    337.213     10.3538             0    519.077     6.72623    0.000000 
2 DURRAN      -0.72      0.177     -4.0820    .000064627      0.273    -2.65184    0.008651 
3 IMPACT    -102.30     31.225     -3.2762    .001241250     48.065    -2.12835    0.034538 
4 LOGPEST    248.95     71.849      3.4650    .000649377    110.598     2.25100    0.025479 
5 DEVLPNG   4404.25    516.524      8.5267    3.7748E-15    795.092     5.53929    0.000000 
6 LOGNTREP  1119.73    424.303      2.6390    .008973789    653.136     1.71439    0.088014 
7 NRREP     -205.38     42.926     -4.7845    .000003335     66.077    -3.10819    0.002158 
 
 
 
(II) Data used: all mentions 
Response variable: time from receipt to publication 
 
___________________________________________________________________________________________   
  
PEST       VIF      SQRTVIF 
 
0.48262    0.76708    0.87583 
___________________________________________________________________________________________   
  
Obs VARIABLE     BETA     SE_OLD      T_OLD     PROB_OLD     SE_NEW      T_NEW     PROB_NEW 
  
1   INTERCPT  12.5045    1.10526     11.3136    0.000000    1.26196     9.90883    0.000000 
2   NSTART     0.0006    0.00011      5.4033    0.000000    0.00012     4.73241    0.000004 
3   DUMJGRP2 -12.8341    1.76724     -7.2623    0.000000    2.01779    -6.36050    0.000000 
4   DURRAN     0.0018    0.00047      3.7408    0.000244    0.00054     3.27627    0.001254 
5   NRREP     -0.6220    0.08548     -7.2769    0.000000    0.09760    -6.37332    0.000000 
6   DUMCGRP   -3.3881    0.64441     -5.2576    0.000000    0.73578    -4.60480    0.000008 
7   LOGAUTH    2.2121    0.87336      2.5329    0.012135    0.99718     2.21837    0.027733 
 
 
 
(III) Data used: all mentions 
Response variable: time from close to publication 
 
___________________________________________________________________________________________ 
 
PEST       VIF      SQRTVIF 
 
0.37837    0.85684    0.92566 
  
___________________________________________________________________________________________ 
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Obs VARIABLE     BETA     SE_OLD      T_OLD     PROB_OLD     SE_NEW      T_NEW     PROB_NEW 
 
 1  INTERCPT  2344.83    266.143     8.81042     0.00000    287.517     8.15545     0.00000 
 2  NSTART      -0.15      0.029    -5.28143     0.00000      0.031    -4.88881     0.00000 
 3  DURRAN      -0.44      0.104    -4.22610     0.00003      0.112    -3.91193     0.00010 
 4  DUMCGRP1  -535.11    149.114    -3.58863     0.00036    161.089    -3.32185     0.00095 
 5  DUMCGRP2    23.51    253.833     0.09262     0.92624    274.219     0.08573     0.93171 
 6  DUMENG    1048.55    364.272     2.87849     0.00415    393.527     2.66451     0.00793 
 7  PRESENTD  -637.95    118.341    -5.39076     0.00000    127.844    -4.99001     0.00000 
 8  DUMCLN1    444.48    149.161     2.97985     0.00301    161.140     2.75833     0.00600 
 9  DUMCLN2    438.23    145.795     3.00575     0.00277    157.504     2.78231     0.00558 
10  DUMANS     523.72    122.078     4.29001     0.00002    131.882     3.97109     0.00008 
11  DEVLPNG   2182.69    423.091     5.15890     0.00000    457.070     4.77539     0.00000 
12  NTREP      243.98     51.860     4.70453     0.00000     56.025     4.35480     0.00002 
13  NRREP      -91.03     29.393    -3.09703     0.00205     31.753    -2.86680     0.00430 
14  IMPACT     -25.62     11.417    -2.24402     0.02522     12.334    -2.07720     0.03823 
15  DUMPUBT3  -354.65    158.095    -2.24328     0.02527    170.792    -2.07652     0.03830 
16  DUMMULT    813.22    163.454     4.97524     0.00000    176.581     4.60538     0.00001 
17  ICGMUL2   1226.46    355.925     3.44585     0.00061    384.509     3.18968     0.00150 
 
 
(IV) Data used: all reportings of results 
Response variable: time from close to submission 
 
Not done: Too few observations 
 
 
(V) Data used: all reportings of results 
Response variable: time from receipt to publication 
 
 
Not done: Too few observations 
 
 
(VI) Data used: all reportings of results 
Response variable: time from close to publication 
 
___________________________________________________________________________________________ 
 
    PEST       VIF      SQRTVIF 
 
0.55167    0.69566    0.83406 
___________________________________________________________________________________________ 
 
Obs VARIABLE     BETA     SE_OLD      T_OLD     PROB_OLD     SE_NEW      T_NEW     PROB_NEW 
  
 1  INTERCPT  2036.56    301.806     6.74791     0.00000    361.852     5.62816     0.00000 
 2  NOQ         47.86     20.309     2.35650     0.01899     24.350     1.96546     0.05014  
 3  NCLOSE      -0.10      0.027    -3.77133     0.00019      0.032    -3.14552     0.00180 
 4  PRESENTD  -461.68    141.864    -3.25439     0.00125    170.089    -2.71436     0.00697 
 5  DUMCLN2   -405.87    151.038    -2.68719     0.00755    181.088    -2.24128     0.02563 
 6  DUMANS     416.20    145.726     2.85604     0.00454    174.719     2.38211     0.01774 
 7  DUMFL      692.59    259.924     2.66458     0.00806    311.637     2.22242     0.02689 
 8  NTREP      136.21     50.084     2.71971     0.00686     60.049     2.26840     0.02391 
 9  LOGPEST    330.63     83.769     3.94693     0.00010    100.436     3.29198     0.00110 
10  DUMDIR1    276.15    171.197     1.61308     0.10762    205.257     1.34541     0.17936 
11  DUMDIR2    339.43    220.885     1.53669     0.12527    264.831     1.28169     0.20079 
12  LPDIR1    -390.87    103.790    -3.76600     0.00019    124.439    -3.14107     0.00183 
13  LPDIR2    -386.69    145.513    -2.65741     0.00823    174.464    -2.21644     0.02730 
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APPENDIX XIII: FOR EACH ANALYSIS, OUTPUT FROM THE  
PRELIMINARY INVESTIGATION IMPOSING A STATIONARY  
M-DEPENDENT CORRELATION STRUCTURE  
 
Key 
PnEST = estimate of the correlation coefficient for elements 
distance n from the leading diagonal, n = 1,2,3,4 and n < m 
 
Estimates of m-step correlation coefficients 
 
 
(I) Data used: all mentions 
Response variable: time from to submission 
___________________________________________________________________________________________                      
 
P1EST      P2EST       P3EST      P4EST 
 
0.75833    0.83217    -0.54919    0.78506 
___________________________________________________________________________________________ 
 
 
(II) Data used: all mentions 
Response variable: time from receipt to publication 
___________________________________________________________________________________________ 
   
 
P1EST      P2EST       P3EST      P4EST 
 
0.53381    0.43775    -0.64546    0.73565 
___________________________________________________________________________________________ 
   
 
(III) Data used: all mentions 
Response variable: time from close to publication 
___________________________________________________________________________________________ 
   
  
P1EST      P2EST      P3EST      P4EST 
 
0.51840    0.31154    0.18015    -0.0511 
 
___________________________________________________________________________________________ 
   
 
(IV) Data used: all reportings of results 
Response variable: Time from close to submission 
 
Not done: Too few observations 
 
 
 
(V) Data used: all reportings of results 
Response variable: time from receipt to publication 
 
Not done: Too few observations 
 
 
 
(VI) Data used: all reportings of results 
Response variable: time from close to publication 
___________________________________________________________________________________________ 
 
 
P1EST      P2EST       P3EST       P4EST 
 
0.66706    0.52135    0.036238    -0.13473 
___________________________________________________________________________________________ 
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APPENDIX XIV: PROGRAM APPLYING THE MANTEL TEST TO COMPARE AN 
ESTIMATED MATRIX HAVING A STATIONARY M-DEPENDENT CORRELATION 
STRUCTURE WITH THE MATRIX FORMED FROM THE RESIDUALS FROM THE 
INDEPENDENCE MODEL 
 
Notes:  
1. In order to use the same test to compare an estimated matrix 
   having an autoregressive correlation structure with the matrix 
   formed from the residuals from the independence model, replace 
   P1EST=0.51840 P2EST=0.31154 P3EST=0.18015 P4EST=-0.0511  
   by P1EST=0.51840 P2EST=0.51840**2  P3EST=0.51840**3   
   P4EST=0.51840**4; 
2. This example uses the response variable ‘time from close of  
   randomization to publication’ and the ‘all mentions’ dataset. 
 
* This program is called MANTEL_CLPUB_MSTEP.SAS; 
* To apply Mantel test on the stationary m-dependent correlation structure  
obtained using the first step of the GEE procedure to calculate a different  
value of Rho for each diagonal i.e. all the elements distance 1 from the leading  
diagonal have value P1EST, all elements distance 2 from the leading diagonal  
have value P2EST, all elements distance 3 have value P3EST and those distance 4 
have value P4EST; 
 
LIBNAME LIBRARY '[LEUK]'; 
LIBNAME LEUKJR '[LEUK.JULIE.RESEARCH]'; 
*OPTIONS FORMDLIM='_' LS=132; 
OPTIONS LS=80; 
*OPTIONS LS=132 PS=43; 
FILENAME MCLPUB '[LEUK.JULIE.RESEARCH]MANTEL_CLPUB.DAT'; 
 
* Let ENUM be the permutation reference number of the 5! = 120 matrices 
obtained using the first step of the GEE procedure to estimate a value of Rho 
for each diagonal (except the leading diagonal); 
DATA TEMP; 
 INPUT ENUM 3. +1 A 1. + 1 B 1. +1 C 1. +1 D 1. +1 E 1.; 
CARDS; 
  1 1 2 3 4 5 
  2 1 2 3 5 4 
  3 1 2 4 5 3 
  4 1 2 4 3 5 
  5 1 2 5 3 4 
  6 1 2 5 4 3 
  7 1 3 4 5 2 
  8 1 3 4 2 5 
  9 1 3 5 2 4 
 10 1 3 5 4 2 
 11 1 3 2 4 5 
 12 1 3 2 5 4 
 13 1 4 5 2 3 
 14 1 4 5 3 2 
 15 1 4 2 3 5 
 16 1 4 2 5 3 
 17 1 4 3 5 2 
 18 1 4 3 2 5 
 19 1 5 2 3 4 
 20 1 5 2 4 3 
 21 1 5 3 4 2 
 22 1 5 3 2 4 
 23 1 5 4 2 3 
 24 1 5 4 3 2 
 25 2 3 4 5 1 
 26 2 3 4 1 5 
 27 2 3 5 1 4 
 28 2 3 5 4 1 
 29 2 3 1 4 5 
 30 2 3 1 5 4 
 31 2 4 5 1 3 
 32 2 4 5 3 1 
 33 2 4 1 3 5 
 34 2 4 1 5 3 
314 
 35 2 4 3 5 1 
 36 2 4 3 1 5 
 37 2 5 1 3 4 
 38 2 5 1 4 3 
 39 2 5 3 4 1 
 40 2 5 3 1 4 
 41 2 5 4 1 3 
 42 2 5 4 3 1 
 43 2 1 3 4 5 
 44 2 1 3 5 4 
 45 2 1 4 5 3 
 46 2 1 4 3 5 
 47 2 1 5 3 4 
 48 2 1 5 4 3 
 49 3 4 5 1 2 
 50 3 4 5 2 1 
 51 3 4 1 2 5 
 52 3 4 1 5 2 
 53 3 4 2 5 1 
 54 3 4 2 1 5 
 55 3 5 1 2 4 
 56 3 5 1 4 2 
 57 3 5 2 4 1 
 58 3 5 2 1 4 
 59 3 5 4 1 2 
 60 3 5 4 2 1 
 61 3 1 2 4 5 
 62 3 1 2 5 4 
 63 3 1 4 5 2 
 64 3 1 4 2 5 
 65 3 1 5 2 4 
 66 3 1 5 4 2 
 67 3 2 4 5 1 
 68 3 2 4 1 5 
 69 3 2 5 1 4 
 70 3 2 5 4 1 
 71 3 2 1 4 5 
 72 3 2 1 5 4 
 73 4 5 1 2 3 
 74 4 5 1 3 2 
 75 4 5 2 3 1 
 76 4 5 2 1 3 
 77 4 5 3 1 2 
 78 4 5 3 2 1 
 79 4 1 2 3 5 
 80 4 1 2 5 3 
 81 4 1 3 5 2 
 82 4 1 3 2 5 
 83 4 1 5 2 3 
 84 4 1 5 3 2 
 85 4 2 3 5 1 
 86 4 2 3 1 5 
 87 4 2 5 1 3 
 88 4 2 5 3 1 
 89 4 2 1 3 5 
 90 4 2 1 5 3 
 91 4 3 2 5 1 
 92 4 3 2 1 5 
 93 4 3 5 1 2 
 94 4 3 5 2 1 
 95 4 3 1 2 5 
 96 4 3 1 5 2 
 97 5 1 2 3 4 
 98 5 1 2 4 3 
 99 5 1 3 2 4 
100 5 1 3 4 2 
101 5 1 4 2 3 
102 5 1 4 3 2 
103 5 2 3 4 1 
104 5 2 3 1 4 
105 5 2 4 1 3 
106 5 2 4 3 1 
107 5 2 1 3 4 
108 5 2 1 4 3 
109 5 3 2 4 1 
110 5 3 2 1 4 
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111 5 3 4 1 2 
112 5 3 4 2 1 
113 5 3 1 2 4 
114 5 3 1 4 2 
115 5 4 1 2 3 
116 5 4 1 3 2 
117 5 4 2 3 1 
118 5 4 2 1 3 
119 5 4 3 1 2 
120 5 4 3 2 1 
; 
 
DATA TEMP1; 
  SET TEMP; 
ROW1=A; 
ROW2=B; 
ROW3=C; 
ROW4=D; 
ROW5=E; 
 
COL1=A; 
COL2=B; 
COL3=C; 
COL4=D; 
COL5=E; 
 
* Let EIJOLD be the corresponding elements of matrix E (the m-step correlation  
structure produced using the first step of the GEE procedure. Here PXEST is  
the estimation of the correlation coefficient between residuals from  
publications X steps apart ie P1EST=0.51840 P2EST=0.31154 P3EST=0.18015  
P4EST=-0.0511); 
 
* To test; 
/* E11OLD=11; 
E12OLD=12; 
E13OLD=13; 
E14OLD=14; 
E15OLD=15; 
E21OLD=21; 
E22OLD=22; 
E23OLD=23; 
E24OLD=24; 
E25OLD=25; 
E31OLD=31; 
E32OLD=32; 
E33OLD=33; 
E34OLD=34; 
E35OLD=35; 
E41OLD=41; 
E42OLD=42; 
E43OLD=43; 
E44OLD=44; 
E45OLD=45; 
E51OLD=51; 
E52OLD=52; 
E53OLD=53; 
E54OLD=54; 
E55OLD=55;*/ 
 
E11OLD=1.00000; 
E22OLD=1.00000; 
E33OLD=1.00000; 
E44OLD=1.00000; 
E55OLD=1.00000; 
 
E12OLD=0.51840; 
E21OLD=0.51840; 
E23OLD=0.51840; 
E32OLD=0.51840; 
E34OLD=0.51840; 
E43OLD=0.51840; 
E45OLD=0.51840; 
E54OLD=0.51840; 
 
E13OLD=0.31154; 
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E31OLD=0.31154; 
E24OLD=0.31154; 
E42OLD=0.31154; 
E35OLD=0.31154; 
E53OLD=0.31154; 
 
E14OLD=0.18015; 
E41OLD=0.18015; 
E25OLD=0.18015; 
E52OLD=0.18015; 
 
E15OLD=-0.0511; 
E51OLD=-0.0511; 
 
ARRAY ROWS {5} ROW1-ROW5; 
ARRAY COLS {5} COL1-COL5; 
ARRAY EIJNEW {5,5} E11NEW E12NEW E13NEW E14NEW E15NEW 
                  E21NEW E22NEW E23NEW E24NEW E25NEW 
                  E31NEW E32NEW E33NEW E34NEW E35NEW 
                  E41NEW E42NEW E43NEW E44NEW E45NEW 
                  E51NEW E52NEW E53NEW E54NEW E55NEW;                   
DO I=1 TO 5; 
  DO J=1 TO 5; 
 IF ROWS{I}=1 AND COLS{J}=1 THEN EIJNEW{I,J}=E11OLD; 
 IF ROWS{I}=1 AND COLS{J}=2 THEN EIJNEW{I,J}=E12OLD; 
 IF ROWS{I}=1 AND COLS{J}=3 THEN EIJNEW{I,J}=E13OLD; 
 IF ROWS{I}=1 AND COLS{J}=4 THEN EIJNEW{I,J}=E14OLD; 
 IF ROWS{I}=1 AND COLS{J}=5 THEN EIJNEW{I,J}=E15OLD; 
 
 IF ROWS{I}=2 AND COLS{J}=1 THEN EIJNEW{I,J}=E21OLD; 
 IF ROWS{I}=2 AND COLS{J}=2 THEN EIJNEW{I,J}=E22OLD; 
 IF ROWS{I}=2 AND COLS{J}=3 THEN EIJNEW{I,J}=E23OLD; 
 IF ROWS{I}=2 AND COLS{J}=4 THEN EIJNEW{I,J}=E24OLD; 
 IF ROWS{I}=2 AND COLS{J}=5 THEN EIJNEW{I,J}=E25OLD; 
 
 IF ROWS{I}=3 AND COLS{J}=1 THEN EIJNEW{I,J}=E31OLD; 
 IF ROWS{I}=3 AND COLS{J}=2 THEN EIJNEW{I,J}=E32OLD; 
 IF ROWS{I}=3 AND COLS{J}=3 THEN EIJNEW{I,J}=E33OLD; 
 IF ROWS{I}=3 AND COLS{J}=4 THEN EIJNEW{I,J}=E34OLD; 
 IF ROWS{I}=3 AND COLS{J}=5 THEN EIJNEW{I,J}=E35OLD; 
 
 IF ROWS{I}=4 AND COLS{J}=1 THEN EIJNEW{I,J}=E41OLD; 
 IF ROWS{I}=4 AND COLS{J}=2 THEN EIJNEW{I,J}=E42OLD; 
 IF ROWS{I}=4 AND COLS{J}=3 THEN EIJNEW{I,J}=E43OLD; 
 IF ROWS{I}=4 AND COLS{J}=4 THEN EIJNEW{I,J}=E44OLD; 
 IF ROWS{I}=4 AND COLS{J}=5 THEN EIJNEW{I,J}=E45OLD; 
 
 IF ROWS{I}=5 AND COLS{J}=1 THEN EIJNEW{I,J}=E51OLD; 
 IF ROWS{I}=5 AND COLS{J}=2 THEN EIJNEW{I,J}=E52OLD; 
 IF ROWS{I}=5 AND COLS{J}=3 THEN EIJNEW{I,J}=E53OLD; 
 IF ROWS{I}=5 AND COLS{J}=4 THEN EIJNEW{I,J}=E54OLD; 
 IF ROWS{I}=5 AND COLS{J}=5 THEN EIJNEW{I,J}=E55OLD; 
  END; 
END; 
FILE MCLPUB; 
  PUT   
                  @10 E11NEW @20 E12NEW @30 E13NEW @40 E14NEW @50 E15NEW /  
                  @10 E21NEW @20 E22NEW @30 E23NEW @40 E24NEW @50 E25NEW /  
@1 'E' ENUM ' = ' @10 E31NEW @20 E32NEW @30 E33NEW @40 E34NEW @50 E35NEW /  
                  @10 E41NEW @20 E42NEW @30 E43NEW @40 E44NEW @50 E45NEW /  
                  @10 E51NEW @20 E52NEW @30 E53NEW @40 E54NEW @50 E55NEW //;  
 
* Let MIJ be the elements of matrix M (the original original correlation 
matrix produced from SAS);  
 
M11=1.00000; 
M12=0.35271; 
M13=0.16092;  
M14=0.16406;   
M15=-0.05110;   
M21=0.35271;  
M22=1.00000;  
M23=0.46667;   
M24=0.40235;  
M25=0.20546;   
M31=0.16092;  
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M32=0.46667;  
M33=1.00000;  
M34=0.66755;  
M35=0.45929;  
M41=0.16406; 
M42=0.40235; 
M43=0.66755; 
M44=1.00000;  
M45=0.75220;   
M51=-0.05110; 
M52=0.20546; 
M53=0.45929; 
M54=0.75220;  
M55=1.00000;  
 
* Mantel's test statistic Z= (sum i=2 to n, sum j=1 to i-1) MijEij. In this 
case Z = (M21*E21) + (M31*E31) + (M32*E32) + (M41*E41) + (M42*E42) + (M43*E43) 
+ (M51*E51) + (M52*E52) + (M53*E53) + (M54*E54); 
 
Z21=M21*E21NEW; 
Z31=M31*E31NEW; 
Z32=M32*E32NEW; 
Z41=M41*E41NEW; 
Z42=M42*E42NEW; 
Z43=M43*E43NEW; 
Z51=M51*E51NEW; 
Z52=M52*E52NEW; 
Z53=M53*E53NEW; 
Z54=M54*E54NEW; 
 
Z=Z21+Z31+Z32+Z41+Z42+Z43+Z51+Z52+Z53+Z54; 
 
* Alternative test statistic r=correlation between lower diagonal elements of M 
and E. Note: This is Pearson's correlation coefficient (parametric test, a 
opposed to Spearman's which is a non-parametric test. PROC CORR would provide 
the same value of r); 
 
MBAR=(M21+M31+M32+M41+M42+M43+M51+M52+M53+M54)/10; 
EBAR=(E21NEW+E31NEW+E32NEW+E41NEW+E42NEW+E43NEW+E51NEW+E52NEW+E53NEW+E54NEW)/10; 
RTOP=Z-(10*MBAR*EBAR); 
RBOTM=(M21**2)+ (M31**2) + (M32**2) + (M41**2) + (M42**2) + (M43**2) +(M51**2) + 
(M52**2) + (M53**2) + (M54**2) -10*(MBAR**2); 
RBOTE=(E21NEW**2) + (E31NEW**2) + (E32NEW**2) + (E41NEW**2) + (E42NEW**2) + 
(E43NEW**2) + (E51NEW**2) + (E52NEW**2) + (E53NEW**2) + (E54NEW**2)  
-10*(EBAR**2); 
R=RTOP/((RBOTM*RBOTE)**0.5); 
 
PROC SORT; 
  BY Z; 
PROC PRINT N; 
  VAR ENUM Z R; 
RUN; 
ENDSAS; 
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APPENDIX XV: OUTPUT FROM GEE ANALYSIS APPLIED TO THE LARGEST 
DATASET WITH EACH CORRELATION STRUCTURE IMPOSED, GIVING THE 
WORKING CORRELATION MATRIX, PARAMETER (β) ESTIMATES AND ESTIMATES 
OF THEIR STANDARD ERRORS, Z- AND P-VALUES 
 
Note: A list of the indicator variables used is given at the end 
of this appendix. 
 
Correlation structure: independence 
 
The GENMOD Procedure 
Algorithm converged 
 
 Working Correlation Matrix 
 
         Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
 
Row1    1.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row2    0.0000   1.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row3    0.0000   0.0000   1.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row4    0.0000   0.0000   0.0000   1.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row5    0.0000   0.0000   0.0000   0.0000   1.0000   0.0000   0.0000   0.0000   0.0000    
Row6    0.0000   0.0000   0.0000   0.0000   0.0000   1.0000   0.0000   0.0000   0.0000    
Row7    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   1.0000   0.0000   0.0000    
Row8    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   1.0000   0.0000    
Row9    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   1.0000    
Row10   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row11   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row12   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row13   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
 
Col10    Col11    Col12    Col13 
 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
1.0000   0.0000   0.0000   0.0000 
0.0000   1.0000   0.0000   0.0000 
0.0000   0.0000   1.0000   0.0000 
0.0000   0.0000   0.0000   1.0000 
  
Analysis Of GEE Parameter Estimates 
Model-Based Standard Error Estimates 
   
                                   Standard   95% Confidence 
                Parameter Estimate    Error       Limits            Z Pr > |Z| 
  
                Intercept 2344.831 266.1429 1823.200 2866.461    8.81   <.0001 
                NSTART     -0.1508   0.0286  -0.2067  -0.0948   -5.28   <.0001 
                DURRAN     -0.4398   0.1041  -0.6437  -0.2358   -4.23   <.0001 
                DUMCGRP1  -535.114 149.1136 -827.371 -242.857   -3.59   0.0003 
                DUMCGRP2   23.5089 253.8332 -473.995 521.0129    0.09   0.9262 
                DUMENG    -1048.55 364.2719 -1762.51 -334.595   -2.88   0.0040 
                PRESENTD  -637.945 118.3405 -869.888 -406.002   -5.39   <.0001 
                DUMCLN1   444.4775 149.1610 152.1273 736.8278    2.98   0.0029 
                DUMCLN2   438.2254 145.7955 152.4715 723.9793    3.01   0.0026 
                DUMANS    523.7168 122.0783 284.4477 762.9860    4.29   <.0001 
                DEVLPNG   2182.688 423.0914 1353.444 3011.932    5.16   <.0001 
                NTREP     243.9777  51.8602 142.3337 345.6218    4.70   <.0001 
                NRREP     -91.0305  29.3928 -148.639 -33.4216   -3.10   0.0020 
                IMPACT    -25.6206  11.4173 -47.9980  -3.2431   -2.24   0.0248 
                DUMPUBT3  -354.653 158.0953 -664.514 -44.7916   -2.24   0.0249 
                DUMMULT   813.2225 163.4538 492.8590 1133.586    4.98   <.0001 
                ICGMUL2   1226.462 355.9247 528.8622 1924.062    3.45   0.0006 
                Scale     1248.802    .        .        .         .      .     
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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Correlation structure: exchangeable 
 
Algorithm converged. 
 
Working Correlation Matrix 
 
         Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
 
Row1    1.0000   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row2    0.0831   1.0000   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row3    0.0831   0.0831   1.0000   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row4    0.0831   0.0831   0.0831   1.0000   0.0831   0.0831   0.0831   0.0831   0.0831    
Row5    0.0831   0.0831   0.0831   0.0831   1.0000   0.0831   0.0831   0.0831   0.0831    
Row6    0.0831   0.0831   0.0831   0.0831   0.0831   1.0000   0.0831   0.0831   0.0831    
Row7    0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   1.0000   0.0831   0.0831    
Row8    0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   1.0000   0.0831    
Row9    0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   1.0000    
Row10   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row11   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row12   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
Row13   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831   0.0831    
  
Col10    Col11    Col12    Col13 
 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
0.0831   0.0831   0.0831   0.0831 
1.0000   0.0831   0.0831   0.0831 
0.0831   1.0000   0.0831   0.0831 
0.0831   0.0831   1.0000   0.0831 
0.0831   0.0831   0.0831   1.0000 
 
 
Analysis Of GEE Parameter Estimates 
                                      
Model-Based Standard Error Estimates 
   
                                     Standard   95% Confidence 
                 Parameter Estimate    Error       Limits            Z Pr > |Z| 
  
     Intercept 2401.406 285.4231 1841.987 2960.825    8.41   <.0001 
                 NSTART     -0.1541   0.0313  -0.2154  -0.0927   -4.92   <.0001 
                 DURRAN     -0.4351   0.1145  -0.6595  -0.2107   -3.80   0.0001 
                 DUMCGRP1  -512.433 162.0403 -830.026 -194.840   -3.16   0.0016 
                 DUMCGRP2   46.4225 274.0935 -490.791 583.6359    0.17   0.8655 
                 DUMENG    -1123.73 359.4823 -1828.30 -419.160   -3.13   0.0018 
                 PRESENTD  -639.023 116.7415 -867.832 -410.213   -5.47   <.0001 
                 DUMCLN1   461.6988 150.3223 167.0725 756.3251    3.07   0.0021 
                 DUMCLN2   432.5392 145.8151 146.7470 718.3315    2.97   0.0030 
                 DUMANS    454.5659 120.9839 217.4417 691.6900    3.76   0.0002 
                 DEVLPNG   2197.779 438.8265 1337.695 3057.864    5.01   <.0001 
                 NTREP     245.0108  54.6656 137.8683 352.1534    4.48   <.0001 
                 NRREP     -88.0270  31.6647 -150.089 -25.9653   -2.78   0.0054 
                 IMPACT    -28.6904  11.3770 -50.9888  -6.3920   -2.52   0.0117 
                 DUMPUBT3  -373.240 155.5935 -678.197 -68.2818   -2.40   0.0164 
                 DUMMULT   791.4276 185.9465 426.9793 1155.876    4.26   <.0001 
                 ICGMUL2   1167.130 395.0436 392.8586 1941.401    2.95   0.0031 
                 Scale     1249.511    .        .        .         .      .     
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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Correlation structure: stationary m-dependent, m = 3 
 
Algorithm converged. 
 
Working Correlation Matrix 
   
        Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
 
Row1    1.0000   0.4545   0.1445  -0.1323   0.0000   0.0000   0.0000   0.0000   0.0000    
Row2    0.4545   1.0000   0.4545   0.1445  -0.1323   0.0000   0.0000   0.0000   0.0000    
Row3    0.1445   0.4545   1.0000   0.4545   0.1445  -0.1323   0.0000   0.0000   0.0000    
Row4   -0.1323   0.1445   0.4545   1.0000   0.4545   0.1445  -0.1323   0.0000   0.0000    
Row5    0.0000  -0.1323   0.1445   0.4545   1.0000   0.4545   0.1445  -0.1323   0.0000    
Row6    0.0000   0.0000  -0.1323   0.1445   0.4545   1.0000   0.4545   0.1445  -0.1323    
Row7    0.0000   0.0000   0.0000  -0.1323   0.1445   0.4545   1.0000   0.4545   0.1445   
Row8    0.0000   0.0000   0.0000   0.0000  -0.1323   0.1445   0.4545   1.0000   0.4545    
Row9    0.0000   0.0000   0.0000   0.0000   0.0000  -0.1323   0.1445   0.4545   1.0000    
Row10   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000  -0.1323   0.1445   0.4545    
Row11   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000  -0.1323   0.1445    
Row12   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000  -0.1323    
Row13   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   
 
 Col10    Col11    Col12    Col13 
  
 0.0000   0.0000   0.0000   0.0000 
 0.0000   0.0000   0.0000   0.0000 
 0.0000   0.0000   0.0000   0.0000 
 0.0000   0.0000   0.0000   0.0000 
 0.0000   0.0000   0.0000   0.0000 
 0.0000   0.0000   0.0000   0.0000 
 0.1445  -0.1323   0.0000   0.0000 
-0.1323   0.0000   0.0000   0.0000 
 0.4545   0.1445  -0.1323   0.0000 
 1.0000   0.4545   0.1445  -0.1323 
 0.4545   1.0000   0.4545   0.1445 
 0.1445   0.4545   1.0000   0.4545                                                
-0.1323   0.1445   0.4545   1.0000 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
  
Intercept 2592.377 296.2506 2011.737 3173.018    8.75   <.0001 
NSTART     -0.1685   0.0336  -0.2345  -0.1026   -5.01   <.0001 
DURRAN     -0.4256   0.1246  -0.6697  -0.1814   -3.42   0.0006 
DUMCGRP1  -485.141 176.6197 -831.309 -138.973   -2.75   0.0060 
DUMCGRP2  160.3201 301.2922 -430.202 750.8420    0.53   0.5947 
DUMENG    -627.782 310.7131 -1236.77 -18.7951   -2.02   0.0433 
PRESENTD  -522.652 102.5747 -723.695 -321.609   -5.10   <.0001 
DUMCLN1   428.3798 139.4245 155.1128 701.6468    3.07   0.0021 
DUMCLN2   279.7651 129.9932  24.9830 534.5471    2.15   0.0314 
DUMANS    255.2884  98.0494  63.1152 447.4617    2.60   0.0092 
DEVLPNG   2292.584 474.5052 1362.570 3222.597    4.83   <.0001 
NTREP     183.2207  51.3591  82.5588 283.8827    3.57   0.0004 
NRREP     -60.2162  30.5487 -120.091  -0.3420   -1.97   0.0487 
IMPACT    -25.0378   9.7081 -44.0654  -6.0101   -2.58   0.0099 
DUMPUBT3  -277.036 138.3691 -548.234  -5.8373   -2.00   0.0453 
DUMMULT   805.6502 202.8144 408.1412 1203.159    3.97   <.0001 
ICGMUL2   1239.207 437.8491 381.0382 2097.375    2.83   0.0047 
       Scale     1260.759    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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Correlation structure: stationary m-dependent, m = 2 
 
Algorithm converged. 
 
Working Correlation Matrix 
                 
  Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
 
Row1    1.0000   0.4514   0.1436   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row2    0.4514   1.0000   0.4514   0.1436   0.0000   0.0000   0.0000   0.0000   0.0000    
Row3    0.1436   0.4514   1.0000   0.4514   0.1436   0.0000   0.0000   0.0000   0.0000    
Row4    0.0000   0.1436   0.4514   1.0000   0.4514   0.1436   0.0000   0.0000   0.0000    
Row5    0.0000   0.0000   0.1436   0.4514   1.0000   0.4514   0.1436   0.0000   0.0000    
Row6    0.0000   0.0000   0.0000   0.1436   0.4514   1.0000   0.4514   0.1436   0.0000    
Row7    0.0000   0.0000   0.0000   0.0000   0.1436   0.4514   1.0000   0.4514   0.1436    
Row8    0.0000   0.0000   0.0000   0.0000   0.0000   0.1436   0.4514   1.0000   0.4514    
Row9    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.1436   0.4514   1.0000    
Row10   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.1436   0.4514    
Row11   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.1436    
Row12   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row13   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
 
Col10    Col11    Col12    Col13 
 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.0000   0.0000   0.0000   0.0000 
0.1436   0.0000   0.0000   0.0000 
0.4514   0.1436   0.0000   0.0000 
1.0000   0.4514   0.1436   0.0000 
0.4514   1.0000   0.4514   0.1436 
0.1436   0.4514   1.0000   0.4514 
0.0000   0.1436   0.4514   1.0000 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept 2578.432 302.0606 1986.405 3170.460    8.54   <.0001 
NSTART     -0.1695   0.0343  -0.2367  -0.1022   -4.94   <.0001 
DURRAN     -0.4244   0.1270  -0.6733  -0.1754   -3.34   0.0008 
DUMCGRP1  -478.640 179.4447 -830.346 -126.935   -2.67   0.0076 
DUMCGRP2  155.8623 304.6515 -441.244 752.9683    0.51   0.6089 
DUMENG    -667.346 316.2724 -1287.23 -47.4632   -2.11   0.0349 
PRESENTD  -528.536 102.2570 -728.956 -328.116   -5.17   <.0001 
DUMCLN1   419.5579 141.1564 142.8964 696.2194    2.97   0.0030 
DUMCLN2   317.6258 132.9789  56.9919 578.2598    2.39   0.0169 
DUMANS    287.9122 103.5654  84.9277 490.8967    2.78   0.0054 
DEVLPNG   2263.555 475.4807 1331.630 3195.480    4.76   <.0001 
NTREP     199.5583  53.4102  94.8763 304.2402    3.74   0.0002 
NRREP     -66.3383  31.6630 -128.397  -4.2799   -2.10   0.0362 
IMPACT    -25.1684  10.1114 -44.9864  -5.3504   -2.49   0.0128 
DUMPUBT3  -301.566 140.2622 -576.475 -26.6576   -2.15   0.0316 
DUMMULT   788.2816 207.5016 381.5858 1194.977    3.80   0.0001 
ICGMUL2   1216.753  447.7949 339.0914 2094.415   2.72   0.0066 
       Scale     1258.024    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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 Correlation structure: stationary m-dependent, m = 1 
 
Algorithm converged. 
 
Working Correlation Matrix 
                 
          Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
 
Row1    1.0000   0.4484   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row2    0.4484   1.0000   0.4484   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row3    0.0000   0.4484   1.0000   0.4484   0.0000   0.0000   0.0000   0.0000   0.0000    
Row4    0.0000   0.0000   0.4484   1.0000   0.4484   0.0000   0.0000   0.0000   0.0000    
Row5    0.0000   0.0000   0.0000   0.4484   1.0000   0.4484   0.0000   0.0000   0.0000    
Row6    0.0000   0.0000   0.0000   0.0000   0.4484   1.0000   0.4484   0.0000   0.0000    
Row7    0.0000   0.0000   0.0000   0.0000   0.0000   0.4484   1.0000   0.4484   0.0000    
Row8    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.4484   1.0000   0.4484    
Row9    0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.4484   1.0000    
Row10   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.4484    
Row11   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row12   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
Row13   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000    
   
    Col10    Col11    Col12    Col13 
     
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000 
    0.0000   0.0000   0.0000   0.0000   
    0.0000   0.0000   0.0000   0.0000 
    0.4484   0.0000   0.0000   0.0000 
    1.0000   0.4484   0.0000   0.0000 
    0.4484   1.0000   0.4484   0.0000 
    0.0000   0.4484   1.0000   0.4484 
    0.0000   0.0000   0.4484   1.0000 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept 2586.432 290.1848 2017.680 3155.184    8.91   <.0001 
NSTART     -0.1692   0.0332  -0.2343  -0.1041   -5.09   <.0001 
DURRAN     -0.4393   0.1229  -0.6801  -0.1984   -3.58   0.0004 
DUMCGRP1  -461.283 173.7127 -801.753 -120.812   -2.66   0.0079 
DUMCGRP2  192.4554 295.9115 -387.521 772.4313    0.65   0.5154 
DUMENG    -614.185 294.0555 -1190.52 -37.8470   -2.09   0.0367 
PRESENTD  -461.486  91.7993 -641.409 -281.563   -5.03   <.0001 
DUMCLN1   406.5547 134.8488 142.2559 670.8535    3.01   0.0026 
DUMCLN2   319.6508 126.8129  71.1021 568.1995    2.52   0.0117 
DUMANS    293.9733  98.9132 100.1070 487.8396    2.97   0.0030 
DEVLPNG   2264.908 471.2528 1341.270 3188.547    4.81   <.0001 
NTREP     184.1264  51.4340  83.3175 284.9353    3.58   0.0003 
NRREP     -69.6618  30.5387 -129.517  -9.8070   -2.28   0.0225 
IMPACT    -22.4326   9.6879 -41.4206  -3.4446   -2.32   0.0206 
DUMPUBT3  -314.162 133.9088 -576.618 -51.7054   -2.35   0.0190 
DUMMULT   798.5519 199.4591 407.6192 1189.485    4.00   <.0001 
ICGMUL2   1226.130 433.1791 377.1145 2075.145    2.83   0.0046 
              Scale     1259.627    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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Correlation structure: autoregressive [AR(1)] 
                              
Algorithm converged. 
 
Working Correlation Matrix 
 
        Col1     Col2     Col3     Col4     Col5     Col6     Col7     Col8     Col9     
       
Row1    1.0000   0.4507   0.2031   0.0915   0.0413   0.0186   0.0084   0.0038   0.0017 
Row2    0.4507   1.0000   0.4507   0.2031   0.0915   0.0413   0.0186   0.0084   0.0038 
Row3    0.2031   0.4507   1.0000   0.4507   0.2031   0.0915   0.0413   0.0186   0.0084 
Row4    0.0915   0.2031   0.4507   1.0000   0.4507   0.2031   0.0915   0.0413   0.0186 
Row5    0.0413   0.0915   0.2031   0.4507   1.0000   0.4507   0.2031   0.0915   0.0413 
Row6    0.0186   0.0413   0.0915   0.2031   0.4507   1.0000   0.4507   0.2031   0.0915 
Row7    0.0084   0.0186   0.0413   0.0915   0.2031   0.4507   1.0000   0.4507   0.2031 
Row8    0.0038   0.0084   0.0186   0.0413   0.0915   0.2031   0.4507   1.0000   0.4507 
Row9    0.0017   0.0038   0.0084   0.0186   0.0413   0.0915   0.2031   0.4507   1.0000 
Row10   0.0008   0.0017   0.0038   0.0084   0.0186   0.0413   0.0915   0.2031   0.4507 
Row11   0.0003   0.0008   0.0017   0.0038   0.0084   0.0186   0.0413   0.0915   0.2031 
Row12   0.0002   0.0003   0.0008   0.0017   0.0038   0.0084   0.0186   0.0413   0.0915 
Row13   0.0001   0.0002   0.0003   0.0008   0.0017   0.0038   0.0084   0.0186   0.0413 
 
 
Col10    Col11    Col12    Col13 
 
0.0008   0.0003   0.0002   0.0001 
0.0017   0.0008   0.0003   0.0002 
0.0038   0.0017   0.0008   0.0003 
0.0084   0.0038   0.0017   0.0008 
0.0186   0.0084   0.0038   0.0017 
0.0413   0.0186   0.0084   0.0038 
0.0915   0.0413   0.0186   0.0084 
0.2031   0.0915   0.0413   0.0186 
0.4507   0.2031   0.0915   0.0413 
1.0000   0.4507   0.2031   0.0915 
0.4507   1.0000   0.4507   0.2031 
0.2031   0.4507   1.0000   0.4507 
0.0915   0.2031   0.4507   1.0000 
   
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept 2589.813 309.0583 1984.070 3195.557    8.38   <.0001 
NSTART     -0.1714   0.0352  -0.2404  -0.1024   -4.87   <.0001 
DURRAN     -0.4207   0.1301  -0.6757  -0.1656   -3.23   0.0012 
DUMCGRP1  -474.045 183.3097 -833.325 -114.764   -2.59   0.0097 
DUMCGRP2  151.9198 310.1821 -456.026 759.8655    0.49   0.6243 
DUMENG    -709.793 318.7329 -1334.50 -85.0883   -2.23   0.0260 
PRESENTD  -546.968 102.7414 -748.337 -345.598   -5.32   <.0001 
DUMCLN1   423.8141 141.6190 146.2460 701.3822    2.99   0.0028 
DUMCLN2   330.8883 133.8130  68.6197 593.1569    2.47   0.0134 
DUMANS    293.6093 105.0567  87.7019 499.5167    2.79   0.0052 
DEVLPNG   2256.449 478.0560 1319.476 3193.421    4.72   <.0001 
NTREP     204.5176  54.3113  98.0695 310.9657    3.77   0.0002 
NRREP     -67.2755  32.3408 -130.662  -3.8887   -2.08   0.0375 
IMPACT    -25.1378  10.1943 -45.1182  -5.1574   -2.47   0.0137 
DUMPUBT3  -316.564 139.8623 -590.689 -42.4390   -2.26   0.0236 
DUMMULT   777.0006 214.1923 357.1915 1196.810    3.63   0.0003 
ICGMUL2   1189.320 460.4376 286.8788 2091.761    2.58   0.0098 
              Scale     1257.180    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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 Indicator variables 
  
 DUMMULT = 1 if MULTIC = Yes (multi-centre) 
 DUMMULT = 0 if MULTIC = Limited or No (single-centre) 
  
 DUMCGRP1 = 1 if CGROUP = Europe 
 DUMCGRP1 = 0 if CGROUP = America or Other 
 
 DUMCGRP2 = 1 if CGROUP = Other 
 DUMCGRP2 = 0 if CGROUP = America or Europe 
 
 DUMENG = 1 if published in full in a language other than English, with an English abstract 
 DUMENG = 0 if published in full in English 
 
 DUMCLN1 = 1 if CLNSG = Yes 
 DUMCLN1 = 0 if CLNSG = No, Possibly or X (not reported) 
 
 DUMCLN2 = 1 if CLNSG = X (not reported) 
 DUMCLN2 = 0 if CLNSG = Yes, No or Possibly 
 
 DUMANS = 1 if ANSWER = Yes or No 
 DUMANS = 0 if ANSWER = X (not reported) 
 
 PUBTYPE3 = 1 if PUBTYPE = Meeting abstract 
 PUBTYPE3 = 0 if PUBTYPE = Journal or Book 
 
 
 Interaction term 
 
 ICGMUL2 = 1 if non-US trial with less than 5 centres participating 
 ICGMUL2 = 0 otherwise  
  
  
325 
APPENDIX XVI: OUTPUT FOR THE LARGEST DATASET COMPARING  
HOW FOR EACH VARIABLE, THE P-VALUE CHANGES WHEN  
DIFFERENT CORRELATION STRUCTURES ARE IMPOSED 
 
 
 ------------------------------ Parameter number=1 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
      INTERCPT        INDP         2344.83      266.143      8.81    <.0001 
      INTERCPT        EXCH         2401.41      285.423      8.41    <.0001 
      INTERCPT        M3           2592.38      296.251      8.75    <.0001 
      INTERCPT        M2           2578.43      302.061      8.54    <.0001 
      INTERCPT        M1           2586.43      290.185      8.91    <.0001 
      INTERCPT        AUTO         2589.81      309.058      8.38    <.0001 
   
 ------------------------------ Parameter number=2 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       NSTART         INDP         -0.1508      0.0286      -5.28    <.0001 
       NSTART         EXCH         -0.1541      0.0313      -4.92    <.0001 
       NSTART         M3           -0.1685      0.0336      -5.01    <.0001 
       NSTART         M2           -0.1695      0.0343      -4.94    <.0001 
       NSTART         M1           -0.1692      0.0332      -5.09    <.0001 
       NSTART         AUTO         -0.1714      0.0352      -4.87    <.0001 
  
 ------------------------------ Parameter number=3 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DURRAN         INDP         -0.4398      0.1041      -4.23    <.0001 
       DURRAN         EXCH         -0.4351      0.1145      -3.80    0.0001 
       DURRAN         M3           -0.4256      0.1246      -3.42    0.0006 
       DURRAN         M2           -0.4244      0.1270      -3.34    0.0008 
       DURRAN         M1           -0.4393      0.1229      -3.58    0.0004 
       DURRAN         AUTO         -0.4207      0.1301      -3.23    0.0012 
  
 ------------------------------ Parameter number=4 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
      DUMCGRP1        INDP        -535.114      149.114     -3.59    0.0003 
      DUMCGRP1        EXCH        -512.433      162.040     -3.16    0.0016 
      DUMCGRP1        M3          -485.141      176.620     -2.75    0.0060 
      DUMCGRP1        M2          -478.640      179.445     -2.67    0.0076 
      DUMCGRP1        M1          -461.283      173.713     -2.66    0.0079 
      DUMCGRP1        AUTO        -474.045      183.310     -2.59    0.0097 
 
------------------------------ Parameter number=5 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
      DUMCGRP2        INDP          23.509      253.833      0.09    0.9262 
      DUMCGRP2        EXCH          46.423      274.094      0.17    0.8655 
      DUMCGRP2        M3           160.320      301.292      0.53    0.5947 
      DUMCGRP2        M2           155.862      304.652      0.51    0.6089 
      DUMCGRP2        M1           192.455      295.912      0.65    0.5154 
      DUMCGRP2        AUTO         151.920      310.182      0.49    0.6243 
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------------------------------ Parameter number=6 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DUMENG         INDP        -1048.55      364.272     -2.88    0.0040 
       DUMENG         EXCH        -1123.73      359.482     -3.13    0.0018 
       DUMENG         M3           -627.78      310.713     -2.02    0.0433 
       DUMENG         M2           -667.35      316.272     -2.11    0.0349 
       DUMENG         M1           -614.19      294.056     -2.09    0.0367 
       DUMENG         AUTO         -709.79      318.733     -2.23    0.0260 
   
 ------------------------------ Parameter number=7 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
      PRESENTD        INDP        -637.945      118.341     -5.39    <.0001 
      PRESENTD        EXCH        -639.023      116.742     -5.47    <.0001 
      PRESENTD        M3          -522.652      102.575     -5.10    <.0001 
      PRESENTD        M2          -528.536      102.257     -5.17    <.0001 
      PRESENTD        M1          -461.486       91.799     -5.03    <.0001 
      PRESENTD        AUTO        -546.968      102.741     -5.32    <.0001 
  
 ------------------------------ Parameter number=8 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DUMCLN1        INDP         444.478      149.161      2.98    0.0029 
       DUMCLN1        EXCH         461.699      150.322      3.07    0.0021 
       DUMCLN1        M3           428.380      139.425      3.07    0.0021 
       DUMCLN1        M2           419.558      141.156      2.97    0.0030 
       DUMCLN1        M1           406.555      134.849      3.01    0.0026 
       DUMCLN1        AUTO         423.814      141.619      2.99    0.0028 
  
 ------------------------------ Parameter number=9 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DUMCLN2        INDP         438.225      145.796      3.01    0.0026 
       DUMCLN2        EXCH         432.539      145.815      2.97    0.0030 
       DUMCLN2        M3           279.765      129.993      2.15    0.0314 
       DUMCLN2        M2           317.626      132.979      2.39    0.0169 
       DUMCLN2        M1           319.651      126.813      2.52    0.0117 
       DUMCLN2        AUTO         330.888      133.813      2.47    0.0134 
 
----------------------------- Parameter number=10 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DUMANS         INDP         523.717      122.078      4.29    <.0001 
       DUMANS         EXCH         454.566      120.984      3.76    0.0002 
       DUMANS         M3           255.288       98.049      2.60    0.0092 
       DUMANS         M2           287.912      103.565      2.78    0.0054 
       DUMANS         M1           293.973       98.913      2.97    0.0030 
       DUMANS         AUTO         293.609      105.057      2.79    0.0052 
  
 ----------------------------- Parameter number=11 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DEVLPNG        INDP         2182.69      423.091      5.16    <.0001 
       DEVLPNG        EXCH         2197.78      438.827      5.01    <.0001 
       DEVLPNG        M3           2292.58      474.505      4.83    <.0001 
       DEVLPNG        M2           2263.56      475.481      4.76    <.0001 
       DEVLPNG        M1           2264.91      471.253      4.81    <.0001 
       DEVLPNG        AUTO         2256.45      478.056      4.72    <.0001 
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----------------------------- Parameter number=12 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
        NTREP         INDP         243.978      51.8602      4.70    <.0001 
        NTREP         EXCH         245.011      54.6656      4.48    <.0001 
        NTREP         M3           183.221      51.3591      3.57    0.0004 
        NTREP         M2           199.558      53.4102      3.74    0.0002 
        NTREP         M1           184.126      51.4340      3.58    0.0003 
        NTREP         AUTO         204.518      54.3113      3.77    0.0002 
 
----------------------------- Parameter number=13 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
        NRREP         INDP        -91.0305      29.3928     -3.10    0.0020 
        NRREP         EXCH        -88.0270      31.6647     -2.78    0.0054 
        NRREP         M3          -60.2162      30.5487     -1.97    0.0487 
        NRREP         M2          -66.3383      31.6630     -2.10    0.0362 
        NRREP         M1          -69.6618      30.5387     -2.28    0.0225 
        NRREP         AUTO        -67.2755      32.3408     -2.08    0.0375 
  
 ----------------------------- Parameter number=14 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       IMPACT         INDP        -25.6206      11.4173     -2.24    0.0248 
       IMPACT         EXCH        -28.6904      11.3770     -2.52    0.0117 
       IMPACT         M3          -25.0378       9.7081     -2.58    0.0099 
       IMPACT         M2          -25.1684      10.1114     -2.49    0.0128 
       IMPACT         M1          -22.4326       9.6879     -2.32    0.0206 
       IMPACT         AUTO        -25.1378      10.1943     -2.47    0.0137 
   
 ----------------------------- Parameter number=15 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
      DUMPUBT3        INDP        -354.653      158.095     -2.24    0.0249 
      DUMPUBT3        EXCH        -373.240      155.594     -2.40    0.0164 
      DUMPUBT3        M3          -277.036      138.369     -2.00    0.0453 
      DUMPUBT3        M2          -301.566      140.262     -2.15    0.0316 
      DUMPUBT3        M1          -314.162      133.909     -2.35    0.0190 
      DUMPUBT3        AUTO        -316.564      139.862     -2.26    0.0236 
  
 ----------------------------- Parameter number=16 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       DUMMULT        INDP         813.223      163.454      4.98    <.0001 
       DUMMULT        EXCH         791.428      185.947      4.26    <.0001 
       DUMMULT        M3           805.650      202.814      3.97    <.0001 
       DUMMULT        M2           788.282      207.502      3.80    0.0001 
       DUMMULT        M1           798.552      199.459      4.00    <.0001 
       DUMMULT        AUTO         777.001      214.192      3.63    0.0003 
 
----------------------------- Parameter number=17 ------------------------------ 
  
                   Correlation      Beta      SE of beta      Z 
      Parameter     structure     estimate     estimate     value    Prob>Z 
  
       ICGMUL2        INDP         1226.46      355.925      3.45    0.0006 
       ICGMUL2        EXCH         1167.13      395.044      2.95    0.0031 
       ICGMUL2        M3           1239.21      437.849      2.83    0.0047 
       ICGMUL2        M2           1216.75      447.795      2.72    0.0066 
       ICGMUL2        M1           1226.13      433.179      2.83    0.0046 
       ICGMUL2        AUTO         1189.32      460.438      2.58    0.0098 
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APPENDIX XVII: OUTPUT FROM THE LINEAR MIXED EFFECTS ANALYSES 
 
Note: The name of the structure as used in this thesis is followed by that used in the SAS 
procedure in brackets where this differs.  
 
Covariance structure: independence (diagonal) 
The Mixed Procedure 
Solution for Fixed Effects 
   Standard 
Effect       Estimate       Error      DF    t Value    Pr > |t| 
 
Intercept     2344.83      266.14     564       8.81      <.0001 
NSTART        -0.1508     0.02855     564      -5.28      <.0001 
DURRAN        -0.4398      0.1041     564      -4.23      <.0001 
DUMCGRP1      -535.11      149.11     564      -3.59      0.0004 
DUMCGRP2      23.5089      253.83     564       0.09      0.9262 
DUMENG       -1048.55      364.27     564      -2.88      0.0041 
PRESENTD      -637.95      118.34     564      -5.39      <.0001 
DUMCLN1        444.48      149.16     564       2.98      0.0030 
DUMCLN2        438.23      145.80     564       3.01      0.0028 
DUMANS         523.72      122.08     564       4.29      <.0001 
DEVLPNG       2182.69      423.09     564       5.16      <.0001 
NTREP          243.98     51.8602     564       4.70      <.0001 
NRREP        -91.0305     29.3928     564      -3.10      0.0021 
IMPACT       -25.6206     11.4173     564      -2.24      0.0252 
DUMPUBT3      -354.65      158.10     564      -2.24      0.0253 
DUMMULT        813.22      163.45     564       4.98      <.0001 
ICGMUL2       1226.46      355.92     564       3.45      0.0006 
 
Covariance structure: exchangeable (compound symmetry)         
        
   Standard 
Effect       Estimate       Error      DF    t Value    Pr > |t| 
 
Intercept     2415.19      289.73     186       8.34      <.0001 
NSTART        -0.1547     0.03192     186      -4.85      <.0001 
DURRAN        -0.4341      0.1167     186      -3.72      0.0003 
DUMCGRP1      -509.13      164.89     186      -3.09      0.0023 
DUMCGRP2      51.1239      278.64     186       0.18      0.8546 
DUMENG       -1138.99      358.57     378      -3.18      0.0016 
      PRESENTD      -639.94      116.45     378      -5.50      <.0001 
      DUMCLN1        467.20      150.59     378       3.10      0.0021 
      DUMCLN2        433.02      145.83     378       2.97      0.0032 
      DUMANS         441.39      120.79     378       3.65      0.0003 
      DEVLPNG       2201.15      442.99     186       4.97      <.0001 
      NTREP          245.14     55.2231     378       4.44      <.0001 
      NRREP        -87.9852     32.1093     378      -2.74      0.0064 
      IMPACT       -29.1786     11.3668     378      -2.57      0.0106 
      DUMPUBT3      -377.39      155.14     378      -2.43      0.0155 
      DUMMULT        786.06      190.52     186       4.13      <.0001 
      ICGMUL2       1154.85      403.65     186       2.86      0.0047 
  
Covariance structure: autoregressive            
                     
Standard 
Effect       Estimate       Error      DF    t Value    Pr > |t| 
 
Intercept     2679.02      335.96     186       7.97      <.0001 
NSTART        -0.1804     0.03914     186      -4.61      <.0001 
DURRAN        -0.4158      0.1446     186      -2.88      0.0045 
DUMCGRP1      -442.88      202.09     186      -2.19      0.0297 
DUMCGRP2       203.47      341.55     186       0.60      0.5521 
DUMENG        -610.83      294.97     378      -2.07      0.0391 
PRESENTD      -508.62     94.1749     378      -5.40      <.0001 
DUMCLN1        420.11      133.93     378       3.14      0.0018 
DUMCLN2        310.96      125.01     378       2.49      0.0133 
DUMANS         231.08     95.9865     378       2.41      0.0165 
DEVLPNG       2274.07      514.36     186       4.42      <.0001 
NTREP          184.81     53.3658     378       3.46      0.0006 
NRREP        -58.9015     32.4150     378      -1.82      0.0700 
IMPACT       -23.3669      9.4001     378      -2.49      0.0134 
DUMPUBT3      -298.02      128.63     378      -2.32      0.0210 
DUMMULT        760.73      242.27     186       3.14      0.0020 
ICGMUL2       1171.89      518.39     186       2.26      0.0249 
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 Covariance structure: stationary m-dependent, m = 3 
(banded Toeplitz)           
 
                                  Standard 
         Effect       Estimate       Error      DF    t Value    Pr > |t| 
  
         Intercept     2798.35      346.96     186       8.07      <.0001 
         NSTART        -0.1962     0.04215     186      -4.66      <.0001 
         DURRAN        -0.4524      0.1554     186      -2.91      0.0040 
         DUMCGRP1      -390.28      216.94     186      -1.80      0.0736 
         DUMCGRP2       381.91      374.11     186       1.02      0.3087 
         DUMENG        -181.19      206.64     378      -0.88      0.3811 
         PRESENTD      -294.76     63.2705     378      -4.66      <.0001 
         DUMCLN1        308.29     96.1685     378       3.21      0.0015 
         DUMCLN2        180.88     83.1247     378       2.18      0.0302 
         DUMANS         135.47     59.6526     378       2.27      0.0237 
         DEVLPNG       2302.79      584.62     186       3.94      0.0001 
         NTREP         81.8924     38.9355     378       2.10      0.0361 
         NRREP        -33.5013     24.3684     378      -1.37      0.1700 
         IMPACT        -5.9639      5.9422     378      -1.00      0.3162 
         DUMPUBT3      -114.50     86.1129     378      -1.33      0.1845 
         DUMMULT        879.92      260.81     186       3.37      0.0009 
         ICGMUL2       1317.19      568.10     186       2.32      0.0215 
   
Covariance structure: stationary m-dependent, m = 2  
(banded Toeplitz)           
   
                                  Standard 
         Effect       Estimate       Error      DF    t Value    Pr > |t| 
  
         Intercept     2656.70      289.62     186       9.17      <.0001 
         NSTART        -0.1789     0.03399     186      -5.27      <.0001 
         DURRAN        -0.4402      0.1263     186      -3.49      0.0006 
         DUMCGRP1      -397.22      177.40     186      -2.24      0.0263 
         DUMCGRP2       274.81      304.30     186       0.90      0.3677 
         DUMENG        -412.62      255.00     378      -1.62      0.1065 
         PRESENTD      -345.69     75.3982     378      -4.58      <.0001 
         DUMCLN1        370.90      121.08     378       3.06      0.0023 
         DUMCLN2        319.05      112.67     378       2.83      0.0049 
         DUMANS         272.23     84.9148     378       3.21      0.0015 
         DEVLPNG       2274.04      486.10     186       4.68      <.0001 
         NTREP          139.47     48.0213     378       2.90      0.0039 
         NRREP        -58.5385     29.4615     378      -1.99      0.0476 
         IMPACT       -17.8250      8.5695     378      -2.08      0.0382 
         DUMPUBT3      -307.83      114.98     378      -2.68      0.0077 
         DUMMULT        782.77      205.68     186       3.81      0.0002 
         ICGMUL2       1202.49      447.82     186       2.69      0.0079 
  
Covariance structure: stationary m-dependent, m = 1  
(banded Toeplitz)           
   
                                  Standard 
         Effect       Estimate       Error      DF    t Value    Pr > |t| 
  
         Intercept     2344.83      266.14     186       8.81      <.0001 
         NSTART        -0.1508     0.02855     186      -5.28      <.0001 
         DURRAN        -0.4398      0.1041     186      -4.23      <.0001 
         DUMCGRP1      -535.11      149.11     186      -3.59      0.0004 
         DUMCGRP2      23.5089      253.83     186       0.09      0.9263 
         DUMENG       -1048.55      364.27     378      -2.88      0.0042 
         PRESENTD      -637.95      118.34     378      -5.39      <.0001 
         DUMCLN1        444.48      149.16     378       2.98      0.0031 
         DUMCLN2        438.23      145.80     378       3.01      0.0028 
         DUMANS         523.72      122.08     378       4.29      <.0001 
         DEVLPNG       2182.69      423.09     186       5.16      <.0001 
         NTREP          243.98     51.8602     378       4.70      <.0001 
         NRREP        -91.0305     29.3928     378      -3.10      0.0021 
         IMPACT       -25.6206     11.4173     378      -2.24      0.0254 
         DUMPUBT3      -354.65      158.10     378      -2.24      0.0255 
         DUMMULT        813.22      163.45     186       4.98      <.0001 
         ICGMUL2       1226.46      355.92     186       3.45      0.0007 
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APPENDIX XVIII: OUTPUT FROM GEE ANALYSIS APPLIED TO  
THE FIVE OTHER DATASETS USING THE FINAL CHOICE OF  
CORRELATION STRUCTURE, STATIONARY M-DEPENDENT, M=2 
 
(I) Data used: all mentions 
Response variable: time from close to submission   
 
The GENMOD Procedure 
 
Algorithm converged. 
 
Working Correlation Matrix 
 
           Col1      Col2      Col3      Col4      Col5      Col6      Col7      Col8       
 
Row1     1.0000    0.5276    0.4617    0.0000    0.0000    0.0000    0.0000    0.0000     
Row2     0.5276    1.0000    0.5276    0.4617    0.0000    0.0000    0.0000    0.0000     
Row3     0.4617    0.5276    1.0000    0.5276    0.4617    0.0000    0.0000    0.0000     
Row4     0.0000    0.4617    0.5276    1.0000    0.5276    0.4617    0.0000    0.0000     
Row5     0.0000    0.0000    0.4617    0.5276    1.0000    0.5276    0.4617    0.0000     
Row6     0.0000    0.0000    0.0000    0.4617    0.5276    1.0000    0.5276    0.4617     
Row7     0.0000    0.0000    0.0000    0.0000    0.4617    0.5276    1.0000    0.5276     
Row8     0.0000    0.0000    0.0000    0.0000    0.0000    0.4617    0.5276    1.0000     
Row9     0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.4617    0.5276     
Row10    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.4617     
Row11    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000     
Row12    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000     
 
  Col9     Col10     Col11     Col12 
 
0.0000    0.0000    0.0000    0.0000 
0.0000    0.0000    0.0000    0.0000 
0.0000    0.0000    0.0000    0.0000 
0.0000    0.0000    0.0000    0.0000 
0.0000    0.0000    0.0000    0.0000 
0.0000    0.0000    0.0000    0.0000 
0.4617    0.0000    0.0000    0.0000 
0.5276    0.4617    0.0000    0.0000 
1.0000    0.5276    0.4617    0.0000 
0.5276    1.0000    0.5276    0.4617 
0.4617    0.5276    1.0000    0.5276 
0.0000    0.4617    0.5276    1.0000 
 
 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept 3178.243 340.8240 2510.240 3846.246    9.33   <.0001 
DURRAN     -0.6232   0.1956  -1.0066  -0.2398   -3.19   0.0014 
IMPACT    -104.060  30.8414 -164.508 -43.6115   -3.37   0.0007 
LOGPEST   257.3812  68.4086 123.3028 391.4596    3.76   0.0002 
DEVLPNG   4370.561 516.3852 3358.465 5382.657    8.46   <.0001 
LOGNTREP  871.3414 414.7244  58.4965 1684.186    2.10   0.0356 
NRREP     -147.811  45.7156 -237.412 -58.2102   -3.23   0.0012 
              Scale     1265.495    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
 
 
  
331 
(II) Data used: all mentions 
Response variable: √(time from receipt to publication) 
 
Algorithm converged 
 
Working Correlation Matrix 
 
          Col1      Col2      Col3      Col4      Col5      Col6      Col7      Col8       
 
Row1     1.0000    0.0006   -0.2442    0.0000    0.0000    0.0000    0.0000    0.0000     
Row2     0.0006    1.0000    0.0006   -0.2442    0.0000    0.0000    0.0000    0.0000     
Row3    -0.2442    0.0006    1.0000    0.0006   -0.2442    0.0000    0.0000    0.0000     
Row4     0.0000   -0.2442    0.0006    1.0000    0.0006   -0.2442    0.0000    0.0000     
Row5     0.0000    0.0000   -0.2442    0.0006    1.0000    0.0006   -0.2442    0.0000     
Row6     0.0000    0.0000    0.0000   -0.2442    0.0006    1.0000    0.0006   -0.2442     
Row7     0.0000    0.0000    0.0000    0.0000   -0.2442    0.0006    1.0000    0.0006    
Row8     0.0000    0.0000    0.0000    0.0000    0.0000   -0.2442    0.0006    1.0000     
Row9     0.0000    0.0000    0.0000    0.0000    0.0000    0.0000   -0.2442    0.0006     
Row10    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000   -0.2442     
Row11    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    
Row12    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000     
 
    
 
  Col9     Col10     Col11     Col12 
 
 0.0000    0.0000    0.0000    0.0000     
 0.0000    0.0000    0.0000    0.0000     
 0.0000    0.0000    0.0000    0.0000     
 0.0000    0.0000    0.0000    0.0000     
 0.0000    0.0000    0.0000    0.0000     
 0.0000    0.0000    0.0000    0.0000      
-0.2442    0.0000    0.0000    0.0000 
 0.0006   -0.2442    0.0000    0.0000 
 1.0000    0.0006   -0.2442    0.0000 
 0.0006    1.0000    0.0006   -0.2442 
-0.2442    0.0006    1.0000    0.0006 
 0.0000   -0.2442    0.0006    1.0000 
 
 
Indicator variables 
 
DUMJGRP2 = 1 if JGROUP = Other 
DUMJGRP2 = 0 if JGROUP = America or Europe 
 
DUMCGRP1 = 1 if CGROUP = Europe 
DUMCGRP1 = 0 if CGROUP = America or Other 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept  12.3444   1.0641  10.2589  14.4300   11.60   <.0001 
NSTART      0.0006   0.0001   0.0004   0.0008    6.07   <.0001 
DUMJGRP2  -12.8175   1.7665 -16.2798  -9.3551   -7.26   <.0001 
DURRAN      0.0017   0.0005   0.0008   0.0026    3.73   0.0002 
NRREP      -0.6469   0.0851  -0.8136  -0.4801   -7.60   <.0001 
DUMCGRP1   -3.3324   0.6392  -4.5852  -2.0797   -5.21   <.0001 
LOGAUTH     2.2717   0.8689   0.5686   3.9748    2.61   0.0089 
              Scale       3.1934    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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(III) Data used: all mentions 
Response variable: time from close to publication 
 
The output for this analysis has been given in Appendix XV. 
 
 
  
 
 
(IV) Data used: all reportings of results 
Response variable: time from close to submission 
 
Algorithm converged. 
 
Working Correlation Matrix 
 
             Col1         Col2         Col3         Col4         Col5         Col6          
 
Row1       1.0000       0.5657       0.0650       0.0000       0.0000       0.0000 
Row2       0.5657       1.0000       0.5657       0.0650       0.0000       0.0000 
Row3       0.0650       0.5657       1.0000       0.0000       0.5657       0.0650 
Row4       0.0000       0.0650       0.5657       1.0000       0.5657       0.0650 
Row5       0.0000       0.0000       0.0650       0.5657       1.0000       0.5657 
Row6       0.0000       0.0000       0.0000       0.0650       0.5657       1.0000 
Row7       0.0000       0.0000       0.0000       0.0000       0.0650       0.5657 
Row8       0.0000       0.0000       0.0000       0.0000       0.0000       0.0650 
 
Col7         Col8 
 
0.0650       0.0000 
0.5657       0.0650 
1.0000       0.5657 
0.5657       1.0000 
 
 
Indicator variables 
 
DUMPN = 1 if POSNG = X (not reported) 
DUMPN = 0 if POSNG = Null, Negative, Opposite or Positive 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept 2011.066 185.8980 1646.712 2375.419   10.82   <.0001 
NOQ        95.0424  32.5245  31.2956 158.7893    2.92   0.0035 
PRESENTD  -599.944 190.4868 -973.291 -226.597   -3.15   0.0016 
IMPACT    -93.3368  32.4989 -157.033 -29.6402   -2.87   0.0041 
LOGPEST   236.0925  60.5592 117.3987 354.7863    3.90   <.0001 
DUMPN     624.4268 311.3094  14.2717 1234.582    2.01   0.0449 
              Scale     1059.887    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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(V) Data used: all reportings of results 
Response variable: time from receipt to publication 
 
Algorithm converged. 
 
Working Correlation Matrix 
 
             Col1         Col2         Col3         Col4         Col5         Col6          
 
Row1       1.0000      -0.5996       0.0805       0.0000       0.0000       0.0000        
Row2      -0.5996       1.0000      -0.5996       0.0805       0.0000       0.0000        
Row3       0.0805      -0.5996       1.0000      -0.5996       0.0805       0.0000        
Row4       0.0000       0.0805      -0.5996       1.0000      -0.5996       0.0805        
Row5       0.0000       0.0000       0.0805      -0.5996       1.0000      -0.5996        
Row6       0.0000       0.0000       0.0000       0.0805      -0.5996       1.0000       
Row7       0.0000       0.0000       0.0000       0.0000       0.0805      -0.5996        
Row8       0.0000       0.0000       0.0000       0.0000       0.0000       0.0805       
 
 
  Col7         Col8 
 
 0.0000       0.0000 
 0.0000       0.0000 
 0.0000       0.0000 
 0.0000       0.0000 
 0.0000       0.0000 
 0.0805       0.0000 
-0.5996       0.0805 
 1.0000      -0.5996 
-0.5996       1.0000 
 
 
Indicator variables 
 
DUMMULT = 1 if MULTIC = Yes or Limited (multi-centre)   
DUMMULT = 0 if MULTIC = No (single-centre)     
  
DUMINT = 1 if INTERNL = Yes (international)     
DUMINT = 0 if INTERNL = Limited or No (single-country)  
  
DUMANS1 = 1 if ANSWER = Yes     
DUMANS1 = 0 if ANSWER = No or X (not reported)      
   
DUMJGRP1 = 1 if JGROUP = Europe 
DUMJGRP1 = 0 if JGROUP = America or Other 
 
DUMJGRP2 = 1 if JGROUP = Other 
DUMJGRP2 = 0 if JGROUP = America or Europe 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter     Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept     130.8163  35.3986  61.4363 200.1962    3.70   0.0002 
DUMINT        -417.780  99.9902 -613.758 -221.803   -4.18   <.0001 
DUMMULT       132.8854  24.7516  84.3732 181.3977    5.37   <.0001 
DUMJGRP1      -160.416  32.3132 -223.749 -97.0835   -4.96   <.0001 
DUMJGRP2      -385.418  72.1713 -526.871 -243.965   -5.34   <.0001 
DURRAN          0.1198   0.0178   0.0850   0.1545    6.75   <.0001 
DUMANS1        60.9252  21.8332  18.1328 103.7176    2.79   0.0053 
IMPACT         -8.0550   4.8317 -17.5250   1.4150   -1.67   0.0955 
DUMINT*IMPACT  48.4723  13.9574  21.1163  75.8283    3.47   0.0005 
     Scale         119.6587    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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(VI) Data used: all reportings of results 
Response variable: time from close to publication 
 
 
Algorithm converged. 
 
Working Correlation Matrix 
   
     Col1         Col2         Col3         Col4         Col5         Col6          
 
Row1       1.0000       0.5526       0.1911       0.0000       0.0000       0.0000        
Row2       0.5526       1.0000       0.5526       0.1911       0.0000       0.0000        
Row3       0.1911       0.5526       1.0000       0.5526       0.1911       0.0000        
Row4       0.0000       0.1911       0.5526       1.0000       0.5526       0.1911        
Row5       0.0000       0.0000       0.1911       0.5526       1.0000       0.5526        
Row6       0.0000       0.0000       0.0000       0.1911       0.5526       1.0000        
Row7       0.0000       0.0000       0.0000       0.0000       0.1911       0.5526        
Row8       0.0000       0.0000       0.0000       0.0000       0.0000       0.1911        
 
 
Col7         Col8 
 
0.0000       0.0000 
0.0000       0.0000 
0.0000       0.0000 
0.0000       0.0000 
0.1911       0.0000 
0.5526       0.1911 
1.0000       0.5526 
0.5526       1.0000 
 
 
Indicator variables 
 
DUMANS = 1 if ANSWER = Yes or No 
DUMANS = 0 if X (not reported) 
 
DUMDIR1 = 1 if POSNG = Positive 
DUMDIR1 = 0 if POSNG = Negative, Null, Opposite or X (not reported) 
  
DUMDIR2 = 1 if POSNG = Negative 
DUMDIR2 = 0 if POSNG = Positive, Null, Opposite or X (not reported) 
 
 
 
Analysis Of GEE Parameter Estimates 
 
Model-Based Standard Error Estimates 
 
Standard   95% Confidence 
Parameter       Estimate    Error       Limits            Z Pr > |Z| 
 
Intercept       2334.615 304.2938 1738.210 2931.019    7.67   <.0001 
NCLOSE           -0.1281   0.0333  -0.1934  -0.0629   -3.85   0.0001 
PRESENTD        -355.426 111.2406 -573.454 -137.399   -3.20   0.0014 
DUMANS          302.9117 120.3815  66.9682 538.8551    2.52   0.0119 
NTREP           108.7966  40.3946  29.6246 187.9685    2.69   0.0071 
LOGPEST         313.6706  66.0366 184.2413 443.0999    4.75   <.0001 
DUMDIR1         241.5361 147.3340 -47.2332 530.3055    1.64   0.1011 
DUMDIR2         377.0421 183.5213  17.3469 736.7373    2.05   0.0399 
LOGPEST*DUMDIR1 -328.093  85.6308 -495.926 -160.260   -3.83   0.0001 
LOGPEST*DUMDIR2 -325.913 118.8067 -558.769 -93.0558   -2.74   0.0061 
    Scale           1262.351    .        .        .         .      . 
NOTE: The scale parameter for GEE estimation was computed as the square root of the 
normalized Pearson's chi-square. 
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APPENDIX XIX: THE RESULTS OF THE ‘HOW LONG?’ ANALYSES IN THE  
CONTEXT OF OTHER STUDIES IDENTIFIED IN A LITERATURE SEARCH 
 
REFERENCE 
SET OF TRIALS USED 
OUTCOME MEASURE(S) 
TRIAL CHARACTERISTICS COLLECTED 
RESULTS 
 
Liebeskind et al (1999) (abstract) 
All controlled clinical trials in acute ischaemic 
stroke reported in English from 1957-1997, 
compiled from a computerized MEDLINE search 
and international trials registers. 127 reports 
describing 52 interventions. 
# Start of accrual period to publication 
Submission of article to acceptance for 
publication 
Combination of statistical significance and   
direction of result such that 
*Positive = significant result in favour of 
experimental arm 
*Negative = non significant result or significant 
result in favour of control arm  
Number of patients 
Timing of publication 
Funding: charity vs. corporate vs. not known 
Time from start to publication shorter for positive 
than for negative trials (median 3.5 vs. 4.4 yrs) log 
rank p=0.079 
For subgroup of corporate funded trials difference 
is greater (median 3.5 vs. 4.7 yrs) 
Time from submission to acceptance also shorter 
for positive than for negative trials (median 0.17 
vs. 0.44 yrs) p=0.011 
Misakian and Bero (1998) (full paper) 
Studies on passive smoking in humans and 
animals funded between 1981 and 1995. Source: 
78 investigators contacted, 65 responded, who had 
conducted 61 studies, of which 47 had been 
published. 
# Year funding began to year of publication of 
first results (funding start date used as 
completion date difficult to define) 
Statistically significant results vs. not 
*Statistically significant = statistically significant 
association between passive smoking and a 
harmful health effect 
*Not statistically significant = results do not 
indicate a statistically significant association 
*Mixed=multiple primary outcomes measured and 
at least one was statistically significant 
Statistical significance defined as p<0.05 or odds 
ratio with confidence interval not overlapping 1.   
Experimental design vs. observational 
Animal vs. human studies 
Number of patients <=500 vs. >500 
Health outcome measure 
Funding source: government vs. private vs. 
tobacco industry vs. other 
Funding: external vs. internal, <=5 yrs vs.  >5yrs 
Median time to publication 5 yrs (95% CI, 4-7 yrs) 
for non-significant results and 3 yrs (95% CI 3-5 
yrs) for statistically significant results. p=0.004 
Statistically significant results (p=0.004), 
experimental study design (p=0.01), study size 
<=500 (p=0.01) and animals as subjects (p=0.03) 
were predictive of time to publication 
(proportional hazards models or nonparametric 
Wilcoxon test). 
Studies of human subjects only; only statistical 
significance is predictive of publication (p=0.007) 
Multivariate analysis of all studies: statistical 
significance (p=0.001) and study design (p=0.01) 
were only independent predictors. 
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Cheng et al (1998) (abstract) 
The 199 abstracts describing 180 randomized 
controlled trials in cystic fibrosis listed in 
Cochrane CF Group’s register at end of 1995. 
Abstracts initially identified from hand-searching 
44 meeting abstract books over 30 yrs. Register 
searched for subsequent full reports. Only 32% of 
178 abstracts analysed were subsequently 
published in full 
Time from publication as abstract to 
publication as full report 
Experimental treatment as effective or better than 
control vs. not 
Number of patients 
No difference in time to publication when 
abstracts stratified according to conclusions or 
sample size. No significant association (p>0.05) 
between time to publication and both sample size 
and conclusions together.  
Method: log rank test. 
Stern and Simes (1997) (full paper) 
Cohort of 748 eligible studies submitted to Royal 
Prince Alfred Hospital Ethics Committee, 
Australia, between 1979 and 1988 were examined 
retrospectively. 
 
 
# Time from approval by ethics committee to 
first publication 
For quantitative studies: 
*Statistical significance of results defined as 
positive (p<0.05) vs. negative (p>=0.10) versus 
indefinite conclusions (0.05<=p<0.10) 
For qualitative studies: 
Subjective assessment by the principal 
investigator: striking, important & definite vs. 
unimportant & negative findings 
Research design using trial vs. non-trial design 
Science importance rating of study by investigator 
Funding: pharmaceutical vs. non-pharmaceutical 
and external vs. internal vs. none 
Studies with non-comparable study groups 
Clinical trials randomized or not 
Study is part of degree or not 
Single- vs. multi-centre data collection sites 
Sample size <100 vs. >=100 
Research department undertaking the study 
Year of study approval 
Outcome qualitative vs. quantitative 
For clinical trials placebo control & blinding vs. 
not 
Of the 218 studies analysed with test of 
significance, those with positive results had shorter 
time to publication than those with negative 
results, median 4.8 vs. 8.0 yrs. 
Finding stronger for the subgroup of 130 clinical 
trials, with median times 4.7 and 8.0 yrs. 
Results not materially changed after adjusting for 
other significant predictors.  
Studies with indefinite conclusions took even 
longer time to publication than studies with 
negative results (median not yet reached). 
For 103 studies where outcome rated qualitatively: 
No clear evidence. 
Method: Cox regression. 
Handysides (1996) (abstract) 
The 48 papers published in the Communicable 
Disease Report Review in 1995. 
Time from receipt by journal to publication Mean time from receipt to publication is 5 mths. 
Abstract does not compare by trial characteristics. 
Full paper not available. 
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Dickersin and Min (1993) (abstract) 
Meta-analysis of the authors’ study plus 3 others 
found in literature search. All have prospective 
design, followed cohort of health-related research 
projects, started around same time, used similar 
study design and data collection forms.  
Study findings: 
*Results ‘significant’ if judged by investigator to 
be either statistically significant or ‘of great 
importance’ 
Publication status: publication as abstract, journal 
article, book chapter or letter to the editor. 
No results given on time to publication. However 
refers to Stern and Simes (1997) previously 
described and to Ioannidis (1998) (see below), 
stating “ … it takes longer for ‘negative’ studies to 
be published than ‘positive’ studies.“ 
Chew (1991) (abstract) 
Rejected manuscripts that were originally 
submitted to the American Journal of 
Roentgenology (AJR) during the first 5 months of 
1986. MEDLINE searches conducted 45-54 
months after dates of rejection by AJR located 162 
(64%) published papers out of a consecutive series 
of 254 manuscripts rejected by AJR (69% rejected 
major papers and 62% rejected case reports). The 
papers had been published in 30 different 
radiologic and 27 non-radiologic journals. 
Time from rejection from AJR to publication 
elsewhere 
Mean time lapse between rejection by AJR and 
publication elsewhere is 15 mths. 
The delay in publication was greater for papers 
published in non-radiologic and foreign journals 
than for papers published in radiologic and 
American journals. 
Most of the journals of eventual publication 
published fewer papers, had smaller circulations 
and had lower impact factors than the AJR. 
Ioannidis (1998) (full paper) 
Prospective cohort of randomized phase 2 and 3 
trials conducted by two multi-centre trialist groups 
from 1986 to 1996. 109 efficacy trials in human 
immunodeficiency virus infection sponsored by 
National Institutes of Health of which 101 were 
eligible for analysis.     
 
Time from start of enrolment to completion of 
follow-up 
Time from completion of follow-up to 
publication 
# Time from start of enrolment to publication 
*Statistically significant findings in favour of an 
experimental arm vs. of control arm vs. of neither 
arm vs. results pending 
Sample size >1000 vs. 200-1000 vs. <200 
Accrual to target ratio <0.5 vs. >=0.5 
Trialist group CPCRA vs. ACTG 
Population paediatric vs. adult 
Domain: Antiretroviral treatment vs. 
Complications of HIV 
Double-blind design vs. not 
Data management: Pharmaceutical industry vs. 
Other federally sponsored 
 
 
 
Median time from start of enrolment to publication 
was 5.5 yrs, substantially longer for negative trials 
than for results favouring an experimental arm (6.5 
vs. 4.3 yrs p<0.001, hazard ratio for time to 
publication for positive vs. negative trials 3.7;95% 
CI 1.8-7.7), mostly attributable to differences in 
time from completion of follow-up to publication 
(median 3.0 vs. 1.7 yrs p<0.001). On average, 
trials with significant results favouring any arm 
completed follow-up slightly earlier than trials 
with non significant results (median 2.3 vs. 2.5 yrs 
p=0.045), but long-protracted trials often had low 
event rates and failed to reach statistical 
significance, while trials that were terminated 
early had significant results. Positive trials were 
submitted for publication significantly more 
rapidly after completion than were negative trials 
(median 1.0 vs. 1.6 yrs p=0.001) and were 
published more rapidly after submission  (median 
0.8 vs. 1.1 yrs p=0.04).  
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This project 
All properly randomized trials which began before 
1 January 1988** and all publications referring to 
these trials, as identified by the Cancer Overviews 
Group, which were published prior to 1/1/2000.  
(**This was the set of trials included in the Second 
International Collaborative Workshop on 
Childhood ALL Studies at the end of 1992) 
Trials still open to randomization are included, as 
well as those that have closed. 
 
For article first reporting results: 
Time from close to submission of article 
Time from receipt to publication 
Time from close to publication 
The following characteristics had few enough 
missing values to be included and preliminary 
graphs suggested they may have an effect: 
Funding source 
Number of randomizations 
Number of arms 
Number of questions 
Number of patients 
Start  and close dates of accrual period 
Duration of accrual period 
Type of treatment (chemotherapy, radiotherapy, 
transplant, antibiotic) 
First-line vs. relapse/refractory  
Equivalence trial vs. not 
Age eligibility: Children vs. children + adults 
Multi-centre (>=5) vs. limited (2-4) vs. single- 
centre 
Target number of centres reached vs. not 
International vs. limited vs. single-country 
Country group of trialist 
Conducted in ‘developing’ country vs. ‘developed’ 
Statistical significance (numerical measure based 
on spacings between log e (typical value for 
category) 
Statistical significance not reported vs. reported 
Direction of results: + vs. – vs. null vs. opposite 
(i.e. + and -) vs. not reported 
Clinical significance of results: Yes vs. possibly 
vs. no vs. not reported 
Main questions answered vs. not 
Subgroup results reported vs. not 
Reported in journal, book or as meeting abstract  
Impact factor of journal 
Time from close to submission is longer for 
randomizations with the following characteristics: 
Earlier close date (p=0.0036) 
Multi-centre participation (p=0.0063) 
Conducted in a European country (p=0.0008) 
Conducted in a country other than North America 
or Europe (p=0.0007), the latter having a greater 
effect than the former. 
Published in a high impact factor journal 
(p=0.0242) 
Direction of result not negative (p=0.0147) 
Direction of result not positive or null (p=0.0107),  
i.e. negative are published faster than positive/ null 
results, with opposite results and randomizations 
where results are not reported taking longest. 
(F statistic=5.36, p-value=0.0002, R2=0.460099 
based on all 52 observations) 
 
Time from receipt to publication is longer for 
randomizations with the following characteristics: 
Funded by charity as well as Government money 
(p=0.0003) 
Reported in an article which mentions a larger 
number of trials (p=0.0001) 
Reported in an article which mentions a smaller 
number of randomizations (p<0.0001) 
Has been presented at a major meeting (p=0.0032) 
Results not clearly reported as clinically 
significant  (p=0.0056) 
Results not clearly reported as not clinically 
significant (p=0.0040) 
i.e. results not clinically significant are published 
faster than those which are, with those 
randomizations for which clinical significance is 
not reported taking longest. 
(F statistic=9.81, p-value<0.0001, R2=0.583463 
based on 49 out of 60 observations) 
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Journal/book/abstract  has no impact factor vs. has 
Country group of publisher 
Country group of trialists and publisher same vs. 
not 
Article published in English vs. not 
Results presented at major meeting? 
Number of trials mentioned in article 
Number of randomizations mentioned in article 
Number of authors 
These variables were considered but ruled out due 
to a high proportion of missing values and/or on 
the basis of preliminary graphs: 
Length of follow-up period 
Eligibility risk group 
Target accrual reached vs. not 
Correct timing of a late randomization vs. not 
Method of randomization: central computer vs. 
notification central office vs. sealed envelopes 
Randomization design: simple vs. block vs. 
minimization of imbalance 
Attempt to balance vs. not 
Statistical technique used 
Time from close to publication is longer for 
randomizations with the following characteristics: 
Main effects: 
Short duration of accrual period (p=0.0002) 
No clear indication of whether clinically 
significant or not is given (p=0.0060) 
Reported in a journal with an impact factor 
associated with it (p<0.0001) 
Results less statistically significant (0.0153) 
Interactions: 
Conducted by European trialists and reported in a 
publication with a high impact factor (p=0.0006) 
Conducted outside Europe and reported in a 
publication with a lower impact factor  (p=0.0062) 
Conducted in North America or Europe and results 
not null (p=0.0127) 
Conducted elsewhere and results are null 
(p=0.0023) 
(F statistic=9.10, p-value<0.0001, R2=0.364055 
based on all 170 observations) 
 
Note:  * definition of statistical significance differs from that used in this project 
# definition of ‘time to publication’ differs from that used in this project (i.e. time from close of accrual period to publication) 
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APPENDIX XX: ALGORITHMS AND SAS COMMANDS  
FOR PERFORMING THE ‘HOW WIDE?’ ANALYSES 
 
(i) Algorithm for obtaining a suitable dataset for addressing the ‘How wide?’ questions i.e. 
ever/never reported and frequency of reporting 
 
• The last part of the main data management program (JMAIN.SAS) outputs 2 datasets – one 
containing all records, the other all records which contain results. In each of these, there is 
an order number of the publication record relating to the randomization to which it belongs 
(ALLORDER in the all records dataset, and RESORDER in the results dataset). In each 
case retain only the randomization ID (RANID) and the order number. Records are ordered 
by RANID and within that by ALLORDER/RESORDER. 
• From each database keep only the last record for each randomization. Rename 
ALLORDER as NMENT (the number of articles in which each randomization is 
mentioned) and RESORDER as NRES (the number of articles in which the results of each 
randomization are reported) 
• Merge both of the above with the definitive records database, by variable RANID 
• If  NMENT is missing set NMENT to zero 
If  NRES is missing set NRES to zero  
• Create new variables MENTND (ever mentioned) and RESPUB (results ever published) 
using NMENT and RESPUB 
 
(ii) SAS commands for performing logistic regression 
 
PROC LOGISTIC DESCENDING; 
  CLASS DEVLPNG FIRSTL; 
  MODEL MENTND= NSTART FIRSTL DEVLPNG DURRAN/EXPB; 
RUN; 
 
Notes 
1. Select response level of interest to be reported=yes by using DESCENDING 
2. Command EXPB outputs the exponentiated values of estimates  
 
(iii) SAS commands for performing Poisson or negative binomial regression 
 
PROC GENMOD; 
  CLASS DEVLPNG DUMMULT3 EQUIV FIRSTL DUMCGRP3; 
  MODEL NMENT= NSTART DEVLPNG DUMMULT3 LOGSIZE EQUIV FIRSTL 
    DUMCGRP3/DIST=NEGBIN OFFSET= LNSTCUT LINK=LOG; 
  OUTPUT OUT=TEMP3 P=YHAT RESCHI=RESID STDRESCHI=STRESID; 
RUN; 
 
Notes 
1. Set DIST = NEGBIN for the negative binomial model 
          DIST = POISSON for the Poisson distribution 
    For both, the link function, LINK=LOG 
2. Offset variable LNSTCUT = ln (CUTANAL - NSTART) 
     i.e. natural log of the time between the date the randomization opened for recruitment and the 
     cut-off date for analysis (28/11/00). For the frequency of mentions analysis, start date chosen 
     rather than close date so that mentions before randomization has closed will fall within this 
     period. For the frequency of reportings of results analysis close date was used. 
3. Output statement provides fitted values (YHAT), residuals (RESID) and standardised residuals 
    (STRESID) for testing model assumptions
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APPENDIX XXI: OUTPUT FROM NEGATIVE BINOMIAL AND  
POISSON REGRESSIONS TO MODEL (a) FREQUENCY OF  
MENTIONS AND (b) FREQUENCY OF REPORTING RESULTS 
 
(a) Response = frequency of mentions 
Model = negative binomial 
                                 
The GENMOD Procedure 
  
                                Model Information 
                     Data Set                   LEUKJR.DEFIN 
                     Distribution          Negative Binomial 
                     Link Function                       Log 
                     Dependent Variable                NMENT 
                     Offset Variable                 LNSTCUT 
                     Observations Used                   188 
                     Missing Values                       55 
    
                      Criteria For Assessing Goodness Of Fit 
   
           Criterion                 DF           Value        Value/DF 
  
           Deviance                 180        185.3164          1.0295 
           Scaled Deviance          180        185.3164          1.0295 
           Pearson Chi-Square       180        178.3175          0.9907 
           Scaled Pearson X2        180        178.3175          0.9907 
           Log Likelihood                       51.8054                 
  
   Algorithm converged.                                                        
                         Analysis Of Parameter Estimates 
   
                               Standard       Wald 95%          Chi- 
  Parameter      DF  Estimate     Error   Confidence Limits   Square  Pr > ChiSq 
  
  Intercept       1  -11.6794    0.4778  -12.6158  -10.7430   597.62      <.0001 
  NSTART          1    0.0001    0.0000    0.0001    0.0002    30.89      <.0001 
  DEVLPNG     0   1    0.9101    0.3043    0.3136    1.5065     8.94      0.0028 
  DEVLPNG     1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  DUMMULT3    0   1    0.4908    0.1438    0.2090    0.7725    11.66      0.0006 
  DUMMULT3    1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  LOGSIZE         1    0.6256    0.1261    0.3785    0.8727    24.62      <.0001 
  EQUIV       0   1   -0.2538    0.1076   -0.4647   -0.0430     5.57      0.0183 
  EQUIV       1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  FIRSTL      1   1    0.5924    0.2230    0.1553    1.0296     7.06      0.0079 
  FIRSTL      2   0    0.0000    0.0000    0.0000    0.0000      .         .     
  DUMCGRP3    0   1    0.2625    0.1095    0.0479    0.4771     5.75      0.0165 
  DUMCGRP3    1   0    0.0000    0.0000    0.0000    0.0000      .         .     
   
  Dispersion      1    0.0214    0.0363    0.0008    0.5903                      
  
 NOTE: The negative binomial dispersion parameter was estimated by maximum  
       likelihood. 
 
 
Indicator variables 
 
DUMMULT3 = 1 if MULTIC = Yes or Limited (multi-centre) 
DUMMULT3 = 0 if MULTIC = No (single-centre) 
 
DUMCGRP3 = 1 if CGROUP = Europe or Other 
DUMCGRP3 = 0 if CGROUP = America 
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Model = Poisson 
 
                               The GENMOD Procedure 
  
                                Model Information 
                        Data Set              LEUKJR.DEFIN 
                        Distribution               Poisson 
                        Link Function                  Log 
                        Dependent Variable           NMENT 
                        Offset Variable            LNSTCUT 
                        Observations Used              188 
                        Missing Values                  55 
  
 
                      Criteria For Assessing Goodness Of Fit 
   
           Criterion                 DF           Value        Value/DF 
  
           Deviance                 180        196.2034          1.0900 
           Scaled Deviance          180        196.2034          1.0900 
           Pearson Chi-Square       180        189.3096          1.0517 
           Scaled Pearson X2        180        189.3096          1.0517 
           Log Likelihood                       51.6094                 
  
   Algorithm converged.                                                        
  
                         Analysis Of Parameter Estimates 
   
                              Standard       Wald 95%          Chi- 
  Parameter     DF  Estimate     Error   Confidence Limits   Square  Pr > ChiSq 
  
  Intercept      1  -11.6814    0.4668  -12.5963  -10.7665   626.26      <.0001 
  NSTART         1    0.0001    0.0000    0.0001    0.0002    32.90      <.0001 
  DEVLPNG    0   1    0.9082    0.3004    0.3194    1.4970     9.14      0.0025 
  DEVLPNG    1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  DUMMULT3   0   1    0.4925    0.1382    0.2217    0.7634    12.71      0.0004 
  DUMMULT3   1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  LOGSIZE        1    0.6259    0.1220    0.3868    0.8650    26.32      <.0001 
  EQUIV      0   1   -0.2546    0.1033   -0.4571   -0.0521     6.07      0.0137 
  EQUIV      1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  FIRSTL     1   1    0.5943    0.2193    0.1645    1.0241     7.34      0.0067 
  FIRSTL     2   0    0.0000    0.0000    0.0000    0.0000      .         .     
  DUMCGRP3   0   1    0.2632    0.1061    0.0552    0.4711     6.15      0.0131 
  DUMCGRP3   1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  Scale          0    1.0000    0.0000    1.0000    1.0000                      
  
 NOTE: The scale parameter was held fixed. 
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(b)  Response = frequency of reporting results 
Model = Poisson 
 
                               The GENMOD Procedure 
  
                                Model Information 
  
                        Data Set              LEUKJR.DEFIN 
                        Distribution               Poisson 
                        Link Function                  Log 
                        Dependent Variable            NRES 
                        Offset Variable            LNCLCUT 
                        Observations Used              188 
                        Missing Values                  55 
  
                      Criteria For Assessing Goodness Of Fit 
   
           Criterion                 DF           Value        Value/DF 
  
           Deviance                 182        193.6045          1.0638 
           Scaled Deviance          182        193.6045          1.0638 
           Pearson Chi-Square       182        173.5242          0.9534 
           Scaled Pearson X2        182        173.5242          0.9534 
           Log Likelihood                      -97.5575                 
  
   Algorithm converged.                                                        
  
                         Analysis Of Parameter Estimates 
   
                              Standard       Wald 95%          Chi- 
  Parameter     DF  Estimate     Error   Confidence Limits   Square  Pr > ChiSq 
  
  Intercept      1  -11.9120    0.5721  -13.0334  -10.7907   433.50      <.0001 
  NCLOSE         1    0.0001    0.0000    0.0001    0.0002    30.55      <.0001 
  DEVLPNG    0   1    1.5879    0.4518    0.7023    2.4734    12.35      0.0004 
  DEVLPNG    1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  DUMMULT3   0   1    0.7270    0.1396    0.4533    1.0006    27.10      <.0001 
  DUMMULT3   1   0    0.0000    0.0000    0.0000    0.0000      .         .     
  LOGSIZE        1    0.4545    0.1332    0.1935    0.7154    11.65      0.0006 
  TXCHEMO4   B   1    0.3315    0.1120    0.1120    0.5511     8.76      0.0031 
  TXCHEMO4   D   0    0.0000    0.0000    0.0000    0.0000      .         .     
  Scale          0    1.0000    0.0000    1.0000    1.0000                      
  
 NOTE: The scale parameter was held fixed. 
 
 
Indicator variables 
 
DUMMULT3 = 1 if MULTIC = Yes or Limited (multi-centre) 
DUMMULT3 = 0 if MULTIC = No (single-centre)  
 
TXCHEMO4 = B if TXCHEMO = Immunotherapy or Radiotherapy 
TXCHEMO4 = D if TXCHEMO = Chemotherapy or Antibiotic 
 
 
Model = negative binomial 
 
Note: 
The output is identical to that for the Poisson model except for 
the following:  
 
 WARNING: Negative of Hessian not positive definite.                         
 
                         Analysis Of Parameter Estimates 
   
  Dispersion      0    0.0000    0.0000    0.0000    0.0000                      
  
 NOTE: The negative binomial dispersion parameter was estimated by maximum  
       Likelihood. 
